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The Cre/loxP site-specific recombinase system evolved within bacteriophage PI as a
mechanism to maintain correct unit copy segregation of the prophage within host
cells. This thesis reports the application of this system to regulate gene expression in
murine cells. To achieve the regulation of gene expression a novel floxed STOP
cassette was designed, constructed and tested in murine embryonic fibroblasts (EF)
and embryonic stem (ES) cells. It was shown that the floxed STOP cassette could be
used successfully to regulate the transcription of the Enhanced Green Fluorescent
Protein (EGFP) marker gene in ES cells. However, no expression of the EGFP gene
could be detected at the protein level and several reasons for this observation are
discussed.
The floxed STOP cassette was also utilised in strategies to achieve conditional
expression of the tumour suppressor gene p53. A complex array of biological
functions have been assigned to p53. For example, p53 is known to be involved in
the regulation of apoptosis, multiple cell cycle checkpoints and the onset of
replicative cellular senescence. The development of novel approaches to achieve
conditional p53 expression should be a valuable tool and permit further investigation
into the pleiotropic nature of p53 function. Therefore, the floxed STOP cassette was
used to regulate the expression of a p53 cDNA in p53 null primary EF cells in vitro.
The upregulation of p53 expression after Cre administration was detected, but at a
low frequency, by immunohistochemistry. The response of EF cells to the
expression of p53 in terms of replicative cellular senescence was also characterised,
including the first description of senescence-associated (3-galactosidase expression in
any murine cell. The floxed STOP technology was also used in an attempt to
regulate the expression of the endogenous murine p53 gene in vivo. The successful
integration of the floxed STOP cassette, via an inducible gene targeting strategy, into
the murine p53 locus of ES cells is reported.
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Two methods were explored to achieve regulated expression of Cre recombinase in
vitro, the novel technology of recombinant adenoviridiae and the identification of
embryonal stem cell differentiation state-specific promoter regulatory sequences.
In conclusion, this thesis has explored the feasibility of using Cre/loxP-based
technologies to regulate gene expression. Several test plasmids were constructed and
characterised and all demonstrated that the application of floxed STOP-based
approaches is not as straightforward as suggested by the relatively small body of








The relevance of animal models of human disease is particularly well illustrated with
the example of cancer. The pathogenesis of cancer is a multi-step process
characterised by the accumulation of critical genetic lesions within the cell. To date,
many studies have described a bewildering variety of molecular genetic
abnormalities, the significance of which to pathogenesis is often obscure. Indeed, it
is probable that many of these abnormalities are epiphenomenal rather than of crucial
importance. Furthermore, despite the value of such genetic and epidemiological
approaches, they are limited and essentially descriptive. Thus considerable effort and
resources have been directed towards creating accurate animal models of human
diseases, such as cancer. Although animal models may never provide exact
representations of a human disease, they do permit dissection of specific molecular
and biochemical pathways that may be involved. Furthermore, they allow a variety
of genetic manipulations that would be technically and ethically impracticable with
human tissues.
1.2. Background - Animal Models of Human Disease
The mouse has become one of the most commonly used disease model systems. The
reasons for this are manifold, their small size, relative resistance to infection, large
litter size and a short generation time. Perhaps the most significant advantage in
early studies was the observed variation in coat colour, the study of which allowed
some of the earliest insights into mouse genetics. For example, the inheritance
patterns of the coat colour marker albino was used for the first breeding experiment
to demonstrate Mendelian inheritance in the mouse (Castle & Allen, 1903).
As the field of mammalian genetics expanded, researchers moved on to study and
identify the genetic traits associated with non-coat colour related variations in mice.
These studies resulted in the characterisation of over 1000 spontaneously arising
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mutations (Doolittle, 1996). In depth analysis of such mutations revealed that many
showed phenotypic similarities to human diseases. Hence, the potential of the mouse
as a model system for human disease became apparent. However, it was obvious that
a more efficient system for generating and characterising mutations was needed
rather than relying on the spontaneous generation of interesting mutations. For
example, several thousand genetic diseases are known in humans (McKusick, 1978)
the vast majority of which have no direct parallel in experimental animals. One way
of circumventing this problem was the use of random mutagenesis protocols, such as
the treatment of male mice with ethylnitrosourea (ENU) or chlorambucil (Russell et
al, 1989) and subsequently to screen offspring for dominant or recessive mutations.
A notable success with this technique was the generation ofMin mice (multiple
intestinal neoplasia) that have a mutation in the mouse homologue of the human APC
(adenomatous polyposis coli) gene (Moser et al, 1990). The introduced mutation
results in the expression of a truncated Ape protein and these animals have provided a
valuable model system for the related human disease, Familial Adenomatous
Polyposis Coli (FAP) (Groden et al, 1991). However, it should be noted that while
human FAP patients and the Min mouse have mutations in homologous genes, the
phenotypes are not identical (see Lovejoy et al, 1996).
Since the production of the first animal models of human disease, such as the Min
mouse, technological advances and refinements of the concept being examined have
led to increasingly accurate and informative models. For example, as individual
genes important in disease processes were characterised, the newer technologies of
transgenic mouse production and gene targeting allowed a more direct analysis of the
molecular function of such genes. This work is discussed below.
1.2.1. Transgenic Mice
The first reported transgenic mice were produced by injecting purified SV40 genomic
DNA into the blastocoel cavity of mouse blastocysts. Viral DNA sequences could be
detected in the tissues of resulting animals indicating the successful integration of
viral genomes into host chromosomes (Jaenisch et al, 1974). Today transgenic mice
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are most commonly produced by microinjection ofDNA directly into the pronuclei
of fertilised mouse eggs (Gordon et al, 1980).
Since their development, transgenic strains of mice have proved to be valuable tools
in the study of the genetics and pathogenesis of many human diseases. Phenotypic
alterations which occur as a direct consequence of transgene expression can provide
evidence to implicate specific genes in a given disease process. Where transgene
expression can be shown to model human disease, such mice could be used as test
systems to determine the efficacy of treatment regimes and crossing onto different
backgrounds may reveal extragenic modifiers of the phenotype.
However, the transgenic approach has limitations. For example, both the copy
number and position of transgene integration cannot be predicted, yet both of these
parameters can exert significant influence over phenotype (reviewed by Palmiter &
Brinster, 1986). Also, because of the random nature of integration there is a
significant risk of insertional mutagenesis. If the transgene integrates within a coding
sequence and abolishes expression, the transgenic phenotype will be complicated by
additional effects due to loss of expression of the endogenous gene. Perhaps the
most significant drawback to transgenic models generated through pronuclear
injection is the difficulty in creating null alleles as exogenous genetic material can
only be added to the genome.
A major advance in our ability to create mouse models of human disease was the
development of gene targeting technology that facilitates the introduction of specific
mutations into the mouse germline.
1.2,2. Introduction of Specific Alterations into the Mammalian Genome
Gene targeting is the term used to describe the introduction of defined genetic
alterations into the genome of the mouse, an approach that takes advantage of two
technological developments. Firstly, isolation and characterisation of pluripotent ES
cell lines (see Section 1.2.2.1) and secondly, the harnessing of the cellular
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homologous recombination machinery to permit site-specific mutagenesis (see
Section 1.2.2.2). Together these provided a powerful tool for introducing specifically
engineered mutations into ES cells, allowing the generation of precisely defined
mutant mouse strains.
1.2.2.1. Mouse Embryo-Derived Cell Types
1.2.2.1.a. Embryonal Carcinoma Cells
Two morphologically distinct cell populations can be distinguished within a 3.5
d.p.c. mouse embryo. Firstly, cells from the inner cell mass (ICM) and secondly
those which form the trophectoderm. The second differentiation process that occurs
in the blastocyst prior to implantation is the division of the ICM into primitive
endoderm and epiblast (discussed in greater depth in Hogan et al, 1986). Several
lines of evidence exist which demonstrate that the ICM and epiblast are the
pluripotential tissues of the early embryo that constitute the germ-line and give rise to
all somatic tissues of the embryo proper, in addition to some of the extraembryonic
components (reviewed in Smith, 1992).
The ectopic grafting of early mouse embryos results in the high frequency generation
of teratocarcinomas (Solter et al, 1970). Grafts from 8.5 d.p.c. embryos generate
only fully differentiated, benign teratomas, whereas approximately 50% of grafts
from 6.5-7.5 d.p.c. embryos give rise to malignant teratocarcinomas (Damjanov et al,
1971). Both teratocarcinomas and teratomas arise by differentiation from a
pluripotential malignant cell population, the embryonal carcinoma (EC) cells. If all
the EC cells in a tumour differentiate, the result is a teratoma. However, any residual
undifferentiated EC cells give rise to a malignant teratocarcinoma. The epiblast
origin of such tumours has been established by dissection of the embryos prior to
ectopic grafting (Diwan & Stevens, 1976).
EC cells share a high level of morphological, ultrastructural and biochemical identity
with ICM/epiblast cells. Indeed there is evidence that EC cells do not differ
intrinsically in any irreversible way from normal epiblast cells, but are malignant due
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to an abnormal microenvironment. For example, some EC cell lines are able to
contribute to the host ICM when reintroduced into a blastocyst (Mintz & Ulmensee,
1975) or aggregated with morulae (Stewart, 1982). Although pluripotency of a
specific EC cell line has been reported (Stewart & Mintz, 1981), the vast majority of
such cell lines are aneuploid. This has imposed significant limitations on the
application of the EC cell system for the transgenic modification of the mouse germ-
line or as a model system for the study of mouse embryogenesis.
1.2.2.1,b. Embryonal Stem Cells
These limitations were circumvented in 1981 with publications from two laboratories
which reported the derivation of non-transformed, pluripotential early embryonic
stem cells, ES cells (Evans & Kaufman, 1981; Martin, 1981). ES cells were derived
from the ICM of 3.5 d.p.c. blastocysts and were initially maintained in vitro by co-
culture with feeder layers. Extensive ES cell differentiation was observed when the
cells were cultured in the absence of feeder cells, implying that the maintenance of
the undifferentiated stem cell phenotype is an active process (Smith & Hooper,
1987). The need for co-culture with feeder layers was bypassed with the discovery
that undifferentiated ES cells could be maintained in medium conditioned by the
Buffalo rat liver cell line BRL (Smith & Hooper, 1987). The macromolecule
subsequently identified as a potent inhibitor of ES cell differentiation was
Differentiation Inhibiting Activity (DIA) (Williams et al, 1988), identical to the
previously described D-Factor (Tomida et al, 1984) or Leukaemia Inhibitory Factor
(LEF) (Gearing et al, 1987). The culturing of ES cells in the presence of DIA/LIF and
medium additionally supplemented with (3-mercaptoethanol and serum is sufficient
to maintain an undifferentiated pluripotential population (Nichols et al, 1990).
However, even with these culture conditions a background of spontaneous
differentiation is observed (reviewed in Smith, 1992).
1.2.2.1.c. ES Cell Differentiation
As already mentioned, if ES cells are cultured at low density in the absence of LIF,
differentiation occurs, generating cells which are morphologically distinct from the
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starting population (Smith & Hooper, 1987). The population of differentiated cells is
thought to contain a mixture of endoderm and ill-defined mesoderm-like cells
(Mummery et al, 1990).
ES cells cultured at higher density in the absence of LIF proliferate, forming groups
of cells. Cell clumps can either be dislodged manually or cultured on bacterial grade
plasticware in which case they never adhere. The end result of either approach is the
same; the production of suspension aggregates containing differentiated ES cells.
These aggregates are called embryoid bodies due to their superficial resemblance to
the egg cylinder of a day 6 mouse embryo. The level of differentiation of the cells
which constitute an embryoid body can be further increased by allowing them to
adhere to a tissue culture dish and form outgrowths (discussed in greater depth in
Hooper, 1992).
ES cell differentiation can also be induced by retinoic acid (RA) exposure.
Interestingly, the exposure of ES cells to RA can give rise to distinct differentiation
products depending on the presence or absence of LIF (Mummery et al, 1990).
Furthermore, concentration dependent effects have also been observed when
embryoid bodies are exposed to RA (Fisher et al, 1989). Exposure to specific growth
factors can also influence the differentiation products generated from embryoid
bodies, for example, nerve growth factor exposure increases the yield of neuron-like
cells (Wobus et al, 1988).
Despite characterisation of the morphological endpoints of ES cell differentiation, the
underlying molecular changes are unclear. However, recent research has identified
some of very early events after the induction of differentiation. For example, Stat5 is
not expressed in undifferentiated ES cells yet transcripts were detectable as early as
12 hours after treatment with RA and 36 hours after withdrawal of LIF (Nemetz &
Hocke, 1998). In addition, ES cells cultured in the presence of LIF express low or
undetectable levels of cyclin E/CDK2, p21, p27 and Cyclin D/CDK4. Withdrawal of
LIF stimulates the upregulation of expression of all of the above and activates the
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expression of Brachury and Goosecoid, two early markers of mesoderm
differentiation (Savatier, 1995).
1.2.2.1.d. ES Cell-Mediated Transgenesis
As with EC cells, ES cells can also be re-introduced into blastocysts to generate
chimaeric progeny (Bradley et al, 1984). However, while the abnormal karyotype
characteristic of the majority of EC cell lines makes germ-line colonisation
infrequent, the normal chromosome complement of ES cells allows reproducible
germ-line colonisation. The pluripotential nature of ES cells made them an ideal
system with which to attempt transgenic manipulation of the mouse genome but to
achieve this goal, the twin technologies of genetic manipulation in vitro and ES cell
germ-line transmission needed to be combined. Despite initial problems (Stewart et
al, 1985; Evans et al, 1985), in 1986 the first paper was published which reported the
successful generation of transgenic mice via the ES cell route (Gossler et al, 1986).
This early work focussed on the addition of genetic material to ES cells either by
transfection or retroviral infection but the logical next step was the manipulation of
specific endogenous genes. This was achieved by two independent research groups
working on the same gene, hypoxanthine guanine phoshoribosyl transferase (Hprt)
(Hooper et al, 1987; Kuehn et al, 1987). The Hprt gene was an ideally suited to this
approach for several reasons. In both humans and mice the gene is X-linked thus
male cells are hemizygous, Hprt null cells can be separated from their wild type
counterparts on the basis of altered drug sensitivity and the generation of Hprt null
mice offered the tantalising possibility of a mouse model of the human disease,
Lesch-Nynan syndrome which is caused by Hprt deficiency (Nyhan, 1973).
Although both groups were successful in introducing mutations into the Hprt gene
and subsequent generation of mutant mice no phenotypic alterations were observed
in these animals. Further work suggested that differences in purine metabolism
between mice and humans were to blame for the absence of a phenotype in the Hprt
null animals (Redhead et al, 1996). Nevertheless, this work was a crucial
breakthrough that simultaneously demonstrated both the potential of this technology
and the limitations of mouse models of human disease.
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The generation of Hprt null mice was not achieved by gene targeting and instead
relied on random mutagenesis, either chemical or insertional. While these
approaches demonstrated the feasibility of ES cell genetic manipulation in vitro and
subsequent return to host blastocysts they were unsuitable for the specific
modification of non-selectable genes. It was with this aim in mind that gene
targeting was developed (see Section 1.2.2.3.)
1.2.2.2. Homologous Recombination
Homologous recombination (HR) describes the process of DNA strand breakage and
reunion which occurs between chromosomes within regions of sequence homology.
This process occurs in prokaryotic organisms and in eukaryotic organisms during
meiosis, mitosis and DNA repair (reviewed in Bollag et al, 1989).
HR in mammalian cells can occur between introduced exogenous DNA molecules
(Extra-Chromosomal Recombination, ECR), between homologous sequences within
a chromosome (Intra-Chromosomal Recombination, ICR), between homologous
sequences on sister chromatids (Inter-Chromosomal Recombination) and finally
between an introduced piece ofDNA and a chromosomal sequence (gene targeting).
All of these types of recombination are thought to proceed by similar, but poorly
defined, molecular mechanisms within cells.
Two major models have been proposed to explain homologous recombination. Both
postulate that HR is initiated by the generation of a single strand ofDNA (ssDNA).
The free end of the ssDNA molecule subsequently invades a homologous double
stranded DNA duplex producing a heteroduplex structure. As the donor ssDNA
molecule pairs with the recipient dsDNA sequence a loop of uncut recipient DNA
(D-loop) is displaced from the heteroduplex. The two models differ in the
mechanism by which this structure is resolved. In the Meselson-Radding model of
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Figure 1.1 - The Meselson-Radding Model ofHomologous Recombination
The Meselson-Radding Model of Homologous Recombination.
A) Recombination is initiated by the formation of a single strand nick in one DNA
molecule.
B) At the 3' end of the nick site repair synthesis begins leading to the displacement
of the single strand ofDNA which then invades the other DNA duplex. This
invasion displaces a D-loop in the other homologue.
C) The D-loop is degraded and an asymmetric heteroduplex is created.
D) Ligation produces a Holliday junction that is able to migrate along the DNA
molecules.
E) The Holliday junction can be resolved in two ways firstly, by simply cutting the
crossed strands giving the recombination products shown. Such products are the
result of gene conversion without crossover.
F) In the second alternative, the Holliday junction undergoes isomerisation and then
strand cleavage generating crossover products, also with segments that have
undergone gene conversion.
i iglii c i. i — The Mesehon Ruilding Model oj Homologous Recombination
Figure 1.2 —The Double Strand Break Model ofHomologous Recombination
The Double Strand Break Model of Homologous Recombination.
A) Recombination is initiated by the formation of a double strand break in one DNA
molecule.
B) One single strand DNA molecule from the double strand break site then invades
the duplex of the other homologue leading to the displacement of a D-loop which
is enlarged by repair synthesis. To complete the repair of the double strand break,
repair synthesis is initiated from the second 3' end at the original double strand
break site.
C) Ligation then generates two Holliday junctions, both of which can move via
branch migration. The two Holliday junctions can be resolved in four different
ways.
D) Neither junction undergoes isomerisation and the crossed strands within the
junctions are cut.
E) If the left hand Holliday junction undergoes isomerisation the recombination
products shown in E) are the outcome.
F) If the right hand Holliday junction undergoes isomerisation the recombination
products shown in F) are the outcome.
G) If both the left and right hand Holliday junctions undergo isomerisation the
recombination products shown in G) are the outcome.
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HR the D-loop is degraded creating a free end of ssDNA in the recipient molecule
(Meselson & Radding, 1975). The free ssDNA end in the recipient is then able to
ligate to the remaining free end in the donor molecule forming an exchange structure
called a Holliday Junction (Holliday, 1964) (Figure 1.1). The Double-Strand Break-
Repair Model of homologous recombination also envisages the generation of a D-
loop but rather than this sequence being degraded it acts as a template for repair
synthesis of the donor strand (Orr-Weaver et al, 1981). After repair synthesis is
complete ligation of free ssDNA ends results in the formation of two Holliday
Junctions (Figure 1.2). In both of these models the junction(s) between the two
homologues are able to migrate along the DNA by continued strand transfer within
the crossover(s). Depending on how the Holliday Junctions are resolved several
outcomes are possible, the reciprocal exchange of genetic material (crossover), a non-
reciprocal exchange (gene conversion), or a gene conversion with an associated
crossover (Figure 1.3).
1.2.2.3. Gene Targeting
The term gene targeting is used to describe the introduction of defined modifications
into specific chromosomal loci via HR with exogenous DNA sequences (termed
targeting vectors). The first endogenous gene to be modified by HR with a targeting
vector was the human P-globin gene (Smithies et al, 1985) and the targeted
modification of different loci within other non-ES cell lines has since been reported
by other groups (for example, Adair et al, 1989).
For the same reasons that the endogenous Hprt gene was the target of early
mutagenesis strategies (Section 1.2.2.1), it was also used for the development and
optimisation of gene targeting protocols in ES cells. Subsequently, two groups
reported the disruption of the gene via HR in ES cells (Doetschman et al, 1988;
Thomas & Capecchi, 1987). The application of gene targeting to non-selectable
genes required the development of novel targeting strategies and this work is
summarised in the following sections.
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Figure 1.3 - Types ofRecombination Event
If the two DNA duplexes shown at the top of this figure undergo recombination there
are four types of outcome (one thick black line represents a double stranded DNA
duplex).
A) Reciprocal exchange when there is a straightforward exchange of genetic
material between the DNA duplexes.
B) Gene conversion occurs after a non-reciprocal exchange of genetic material
whereby the genetic information is copied from one duplex to another.
C) Gene conversion with an associated crossover.
D) Non-conservative recombination. As the name implies, when DNA duplexes
undergo this type of recombination event, DNA is lost from opposite ends of the
molecules and the remaining DNA is sufficient only to reconstitute one duplex.











1.2.2.4. Gene Targeting Strategies
1.2.2.4.a. Insertion Type (O-Type) Targeting Strategies
Insertion type targeting strategies have been developed to allow the introduction of
subtle mutations into target genes by a two step approach termed either 'Hit and Run'
(Hasty et al, 1991) or 'In-Out' (Valancius & Smithies, 1991) (Figure 1.4). In the first
stage of this process O-type targeting vectors, linearised within the region of
homology, integrate into the genome via a single crossover event within the region of
homology. This insertion event creates a duplication of the region of homology
within the targeted genomic locus but importantly specific mutations can be
introduced into the targeting vector. In the second stage of this process, reversion,
the duplication of homology is resolved via intra-chromosomal HR. Two outcomes
are possible, the first is that all integrated vector derived sequences are lost and the
locus is restored to wild type. The second is that vector derived homologous
sequences, including any engineered mutations, are retained and a region of
chromosomal sequence is lost.
Interestingly, significantly different targeting and reversion frequencies have been
reported by groups using identical strategies on different loci. For example, when
'Hit and Run' targeting was used to create duplications of homology at both the Hprt
and Hox-2.6 loci, the frequency of reversion was 1000 times greater at the Hox-2.6
locus (Hasty et al, 1991). Hence, while this work demonstrated the feasibility of
insertion type targeting strategies it also highlighted the locus-dependent nature of
both targeting and reversion frequencies.
1.2.2.4.b. Replacement Type (£2-Type) Targeting Strategies
A typical replacement targeting vector consists of two regions ofDNA homologous
to the target locus that are interrupted by a positive selection marker e.g. neomycin
phosphotransferase (neo) or puromycin N-acetyltransferase (pac) (see Section
1.2.2.6). This type of vector is linearised outwith the regions of homology as the aim
is to insert only the selectable marker, not the whole vector, into the chromosome.
The selectable marker can either replace part of the genomic sequence and so
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Figure 1.4 -An Insertion or "In and Out" Gene Targeting Strategy
Insertion type targeting vectors are linearised within the region of homology (hatched
boxes). When such vectors are introduced into cells, a single crossover event
mediated by homologous recombination between the chromosomal target sequence
and the region of the homology, results in the integration of the complete vector into
the target locus. This is referred to as the "in" or "hit" event and generates a
duplication of homology within the target locus. The duplication of homology can be
resolved in two ways.
A) Homologous recombination results in the loss of all targeting vector derived
sequences from the target locus, which is consequently restored to wild type.
B) Homologous recombination results in the excision of some targeting vector
derived sequences but also some chromosomally derived sequences from the
target locus. Crucially, the original region of homology present within the
targeting vector is retained within the target locus and if this had been previously
engineered to contain subtle mutations (*), these will be introduced in the target
locus.
Both ways of resolving the duplication of homology are referred to as either the "out"
or "run" event. The types of selectable markers that can be incorporated into insertion
type targeting vectors are discussed in Section 1.2.2.6.
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introduce a deletion, or insert into the genomic sequence thereby disrupting the target
gene. Both outcomes are therefore designed to disrupt expression of the endogenous
gene (Figure 1.5). This simple replacement strategy can be used successfully to
create null alleles but it cannot be used to introduce subtle non-selectable mutations.
To address this difficulty the basic replacement strategy has been further developed
in the "Double Replacement" (Stacey et al, 1994) or "Tag and Exchange" methods
(Askew et al, 1993) (Figure 1.6).
Both of these methods involve two separate rounds of gene targeting with two
separate vectors, the outcome of which is the introduction of subtle non-selectable
mutations into a target gene. The first step uses a normal £2-type vector with a
positive selectable marker. The resultant clones are screened and any that have
correctly undergone the first round of homologous recombination, are electroporated
with a second vector. This vector replaces the previously introduced selectable
marker in the target locus with sequence containing a non-selectable mutation via a
second round of homologous recombination. The second recombination event is
selected for using negative selection so that only clones which have lost the selective
marker and gained the introduced mutation will survive.
Another variation on this theme is the "Plug and Socket" (Detloff et al 1994) (Figure
1.7). In this system the first round targeting vector introduces one functional and one
crippled positive selection marker into the target locus via HR. The second round
vector carries DNA sequences which undergo HR with the integrated first vector,
resulting in the deletion of the functional positive selection gene, simultaneous
reconstitution of the crippled marker and the introduction of any predetermined
mutations into the target locus. Such clones can then be selected for on the basis of
expression of the crippled marker gene. This system has the advantage that
expression of the crippled marker gene is strictly dependent upon HR, unlike the
double replacement or tag and exchange strategies in which loss of the negative
selectable gene can occur by HR-independent mechanisms. Nevertheless, these
methods do have the advantage of not leaving any marker sequence at the target
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Replacement type targeting vectors are linearised outwith the region of homology
(hatched boxes). When such vectors are introduced into cells, a double crossover
event mediated by homologous recombination between the chromosomal target
sequence and the vector-derived region of the homology, results in the replacement of
part of the target locus with the marker cassette and surrounding vector derived
homologous sequence. This type of replacement targeting strategy is commonly used
to insert selectable marker cassettes within the coding sequence of a target gene
generating a null allele.
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Figure 1.6 - Double Replacement and Tag and Exchange Gene Targeting
Tag and Exchange gene targeting strategies are mediated by two rounds of
replacement gene targeting (see also previous figure). In the "tag" or first
replacement step a standard linearised replacement targeting vector is introduced into
cells. The vector is linearised outwith the region of homology (hatched boxes) and a
double crossover event mediated by homologous recombination between the
chromosomal target sequence and the vector-derived region of the homology, results
in the replacement of part of the target locus with the marker cassette and surrounding
vector derived homologous sequence.
In the second replacement step, or "exchange", another targeting vector is introduced
into cells which are known to have undergone the first replacement step. A double
crossover event mediated by homologous recombination then exchanges the
chromosomal ly integrated marker gene for sequences derived from the second
targeting vector. Importantly, if the second replacement vector was previously
engineered to contain a subtle, non-selectable mutation this will be introduced into the
target locus. The types of selectable markers used Tag and Exchange or Double
Replacement targeting strategies are discussed in more detail in Section 1.2.2.6.
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locus after completion of the second round of targeting whereas after the plug and
socket strategy is complete the reconstituted crippled marker gene is retained.
The types of selectable markers that can be used in these strategies are discussed in
more detail in Section 1.2.2.6.
1.2.2.5. Factors Affecting Homologous Recombination
Gene targeting takes advantage of the fact that HR will occur between introduced
exogenous sequences and endogenous chromosomal sequences within mammalian
cells. The ratio of HR events to random integrations in mammalian cells is about 10"
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(Thomas & Capecchi, 1987) and while the exact molecular details of HR are
unclear several key parameters that affect its efficiency have been defined.
One significant factor is the extent of the homology between the targeting vector and
the chromosomal DNA. In general, the greater the homology the more efficient the
process (Thomas & Capecchi, 1987). Importantly, homologous recombination
efficiency is unaffected by the length of non-homologous sequence introduced, for
example, selectable markers included within the targeting vector (Mansour et al,
1990). When gene targeting was first developed it was thought that the rate limiting
step in the process would be the search by the targeting vector for cognate
homologous sequences within the chromosomal DNA. However, it has been
demonstrated that targeting efficiencies are unaltered by both the number of target
sequences in the genome (Zheng & Wilson, 1990) and the number ofDNA
molecules introduced into each cell (Thomas et al, 1986). Therefore, electroporation
conditions have been optimised to result primarily in single-site, single-copy
insertions of targeting vector DNA (Thomas & Capecchi, 1987). These conditions
dramatically reduce the probability of homologous and non-homologous
recombination events occurring within one cell without reducing the actual frequency
of homologous recombination.
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Figure 1.7- Plug and Socket Gene Targeting
Plug and Socket gene targeting strategies are mediated by two rounds of replacement
gene targeting in a manner analogous to Tag and Exchange targeting. The only
difference between the two types of strategies is the selectable marker used. In the
first replacement step or "plug", a replacement targeting vector, linearised outwith
the region of homology is introduced into cells. A double crossover event mediated
by homologous recombination between the chromosomal target sequence and the
vector-derived region of the homology, results in the replacement of part of the target
locus with vector derived sequences. The vector-derived sequences introduced into
the target locus include a functional positive selectable marker and a crippled
positive selectable marker. It should be noted that a single crossover event and
subsequent branch migration of the Holliday junction could equally well mediate this
type of targeting event.
In the second replacement step, or "socket", another targeting vector is introduced
into cells that are known to have undergone the first replacement step. A double
crossover event mediated by homologous recombination then exchanges the
chromosomally integrated marker gene for sequences derived from the second
targeting vector. This reaction simultaneously deletes the first positive selectable
marker from the target locus and reconstitutes the second positive selectable maker.
Hence, unlike Tag and Exchange the outcome of this type of strategy is the
introduction of a marker cassette into the target locus rather than a subtle non-
selectable mutation.
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The presence ofDNA ends has also been shown to increase the frequency of
recombination (Folger et al, 1982). This effect is concentration dependent, when high
levels of plasmid DNA are introduced into mammalian cells the frequency of insertion
is independent of the physical form of the DNA, supercoiled or linear. However, at
lower DNA levels the frequency of linear plasmid DNA insertion was approximately
40 times greater than for supercoiled (Folger et al, 1982). These observations led to
the hypothesis that linear DNA molecules may be an obligatory reaction intermediate
for recombination to occur between host chromosomes and exogenous DNA hence
linearised targeting vectors are used in gene targeting experiments.
Cell cycle position also alters the ability of a cell to mediate homologous
recombination, a peak of activity has been reported in early S phase (Wong &
Cappechi, 1987). Furthermore, the efficiency of gene targeting is also significantly
affected by the cell cycle rate of an ES cell culture, higher efficiencies are observed in
cultures with shorter mean doubling times (Udy et al, 1997). The effect of
transcriptional activity at the target locus on recombination efficiency is unclear.
Early reports showed that homologous recombination efficiencies were not
significantly different between transcriptionally active and silent loci (Smithies et al,
1985) however contradictory evidence has subsequently been published (Nickoloff&
Reynolds, 1990). Perhaps the major consideration about the transcriptional status of
a target gene should be the type of selection system used, for example a targeting
strategy based on the use of promoter-less selectable cassette can only be applied to
genes that are actively expressed in ES cells (discussed in more depth in Section
1.2.2.6.d).
1.2.2.6. Introducing Exogenous DNA into ES cells and Identifying
Recombinants
In order for recombination to occur between an exogenous DNA molecule and a
chromosomal target it is first necessary to introduce the DNA into ES cells. As
discussed above electroporation has become the method of choice. However,
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because of the relatively low transfection efficiencies only a minority of cells will
carry the introduced DNA (transformation frequencies of 10"5 to 10"2 have been
reported, reviewed in Mansour, 1990). Therefore, it is necessary to select the
successfully transfected cells, usually by the acquisition of a novel drug resistance,
via the introduction of appropriate expression cassettes included in the targeting
construct. The strategies used to select transfected cells can be grouped into three
types, positive selection, positive/negative selection (PNS) and the use of promoter-
less selectable genes. The relative advantages and limitations of all of these
approaches are discussed below.
1.2.2.6.a. Positive Selection
All cells that acquire a positive selectable drug resistance gene should survive
exposure to the corresponding drug at an appropriate concentration. Examples of this
type of system include the bacterial neomycin phosphotransferase gene (neo) which
confers resistance to the neomycin analogue G418 (Southern & Berg, 1982), the
hygromycin phosphotransferase (hyg) and puromycin N-acetyltransferase (pac)
genes which confer resistance to hygromycin B (Te Riele et al, 1990) and puromycin
(Vara et al, 1985) respectively.
The electroporation of a targeting vector into a population of cells will result in the
uptake and integration of that DNA molecule into the genome of a proportion of
those cells. If one of the above positive selection markers was included in the
introduced targeting vector then the exposure of the cell population to the
corresponding drug will select for cells which have acquired the novel drug
resistance. However, the introduced DNA may be incorporated into the cell genome
in two ways. Firstly and most frequently, via random integration or secondly, via
homologous recombination. This simple positive selection strategy is unable to
distinguish between these two alternatives and has been superseded by the more
sophisticated strategies discussed below.
1.2.2.6.b. Positive/Negative Selection
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Positive/negative selection (PNS) was devised in an attempt to enrich the selected
cell population for those in which HR-mediated rather than random integration
events have occurred.
The PNS strategy relies on the observations that random integration proceeds through
and preserves the ends of incoming, exogenous DNA vectors whereas HR does not
require that the ends of the vector be homologous with the target sequence (Thomas
et al, 1986). Therefore a PNS replacement vector carries an independently expressed
positive selectable marker (Section 1.2.2.6.a) and a negative selectable marker that is
placed within the plasmid backbone, outwith the region of homology used for HR.
Random integration of the PNS vector will preserve the negative selectable marker
and this can be used for counter-selection with an appropriate drug. During HR
however, the negative selectable gene is lost as it is located distal to the region of
homology between vector and target and so is excluded from the crossover event.
The most frequently used negative drug selection marker is the Herpes simplex virus
thymidine kinase gene (HSV-r&) (Mansour et al, 1988) although other genes such as a
diphtheria toxin A (DT-A) have been used successfully (Yagi et al, 1990). The
expression of HSV-tk renders cells sensitive to the nucleoside analogues FIAU
(Borelli et al, 1988) and gancyclovir (Mansour et al, 1988) whereas the DT-A gene
encodes an intrinsically toxic protein (Pappenheimer, 1977).
PNS has been used to target both ES cell expressed and non-expressed genes and has
been reported to yield enrichments, from tenfold to 2,000-fold of HR relative to
random integration events (Thomas & Capecchi, 1990; Mansour et al, 1988),
I.2.2.6.C. Double Replacement/Tag and Exchange Targeting Strategies
The second instance when the presence of a negative selection marker is required is
during 'Double Replacement' or 'Tag and Exchange' targeting strategies (Section
1.2.2.4.b). Both of these methods use two separate rounds of targeting to introduce a
subtle non-selectable mutation into the locus of interest. To achieve this a drug
resistance marker is needed which can be both positively selected for after the first
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round of targeting and negatively selected against after the second round. Two such
selectable markers are the Hprt gene and neo/HSV-tk expression cassette.
Expression of the Hprt gene can be selected for by culturing cells in HAT medium
(Littlefield, 1964). Importantly, selection for the expression of an exogenously
introduced Hprt gene is dependent upon the host cell lacking any endogenous Hprt
enzyme activity. Such ES cell lines are now available, for example the HM-1 ES cell
line (Magin et al, 1992).
HAT medium selection relies on the role of the Hprt enzyme within the cellular
purine metabolism pathway. Cells have two pathways to synthesise
mononucleotides, the first is a salvage pathway in which Hprt operates and the
second is de novo synthesis independent of Hprt status. HAT medium supplies
hypoxanthine as a substrate for the salvage pathway while aminopterin is used to
block the de novo synthesis route. The final component ofHAT medium is
thymidine, this is needed by cells to circumvent the aminopterin-dependent inhibition
of the thymidylate synthase reaction. The outcome of this selection is that all cells
will be unable to synthesise mononucleotides de novo due to aminopterin, but only
those expressing Hprt will be able to take advantage of the supplied hypoxanthine via
the Hprt-dependent salvage pathway.
To select against cells which express Hprt the drug 6-thioguanine (6-tG) is used
(Stutts & Brockman, 1963). This guanine analog is a substrate for the Hprt enzyme
and undergoes a phosphoribosylation reaction to generate 6-thioguanine
monophosphate (6-thioGMP). High levels of 6-thioGMP within cells inhibit the
biosynthesis of guanine nucleotides and this inhibition eventually results in the death
of all cells that express Hprt (Miech et al, 1967).
The neo/HSV-tk expression cassette has also been used successfully in double
replacement targeting strategies (Askew et al, 1993). The HR-mediated integration
of the first round targeting vector is selected for using G418 (Southern & Berg,
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1982). The HR-mediated exchange reaction at the target locus with the incoming
second round vector is predicted to result in the loss of the neo/HSV-tk expression
cassette and loss of the HSV-tk gene can be selected for using FIAU (Borelli et al,
1988) or gancyclovir (Mansour et al, 1988).
1.2.2.6.d. Crippled Selectable Marker Genes
An alternative strategy for the enrichment of HR events is to use a selectable marker
gene in the construct lacking either a functional promoter (Doestchman et al, 1988),
polyadenylation sequence (Schwartzberg et al, 1989) or that requires the trapping of
an enhancer element (Jasin & Berg, 1988). In this type of strategy the expression of
the positive selection marker is HR-dependent as it is unlikely that random
integration will juxtapose appropriate activating sequences adjacent to the crippled
selection cassette.
High targeting efficiencies have been reported with the use of promoter-less or
otherwise crippled selectable genes. For example, the targeted disruption of an
endogenous gene, Hprt, using selection with a promoter-less neo gene has been
demonstrated in ES cells with a targeting frequency of 67% (Doestchman et al,
1988). Interestingly, this targeting frequency was higher than that reported by
Thomas & Capecchi despite the fact that the these authors targeted the same locus
and used an insertion targeting vector containing a larger region of genomic
homology (Thomas & Capecchi, 1988). The use of an enhancerless xanthine
guanine phophoribosyltransferase (gpt) gene has been reported to yield an estimated
100-fold enrichment for targeted integrations without direct selection at the target
locus (Jasin & Berg, 1988). Homologous integrations accounted for 44% of the gpt+
cells. As well as using FIR recombination to insert crippled drug resistance genes
into target loci the technique has also been used to insert histochemically detectable
reporter genes. For example, a promoter-less figeo gene, a fusion of the neo and
LacZ genes (Friedrich & Soriano, 1991) was targeted into the Oct-4 locus
(Mountford et al, 1994). This strategy not only resulted in a very high targeting
efficiency (70-80%) but also placed (3geo expression under the control of the
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endogenous Oct-4 promoter allowing direct visualisation of promoter activity in in
vitro and in vivo (Mountford et al, 1994).
The major consideration about the use of promoter-less or crippled positive selection
marker genes is the expression levels of the target gene within ES cells. A promoter-
less marker gene can only be used for gene targeting if the target gene is actively
expressed in ES cells. The level of target gene expression must also be considered.
For example, if the target gene is more strongly expressed in differentiated
derivatives of the ES cells, the selection procedure may enrich for these at the
expense of the pluripotent population (reviewed in Hooper, 1992).
1.3. Inducible Gene Targeting
The advent of gene targeting has permitted the generation of numerous mouse strains
that carry specifically engineered modifications in a gene of choice, knock-out mice.
The technique has become an established methodology of reverse genetics, i.e. the
determination of gene function by the ablation or modification of target gene
expression in vitro or in vivo (Berg, 1993).
While standard gene targeting strategies have furthered our understanding of the
function of many genes this approach is limited. Amongst the key problems is the
phenomenon of embryonic lethality where target gene function is critical for the
successful completion of the developmental program making it impossible to study
loss of gene function in adult, differentiated tissues. Although embryonic lethality
cannot be overcome with standard gene targeting, novel inducible gene targeting
strategies now under development should allow conditional target gene expression
and provide significant insights into gene function.
The aim of inducible gene targeting is to allow the experimenter to determine both
the time and location at which gene function is ablated or restored. For example,
genes can be switched off in the adult mouse, so circumventing the phenotype of
embryonic lethality. The conditional control of gene expression in a tissue-specific
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manner will also permit a dissection of the often complex phenotypes of knockout
animals so increasing our understanding of the pleiotropic nature of gene function.
For example, the ability to knockout genes in specific somatic tissues will provide a
model system in which to study human somatically acquired genetic diseases such as
cancer. This type of analysis is extremely difficult with standard gene targeting as
both tumour suppressor genes and proto-oncogenes commonly have vital
developmental roles, the absence of which can be incompatible with survival in the
mutant mice. Finally, inducible gene targeting should also provide an in vivo model
system for the study of gene therapy. Just as gene function can be specifically
ablated in the adult mouse, expression could also be restored. This type of study
should provide valuable data about both the feasibility and efficacy of gene therapy in
humans.
The main technologies used to achieve inducible gene targeting are the recombinase-
based Cre/loxP (Abremski et al, 1983) and FLP/frt (Broach & Hicks, 1980) systems
isolated from bacteriophage PI and Saccharomyces cerevisiae respectively and are
reviewed below.
1.3.1. The Flp/frt System : Background
The Flp gene of the 2-pm circle plasmid of Saccharomyces cerevisiae encodes a
conservative site-specific DNA recombinase protein that is involved in the
amplification of that plasmid (Volkert & Broach, 1986). Both Flp and Cre
recombinases (Section 1.3.2.) are members of the integrase family of recombinases,
all of which show a high level of sequence conservation within the catalytic domain
and related catalytic mechanisms (Argos et al, 1986). Flp mediates a recombination
event between two 48bp FRT sites (Meyer-Leon et al, 1984). Each FRT site includes
two inverted 13bp symmetry elements (a and b) surrounding an 8bp core region and a
third 13bp symmetry element (c) present in the direct orientation (Figure 1.8). The
third 13bp symmetry element has been shown to be dispensable for recombination
both in vitro and in vivo (Proteau et al, 1986). Flp molecules
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Figure 1.8 - The FLP Recombinase System
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binds to an FRT site in an ordered fashion; binding to the b element occurs first, then
binding to a and finally to c (Andrews et al, 1987; Beatty & Sadowski, 1988). When
two Flp molecules are bound to symmetry elements a and b, a bend of approximately
60° is introduced into the DNA, binding of a third protein to element c increases the
DNA bend to greater than 144° (Schwartz & Sadowski, 1990). Intermolecular
protein-protein interactions between the individual Flp molecules bring the two
partner FRT sites together to form a synaptic complex (Amin & Sadowski, 1990).
Site-specific cleavage results from a nucleophilic attack by Tyr343 on the
phosphodiester backbone of DNA within the core of the FRT site (Jayaram, 1994).
The Flp-mediated DNA bending is thought to be important in facilitating DNA
strand separation and exchange in the core region (Zhu & Sadowski, 1998).
The Flp recombinase system has been shown to work efficiently in a number of
experimental systems including the mouse. For example, several Flp-transgenic
mouse strains have been developed. These include TgN(hACTB::Flp) in which Flp
expression is driven from the global human (3-actin promoter (Dymecki, 1996),
Wntl::Flp in which Flp expression is directed to the developing nervous system
(Dymecki & Tomasiewicz, 1998) and rPOMC-Flp in which sequences from the rat
pro-opiomelanocortin promoter were used to direct Flp expression to the pituitary
gland (Vooijs et al, 1998). Furthermore, a ligand inducible Flp recombinase has also
been developed allowing temporal as well as spatial control of gene expression
(Logie & Stewart, 1995).
The Flp system has also been used in inducible gene targeting strategies. For
example, the insertion of two FRT sites flanking exon 19 of the mouse
retinoblastoma gene allowed its inducible inactivation in vivo and demonstrated the
tumour-suppressor function of this gene (Vooijs et al, 1998). Flp has also been used
to manipulate FRT-containing transgene arrays in zygotes (Ludwig et al, 1996) and
to engineer large-scale chromosome manipulations in vitro (Aladjem et al, 1997).
1.3.2, The Cre/loxP System : Background
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Cre recombinase (causes recombination) is an enzyme produced by bacteriophage
PL Within the bacteriophage Cre has two roles, firstly to circularise the viral
genome should this fail to be carried out by host cell recombination machinery
(Segev & Cohen, 1981) and secondly, to maintain correct unit copy segregation of
the prophage by resolving any dimeric molecules into monomers prior to cell
division (Austin et al, 1981). Cre does not act randomly throughout the
bacteriophage genome but will only stimulate recombination at specific sequences
encoded within loxP sites Qocus of crossover (X)). A loxP site consists of 34 base
pairs (bp) of DNA arranged in three components, two 13bp inverted repeats
separated by an 8bp non-symmetrical spacer region (Hoess et al, 1982) (Figure 1.9).
DNA footprinting studies have shown that one molecule of Cre binds to one 13bp
repeat, so each complete loxP site is bound by two molecules of recombinase (Hoess
& Abremski, 1984). Intriguingly, both Flp (Section 1.3.1.) and Cre recombinase
have also been shown to bind single-stranded DNA molecules in a sequence specific
manner (Zhu & Sadowski, 1998). The biological significance of these observations
has yet to be determined.
X-ray crystallography techniques have been used to determine the exact
macromolecular structures involved in Cre-mediated recombination (Guo et al,
1997). The reaction proceeds in a sequential manner with double strand exchange
occurring after two rounds of single strand cleavage and re-ligation. The first step in
this recombination event is the binding of two molecules of recombinase to one loxP
site. A recombination synapse is then formed involving two loxP sites and four
associated recombinase molecules. Within this synapse structure the recombinase
molecules form a tetrameric ring around the central active site. The Cre tetramer
holds the loxP sites in a square-planar layout by introducing a sharp bend within the
8 bp spacer region. In this conformational state the two spacer regions, the sites of
cleavage and strand re-ligation during recombination, protrude into the active site.
During the formation of the synapse a tyrosine residue conserved in all integrase
family members (position 324 in Cre) from one of each pair of recombinases attacks
the DNA substrate. This nucleophilic attack leads to the formation of a covalent
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Figure 1.9 - The Cre/LoxP System






























phosphotyrosine bond between one half of the loxP site and one molecule of Cre.
Two free 5' ends of single stranded DNA are also formed as a result of this reaction.
The free 5'ends ofDNA then act as nucleophiles and attack the phosphotyrosine
intermediates generated above. Importantly, the free end ofDNA from one loxP site
attacks the phosphotyrosine intermediate of the second loxP site, leading to strand
exchange within a four-way Holliday junction structure. The four-way synapse is
then resolved by a second round of cleavage and strand exchange reactions
generating recombinant products.
Using the mechanism described above, the Cre/loxP system is able to carry out two
types of recombination event depending on the relative orientation of the two loxP
sites (Figure 1.9). As the two inverted repeats within a loxP site are pallindromic it is
the nonsymmetrical 8bp spacer that confers directionality. When the spacer regions
of two loxP sites are directly repeated any intervening DNA (described as floxed)
will be excised, whereas inversion will occur when the loxP sites are in opposite
orientations. Interestingly, when the asymmetry of loxP sites is destroyed and
symmetrical sites are constructed both excision and inversion recombination products
result with equal frequency (Hoess et al, 1986).
The exciting potential of the Cre/loxP system became apparent when it was shown
that the enzyme will catalyse recombination in the absence of ATP, co-factors or
topoisomerase activity (Abremski & Hoess, 1984). Most importantly, the system
will also function in eukaryotic cells (Sauer, 1987; Sauer & Henderson, 1988). These
observations have subsequently been extended in vivo using transgenic mice and it
was this work which first demonstrated the potential application of this system to
conditional gene targeting (Orban et al, 1992; Lakso et al, 1992).
1.3.3. Applications of the Cre/loxP System: Inducible Gene Targeting
To achieve conditional gene expression using Cre/loxP technology there are two
basic requirements. The first is the ability to regulate the expression of Cre
recombinase and the second is the generation of a floxed target gene.
yl-
Regulated expression of Cre can be achieved by several methods, the use of inducible
or tissue specific promoters to drive the expression of Cre or viral delivery systems.
All of these approaches have been demonstrated successfully in vivo and in vitro and
are reviewed in the subsequent sections.
The generation of floxed target genes can also be achieved in a multitude of ways
depending on the desired outcome of recombination, either target gene activation or
inactivation. The types of strategy used can be grouped by the nature of the
recombination event they are engineered to produce, either insertion or excision. All
approaches designed to confer conditional gene expression are also reviewed in the
subsequent sections.
1.3.3.1. Regulating the Activity of Cre Recombinase
1.3.3.l.a. Tissue-specific Promoters
In order to achieve the conditional expression of a target gene within any given tissue
of a transgenic mouse it is first necessary to be able to express Cre specifically within
that tissue. With this aim in mind a variety of transgenic mice which express Cre
from different tissue-specific promoters have been generated.
Adipose tissue-specific expression has been achieved by coupling Cre expression to
the adipose protein 2 (aP2) gene regulatory element in transgenic mice (Barlow et al,
1997). Other somatic tissues to which Cre expression has been targeted include the
mammary gland (Wagner et al, 1997; Selbert et al, 1998), basal cells of the skin
(Tarutani et al, 1997), the heart (Agah et al, 1997), the forebrain (Tsien et al, 1996a),
thymocytes (Orban et al, 1992), the kidney (Nelson et al, 1998), the pancreas (Ray et
al, 1998) and the eye (Lakso et al, 1992).
Cre expression has also been targeted to the female germ line by placing it under the
control of zona pellucida 3 (Zp3) gene regulatory elements (Lewandoski et al, 1997).
The Zp3 promoter is normally only active in the oocyte prior to the first meiotic
52
division and as such Zp3-Cre transgenic animals do not show any expression of ere
in somatic tissues. Likewise, expression of Cre recombinase has been targeted to the
male germline using the mouse protamine 1 promoter (Prml) (O'Gorman et al,
1997). The Prml promoter allows expression of Cre recombinase within the testis
although some degree of ectopic expression was seen in all Prml-Cre founder
animals. The Synaptonemal Complex Protein 1 (Sycpl) promoter has also been used
to generate testicular-specific expression of Cre recombinase (Vidal et al, 1998).
As well as the ability to express Cre in germ cells, expression has also be targeted to
the earliest stages of embryogenesis using the adenovirus Ella promoter (Lakso et al,
1996), the nestin promoter in the balancer strain (Betz et al, 1996) and the c-kit
promoter (Bergqvist et al, 1998). Interestingly, the c-kit-Cre mice display
homogenous chimerism in tissues of the same individual but varied between different
individual offspring (Bergqvist et al, 1998). Recent publications have reported
expression of Cre recombinase in a tissue-specific manner during embryogenesis, to
areas such as the embryonic midbrain-hindbrain constriction region using the
Engrailed-2 promoter (Zinyk et al, 1998) and the developing neural tube using
regulatory sequences from the Wntl gene (Danielian et al, 1998).
Not all attempts at achieving tissue-specific expression of Cre recombinase are
successful however. For example, a transgenic mouse strain engineered to express
Cre under the control of the platelet endothelial cell adhesion molecule-1 promoter
(PECAM-1) was predicted to express Cre only in endothelial cells (Terry et al,
1997). However when the PECAM-l/Cre mouse was crossed to a floxed mouse, the
progeny were seen to have undergone recombination in all tissues. The conclusion
from this work is that if the promoter is even briefly active during an early stage of
development this can be sufficient to induce floxing in a non-tissue-specific manner.
Other groups have also reported this problem, for example, the balancer strain
described above was originally predicted to give central nervous system specific
expression (Betz et al, 1996).
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1.3.3.1.b. Cre Fusion Proteins
Several groups have demonstrated that the activity of cre recombinase can be
controlled in vivo by generating fusion proteins between Cre and the ligand binding
domains (LBD's) of various steroid receptors. In the absence of ligand the LBD
suppresses recombination by a mechanism thought to involve steric hindrance
through its association with members of the heat shock protein (HSP) family (Picard
et al, 1990). Upon the addition of ligand the HSPs are displaced and the ligand binds
the LBD. This binding then removes the steric constraints on Cre and the enzyme is
once more able to catalyse recombination.
A number of different Cre-LBD fusions have been reported to date. For example,
Cre fused to the LBD of the glucocorticoid receptor will respond to the steroids
dexamethasone, aldosterone and the synthetic steroid RU486 (Dias et al, 1998). As
this Cre fusion would respond to endogenous steroids in an in vivo setting it can only
be used in cultured cells. However a mutant form of the LBD which is only activated
in response to the synthetic inducers such as RU486 has been used to create a Cre
fusion protein more suitable for use in vivo (Kellendonk et al, 1996; Brocard et al,
1999). Several groups have reported the generation of Cre fusion proteins with a
mutated oestrogen receptor LBD of either mouse (Zhang et al, 1996) or human origin
(Schwenk et al, 1998; Feil et al, 1997; Feil et al, 1996; Brocard et al, 1997). The
mutated LBD in all of these constructs renders Cre activity dependent upon the
addition of the synthetic inducer tamoxifen rather than upon endogenous oestrogens.
The technology of inducible promoters has now been combined with tissue-specific
promoters to permit simultaneous spatial and temporal regulation of Cre expression
(Kellendonk et al, 1999).
1.3.3.I.e. Inducible Promoters
The use of inducible promoters permits temporal control over Cre expression but not
usually tissue-specificity as global promoter activity occurs following induction. To
date, there have only been two published reports of Cre expression being regulated
via an inducible promoter. One group has generated a strain of transgenic mice
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which express a tetracycline regulated Cre. In these animals Cre will be expressed
only in the absence of tetracycline and expression can be abolished by the addition of
tetracycline (St-Onge et al, 1996). A second group has generated transgenic mice
expressing Cre under the control of the interferon alpha or 6 inducible promoter Mx-
1 (Kuhn et al, 1995). Cre expression can be induced in these animals by
intraperitoneal injection of interferon a or 6 or the synthetic inducer pI-pC although
there are variations in the efficiency of induction between different tissues.
1.3.3.1.d. Global Promoters
The technologies discussed above have focussed on methods to regulate Cre activity
to specific timepoints or tissues, however, not all Cre transgenic strains are
developed with this aim in mind. Several groups have developed strains of mice in
which global promoters drive Cre expression from the earliest stages of development.
For example, a hybrid control element containing the immediate early enhancer of
the cytomegalovirus and the chicken B-actin promoter (CAG) directed Cre
recombinase expression constitutively throughout development (Sakai & Miyazaki,
1997). As well as virally derived enhancer sequences viral promoters have also been
used in the generation of Cre transgenics. The deleter strain produced in Rajewskys
laboratory expresses Cre from a human cytomegalovirus minimal promoter in all
tissues of the mouse (Schwenk et al, 1995). These authors suggest that such strains
should serve as a useful tool for the introduction of prescribed genetic modifications
into the mouse embryo at the zygote stage. Furthermore, the ability to express Cre in
all tissues of the developing embryo should permit a comparison of the null
phenotype with that arising from the recombined floxed allele engineered as part of
an conditional gene inactivation targeting strategy.
1.3.3.1.e. Viral Delivery
Three groups first reported the development of recombinant adenoviruses which
express Cre recombinase, AdCre (Anton & Gramham, 1995; Sakai et al, 1995;
Kanegae et al, 1995), although similar technologies have been now been developed
by other groups. All of these groups used the same basic strategy, in which sections
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of the wild type virus genome, such as sequences encoding the El and E3 genes are
replaced with a Cre expression construct. Such recombinant viruses are replication
deficient but still capable of host cell infection. AdCre has several other advantages,
the viruses can be generated at high titres (109-10n pfu/ml), they can infect dividing
and non-dividing cells and they integrate only very rarely into the genomes of
eukaryotic cells. As these viruses are non-replicating they will persist briefly as
extrachromosomal molecules but will eventually be lost from dividing cells hence
they offer only transient gene expression. However, as Cre recombinase is only
needed to cause recombination its continued presence in a cell is unnecessary.
Since the development of AdCre it has been used successfully by many groups. As
cultured cells can be exposed directly to the virus very high efficiencies of infection
can be achieved, more so than with standard transient transfection techniques. For
example, infection of CV1 cell lines with AdCre resulted in recombination mediated
gene activation in up to 100% of cells (Kanegae et al, 1995). AdCre technology has
also been used successfully in vivo. The commonest method of introducing AdCre
into mice is by intravenous injection (IV) but this route does not lead to uniform
infection of somatic tissues. When transgenic mice which contain a recombination
reporter construct were infected with AdCre via IV injection high levels of
recombination were seen in the liver and spleen but lower levels of recombination
were detected in the kidney, heart and lung with trace levels found in the brain
(Wang et al, 1996). However, the fact that the liver is the major site of infection in
animals injected intravenously with Cre has been used to their advantage by several
groups. For example, Cre-mediated liver specific activation of a Hepatitis C virus
transgene was used to investigate the immune responses and pathogenesis of HCV
infection (Wakita et al, 1998). Cre-mediated gene deletion specifically in the liver
has also been reported using this method of infection (Rohlmann et al, 1998) but
because of the low levels of infection described in tissues other than the liver this
method is not strictly tissue specific. One way around this would be the development
of a recombinant adenovirus that expressed Cre under the control of a liver specific
promoter. A related development was recently reported, a recombinant adenovirus in
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expression is driven from the a-fetoprotein (AFP) promoter (Sato et al, 1998).
While this adenovirus is able to infect the normal range of cell types, Cre is only
expressed in cells that also express the carcinoembryonic antigen, a-fetoprotein.
Intravenous injection is not the only way to introduce adenovirus in vivo. Because
adenovirus will not diffuse far away from the site of injection it can be introduced
into tissues directly, for example into the colorectum (Shibata et al, 1997), the heart
(Agah et al, 1997) or by stereotaxic injection into the brain (Wang et al, 1996).
Despite all of the advantages of the AdCre system described above, it is not without
its problems. In vitro, high doses of replication deficient adenoviruses can result in
cytopathology and even cell death. In vivo, exposure of mice to adenovirus can
initiate an inflammatory response, for example in the liver a lymphocytic infiltration
characteristic of adenoviral infection (Yang et al, 1994). There is also evidence that
cells infected by adenovirus can be eliminated by the immune system. For example,
immunisation of mice with a recombinant LacZ expressing adenovirus elicited a
cytotoxic T lymphocyte (CTL) response against both viral antigens and the transgene
product, (3-galactosidase (Yang et al, 1996). More recent evidence indicates that
provided the mice are tolerant of the adenovirus-encoded transgene product
persistence of expression can be achieved (Michou et al, 1997). However, as the
Cre/LoxP system requires only transient expression to induce a heritable genetic
change in the host cell not all cells which have undergone recombination will retain
the non-replicating adenovirus and so should escape destruction by the host immune
system.
Because of the potential side effects of AdCre discussed above it is important that
appropriate controls are included during the analysis of phenotypes resulting from
AdCre-mediated gene rearrangements.
As well as recombinant adenoviridae genetically engineered to express Cre
recombinase other types of viruses have also been modified with this aim in mind. A
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recombinant Cre-expressing retrovirus has been reported (Choulika et al, 1996) and
focal delivery of the Herpes Simplex virus-Cre (HSV-Cre) into the dorsal
hippocampus resulted in successful transgene recombination and detectable
phenotypic alterations in vivo (Brooks et al, 1997). Such HSV amplicon vector
technology can also be coupled with tissue specific promoters allowing even greater
control of expression localisation than with focal delivery alone (Kaplitt et al, 1994).
1.3.3.1.f. Other Cre Delivery Systems
While the most frequently used methods of introducing Cre, in vitro or in vivo, have
been discussed in the preceding sections several other methods have been used
successfully by various research groups and are worthy of a brief mention. Standard
gene targeting techniques were used to insert the human PrP coding sequence into the
PrP locus in the mouse. Transient expression of Cre then resulted in the excision of
the selectable marker cassette and the replacement of the endogenous gene with the
human coding sequence, creating a "knock-in" mouse (Kitamoto et al, 1996).
Transient Cre expression was achieved by the microinjection of a circular Cre
encoding plasmid into pronuclei. These Cre-treated pronuclei were then transferred
into pseudopregnant female mice and the progeny screened for the Cre-mediated
recombination event at the target locus.
In a similar approach, targeted ES cells have also been treated directly with Cre
recombinase. Several groups have reported the successful introduction of Cre into
ES cells by electroporation with supercoiled Cre encoding plasmids (Zou et al, 1994;
Gu et al, 1993; Li et al, 1996) and also calcium phosphate/DNA co-precipitation
(Gagneten et al, 1997).
1.3.3.2. Inducible Control of Gene Expression Using the Cre/loxP System
Having achieved regulated Cre expression the next step is the generation of the
floxed substrate. Because the Cre/loxP system is able to catalyse three types of
recombination event, namely, excisive recombination, site-specific insertion and
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inversion several different strategies have been developed to allow conditional gene
expression.
1.3.3.2.a. Site-specific Insertion
The presence of a single loxP site within a chromsome will act as a target for
insertional recombination with any introduced exogenous DNA constructs that also
contain a single loxP site. The target loxP site can be introduced via gene targeting
into a specific location or positioned at random within the genome by illegitimate
recombination. Whichever method is used the site of the target loxP site remains
fixed such that any subsequent insertional recombination events will occur at this
predetermined locus. This strategy of site-specific integration has been successfully
demonstrated using loxP-/£ (Sauer & Henderson, 1990) and loxP-neo constructs as
well as a loxP-/acZ marker gene used to analyse the scale of position effect on
marker gene expression (Fukushige & Sauer, 1992).
Because this technology provides a way to reproducibly insert exogenous DNA into
defined chromosomal locations it has allowed significant advances to be made in the
study of cA-acting control elements that regulate gene expression in relation to
chromosomal context. For example, Cre-mediated site-specific insertion was used to
gain insights into the poorly defined mechanism of action of the Locus Control
Region (LCR) enhancer present within the human (3-globin locus (Bouhassira et al,
1997). The ability to reproducibly insert expression constructs into a defined
chromosomal location allowed the first rigorous assessment of transcriptional
regulation by subdomains of the LCR demonstrating that these enhancer sequences
act to increase both the probability of gene expression and the rate of transcription
(Bouhassira et al, 1997).
The relative importance of chromosomal context and endogenous promoter activity
can be separated with this approach circumventing the problem of position effect and
allowing a more meaningful analysis of promoter activity. A construct which
included the minimal human p53 promoter and the chloramphenicol
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acteyltransferase (CAT) gene was co-transfected with a Cre-expression vector into
mouse NIH 3T3 cells (Bethke & Sauer, 1997). Clones that represented single copy,
stable integration events were selected and the levels of CAT expression were
assayed in response to various genotoxic insults. The Cre-mediated site-specific
insertion of the expression construct permitted a position effect-independent
demonstration of strong p53 promoter induction after mitomycin C exposure (Bethke
& Sauer, 1997).
1.3.3.2.b. Site-specific Excisional Recombination of Exogenous DNA Sequences
The ability of Cre to mediate excisive recombination of exogenous DNA sequences
has been used by many groups to achieve conditional gene expression all of whom
used the same basic strategy. The target gene is placed under the control of a given
promoter but the insertion of a floxed inactivating cassette between the transgene
promoter and downstream coding sequence confers Cre-mediated control of
expression. In the absence of Cre transgene expression is blocked by the presence of
the inactivating cassette. After expression of Cre the floxed cassette is lost and
transgene expression activated (reviewed in depth in Section 2.2).
I.3.3.2.C. Site-specific Excisional Recombination of Endogenous DNA
Sequences
This type of strategy has been applied to achieve inducible inactivation of gene
expression, for example, temporal specific or tissue-specific knockouts in vitro and
in vivo. Whatever the target gene the basic approach is the same, the introduction of
two directly repeated loxP sites into the gene of interest and then regulated
expression of Cre recombinase.
To date, recombination-dependent gene inactivation has been demonstrated in vivo
by several groups but varying degrees of success have been reported in obtaining
mutant mice with relevant phenotypes. The mice reported so far range from having
no observable phenotype to one of embryonic lethality. For example, the DNA
polymerase (3 gene has been conditionally inactivated in T-cells (Gu et al, 1994) and
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also in a temporally specific manner (Kuhn et al, 1995) but both of these conditional
knockouts had no obvious phenotype. At the other end of the scale, mice
homozygous for a floxed allele of the mitochondrial transcription factor A (TFAM)
gene die prior to day E10.5 (Larsson et al, 1998). All of this work serves to highlight
the fact that while Cre/loxP technology can offer a way to circumvent the problem of
embryonic lethality both the target gene and the Cre recombinase delivery strategy
must be chosen carefully. For example, in the TFAM experiments Cre expression
was driven from the P-actin promoter so directing expression to the preimplantation
embryo. As a result the floxed animals underwent recombination at an early stage in
development making them little different from constitutively null animals which
could have been generated using standard gene targeting techniques.
Despite these problems other groups have been more fortunate in both their choice of
target gene and Cre delivery strategy. For example, Taruntani et al, used an
inducible gene targeting strategy to construct a conditional allele of the murine X-
linked Phosphatidylinositolglycan class A (Pig-a) gene (Tarutani et al, 1997).
Somatically acquired mutation(s) in the PIG-A gene in humans are responsible for
Paroxsymal Nocturnal Haemoglobinuria (Rosse & Ware, 1995) and Pig-A null ES
cells are incapable of making a significant contribution to chimaeras thereby
precluding the generation of a Pig-A knockout mouse (Takeda & Kinoshita, 1995).
To create a conditional allele of the Pig-A gene two directly repeated loxP sites were
inserted on either side of exon 6. The floxed mice were then mated with a second
transgenic strain that expressed Cre recombinase under the control of the skin-
specific keratin 5 promoter (Taruntani et al, 1997). Cre-mediated inactivation of the
Pig-A gene in hemizygous floxed male animals resulted in death 1-3 days after birth,
however lethality was not observed in the floxed female mice. Both sexes displayed
altered skin characteristics relative to wild type including, scaly and wrinkly skin
with a reduced lipid component. The application of this inducible gene targeting
strategy to the Pig-A gene provided insights into gene function that were
unobtainable with standard gene targeting.
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A variety of other genes have also been analysed with this approach. LoxP sites were
targeted into the N-methyl-D-aspartate receptor 1 gene (NMDAR1) and using
forebrain specific expression of Cre the function of this receptor was ablated
specifically in one region of the hippocampus (Tsien et al, 1996b). The Cre/loxP
system also permitted the study of the developmentally important B cell antigen
receptor (BCR) complex (Lam et al, 1997). Complete ablation of the BCR would
lead to a total block in B cell production during early development precluding an
analysis of its function in mature B cells. Using the Cre/loxP system mutant mice
were generated in which BCR function could be specifically abolished in mature B
cells providing the first direct evidence for the role of BCR expression and the
persistence of mature B cells in the peripheral immune system.
This technology has been taken one step further to generate an allelic series of
mutations at one given locus (Meyers et al, 1998). Using one round of standard gene
targeting two FRT sites, for the Flp recombinase (Broach & Hicks, 1980), two loxP
sites and a neo cassette were inserted into the Fgf8 gene generating an Fgf8neo allele.
When these mice were crossed to a strain which expressed Cre from the human (3-
actin promoter excisive recombination resulted in the generation of a null allele,
FgF8A2'3n. Mice with the null allele displayed a defect in gastrulation and hence
embryonic lethality. This deletion phenotype was more severe than that displayed by
mice that carried the Fgf8"e" insertion allele, these animals showed perinatal lethality.
This observation led to the classification of the Fgf8neo insertion allele as
hypomorphic. The third allele that can be derived from the parental Fgf8'ieo was
generated by crossing the mice to a second transgenic strain which express Flp. Flp
mediated excisive recombination leads to the loss of the neo cassette from the Fgf8"e0
allele, two intronic loxP sites are retained but this allele, Fgf8flox is functionally
equivalent to wild type. Finally, the Fgftfox allele can be inactivated by subsequent
expression of Cre giving the fourth possible allele in this allelic series.
Previously, gene targeting technologies have been directed at the creation of null
alleles whereas the paper by Meyers et al, is the first to report the construction of an
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allelic series of mutations all of which can be derived from one targeted progenitor
mouse strain. This type of approach not only increases the productivity of gene
targeting but also permits a more complete analysis of gene function. The ability to
use Flp and Cre recombinases in parallel also increases the complexity of genetic
modifications possible.
Another advantage of the Cre/loxP-based inducible gene targeting relative to
standard targeting techniques is the ability to analyse specific splice variants. For
example, the a6 integrin gene encodes two mRNAs, a6A and a6B generated by
alternative splicing. Conditional gene targeting was used to delete the a6A specific
exon and a mild phenotype of altered cell migration resulted, demonstrating that the
two splice variants are not functionally equivalent (Gimond et al, 1998). The same
exon-specific knockout approach has also been used successfully to investigate the
function of the (31D integrin splice variant (Baudoin et al, 1998).
1.3.3.2.d. Chromosomal Manipulations Using Cre/loxP
The applications of Cre/loxP system are not limited to the manipulation of specific
transgenic loci, the technology can also be applied to chromosome engineering. The
feasibility of using Cre/loxP technology to engineer large-scale chromosomal
manipulations into the eukaryotic genome was first demonstrated in plants (Qin et al,
1994) however this technology was rapidly applied to the mammalian genome.
For example, the human chromosome translocation t(6:9), associated with a specific
subtype of acute myeloid leukaemia was modelled in ES cells using the Cre/loxP
system. Two loxP sites of identical orientation were introduced by standard gene
targeting techniques, one into each target chromosome. Transient expression of Cre
recombinase in doubly targeted ES cell clones resulted in a site-specific reciprocal
exchange of chromosome arms beyond the position of the loxP sites generating a
balanced translocation between non-homologous chromosomes (van Deursen et al,
1995). An identical approach was also used to successfully engineer a t(12; 15)
translocation commonly found in mouse plastocytomas in ES cells (Smith et al,
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1995). As well as translocations the Cre/loxP system has also been used to introduce
deletions into the genomes of ES cells, for example, deletions ranging from 90kb to
3-4cM have been successfully generated on mouse chromosome ll(Ramirez-Solis et
al, 1995).
1.3.4. Historical Perspective
This research project was initiated during the autumn of 1995. At this time the
potential of the Cre and Flp recombinase systems was apparent but very little
groundwork had been done. As the majority of the preliminary characterisation
experiments were carried out in non-mammalian species few research tools were
available. For example, only two Cre transgenic mouse had been published (Lakso et
al, 1992, Orban et al, 1992) and none of the viral delivery methods had even been
developed (Section 1.3.3.1.e). The first use of the Cre/loxP system in an inducible
gene targeting strategy was published in the summer of 1994 (Gu et al, 1994) but it
would be another 15 months before a second mouse was reported (Kuhn et al, 1995).
This indicates that we were in the very early stages of the development of this
technology and highlights the ambitious nature of this PhD project. The central aim
of this project was to apply the Cre/loxP system to design a gene targeting strategy
that would create a mouse with a conditional allele of the tumour suppressor gene
p53 (Section 1.4). In order to achieve this, a novel mechanism of regulating both
exogenous and endogenous gene expression was developed, the technical problems
of Cre delivery were overcome and an inducible gene targeting strategy was designed
and implemented. As there were few, if any, precedents in the literature for this type
of work a significant proportion of the duration of this project was spent
characterising and defining the limitations of the Cre/loxP system.
An introduction to the target gene for this project, murine p53, is given in the
following section (Section 1.4) and the results of work with the Cre/loxP system are
discussed in Chapters 2-5.
1.4. p53
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From its ignominious beginning as a protein that stubbornly bound to SV40 large T
antigen (TAg) (Lane & Crawford 1979), p53 has become the subject of worldwide
research. Despite its initial classification as an oncogene the function of wild type
p53 as a tumour suppressor gene has now been established. The fact that p53 is the
most frequently mutated tumour suppressor gene in all human cancers testifies to its
importance in tumourigenesis (Hollstein et al, 1994). Furthermore, human families
with Li-Fraumeni syndrome have a germ line mutation of the p53 gene and display a
predisposition to cancer (Malkin et al, 1990 and Srivastava et al, 1990) and p53 null
mice generated by gene targeting are highly predisposed to malignancy (Donehower
et al, 1992; Jacks et al, 1994; Purdie et al, 1994).
1.4.1. Genomic Organisation and Transcriptional Regulation of p53
The mouse p53 gene spans 12kb and lies on chromosome 11 (Rotter et al, 1984 and
Czosnek et al, 1984). It consists of 11 exons of which 10 contribute to the translation
product as exon 1 is transcribed but not translated (Bienz et al, 1984).
The promoter region of mouse p53 lies directly upstream of exon 1 and the
regulatory motifs present within it stretch over approximately 300bp of DNA. The
promoter lacks any of the standard consensus sequences commonly found in most
eukaryotic promoters such as CAAT or TATA boxes, but contains sequence elements
characteristic of a TATA-less promoter (Figure 1.10) including an initiator element (-
2 to +5bp) required to position the start-site of transcription in TATA-less promoters
(O'Shea-Greenfield & Smale, 1992). The promoter region of p53 also contains
binding sites for a variety of general transcription factors. These include Spl (-44 to
-50bp) (Bienz-Tadmor et al, 1985 and Dynan 1986), nuclear factor-1, NF-1, (+5 to
+17 bp) (Ginsberg et al, 1990), ETF or an ETF-like factor (+63 to +66bp) (Hale &
Braithwaite, 1995), PF-1 (-64 to -57bp) (Ginsberg et al, 1990) and the basic helix-
loop-helix (bHLH) family of transcription factors (+70 to +75bp) (Ronen et al,
1991). Key members of the bHLH family are the transcription factors c-Myc and
Max, which form a heterodimer and bind at this motif (Reisman et al, 1993) and USF




The Promoter Structure and Genomic Organisation of the Murine
A) Detailed p-53 promoter structure (not to scale).
Dyad symmetry element
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Transcription start site (s Ibp)
The p53 promoter spans 41 Ibp and includes numerous protein binding sites (thick
black lines). Transcription is initiated within the Initiator element (In) (-2 bp +5bp)
(O'Shea-Greenfield & Smale, 1992) as indicated by the red arrow. To the 5' of the In
element lie three protein binding sites, TT-2 (Hale & Braithwaite, 1995), PF-1
(Ginsberg et at, 1990) and Sp-1 (Bienz-Tadmor et at, 1985; Dynan, 1986). A further
three protein binding sites lie downstream of the In, NF-1 (Ginsberg et at, 1990), ETF
(Hale & Braithwaite, 1995) and bllLII (Ronen et at, 1991). The position of the
proposed dyad symmetry element present in the 5 ' region of the p53mRNA is also
indicated (+5-+108bp) (Bicnz et at, 1984).














The promoter region is indicated (blue line) as are the 11 exens (black boxes) and 10
intervening introns (thin black line). The mRNA (red line) and protein products
(green line) expressed from this locus are also shown.
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Rotter, 1993). The protein binding site PF-2 (approx. -195 to -169bp) has also been
demonstrated to be absolutely required for the activity of the murine p53 promoter
although the exact protein involved remains to be identified (Hale & Braithwaite,
1995).
In addition to the protein binding sites described above, murine p53 also contains a
putative stem loop structure within the 5 untranslated region (5'UTR) (Bienz et al,
1984). This region of dyad symmetry is highly conserved among species (Bienz-
Tadmor et al, 1985) and has been postulated to mediate a regulatory interaction
between the p53 protein and its own mRNA (Mosner et al, 1995).
Two intronic regulatory elements have also been described. In the human gene there
is a strong promoter within intron 1 (Reisman et al, 1988) and an intron 1 initiated
transcript is also seen from the mouse gene, but it is in the antisense orientation with
respect to the coding p53 sequence (Knochbin & Lawrence, 1989). The second
intronic regulatory element lies within intron 4 of the mouse p53 gene. p53 cDNA
expression constructs lacking intron 4 showed an approximate 10 fold decrease in
protein expression relative to genomic constructs or cDNAs including intron 4
(Hinds et al, 1989). This finding has since been extended to transgene constructs
within mice (Lozano & Levine, 1991). The exact mechanism of action of this
regulatory element is unclear however recent work has demonstrated the importance
of a specific, but as yet uncharacterised, protein interaction with sequences within
intron 4 (Beenken et al, 1994).
1.4.2. p53 : Functional Domains and Structure
The primary sequence of p53 is highly conserved between species and five domains,
I to V, of the protein display particularly high levels of sequence conservation (Soussi
et al, 1990). Domains I, III, IV and V are all contained in one exon each, respectively
exons 2, 5, 7 and 8, while domain II is encoded by both exons 4 and 5. Domain I is
located within the highly acidic amino terminus of p53 whereas II-V lie within the
central core region of the protein. Various functional elements have been
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Schematic representation of the major functional domains of mouse p53. Black
boxes indicate the relative position of each domain, the functions are indicated at the
right hand side of the diagram. Grey boxes indicate the positions of the five (I-V)
evolutionary conserved domains. Approximate amino acid numbers are shown at the
left hand side of the diagram.
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described within these domains and are discussed in the following sections and
represented in Figure 1.11.
1.4.2.1. p53: The Amino Terminus
The transcriptional activation function of p53 was originally mapped to its acidic
amino terminus (Fields & Jang, 1990) but this domain has since been more precisely
defined as lying within amino acids 1-42 (Unger et al, 1992).
All transcriptional activators act as adaptor molecules, binding to both DNA and
components of the transcription machinery thereby accelerating the association of
such molecules with DNA and increasing the rate of transcriptional initiation.
Consistent with its function as a transcriptional transactivator, p53 has been shown to
bind to several component of the cells transcription machinery. These include, TBP
(Seto et al, 1992) and the human TAF's TAFn32 and TAFn70 (Thut et al, 1995) all
of which are subunits of the general transcription factor TFIID. A p53 protein with
mutations at residues 22 and 23 was unable to interact with TAFn32 and TAFn70 and
was defective in transcriptional activation (Thut et al, 1995). Other proteins that
interact with the amino terminus of p53 include the general transcription factor Sp-1
(Borellini & Glazer, 1993) and p62 subunit of the dual transcription/repair factor,
TFIIH (Xiao et al, 1994). Weak binding has also been detected between p53 and
TFHB in vitro (Liu et al, 1993) although more recent evidence would seem to
indicate that the p53/TFIIB interaction might be indirect (Liu & Berk, 1995).
As well as binding to components of the RNA polymerase II transcription system the
N terminus of p53 has also been shown to bind to TFIIIB (Chesnokov et al, 1996)
and act as a general suppressor of RNA polymerase m transcription (Cairns & White,
1998). Furthermore, the binding site for the Mdm2 protein, a key negative regulator
of p53 activity, has also been mapped to the N-terminal of p53. The biological
significance of these interactions is discussed in more detail in Sections 1.4.5.1,
1.4.5.2. and 1.5.3.2 respectively.
69
1.4.2.2. p53 : The Proline Rich Linker
The existence of a proline rich linker functional domain within the p53 molecule was
first postulated after the observation that Pro-X-X-Pro motifs were present (amino
acids 60-82 in mouse) and such motifs were already known to have functional
implications in other proteins.
The use of deletion mutants demonstrated that the proline-rich linker was dispensable
for the transactivation function of p53 but such mutants had severely compromised
growth suppression activity (Walker & Levine, 1996). An explanation for this
compromised growth suppression activity was provided by the discovery that the
proline rich linker domain is necessary for the induction of p53-dependent apoptosis
(Sakamuro et al, 1997).
Having demonstrated the functional importance of the proline-rich linker domain, the
race was on to understand this function at the molecular level. The Pro-X-X-Pro
motifs in the linker are characteristic of a Src homology 3 domain (SH3) (reviewed in
Pawson, 1995). All known SH3 domains contain at least one Pro-X-X-Pro motif and
all recognise proline-rich sequences, for example, other SH3 domains (Cohen et al,
1995). Therefore, it is reasonable to hypothesise that a cellular SH3 domain-
containing protein must bind to the p53 SH3 domain. One candidate for the cellular
SH3 domain-containing protein is the product of the gas-1 gene. The gas genes
(growth arrest specific) were originally identified by virtue of their increased
expression in nonproliferating, Go, cells (Schneider et al, 1988). gas-1 is a
membrane-associated protein which, when ectopically expressed, blocks Go-S phase
transition in a p53-dependent manner (Del Sal et al, 1995). It has since been shown
that gas-1 regulated growth suppression does not involve the sequence-specific
transactivation function of p53 but is actually mediated by the proline-rich linker
domain of p53 (Ruaro et al, 1997). As gas-1 is an integral membrane protein, the
growth suppression signal could be communicated to intracellular p53 by the
hypothesised p53 SH3 domain binding protein.
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1.4.2.3. p53 : The Core Domain
The central core of p53 encompasses amino acids 100-300 and the evolutionarily
conserved domains II to V lie within this region. The first function to be assigned to
the core domain of p53 was sequence-specific DNA binding (Pavletich et al, 1993).
Once p53 is activated, for example in response to DNA damage, it binds DNA in a
sequence specific manner. p53 recognises and binds to four copies of the consensus
pentamer sequence 5'RRRCA/T 3' arranged in alternating orientations with variable
distance between the two pairs (-> C- X -> where each arrow represents one
pentamer and X represents variable spacing) (El Diery et al, 1992). Consensus
sequences have been identified within the promoters of many cellular genes and the
binding of p53 to these sites stimulates their transcription. Both the mechanism of
transcriptional transactivation (Section 1.4.2.1) and a review of p53 target genes
(Section 1.4.5.1) are included elsewhere in this review.
The functional importance of this sequence specific DNA binding domain had been
indicated by the observation that the vast majority of tumour-associated p53
mutations were clustered within this central core of the gene, particularly in the four
highly conserved domains (Hollstein, 1994). It was only when the co-crystal
structure of p53 bound to its cognate DNA binding site was solved, that the critical
importance of these domains became apparent. Within the DNA-binding element of
p53, which contacts both the major and minor grooves of the DNA, the residues most
frequently mutated in cancer patients make critical contributions to sequence-specific
DNA binding (Cho et al, 1994).
The original work delineating the p53 core domain also demonstrated that p53 was a
zinc metalloprotein (Pavletich et al, 1993). The three dimensional structure of the
DNA binding domain is maintained partly by a tetrahedrally co-ordinated zinc ion.
This interaction is biologically important because if the ion is removed by metal
chelating agents p53 conformation is altered and sequence specific DNA binding
inhibited (Hainaut & Milner, 1993). The presence of the metal ion also confers
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redox status sensitivity upon p53 and this topic is discussed in more detail in Section
1.4.3.4.
Interestingly, the core domain has also been shown to be the site of 3' to 5'
exonuclease activity (Mummenbrauer et al, 1996). However, this exonuclease
activity is specific to the latent form of p53 and the presence of such contrasting
functions, sequence-specific DNA binding and DNA degradation illustrates the high
level of regulation of p53 activity. Finally, the core domain is also a binding site for
a variety of cellular and viral proteins and this will be discussed in Section 1.4.5.4.
1.4.2.4. The Carboxy Terminus of p53
The carboxy terminus of p53 contains can be functionally divided into three
subdomains. A flexible linker connecting the core domain to the carboxy terminus
(amino acids 300-317), a tetramerisation domain (amino acids 317-357) and, at the
extreme end of the carboxy terminal, a small span of highly basic residues (amino
acids 361-387 in the mouse protein).
The tetramerisation domain of p53 allows the protein to self-aggregate and form
dimeric and tetrameric (dimers of dimers) species (Stenger et al, 1992). Truncation
mutants lacking the last 47 amino acids fail to form tetrameric complexes (Milner et
al, 1991). This interaction is biologically relevant as it is the tetrameric form of p53
that binds DNA sequence-specifically with the highest affinity (Hainaut et al, 1994).
The last thirty or so predominantly basic amino acids of p53 make up the extreme
carboxy terminal subdomain. Despite its small size, multiple biological functions
have been assigned to this subdomain. These include the regulation of the p53
activity as extensive data has confirmed that this span of basic amino acids acts as an
autoinhibitory domain (See Section 1.4.3.1.a), and the regulation of the cellular
localisation of p53 (Ostermeyer et al, 1996, and Section 1.4.3.1 .b).
1.4.3. Mechanisms of p53 Activity Regulation
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1.4.3.1. p53 in the Normal Cell
Under normal circumstances, p53 levels within cells are low. This is due to the short
half-life (approximately 15 minutes) of the protein (Kamijo et al, 1998). However,
after DNA damage a rapid accumulation of p53 is observed within cells (Maltzman
& Czyzyk, 1984). This occurs without altering the level of p53 mRNA and
correlates with an increase in protein half-life (reviewed in Kubbutat & Vousden,
1998). The regulatory mechanisms responsible for the variable half-life of p53 are
gradually being elucidated and this data is discussed below.
1.4.3.1.a. Latent p53
When human or mouse p53 is overexpressed as a heterologous protein in bacterial
cells, the purified protein is predominantly in a latent, oligomeric state (Hupp et al,
1992). This protein is correctly folded and is not denatured but has a very low
affinity for sequence specific DNA binding (Hupp & Lane, 1994b). Subsequent
work has demonstrated that these latent p53 molecules are not simply an artefact of
the expression system but do exist within normal cells. Furthermore, these latent
molecules have functions discrete from those of active p53 (Wu et al, 1997). For
example, the latent state-specific 3'-5' exonuclease activity of the p53 core domain
(Mummenbrauer et al, 1996) and the various latent state-specific activities of the C-
terminal domain. These include non-specific DNA binding (Wang et al, 1993), single
strand nucleotide binding and RNA or DNA strand annealing (Oberosler et al, 1993),
strand transfer (Bakalkin et al, 1994) and the recognition of one to three nucleotide
long insertion or deletion mismatches in DNA repair (Lee et al, 1995). The nature of
the latent state-specific activities of p53 has led to the proposal that this form of the
protein may be involved in proofreading and regulating the repair of endogenous
DNA damage (Wu et al, 1997).
The last 30 amino acids of the C-terminal of p53 form an autoinhibitory domain and
are central to the regulation of the latent state. If these residues are deleted, bound by
an antibody or phosphorylated, p53 is strongly stimulated to bind DNA in a sequence
specific manner (Hupp et al, 1992; Halazonetis et al, 1993 and Takenaka et al,
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1995). For example, the naturally occurring splice variant of mouse p53, ASp53, in
which the wild type C-terminal amino acids are deleted (Arai et al, 1986) is
constitutively active for sequence-specific DNA binding but lacks any non-specific
binding activity (Bayle et al, 1995).
Because of the distal location of the C-terminal residues from the core DNA binding
domain, allostery has been proposed as the mechanism of autoinhibition (Hainaut et
al, 1994; Hupp & Lane, 1994b). According to the allosteric theory, in the latent state
p53 is unable to bind DNA in a sequence-specific manner, this conformation is
maintained by intramolecular (or intermolecular between different subunits of a
tetramer) interactions between the C-terminal and other regions of the p53 protein. If
phosphorylation or protein binding disrupts this physical interaction, p53 will be
flipped into an alternative, active, conformation with increased sequence-specific
DNA binding affinity. A large body of evidence exists which supports this
hypothesis. For example, several authors have shown that the binding of synthetic
peptides to the C-terminal of p53 activates sequence-specific DNA binding by p53
(for example, Hupp et al, 1995). Furthermore, using antibodies specific for different
conformational states of p53 it has been demonstrated that different epitopes are
exposed in latent relative to active forms of p53, suggesting the p53 protein may exist
in one of at least three different conformational states of within cells (reviewed in
Milner, 1995).
The existence of multiple conformational states of p53 is thought to account for the
variable half-life observed for the protein. In normal cells, the vast majority of p53 is
in the latent state and as such is subject to protease-mediated degradation. For
example, p53 has recently been demonstrated to be a substrate of the Ca++ dependent
neutral protease, calpain (Pariat et al, 1997). The strongest evidence for a role for
calpain in p53 degradation comes from experiments showing that expression of
calpastatin, a physiological inhibitor of calpain, leads to an elevated p53 level (Pariat
et al, 1997). Interestingly, calpain activity is translocated into the nucleus just prior
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to the onset of DNA synthesis suggesting that calpain-mediated p53 cleavage during
G1 allows cells to enter S phase (Zhang et al, 1997).
Latent p53 is also subject to ubiquitin-dependent proteolysis via the proteasome in an
Mdm-2-dependent regulatory pathway (Haupt et al, 1997; Kubbutat et al, 1997 and
Section 1.4.3.2.)
In conclusion, latent p53 is subject to efficient protease-mediated degradation.
However, when p53 is activated, for example after DNA damage, it undergoes a
conformational change and is less efficiently targeted for protease-mediated
degradation. This results in an increased protein half-life (approximately 75 minutes
after y-irradiation, Kamijo et al, 1998) and higher levels of p53 activity within such
cells. The detailed mechanism of p53 induction and stabilisation and the role of
Mdm2 in regulating p53 activity are discussed in Sections 1.4.4. and 1.4.3.2.
respectively.
1.4.3.1.b. Cellular Compartmentalisation
Cellular compartmentalisation has also been proposed as a mechanism used by cells
to regulate p53 activity. While p53 is usually thought of as a nuclear protein several
groups have reported cytoplasmic p53 in both normal (Takahashi & Suzuki, 1994)
and transformed cells (Moll et al, 1992). Subsequent experiments have provided
tantalising evidence of the biological importance of these observations. For example,
several groups have reported that the subcellular localisation of p53 varies during the
cell cycle, with cytoplasmic sequestration during G1 and nuclear localisation once S
phase has been initiated (Martinez et al, 1991; Takahashi & Suzuki, 1994). Impaired
nuclear entry by p53 has also been implicated as a non-mutational mechanism to
inactivate p53 function during tumourigenesis. In neuroblastoma-derived cell lines
which express wild type p53 no nuclear accumulation is observed after treatment
with DNA damaging agents which correlates with an impaired p53-mediated G1
arrest in these cells (Moll et al, 1996). In addition, mutant forms of p53 have
allowed insights into the regulation of the cellular compartmentalisation of p53. For
75
example, one mutant has been identified that displays a dominant negative nuclear:
cytoplasmic shuttling defect, resulting in nuclear exclusion, sufficient to confer
transforming activity onto the protein (Crook et al, 1998). A temperature sensitive
mutant p53 protein has also been identified, at the permissive temperature the protein
is nuclear and confers G1 arrest on such cells, however when cells are shifted up to
the restrictive temperature p53 becomes cytoplasmic and cell growth resumes
(Gannon & Lane, 1991).
In order to understand the regulation of p53 localisation it has been necessary to
identify other proteins involved. These can be divided into two populations, first,
those that interact directly with p53 and maintain cellular compartmentalisation
including several members of the heat shock protein family (Sephernia et al, 1996;
Dasgupta & Momand, 1997). Second, those proteins that do not interact directly
with p53, but may which may act to regulate p53 cellular compartmentalisation. For
example, bcl-2 is known to inhibit p53-dependent apoptosis (Chiou et al, 1994) and
one possible mechanism for this is bcl-2 mediated nuclear exclusion of p53 (Beham
et al, 1997).
1.4.3.2. Negative Autoregulation by Mdm2
The mdm2 gene was originally identified because of its amplification in transformed
mouse cell lines (Cahilly-Synder et al, 1987). Subsequent studies showed that the
human homologue was also amplified in a significant number of tumours, for
example sarcomas (Oliner et al, 1992). An insight into the underlying oncogenic
mechanism of mdm2 was gained when its relationship with p53 was determined. It
was demonstrated that mdm2 was able to bind p53 both in vitro and in vivo (Barak &
Oren, 1992; Oliner et al, 1992) resulting in an inhibition of sequence specific
transactivation by p53 (Momand et al, 1992; Oliner et al, 1993a). Two mechanisms
have been proposed to explain this observation, first, that the binding of mdm2 to
p53 prevents sequence specific DNA binding by p53 (Zauberman et al, 1993) or
second, that the binding of mdm2 to p53 may prevent the interaction of p53 with
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components of the cellular transcriptional machinery, for example TATA binding
protein associated factors (TAF's) (Lu & Levine, 1995).
However, the most significant mdm2-mediated mechanism for the regulation of p53
activity involves the targeting of p53 for ubiquitin-directed proteolysis (Haupt et al,
1997; Kubbutat et al, 1997). For example, p53 accumulation was observed in a cell
line defective in the ubiquitinisation process (Chowdary et al, 1994). Furthermore, in
double transient transfection assays p53 is only stable in the presence of mdm2
mutants or after the addition of proteosome inhibitors such as MG132 or lactacystin
(Midgeley et al, 1997). Mdm2 may function as a ubiquitin ligase, directly attaching
the ubiquitin molecule to p53 (Honda et al, 1997). Alternatively, recent studies have
demonstrated that mdm2 contains both nuclear localisation and nuclear export
signals, and specific impairment of nuclear export reduces the ability of mdm2 to
target p53 for degradation (Roth et al, 1998).
The observations that mdm2 is both a transcriptional target of p53 (Juven et al, 1993)
and a promoter of p53 degradation led to a model in which p53 and mdm2 form an
autoregulatory negative feedback loop. However, the existence of this feedback loop
means that p53 stabilisation in response to genotoxic or other stress can only be
achieved by interruption of this pathway. This implies a high level of regulation, and
some of the molecular mechanisms involved have only recently been elucidated.
As the mdm2-targeted degradation of p53 relies on the physical interaction of the two
proteins, an obvious way to regulate the pathway is to control this interaction. One
potential method is by the regulation of the phosphorylation status of p53. Indeed
recent data has demonstrated that DNA damage-dependent changes in site-specific
phosphorylation of p53 do modulate the p53/mdm2 interaction (Shieh et al, 1997 and
Section 1.4.3.3.a.).
An alternative mechanism used to regulate the p53/mdm2 interaction involves the
tumour suppressor gene product plQ^. pl9ARF ig expressed from the INK4a locus
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and forced overexpression induces a p53-dependent cell cycle arrest (Quelle et al,
1995). Two groups have reported that pl9ARF interacts with mdm2, an interaction
which promotes the rapid degradation of mdm2 thereby inhibiting mdm2-targeted
degradation of p53 and resulting in p53 stabilisation (Zhang et al, 1998; Pomerantz et
al, 1998). An alternative model has also been suggested in which rather than
promoting the degradation of mdm2, pl9ARF blocks mdm2-mediated nuclear export
of p53 (Kamijo et al, 1998).
The significance of the p53/mdm2 interaction at the biological level in vivo became
apparent when mdm2 knockout mice were generated. Mdm2 null mice die early in
development but this phenotype is fully rescued by the absence of p53 (Montes de
Oca Luna et al, 1995; Jones et al, 1995), suggesting that the mdm2 null mouse dies
because of its inability to down-modulate p53 during development. Conversely, the
generation of mice that overexpressed mdm2 provided the first evidence for a p53-
independent role for mdm2 in tumourigenesis (Jones et al, 1998).
The mdm2 gene can give rise to various transcripts that may differ in their abilities to
interact with p53. The full length mdm2 protein has a predicted size of 52 kDa but
migrates at 90kDa in SDS-PAGE however proteins ranging from 57 to 85 kDa have
been observed in cells which overexpress mdm2 (Olson et al, 1993; Sigalas et al,
1996). The biological significance of these alternative transcripts and the proteins
they encode is unclear as they have not been observed in nontransformed cells,
normal tissues or during embryogenesis (Sigalas et al, 1996; Montes de Oca Luna et
al, 1996). However, an mdm2 homologue MDMX has been identified (Shvarts et al,
1996). MDMX has significant homology to mdm2 particularly in the p53 binding
domain and is able to inhibit the transactivation function of p53. Unlike mdm2
however, MDMX is not induced by DNA damage or by p53.
1.4.3.3. Covalent Modification of p53
The pleiotropic nature of p53 and the potency of its effects require the cell to tightly
regulate p53 activity. Its function is controlled at the levels of transcription,
78
translation, protein turnover, cellular compartmentalisation and association with
other proteins. p53 is also regulated by post-translational modifications including
multi-site phosphorylation and acetylation. The effectors and biological
consequences of these modifications are discussed below.
1.4.3.3.a. Phosphorylation
p53 contains two distinct phosphorylated regions, the amino and carboxy termini
with the amino terminus being the most extensively phosphorylated part of the
molecule (see Figure 1.12).
Three kinase target sites have been identified in the mouse p53 protein, Ser 4, 6 and 9
which are substrates for casein kinase 1 and the CK 1 -like kinase, PK270 (Milne et
al, 1992). Based on sequence homology the phosphorylation of human p53 on Ser 6
and 9 by the same kinases can also be predicted. Another kinase demonstrated to
phosphorylate the N terminus of p53 in vitro is MAP kinase. Two sites have been
identified in the mouse protein, Ser 73 and Thr 83, although no homologous sites
exist in human p53 (Milne et al, 1994). MAP kinase is a member of the MAP kinase
superfamily and another family member JNK1 also phosphorylates p53 in vitro and
in vivo (Milne et al, 1995). JNK1 is an UV radiation-induced protein kinase which
phosphorylates murine p53 at Ser 34 and based on sequence homology human p53 at
Ser 37 (Milne et al, 1995). A second UV inducible kinase known to phosphorylate
p53 at the N terminus is Raf-1 (Jamal & Ziff, 1995). The final p53 N terminus
kinase identified to date is the double-stranded DNA-Dependent Protein Kinase
(DNA-PK). DNA-PK is activated after binding to DNA containing nicks, gaps or
double strand breaks and once activated is able to phosphorylate many regulatory
proteins, including p53. The target sites within p53 have been identified as Ser 15
and 37 in the human protein and Ser 15 in mouse (Lees-Miller et al, 1992).
Three kinase target sites have been identified within the C terminus of p53. Firstly,
casein kinase II (CKII) phosphorylates Ser 392 of human p53 and the equivalent
residue, Ser 386 on the mouse protein (Hupp et al, 1992). This phosphorylation has
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Relative positions of the major phosphorylation sites of murine p53. At the amino
terminal there are seven residues that are targets for protein kinases, including serines
4, 6 and 9 which are substrates of casein kinase 1 (CK1) and the related kinase
PK270, serine 15 which is a substrate for both Rafl and DNA-PK and serine 34, a
substrate for JNK1 and JNK2. There are two residues which can be phosphorylated
by MAPK within the proline rich linker domain, serine 73 and threonine 83. At the
carboxy terminal of p53 serine 309, adjacent to the major nuclear localisation signal
of p53, is a substrate for both CycB/Cdc2 and CycA/CDK2 complexes. Also serines
370 and 372 are substrates for protein kinase C (PKC) and serine 386 is
phosphorylated by casein kinase II (CKII) and is also the site where a 5.8S rRNA
molecule is covalently attached to the p53 protein.
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been implicated in the regulation of p53 transcriptional repression (Hall et al, 1996)
and in p53 induction in response to UV irradiation (Blaydes & Hupp, 1998).
Secondly, Ser 315 in human p53 (Ser 309 in mouse) is the target phosphorylation site
for the cell cycle regulatory kinases cyclin B/Cdc2 and cyclin A/Cdk2 whereas this
same site is only poorly phosphorylated by cyclin D/Cdk4 and cyclin E/Cdk2
complexes (Wang & Prives, 1995). The third kinase known to phosphorylate the
carboxy terminal of p53, Ser 370 and 372, is protein kinase C (PKC) (Baudier et al,
1992).
Despite the large volume of work in this area the effects of p53 phosphorylation in
vivo have proved difficult to define. However, a number of studies have generated
insights into the mechanism of action of phosphorylation and these can be grouped
into several areas. The first way in which phosphorylation has been proposed to act
is by influencing the stability of p53. For example, the DNA damage-dependent
phosphorylation events at Ser 15 and 37 in human p53 are carried out by DNA-PK
(Shieh et al, 1997), a kinase only active in the presence of abnormal DNA structures
(Gottlieb & Jackson, 1993). This phosphorylation event is thought to induce
significant conformational changes in the p53 protein resulting in a decreased
interaction with mdm2 and subsequent p53 stabilisation (Shieh et al, 1997). This
phosphorylation-dependent mechanism is one way in which the mdm2/p53 negative
autoregulatory feedback loop maybe overcome, for example, in response to genotoxic
insult.
The phosphorylation status of p53 is also thought to regulate the DNA binding
activity of the protein. For example, recombinant p53 has a low sequence-specific
DNA binding activity but this can be increased by CK II phosphorylation in vitro
(Hupp et al, 1992). Recombinant p53 can be activated into a DNA binding form by
PKC (Takenaka et al, 1995) and phosphorylation of Ser 315 by cyclin B/Cdc2 or
cyclin A/Cdk2 was found to selectively influence DNA binding capacity (Wang &
Prives, 1995). The effects of phosphorylation on the DNA binding activity of p53
may be due to induced conformational changes. For example, two studies have
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demonstrated that PKC phosphorylation alters the reactivity of p53 to conformational
specific antibodies (Hupp et al, 1994a; Takenaka et al, 1995). These observations
are consistent with the allosteric theory of p53 regulation, phosphorylation within the
C terminus of p53 disrupts the action of the autoinhibitory domain, causing
conformational changes and activating sequence-specific DNA binding.
Furthermore, phosphorylation status also modulates the transactivation activity of
p53. For example, the N terminus of p53 is phosphorylated by Raf-1 and this
potentiates p53-dependent transcriptional transactivation in vivo (Jamal & Ziff,
1995).
When considering the phospho-regulation of protein activity dephosphorylation is
equally as important as phosphorylation. It has been demonstrated that p53 is
specifically dephosphorylated at the PKC site in vitro by phosphatase 2A(PP2A)
(Schiedtmann et al, 1991; Takenaka et al, 1995). Indeed, small t antigen inhibition
of PP2A may be responsible for the increased p53 phosphorylation observed in SV40
transformed cells (Schiedtmann et al, 1991). The discovery that a target gene of p53,
cyclin G interacts with a regulatory subunit of PP2A in a p53 dependent manner
opens up the possibility of a feedback loop to regulate p53 activity involving these
proteins (Okamoto et al, 1996).
Another important dephosphorylation event for human p53 is the ionising radiation
(IR)-induced dephosphorylation of Ser376 (Waterman et al, 1998). The result of this
dephosphorylation is the creation of a consensus binding site for 14-3-3 proteins.
14-3-3 proteins are so-called because of their particular migration pattern on two-
dimensional DEAE-cellulose chromatography and starch gel electrophoresis. Many
diverse functions have been attributed to members of this protein family, including
the mediation of interactions between signal transduction molecules (reviewed in
Aitken, 1996). However, in the case of p53, the binding of 14-3-3 to the C-terminal
activates p53 sequence-specific DNA binding (Waterman et al, 1998).
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In conclusion, when considering the biological effects of phosphorylation it is
important to remember that the in vivo situation will be significantly more complex
than isolated experiments in vitro can show. For example, the p53 molecule could be
subject to multiple phosphorylations and dephosphorylations by several enzymes
simultaneously. The consequences of multiple events could be significantly different
to the effects of each kinase/phosphatase separately. Substantially more work is
needed in this field before a definitive answer about the role of phosphorylation in
regulating p53 stability and activity can be arrived at.
1.4.3.3.b. Other Posttranslational Modifications of p53
p300 and the closely related histone acetyltransferase (HATs) CBP are nuclear
proteins that regulate transcription by acting as co-activators, they are found
complexed with another HAT, PCAF (Yang et al, 1996). Both p300 and CBP have
been shown to bind p53 in vivo (Gu et al 1997; Lill et al, 1997) and recently the
acetylation of p53 in vivo by p300 has been demonstrated (Gu & Roeder, 1997).
Furthermore, the physical association between p53 and p300 is required for
transactivation of p53 target genes (Thomas & White, 1998) and influences the
biological outcome of the p53 response (see Section 1.4.5.6.d.and Lee et al, 1998).
It is now thought that acetylation of p53 may occur as part of a cascade of post¬
translational modifications of the protein induced after genotoxic insult. An early
response to UV or IR exposure is p53 phosphorylation, for example Serl5
phosphorylation by DNA-PK (Shieh et al, 1997). The phosphorylated protein is then
preferentially and site-specifically acetylated, at Lys 382 in response to IR (by p300)
and Lys320 and 382 (by PCAF and p300 respectively) in response to UV (Sakaguchi
et al, 1998). The phosphorylation of Serl5 also promotes the interaction of p53 with,
and acetylation by, CBP (Lambert et al, 1998). One proposed function of acetylation
is to inhibit the latent state-specific, non-sequence-specific DNA binding activity of
p53 and to promote sequence-specific DNA binding (Sakaguchi et al, 1998).
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Finally, p53 is also subject to the covalent attachment of the 5.8S ribosomal RNA via
a phosphodiester bond to Ser 386 (Fontoura et al, 1992 and Figure 1.12) although the
biological significance of this interaction remains unclear.
1.4.3.4. Redox Regulation
In addition to the mechanisms discussed above p53 activity is also regulated by its
redox and metal ion binding status. p53 must be in a reduced state to bind DNA
(Hainaut & Milner, 1993) and have a metal ion, copper or zinc, bound for full DNA
binding activity (Verhaegh et al, 1997; Hainaut et al, 1995).
The molecular machinery that regulates protein redox status is gradually being
elucidated. For example, the protein Ref-1 was known to regulate the redox state of
a number of proteins and has also been independently identified as a potent activator
of latent p53. It is now known that Ref-1, which also functions as a DNA repair
endonuclease, is a key regulator of p53 activity via both redox-dependent and
independent means (Jayaraman et al, 1997).
1.4.4. Induction of p53
In normal cells levels of p53 activity are very low and the protein displays a short
half-life and rapid turnover. However, in cells exposed to a genotoxic insult or
environmental stress, much higher levels of p53 activity are observed with a
concurrent increase in protein half-life, the so-called "p53 response".
Numerous agents have been defined which can lead to the stabilisation of p53, these
include exposure of cells to either ionising radiation (IR) or UV light generates both
of which generate double strand breaks within the DNA, directly or indirectly. The
presence of these dsDNA breaks is critical for the induction of p53 (Nelson &
Kastan, 1994). In addition to its response to genotoxic stress, p53 has also been
proposed to mediate a more general stress response to suboptimal growth conditions.
Heat, starvation and hypoxic conditions induce p53 (Zhan et al, 1993; Graeber et al
1994). Another stimulus for p53 induction is depletion of ribonucleotide
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triphosphates necessary for RNA synthesis the result of which is a reversible G1 cell
cycle arrest in the absence ofDNA damage (Linke et al, 1996). Furthermore, p53
can be induced by specific oncogenes such as adenovirus E1A (Lowe & Ruley, 1993)
or Myc (Hermeking & Eick, 1994).
As these signals all induce high levels of nuclear p53 protein, they serve to
demonstrate the ability of p53 to integrate signals emanating from diverse upstream
stimuli. At least three distinct molecular pathways that result in p53 induction have
been characterised. First, the induction of p53 in response to bulky DNA lesions
such as those caused by UV irradiation. This pathway is thought to be mediated by
the actions of multiple UV inducible kinases and has been recently reviewed
elsewhere (Agarwal et al, 1998).
The second p53 induction pathway responds to DNA double strand breaks caused by
ER exposure. A key molecule in this pathway is the Atm (Ataxia-telangiecstasia
mutated) gene product. Ataxia telangectasia (AT) is a human autosomal recessive
disorder characterised by hypersensitivity to ionising radiation (IR), radioresistant
DNA synthesis, cancer predisposition and progressive cerebellar ataxia (McKinnon,
1987). Cells derived from AT patients exhibit defective or delayed induction of p53
after IR indicating that Atm is required for the optimal transduction of the DNA
damage signal to the p53 protein (Kastan et al, 1992). Further research has revealed
that Atm is a kinase that phosphorylates and activates the nuclear protein c-Abl only
after DNA damage (Baskaran et al, 1997). Phosphorylated c-Abl then binds to p53
enhancing its transcriptional activation function (Goga et al, 1995). Atm does not
signal to p53 via the c-Abl route alone. As already mentioned, dephosphorylation of
the Ser376 residue of human p53 occurs after exposure to IR, this event is Atm-
dependent as it does not occur in cells from patients with AT (Waterman et al, 1998).
The absence of this site-specific dephosphorylation prevents the interaction of p53
with the signal transduction mediator 14-3-3 proteins and may be causally related to
the delayed kinetics of p53 induction seen in AT cells (Kastan et al, 1992).
Furthermore, Atm is also able to signal directly to p53 as human p53 at least, is now
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known to be phosphorylated at Serl5 by Atm in response to IR (Banin et al, 1998;
Canman et al, 1998).
The third pathway results in the induction of p53 in response to oncogene expression
and involves the pl9ARF tumour suppressor protein. Thus, expression of adenovirus
ElA induces pl9ARF accumulation and the ability of El A to bind and inactivate Rb
solely contributes to pl9ARF accumulation (de Stanchina et al, 1998). As already
described in Section 1.4.3.2, an increase in pl9ARF inhibits mdm2-directed
degradation of p53 resulting in p53 stabilisation (Zhang et al, 1998; Pomerantz et al,
1998). Unlike the ElA protein which is thought to induce pl9ARF by inhibiting Rb
(de Stanchina et al, 1998), Myc induced pl9ARF accumulation is thought to proceed
by numerous mechanisms, one of which is a direct induction at the level of gene
expression (Zindy et al, 1998).
Once p53 has become activated characteristic downstream events are initiated. The
mechanism of action of activated p53 and the downstream events that make up the
"p53 response" are discussed in the following sections.
1.4.5. Biological Activities of p53
1.4.5.1. Transcriptional Activation by p53
Muscle-specific creatine kinase (MCK) was the first mammalian gene identified as
being transcriptionally activated by p53 (Weintraub et al, 1991). Subsequent work
characterising MCK 5' regulatory sequences showed the presence of two p53 binding
sequences (Kern et al, 1991). Since this initial discovery many more transcriptional
targets of p53 have been identified.
The p21 gene (El-Diery et al, 1993; Harper et al, 1993; Xiong et al, 1993b) is
probably the most well studied p53 response gene. p21 is a member of the Cip/Kip
family of cyclin-CDK inhibitors. This protein forms part of a quaternary complex
with cyclin/CDKs and PCNA (Xiong et al, 1993b) and at high concentrations is able
to inhibit the function of CDKs, particularly those active during G1 (Harper et al,
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1993). p21 is not the only component of the cell cycle machinery that is a target gene
of p53, others include cyclin D1 (Chen et al, 1995), cyclin G (Okamoto & Beach,
1994), PCNA (Morris et al, 1996) and Rb (Osifchin et al, 1994).
Several other p53 target genes which play a role in mediating G1 arrest have
subsequently been identified for example, GADD45 (Kastan et al, 1992; Lu and Lane
et al, 1993) and Insulin-like growth factor binding protein 3 (IGF-BP3) (Buckbinder
et al, 1996). GADD45 is thought to act by binding to the replication and repair factor
PCNA, an interaction which may inhibit entry of the cell into S phase (Smith et al,
1994). IGF-BP3 is induced after DNA damage and encodes a secreted protein that
binds IGF, a mitogenic growth factor. IGF signalling is inhibited by binding to IGF-
BP3 so this antimitogenic action provides another pathway by which p53 can
suppress growth. A novel member of this pro-Gl arrest class of p53 target genes has
recently been identified as Siah, the human homologue of the D. melanogaster gene
seven in absentia (Matsuzawa et al, 1998). p53-dependent Siah expression promotes
G1 arrest and cells in which Siah activity is inhibited display a significant reduction
in p53-induced growth arrest (Matsuzawa et al, 1998).
As well as inducing the transcription of genes involved in G1 arrest p53 also
transactivates pro-apoptotic genes. For example, bax, a member of the bcl-2 family,
is upregulated by p53 (Miyashita & Reed, 1995). While the proto-oncogene bcl-2
promotes cell survival and is anti-apoptotic, the bax gene product has an opposing
pro-apoptotic effect (for review see White, 1996). The Fas/APO-1 gene, which
encodes a cell surface receptor capable of transmitting an apoptotic signal upon
ligand binding, is also a candidate p53 response gene. Fas expression can be
increased by wild type p53 (Owen-Schaub et al, 1995) in vitro, and this correlation
has also been observed in vivo (Reinke & Lozano, 1997). Another aptly named pro-
apoptotic gene that is transcriptionally upregulated by p53 is KILLER/DR5 (Wu et
al, 1997).
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Recent work looking at gene induction occurring before the onset of outward
morphological changes characteristic of apoptosis has described a whole new class of
p53 inducible genes, PIG's (Polyak et al, 1997). Two of the fourteen PIG genes had
already been identified as p53 response genes, p21 (see above) and Ei24 (Lehar et al,
1996) however the remaining 12 were newly identified p53 targets. Many of these
genes were related to or encoded known proteins which could generate or respond to
oxidative stress, for example PIG3 is a novel gene the closest relative of which is
NADPH-quinone oxidoreductase (Rao et al, 1992). As NADPH-quinone
oxidoreductase is a potent generator of reactive oxygen species (ROS) and ROS in
turn are powerful inducers of apoptosis (Kroemer et al, 1997) the hypothesis has
been put forward that p53-dependent apoptosis could be due to ROS production by
PIG's.
A novel class of p53 target genes involved in neither G1 arrest or apoptosis are those
that play a role in the control of angiogenesis. As normal cells progress toward
malignancy they must switch to an angiogenic phenotype to attract the
neovascularisation necessary for increased growth. The gain of an angiogenic
phenotype is usually accompanied by loss of p53 function and in agreement with this
two inhibitors of angiogenesis, thrombospondin-1 (Dameron et al, 1994) and BAI1
(Nishimori et al, 1997) have been identified as p53 target genes.
As well as the p53 target genes discussed so far, many more have been identified.
These include Wig-1 (Varmeh-Ziaie et al, 1997), RGS-14 (Buckbinder et al, 1997),
p22/PRGl (Schafer et al, 1998), EGFR (Ludes-Meyer et al, 1996), FAC (Liebetrau et
al, 1997), TGFa (Shin et al, 1995) and matrix metalloproteinase 2 (Bian & Sun,
1997). The list of p53 target genes has recently been dramatically expanded using a
computer based approach to search sequence databases, 55 new p53 target genes
were identified (Bourdon et al, 1997).
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It is noteworthy that p53 also transactivates transcription of its own gene (Deffie et
al, 1993) as well as that of its negative regulator, mdm2 (Juven et al, 1993) allowing
tight control of intracellular p53 levels.
1.4.5.2. Transcriptional Repression by p53
The ability of wild type p53 to repress transcription is less well documented than the
transactivation function of p53 although several authors have reported transcriptional
repression of specific cellular genes. For example, c-fos (Ginsberg et al, 1991),
interleukins 2, 4 and 6 (Pesch et al, 1996; Santhanam et al, 1991), PCNA (Mercer et
al, 1991), MAP4 (Murphy et al, 1996) cyclin A (Yamamoto et al, 1994), the multi¬
drug resistance gene (MDR1) (Chin et al, 1992), the multidrug resistance-associated
protein (MRP) gene (Wang & Beck, 1998) and the Werner's syndrome gene, (WRN)
(Yamabe et al, 1998). The mechanism used by p53 to achieve this transcriptional
repression is still the subject of research. It was originally proposed that p53
repressed transcription from promoters lacking a p53 response element and
containing a TATA box sequence (Mack et al, 1993) through direct interaction with
TBP (Seto et al, 1992). However, exceptions have been found to this rather simplistic
rule (Shen & Shenk, 1994). More recent work has revealed that p53 actually interacts
with TBP via two domains, an N-terminal region and a C-terminal region (Horikoshi
et al, 1995). One model proposes that the N-terminal p53/TBP interaction is needed
for transcriptional activation after sequence-specific DNA binding but both the N and
C terminal regions of p53 are needed to interact with TBP to repress transcription
(Horikoshi et al, 1995).
It is likely that p53 does not repress transcription solely by a pathway involving TBP,
several researchers have obtained data implicating other mechanisms. For example,
p53 binds to and inactivates TFIIIB and acts as a general suppressor of RNA
polymerase III transcription in cells (Cairns & White, 1998). Also, the interaction of
p53 with CCAAT binding factor (CBF), a transcriptional activator, is necessary to
repress transcription from the hsp70 promoter (Agoff et al, 1993). A final novel
mechanism of transcriptional repression by p53 involves Hypoxia-inducible Factor
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(HIF) stimulated transcription. p53 exerts its repressive activity via binding to a
HLF/p300 complex and inhibiting the transcriptional activities of HIF (Blagosklonny
et al, 1998).
A significant indicator of the biological importance of p53-mediated transcriptional
repression was the demonstration that proteins that block p53-dependent apoptosis
also inhibit the transcriptional repression function of p53 while leaving the
transactivation function unaffected. Such proteins include WT-1 (Maheswaran et al,
1995), bcl-2 and the adenovirus E1B-19 kDa protein (Shen & Shenk, 1994).
1.4.5.3. p53 and Translational Control
As well as regulating gene expression at the level of transcription mounting evidence
now exists that p53 is also able to regulate translation of specific genes (reviewed in
Ewen & Miller, 1995a). For example, after TGF-(3 exposure CDK4 mRNA fails to
associate with polysomes and its translation is blocked in a p53 dependent manner
(Ewen et al, 1995b). The exact mechanism of this p53-dependent translational
inhibition is at present unclear. p53 is also thought to regulate the transcription of its
own mRNA allowing rapid translation and increase in protein levels after genotoxic
stress (Mosner et al, 1995).
1.4.5.4. p53 : Direct Interactions With Other Proteins
1.4.5.4.a. Cellular Proteins
In the previous sections, several of the proteins that interact directly have been
mentioned, for example, mdm2, p300 and components of the cellular transcription
machinery and these will not be discussed further in this section which will focus on
other cellular binding partners of p53.
The Wilms' tumour suppressor gene product, WT1 binds p53 resulting in p53
stabilisation and increased DNA binding and transactivation capabilities of p53
(Maheswaran et al, 1993). Other tumour suppressor gene products known to bind
p53 include BRCA1, which binds to the C-terminal of p53 and stimulates the
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transcriptional transactivation activity of p53 (Zhang et al, 1998) and pSS^01
(Garkavtsev et al, 1998). The growth suppression activity of p53 has been shown to
depend on p33ING1expression, for example, interaction between the two proteins is
absolutely necessary for p53-mediated p21 transactivation (Garkavtsev et al, 1998).
A specific subset of proteins with which p53 interacts are involved in DNA repair.
For example, single-strand binding protein RPA (Dutta et al, 1993; He et al, 1993; Li
& Botchan, 1993), TFIIH subunits p62, XPB, XPD (Xiao et al, 1994) the putative
helicase, CSB (Wang et al, 1995) and human Rad51 (Sturzbecher et al, 1996). The
binding of p53 to RPA has been reported to inhibit RPA function and this interaction
is disrupted after UV damage to DNA providing a mechanism by which p53 could
directly modulate nucleotide excision repair (NER) (Abramova et al, 1997). The
XPB and XPD subunits of TFIIH also play a role in NER and p53 binding inhibits
the helicase activity of both of these proteins (Wang et al, 1995). The XPB and XPD
helicases have subsequently been shown to be essential members of the p53-
dependent apoptotic pathway (Wang et al, 1996).
More recent work has revealed that p53 also interacts directly with another
component of TFIIH, cyclin H (Schneider et al, 1998). Cyclin H, along with Cdk7
and Matl make up the heterotrimeric CAK kinase complex (Nigg, 1996). CAK
kinase has two main roles, it phosphorylates and thereby activates the Cdk2/cyclin E
kinase needed to ensure the Gl/S transition (Nigg, 1996) and as a component of
TFIIH phosphorylates RNA polymerase II to allow the elongation of transcription
(Akoulichev et al, 1995). Interestingly, the interaction of p53 with cyclin H results in
a significant downregulation of CAK kinase activity (Schneider et al, 1998).
A number of other cellular proteins that bind p53 have also been identified for which
no obvious function has yet been ascribed. These include p53BPl and 2 (Iwabuchi et
al, 1994), Spot-1 (Elkind et al, 1995), trk kinase (Montano, 1997), p34cdl'2 (Wagner
et al, 1998) and several as yet uncharacterised proteins (Maxwell & Roth, 1993).
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1.4.5.4.b. Viral Proteins
A number of different virally expressed proteins have been shown to bind p53 both
in vitro and in vivo and directly modulate its function. A brief summary of these
interactions is given below.
SV40 TAg binds to the core domain of p53 (Jenkins et al, 1988) and induces an
increase in p53 stability (Oren et al, 1981). This binding blocks the transcriptional
activation function of p53 (Bargonetti et al, 1991) and results in the abrogation of
the apoptosis function of p53 in vivo (McCarthy et al, 1994).
The E6 protein from HPV employs multiple mechanisms to modulate p53 function.
These include targeting the protein for ubiquitin-mediated degradation of p53
(Schneffer et al, 1993) and inhibiting the transactivating and transrepressing
functions of p53 (Mietz et al, 1992; Lechner et al, 1992). The proposed mechanism
for this inhibition of transcriptional control is thought to involve E6-mediated
inhibition of sequence-specific DNA binding by p53 (Thomas et al, 1995).
Another viral protein known to bind directly to p53 is the 55kDa protein encoded by
the adenovirus E1B gene (Sarnow et al, 1982). The binding of E1B 55kDa to p53
inhibits p53-mediated transcriptional activation but does not block sequence specific
DNA binding by p53 (Yew & Berk, 1992). Instead it is thought that E1B 55kDa
protein is a direct repressor of transcription targeted to the DNA by its interaction
with p53 (Yew et al, 1994).
In addition to the well-characterised viral binding partners of p53 several less well
understood interactions of viral proteins and p53 have also been described. These
include the hepaptitis B virus X protein (HBX) which has been shown to bind to p53
and inhibit the transcriptional activation function (Truant et al, 1995). The biological
consequences of this interaction are still unclear. For example, HBX has been
reported to block the nuclear import of p53 (Ueda et al, 1995) yet in other HBX test
systems the p53 response appears to be functionally intact (Puisieux et al, 1995).
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Other members of this newly identified group are the Epstein Barr Virus (EBV)
proteins EBNA-5 (Szekely et al, 1993) and BZLF1 (Zhang et al, 1994). Finally, the
IE84 protein of human cytomegalovirus can bind p53 and is capable of inhibiting the
transactivation function of p53 (Speir et al, 1994).
1.4.5.5. p53-dependent Apoptosis
Apoptosis is a tightly regulated mechanism of cell death, distinct from necrosis,
involving plasma membrane blebbing, loss of cell volume, chromatin condensation
and DNA degradation (Wyllie et al, 1980). This complex process can be initiated by
a variety of stimuli and both p53-dependent and independent apoptotic pathways
have been described (reviewed in Liebermann et al, 1995). p53-dependent apoptosis
can be triggered by a number of different stimuli including DNA damage (Clarke et
al, 1993), oncogene activation (for example, see Hermeking & Eick, 1994), specific
cytokine exposure or deprivation (Canman et al, 1995), hypoxia and heat shock
(Graeber et al, 1994). Conversely, p53-dependent apoptosis can be inhibited by
expression of bcl-2 or the E1B 19kDa protein from adenovirus (Debbas & White,
1993; Chiou et al, 1994) or by the exposure of cells to a variety of growth factors
which act as positive survival signals (for example, see Canman et al, 1995).
Several groups have demonstrated the biological importance of p53-dependent
apoptosis. For example, it acts to suppress transformation of oncogene-expressing
cells (Lowe et al, 1994), inhibits tumour growth and progression in vivo (Symonds et
al, 1994), and, in the embryo, is critical for the suppression of radiation-induced
teratogenesis (Norimura et al, 1996).
One of the major controversies in the field of p53-dependent apoptosis is over the
role of p53-mediated site-specific transcriptional activation (SST). For example,
p53-dependent apoptosis can occur in the absence of RNA and protein synthesis
(Caelles et al, 1994) and p53 SST mutants are capable of inducing apoptosis
although at a slower rate than wild type p53 (Haupt et al, 1995). Conversely, other
groups have reported that SST is critical for p53-dependent apoptosis (Sabbatini et
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al, 1995). Further work now suggests that p53-dependent apoptosis can occur
through both SST-dependent and -independent mechanisms, and that the
requirement for either pathway is determined by the cell type (Haupt et al, 1996).
However, even when apoptosis proceeds via SST-dependent mechanisms the
transactivation of all p53 target genes is not equally important. One of the most
significant pro-apoptotic p53 target genes is bax (Miyashita & Reed, 1995). For
example, some tumour-derived p53 mutants that bind and activate transcription from
the p21 promoter but are unable to activate bax and IGF-BP3 expression display
compromised apoptotic activity (Ryan & Vousden, 1998). The development of the
Death Cycle Model has provided an insight into the significance of bax expression in
p53-mediated SST-dependent apoptosis (Hengartner, 1998). The stabilisation of p53
results in SST-dependent bax expression, this in turn induces depolarisation of the
mitochondrial electropotential gradient (AT'm) allowing the release of cytochrome c
from mitochondrial membranes into the cytoplasm which leads to the activation of
caspase-3 and results in apoptosis (Rosse et al, 1998). This pathway can be inhibited
by the activation of KIT kinase which stabilises the mitochondrial AT'm and inhibits
the production of reactive oxygen species (ROS) suggesting that these two processes
are critical components of a p53-dependent death program (Lee, 1998). The
significance of ROS in p53-mediated SST-dependent apoptosis is supported by the
characterisation of the PIG genes, many of which encode proteins known to generate
or respond to oxidative stress (Polyak et al, 1997)
In contrast, the pathway of p53-mediated SST-independent apoptosis is less well
characterised although two domains of p53 have been implicated in this process, the
proline-rich linker and the extreme C-terminal. Deletion of the proline-rich linker
generates p53 molecules that are SST-competent, able to inhibit tumour cell growth
and cell transformation but cannot induce apoptosis (Sakamuro et al, 1997).
Whereas the mechanism of action of the C-terminal domain in SST-independent
apoptosis has been proposed to involve its interaction with XPB and XPD (Wang et
al, 1996). The observation of attenuated apoptosis induction by the ASp53 splice
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variant which lacks the extreme C-terminal domain would support this hypothesis
(Almog et al, 1997)
1.4.5.6. Cell Cycle Control/Checkpoints and p53
1.4.5.6.a. p53-dependent G1 Arrest
There is now considerable evidence that one of the most significant factors in the
p53-dependent G1 arrest is the transactivation of p21. The up-regulation of p21 has
pleiotropic effects within the cell including inhibition of cyclinE/cdk2 and cyclin
A/Cdc2 kinases (Dulic et al, 1994) and binding to PCNA (Waga et al, 1994). The
binding of p21 to PCNA is sufficient to inhibit SV40 DNA replication in vitro
suggesting a similar p53-dependent mechanism might exist in vivo (Waga et al,
1994). Although p21 upregulation is observed during p53-dependent G1 arrest, the
ability of p53 to induce G1 arrest is not totally dependent on p21 function as
embryonic fibroblasts isolated from p21 null embryos are only partially deficient in
G1 arrest after DNA damage (Deng et al, 1995; Brugarolas et al, 1995).
The p21-independent pathway of p53-mediated G1 arrest may involve other
transcriptional target genes of p53. For example, GADD45 can bind to inhibit PCNA
function thereby inhibiting entry into S phase (Smith et al, 1994) and p53-dependent
Siah expression also promotes G1 arrest (Matsuzawa et al, 1998). Furthermore, the
interaction of p53 with cyclin H in the CAK kinase complex has also been
demonstrated to play a role in G1 arrest. p53 binds to and inhibits the action of CAK
kinase, blocking the phosphorylation of its two substrates, RNA polymerase II and
Cdk2. In turn, the inhibition of Cdk2 phosphorylation acts to block the activity of the
cyclinE/Cdk2 complex and results in G1 arrest (Schneider et al, 1998).
Interestingly, as well as the p53-dependent G1 arrest after DNA damage, p53 has also
been demonstrated to affect the cell cycle in the absence of DNA damage as a
shortened G1 stage was observed in p53 null embryonic fibroblasts (Harvey et al,
1993).
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1.4.5.6.b. p53 and the G2/M Transition
It has been proposed that while the onset of the G2 checkpoint is p53-independent,
p53 may function as a secondary regulator (Guillouf et al, 1995) and play a role in
the G2/M phase transition (Agarwal et al, 1995; Stewart et al, 1995). For example, it
has been proposed that during the DNA damage-dependent G2 delay, p53 may
regulate both double strand break repair and the post-repair exit from the G2 block
(Schwartz et al, 1997).
The underlying molecular mechanisms and downstream targets used by p53 to
regulate the G2/M arrest in response to DNA damage are currently unknown.
However the discovery that cyclin G, a transcriptional target gene of p53, is an
important negative regulator of this checkpoint provides the first insight (Shimizu et
al, 1998).
I.4.5.6.C. p53 and Other Cell Cycle Checkpoints
A number of other cell cycle control functions have been ascribed to p53. For
example, after the treatment of mouse embryonic fibroblasts (MEFs) with
nocodazole, a spindle poison, p53 null MEFs fail to arrest and instead undergo
another round of DNA synthesis in the absence of cell division (Cross et al, 1995).
Based on this observation a mitotic checkpoint function was proposed for wild type
p53. However, subsequent research has shown that p53 is not expressed during
mitosis or required for mitotic arrest and expression occurs only after cells exit the
mitotic arrest (Minn et al, 1996). This p53-dependent spindle checkpoint is now
thought to occur when cells with damaged spindles enter a Gl-like state in which the
p53 dependent arrest would be identical to that seen after DNA damage (Lanni &
Jacks, 1998). The role of p21 in this p53-dependent checkpoint is still under debate,
some groups report an intact spindle checkpoint in the absence of p21 (Deng et al,
1995) while others demonstrate a requirement for functional p21 (Lanni & Jacks,
1998).
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A role for p53 in centrosome homeostasis has also been proposed based on the
observation that p53 null MEFs frequently acquire more than two centrosomes and
undergo mitotic failure (Fukasawa et al, 1996). Although the mechanism involved
remains to be identified, the physical association of p53 and MAP kinase with
centrosomes (Brown et al, 1994; Wang et al, 1997), the knowledge that MAP kinase
is important for centrosome homeostasis and that p53 is a MAP kinase substrate are
suggestive observations (Milne et al, 1994).
1.4.5.6.d. Growth Arrest or Apoptosis ?
One of the fundamental questions in p53 research is how the choice is made between
G1 arrest and apoptosis. It is only with the recent discovery of the functional
interplay between p53 and p300 that the molecular mechanisms employed in this
decision making process are becoming apparent (Avantaggiati et al, 1997).
p300 is a transcriptional activator and the binding of p53 to p300 is essential for p53-
mediated transactivation of the p21 gene (Lee et al, 1998). p21 then augments the
transcriptional transactivation function of the p300/p53 complex resulting in a
positive feedback loop generating high levels of p21 expression leading to G1 arrest.
In addition, the p53/p300 interaction allows cross-talk with the Rb/E2F-1 pathway as
p300 also interacts with E2F-1, meaning that both p53 and E2F-1 are competing for
the same cellular reservoir of p300. This competition between E2F-1 and p53 may
explain why the ectopic expression of high levels of E2F-1 in cultured cells results in
p53-dependent apoptosis (Wu & Levine, 1994). The high levels of E2F-1 sequester
p300 preventing it binding to p53 and so blocking p53 transactivation of p21. The
resultant low levels of p21 expression are insufficient to maintain a stable G1 arrest
so the result is p53-dependent apoptosis.
Alongside p21, another gene product involved in the G1 arrest/apoptosis decision is
mdm2 as the formation of the p53/p300 complex is also necessary for efficient
transactivation of the mdm2 gene (Thomas & White, 1998). The adenovirus E1A
protein binds to and sequesters p300 (Moran, 1993) and cells which express E1A
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upregulate p53 but do not transactivate mdm2. The lack of mdm2 expression in such
cells, means that p53 levels go unchecked leading to apoptosis (Thomas & White,
1998). The induction of p53-dependent apoptosis in E1A expressing cells may also
be related to induction of pl9ARF expression (see Section 1.4.4.).
In conclusion, p300 levels are critical in determining the nature of the outcome after
p53 induction (Figure 1.13). If p300 is sequestered either by high E2F-1 levels or
ElA expression then p53 will be unable to transactivate the expression of p21 or
mdm2. Low levels of p21 will be insufficient to maintain G1 arrest and low mdm2
levels will be insufficient to inhibit p53 activity or efficiently target p53 for
degradation. As such high levels of p53 will lead to apoptosis. This model is
consistent with the earlier observation that the outcome of p53 induction is dependent
on the level of p53 activity present in a cell (Chen et al, 1996).
The above section has focussed on the SST-dependent induction of apoptosis by p53
but p53 is known to induce apoptosis in an SST-independent manner. The
mechanisms by which this is achieved are unclear although a tantalising glimpse has
been provided by the demonstration of p53-facilitated Rb cleavage during apoptosis
(Gottlieb & Oren, 1998).
The presence or absence of survival factors had been demonstrated by several groups
to affect the Glarrest/apoptosis decision (Canman et al, 1995; Gottlieb et al, 1994).
If cells from the interleukin 3 (EL-3) dependent haematopoietic cell-line DA-1 are
exposed to DNA damage, p53 is activated. In the presence of IL-3, p53 activation
results in G1 arrest but in the absence of IL-3 the outcome of p53 activation is
apoptosis (Gottlieb et al, 1994). As such, the wild type p53 status of the cells is
necessary to potentiate Rb cleavage but it is the survival factor withdrawal that
actually turns on the Rb caspase activity (Gottlieb & Oren, 1998). These results were
the first demonstration of a molecular mechanism for co-operation between p53 and
survival factor withdrawal in the modulation of the p53 response.
100
1.4.6. p53 in Development
The development of gene targeting technology allowed the generation of mice with
null p53 alleles (Donehower et al, 1992; Jacks et al, 1994; Purdie et al, 1994).
Homozygous null animals were originally reported as developmentally normal
however a more detailed phenotypic examination has uncovered some problems.
Predominantly female-associated defects in neural tube closure leading to
exencephaly and subsequent anencephaly have been reported by two groups
(Armstrong et al, 1995; Sah et al, 1995). p53 status has also been reported to
influence skeletogenesis with p53 null E. 17 (E.17 refers to embryos which have
completed 17 days of development) embryos displaying delayed cartilage maturation
(Ohyama et al, 1997).
Mdm2 null mice provided a further insight into the role of p53 during development.
Homozygous null mdm2 animals generated by gene targeting display embryonic
lethality at around E.5.5 unless they are doubly null for p53 expression also (Montes
de Oca Luna et al, 1995). This result suggests that the primary role of mdm2 during
development is to negatively regulate p53 hence dysregulated p53 expression is more
detrimental to normal development than a total absence.
Because of the developmental defects observed in a percentage of p53 null embryos
attempts have been made to define the role of p53 during embryogenesis.
Experiments looking at radiation induced teratogenesis in mouse embryos have
demonstrated the protective function of wild type p53 against teratogenic defects
(Norimura et al, 1996). Interestingly, the most frequent developmental defects
induced by ionizing radiation (IR) in p53 null embryos affect the tail and limbs
(Norimura et al, 1996) which are also the sites of maximal p53-SST induction after
IR in wild type embryos (Gottleib et al, 1997).
1.4.7. p53 and Tumourigenesis
Several lines of evidence indicated the importance of p53 in tumourigenesis. For
example, mutation of the p53 gene is one of the most frequently observed genetic
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alterations in carcinogenesis (reviewed in Hollstein et al, 1997). That p53 loss of
function is important in tumour development was further supported by the phenotype
of both mice and humans with compromised p53 function. Patients with Li-
Fraumeni syndrome have a germline mutation in one p53 allele and display a
predisposition to a range of cancers (Malkin et al, 1990; Srivastava et al, 1990) and
p53 null mice generated by gene targeting are highly predisposed to malignancy
(Donehower et al, 1992, Jacks et al, 1994; Purdie et al, 1994).
Because of the pleiotropic nature of p53 function and the multiple p53 inactivation
mechanisms means that p53 loss of function is thought to facilitate tumour
progression in many ways.
1.4.7.1. Attenuated Apoptosis
The use of transgenic mouse models has allowed insights into the role of p53-
dependent apoptosis in tumour suppression. Mice which express HPV E7 protein
(inactivates Rb function) in the lens and retina display high levels of apoptosis,
inhibition of normal cell differentiation and enhanced cell proliferation (Pan & Griep,
1994). However, retinal or lens tumours were only seen when these mice were
crossed to either p53 null animals or a strain expressing the HPV E6 protein (see
Section 1.4.5.4.b) which correlated with a significant reduction in apoptosis in the
affected tumour tissues (Pan & Griep, 1994).
The role of attenuated apoptosis in tumour progression was further demonstrated by
another transgenic mouse model. Transgenic mice expressing a truncated SV40 large
T antigen protein, capable of inactivating Rb function but not p53 developed slow
growing tumours. However, when crossed onto a p53 null background these mice
developed aggressive tumours with attenuated apoptosis (Symonds et al, 1994).
The discovery that hypoxia induces p53-dependent apoptosis provided more support
for a role of apoptosis in tumour progression. Hypoxic conditions, common in areas
within large tumours, select for cells with defects in the apoptotic pathway and in
102
particular p53 mutations. As a result high levels of apoptosis are observed in
tumours with hypoxic regions and functional p53, but not in hypoxic regions of
tumours that have lost wild type p53 function (Graeber et al, 1996).
1.4.7.2. Increased Genomic Instability
The association of p53 loss of function and increased genomic instability has been
established in vitro (Livingstone et al, 1992; Cross et al, 1995). p53 mutations in a
range of human tumours have also been associated with increased aneuploidy or
genomic instability (for example see Blount et al, 1994). Mouse models have again
provided more data to support this hypothesis. Transgenic mice that ectopically
express the Wnt-1 oncogene in the mammary gland develop mammary cancer
(Donehower et al, 1995). When these mice were crossed to p53-deficient mice
tumours developed earlier, displayed a more anaplastic morphology and contained
more chromosomal abnormalities (Donehower et al, 1995).
1.4.7.3. Increased Proliferative Capacity
Another mechanism by which loss of p53 function may contribute to tumour
progression is enhanced cell proliferative capacity. For example, p53 null MEFs
have shorter cell cycle times and higher proliferation rates in vitro than wild type
MEFs (Harvey et al, 1993). This increased proliferative capacity may be partly
explained by the loss of p53-dependent checkpoints within the cell cycle.
1.4.7.4. Increased Invasiveness and Metastasis
Both mouse and human data have suggested a link between loss of p53 function and
the acquisition by a tumour of a malignant, metastatic phenotype but there is still
debate over whether this is a direct result of p53 loss of function or an indirect
consequence. For example, in human colorectal cancer the transition from localised
adenoma to invasive carcinoma is often accompanied by p53 mutation (Fearon &
Vogelstein, 1990) and in prostate cancer p53 mutations are associated with the
metastatic forms of the disease (Bookstein, 1994). The application of the classic two
stage skin carcinogenesis protocol to p53-deficient and normal mice, found that p53
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null mice developed fewer benign papillomas and more malignant carcinomas in a
shorter timespan than treated normal mice. Furthermore, the carcinomas observed in
the p53 null mice tended to be poorly differentiated and more invasive (Kemp et al,
1993).
1.4.7.5. Increased Angiogenesis
In order to support tumour growth beyond the size of a few millimetres angiogenesis
must occur within the tumour mass. The discovery that the transcriptional target
genes of p53 include thrombospondin-1 (TSP-1) (Dameron et al, 1994) and BAI1
(Nishimori et al, 1997), both potent inhibitor of angiogenesis, placed p53 as a central
regulator of angiogenesis. Preliminary evidence also indicates regulation of other
anti-angiogenic genes by p53 (Van Meir et al, 1994). It is also worth noting that as
well as mutation of p53 inhibiting the SST of anti-angiogenic genes specific mutant
forms of p53 are able to transcriptionally upregulate bFGF, a potent angiogenic factor
(Ueba et al, 1994).
1.4.8. p53 Related Proteins
Up until 1997 it was thought that p53 was a unique protein with no other related
molecules. This myth was dispelled with the discovery of p73. Two splice variants
of p73 were originally reported, a and (3 (Kaghad et al, 1997), although more recent
work has led to the identification of two new variants, y and 8 (DeLaurenzi et al,
1998). All four splice variants differ only in their 3' sequence due to alternative exon
splicing but have distinct activities. For example, p73y can efficiently heterodimerise
with all other p73 isoforms whereas p738 binds efficiently to the a and y isoforms
only (DeLaurenzi et al, 1998). All of the p73 isoforms share a high level of sequence
homology with p53, up to 63% in the core domain which suggests some level of
functional redundancy (reviewed in Wiman, 1997). Indeed, p73 is able to
transactivate p21 and induce apoptosis when overexpressed (Kaghad et al, 1997; Jost
et al, 1997) although viral oncoproteins such as adenovirus E1B and SV40 TAg
discriminate between p53 and p73 (Marin et al, 1998) and p73 is not induced after
DNA damage (Kaghad et al, 1997).
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The status of p73 as a tumour suppressor is still under debate. For example, the p73
gene is located on human chromosome lp36 a region that is frequently deleted in a
variety of human cancers although to date, no intragenic mutations have been
identified in human cancer cells (Kaghad et al, 1997). It has been suggested that the
p73 gene may be subject to imprinting while a role for epigenetic control of p53
expression cannot be excluded, there are currently no genetic data that firmly
establish that p73 is a tumour suppressor (DeLaurenzi et al, 1998).
Since the publication of the p73 work a flurry of subsequent papers have described
the identification of other p53 homologues. The newly discovered p53 homologues
can be divided into two groups, depending on their C-terminal structure. The first
includes p53 itself, p73(3 and p51A (Osada et al, 1998). The second group includes
all proteins that have C-terminal extensions that at present are of unknown function.
Members of this group are the squid (Loligo forbesi) p53 protein, the rat KET protein
(Schmale & Bamberger, 1997) and p73a (Kaghad et al, 1997). The absence of
structural data prevents the assignment of the newly identified p73 y and 8 isoforms
and another p53 homologue, NBPp53RE within the two groups described above
(Zeng et al, 1998).
This already complex picture has been further complicated by the discovery of
RB18A (Drane et al, 1997). This protein is not a true homologue of p53 but does
share both antigenic and functional properties and is thought to be an upstream
regulator of p53 activity (Drane et al, 1997).
1.4.9. Conclusions
In the twenty years since p53 was first discovered significant advances have been
made in our understanding of this complex protein. The identification of both
upstream regulators and downstream effectors has facilitated a more complete
understanding of p53 function. Furthermore, the discovery that p53 plays a
significant part in multiple molecular pathways and acts as an integration point for
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many intracellular signals has greatly increased our understanding of the tumour
suppressor function of this protein. However, it is testament to the pleiotropic nature
of p53 function that after twenty years there are still unanswered questions.
1.5. Replicative Cellular Senescence
1.5.1. Introduction
Replicative cellular senescence describes the process of terminal growth cessation
and morphological change displayed by normal animal cells after they have
undergone a finite number of population doublings in vitro (Hayflick & Moorhead,
1961). Cellular senescence is not programmed cell death as these cells are viable in
culture for long periods of time, remaining metabolically active, adherent to the
growth surface (Matsumura et al, 1979) and resistant to apoptosis (Wang, 1995).
Cells display several novel characteristics upon entry into senescence. Senescent
cells enter an irreversible cell cycle block and cannot initiate DNA synthesis in
response to mitogenic stimulation (Cristofalo et al, 1989) although this is not due to a
lack of DNA synthesis machinery (Gorman & Cristofalo, 1985). Furthermore,
senescent cells acquire altered functions and morphology and have been likened to
terminally differentiated cells (Goldstein, 1990).
Two models have been proposed to explain the phenomenon of replicative cellular
senescence. In the first, the cell is seen as passive, simply accumulating mutations
with each round of replication until a critical threshold is reached which triggers
senescence. Conversely, in the programmed control or genetic hypothesis the cell is
envisaged as actively regulating the onset of senescence via an intrinsic, genetically
controlled process. Therefore, at the end of the proliferative life span of a normal
cell an internal genetic programme may be activated which results in the
characteristic morphological and growth arrest changes of replicative cellular
senescence (Macieira-Coelho, 1988). The majority of the experimental evidence
discussed in the following sections supports this second hypothesis.
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1.5.2. Senescence in vivo
The first description of replicative cellular senescence was based on observations in
vitro (Hayflick & Moorhead, 1961), however, evidence now exists which indicates
that senescence is a true in vivo phenomenon and not an artefact of in vitro cell
culture. Morphologically senescent cells have been observed (Bruce, 1991) and
detected histochemically in vivo (Dimri et al, 1995). Serial cell transplantation
experiments have demonstrated that normal cells, but not tumour cells, have a limited
life span in vivo (Daniel et al, 1968) and cells aged in vivo or in vitro share certain
biochemical characteristics (Heydari et al, 1993). The acceptance of senescence as a
true in vivo phenomenon has stimulated research into the functions of this complex
process and two roles have been proposed, in ageing and in neoplasia.
There are several lines of evidence that suggest that cellular senescence in vitro
represents ageing at the cellular level in vivo. Firstly, the maximum cumulative
population doubling that cultured, normal fibroblasts can achieve reflects the average
life span of the species from which they are derived (Stanley et al, 1975). This
observation suggests that the replicative lifespan of cells and the chronological
lifespan of organisms may be controlled by overlapping or interacting genes
(reviewed in Campisi, 1996). Secondly, there is an inverse relationship between the
lifespan in culture and age of the organism from which the cultured cells were
obtained suggesting that cells in renewable tissues may progressively exhaust their
replicative lifespan in vivo during ageing (Martin, 1993). Furthermore, fibroblasts
established from individuals with genetically linked ageing syndromes display a
reduced proliferative capacity (Goldstein, 1969; Goldstein et al, 1989, see also
Section 1.5.4.3.).
The proposed involvement of senescence in neoplastic development is related to the
suppression of growth that occurs as cells enter senescence. The ability of this
process to limit the proliferative capacity of normal cells has led to the hypothesis
that it may act to suppress tumour formation in vivo. In support of this suggestion,
the majority of tumour cell lines can be cultured indefinitely in vitro indicating that
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they have escaped the constraints of replicative senescence (Leibovitz, 1986).
However, not all primary tumours are capable of giving rise to immortal cell lines
(Paraskeva et al, 1988). Therefore, although immortality alone is insufficient for
neoplastic progression, immortal cells are more susceptible to spontaneous,
oncogene-induced or carcinogen-induced progression (Barrett, 1987). In line with
this hypothesis, certain oncogenes, both viral and cellular, also act to extend
replicative lifespan (reviewed in Campisi, 1996). Furthermore, key genes involved in
the establishment and maintenance of senescence include well known tumour
suppressor genes such as p53 and RB.
1.5.3. Genetic Regulation of Senescence
Senescence is characterised by a terminal growth arrest and several lines of evidence
indicate that this arrest occurs in the G1 portion of the cell cycle. For example,
stimulation of senescent cells with serum mitogens induces the expression of some
genes associated with G1 progression in cycling cells but does not permit entry into S
phase (Seshadri & Campisi, 1990). Furthermore, flow cytometric analysis has
confirmed a G1 DNA content for the majority of cells in a senescent population
(Sherwood et al, 1988). The conclusion that senescence-induced growth arrest
occurs in G1 is supported by an analysis of key cell cycle regulatory molecules within
these cells (reviewed in Vojta & Barrett, 1995)
As the cell cycle effector molecules used to implement and maintain this terminal
growth arrest are the same as those required for reversible G1 arrest in normal, non-
senescent cells, the key differences between the two processes must lie in their
upstream regulation. The genetic regulation of senescence is discussed in the
following sections.
1.5.3.1. Chromosomal Localisation of Pro-senescence Genes
The technique of somatic cell hybridisation has been instrumental in dissecting the
genetic regulation of senescence. Fusions between different immortal cell lines can
result in senescent hybrids, indicating that specific immortal cell lines differ in the
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defects they possess in the senescence genetic pathway(s). Using this technique four
different complementation groups have been identified, A, B, C and D (Pereira-
Smith et al, 1988). In theory all the members of one complementation group will
have a similar genetic alteration and so the endpoint of this work was to identify the
specific genes involved. However, it should be noted that certain immortal cell lines
can be assigned to more than one complementation group highlighting the
complexity of senescence regulation (Duncan et al, 1993).
The first step towards the characterisation of individual pro-senescence genes was to
identify which chromosomes carried pro-senescence activity. Microcell-mediated
chromosome transfer has been used to map pro-senescence activity to human
chromosomes 1 (Sugawara et al, 1990), 4 (Ning et al, 1991), 6 (Sandhu et al, 1994),
7 (Ogata et al, 1993), 11 (Koi et al, 1993), 18 (Sasaki et al, 1994) and X (Klein et al,
1991). The senescence-inducing activity of human chromosome 1 has since been
assigned to complementation group C (Hensler et al, 1994), chromosome 4 to group
B (Ning et al, 1991) and chromosome 7 to group D (Ogata et al, 1993). Subsequent
research has led to the identification of two candidate regions, at lq25 and lq41-42,
for a pro-senescence gene on chromosome 1 (Karlsson et al, 1996) and the discovery
of the MORF4 (mortality factor 4) gene on chromosome 4 (Berube et al, 1998).
Recent mapping studies have also helped pinpoint the pro-senescence gene, termed
SEN-6, present on human chromosome 6 (see also Section 1.5.4). One candidate for
SEN6 is the AF6 gene known to be deleted and/or mutated in several TAg-
expressing immortal HDF clones (Prasad et al, 1993). This gene is a tantalising
candidate for SEN-6 as the gene product is known to participate in several signal
transduction pathways and interacts with other cellular proteins such as ras and Ape
(reviewed in Jha et al, 1998).
1.5.3.2. Individual Pro-senescence Genes
Experiments with SV40 large T antigen (TAg) have facilitated the dissection of the
internal senescence-regulatory program and the identification of individual
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senescence regulatory genes. Briefly, normal human diploid fibroblasts (HDFs)
proliferate for approximately 50 population doublings in vitro (Shay & Wright,
1989). After this point, named Ml or the first mortality checkpoint, the cells enter a
characteristic senescent state. Transfection of HDFs with TAg extends their
replicative lifespan beyond Ml and up to approximately 70 population doublings.
Such TAg-expressing cultures then enter a state termed crisis or M2, the second
mortality checkpoint. High levels of cell death are observed in a crisis culture but
proliferation also occurs and rare immortal variants may emerge. These immortal
clones have overcome both the first and second mortality checkpoints (reviewed in
Jha et al, 1998; see Figure 1.14).
1.5.3.2.a. RB
The RB tumour suppressor gene product is a strong candidate as a pro-senescence
regulatory gene as the reintroduction of RB into certain immortal cells is sufficient to
induce a senescent phenotype (Xu et al, 1997).
The RB protein is found at similar levels in young and senescent cells but exists
predominantly in the hypophosphorylated, growth inhibitory form in senescent cells
(Stein et al, 1990). The growth inhibitory activity of the hypophosphorylated form of
the RB protein is due to its ability to bind the E2F transcription factor complex
(Nevins, 1992). This interaction sequesters E2F and inhibits the transcriptional
transactivation function of the protein, it may also cause E2F to actively repress
transcription (Weintraub et al, 1992). The absence of E2F-mediated transcriptional
transactivation in senescent cells has several downstream effects. Genes which
would normally be upregulated by E2F are not, for example, c-fos, which has two
E2F binding sites within its promoter (Chellappan et al, 1991), is transcriptionally
down-regulated in senescent cells (Seshadri & Campisi, 1990). Many other genes
also contain E2F binding sites in their promoters, including cell proliferation genes
whose expression is required to exit G1 (DeGregori et al, 1995). The abrogation of
E2F-mediated transcriptional transactivation in senescent cells is likely to be one of
several mechanism used by cells to maintain senescence as the restoration of E2F-1
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Figure 1.14 - Mortality Checkpoints and Replicative Cellular Senescence
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Normal human diploid fibroblasts (HDFs) will proliferate in vitro for approximately
50 population doublings until they reach the first mortality checkpoint (Ml). Such
cells then enter senescence. EF HDFs are stably transfected with SV40 TAg the
replicative lifespan of the culture is extended beyondMl for approximately 20
population doublings and such cells do not enter senescence. However, at the end of
their lifespan, TAg-expressing cultures reach the second mortality checkpoint (M2)
and enter crisis. Cell death and cell proliferation occur within crisis populations and
rare immortal clones, which have bypassed M2 may arise (reviewed in Jha et al,
1998).
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expression (a component of the E2F transcription complex) is insufficient to induce
cell cycle re-entry in senescent cells (Dimri et al, 1994).
One mechanism by which RB is proposed to regulate senescence is by controlling the
Ml checkpoint. For example, if HDFs are cultured in the presence of antisense
oligonucleotides that inhibit the expression of RB, their lifespan is extended by
approximately 10 population doublings beyond the normal Ml checkpoint (Hara et
al, 1991 and Figure 1.15). Hence, while antisense-mediated reduction of RB
expression can extend a cells replicative lifespan and delay the onset ofMl, it is
insufficient to allow cells to overcomeMl completely. The importance of RB in the
regulation of Ml is further supported by the observation that SV40 TAg-mediated
escape from Ml is dependent upon the inactivation of both RB and p53 (reviewed in
Jha et al, 1998).
1.5.3.2, p53
As with the RB protein, work with SV40 TAg demonstrated a requirement for wild
type p53 activity to maintain an intact first mortality checkpoint. Interestingly, HDFs
cultured in the presence of antisense oligonucleotides that inhibited the expression of
p53 did not have significantly different replicative lifespans to untreated HDFs, yet if
such cells were exposed to both p53 and RB antisense oligonucleotides, Ml was
abolished (Hara et al, 1991 and Figure 1.15). Ml dependence upon both functional
p53 and RB was further supported by the observation that continued proliferation of
post-M2, TAg-transfected immortal HDF clones was dependent upon continued
SV40 TAg expression (Wright et al, 1989). Both the p53 and RB binding functions
of TAg are required to maintain post-M2 proliferation demonstrating that a
functional Ml checkpoint would otherwise be reconstituted that would be sufficient
to induce senescence. The significance of p53 in regulating senescence was further
confirmed by a report documenting senescence induction after the reintroduction of
p53 into an immortal tumour cell line (Sugrue et al, 1997).
In addition, primary embryonic fibroblasts derived from p53 targeted animals
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Figure 1.15 - Effects ofAntisense Oligonucleotides on the Onset ofReplicative
Cellular Senescence
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Normal HDF's will proliferate in culture for approximately 50 population doublings
after which point they reach Ml and enter replicative cellular senescence. HDF's
stably transfected with SV40 TAg continue to proliferate for approximately 70
population doublings beyond Ml after which point they reach M2 and enter a crisis
state. HDFs cultured in the presence of antisense RB oligonucleotides proliferate
beyond the normal Ml point for approximately 10 population doublings before
entering senescence. In contrast, no lifespan extension is observed when HDFs are
cultured in the presence of p53 antisense oligonucleotides. However, if HDFs are
cultured with both p53 and RB antisense oligonucleotides Ml is abolished and the
cells behave identically to those stably transfected with Sv40 TAg (Hara et al, 1991).
These experiments have formed the basis of the hypothesis that the Ml checkpoint is
dependent on both p53 and RB function and although this work was carried out in
human cells an analogous mechanism is thought to exist in murine cells.
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display different growth characteristics relative to normal cells. p53 homozygous
null EFs will proliferate for over 50 passages in vitro with no obvious senescent
phase whereas both heterozygous and wild type fibroblasts enter senescence by
approximately passage 20 (Harvey et al, 1993). While the constitutive absence of
p53 expression can explain the prolonged proliferation of p53 null EFs pastMl,
continued growth of the culture must be dependent upon the acquisition of other
mutations, this may correlate with the high levels of genetic instability reported in
these cells (Harvey et al. 1993; see also Section 1.5.4).
It should be noted that although the levels of p53 transcription do not change as a cell
approaches senescence, p53 activity increases as there is a shift from the latent to the
active form of the molecule (Atadja et al, 1995).
I.5.3.2.C. p21
The p21 gene was first identified as it encoded an mRNA that was present at higher
levels in senescent cells than in young cells (Noda et al, 1994). Subsequent work
revealed that p21 forms a quaternary complex with cyclins, cyclin-dependent kinases
(CDKs) and PCNA (Xiong et al, 1993). This interaction inhibits the activity of the
complexed CDK; hence p21 acts to block CDK-mediated phosphorylation of the RB
protein (Harper et al, 1993). Although re-expression of p21 in spontaneously
immortalised, p53 null human fibroblasts is sufficient to induce senescence (Vogt et
al, 1998), senescence is not strictly dependent on p21 expression (Medcalf et al,
1996). These seemingly contradictory results only serve to highlight the complexity
of the multiple genetic pathways that are thought to regulate senescence.
1.5.3.2.d. pl6INK4a
pl6'NK4a was originally identified as a protein that bound the cyclin dependent kinase
CDK4 and it was subsequently shown to be a specific inhibitor of the kinase
activities of both CDK4 and CDK6 ( Serrano et al, 1993). One of the substrates of
CDKs 4 and 6 is the RB protein (reviewed in Weinberg, 1995), the combination of
high levels of p21 and pl6INK4a in senescent cells should act in concert to maintain
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RB in a growth inhibitory, hypophosphorylated form. As pl6IN acts t0 negative'y
regulate cellular proliferation it was put forward as a candidate tumour supptessor
gene. This was confirmed when high frequencies of hemizygous and homozygous
deletions of the pl6INK4a locus were observed in both primary tumours and tumour
cell lines (reviewed in Larsen, 1996). In fact, of all of the genes which encode cell
cycle components, the pl6INK4a gene is the most frequently inactivated or mutated
during tumourigenesis (reviewed in Hirama & Koeffler, 1995).
The accumulation of pl6INK4a in senescent cells provided the first clue that this
protein was also involved in the regulation of cellular senescence (Loughran et al,
1996). In addition, loss of pl6INK4a facilitates immortalisation in many systems
(Serrano et al, 1996), and the viral oncoprotein Tax from HTLV-1 inactivates
pl6'N^4a by djrect; physical interaction and thereby promotes immortalisation (Suzuki
et al, 1996). The recent demonstration that the restoration of pl6INK4a expression in
spontaneously immortalised fibroblasts is sufficient to induce senescence confirms
the significance of this protein in the regulation of senescence (Vogt et al, 1998).
1.5.3.2.e. p33ING1
The p33INGI tumour suppressor gene was identified using a cloning strategy to
distinguish genes whose expression is specifically reduced in cancer cells
(Garkavtsev et al, 1996). Further research has revealed that p33ING1 is a component
of the p53 signalling pathway and that overexpression of p33INGi inhibits cell
proliferation in a p53-dependent manner (Garkavtsev et al, 1998). The
demonstration that pSS1™31 expression is specifically upregulated in senescent cells
and that expression of antisense p33ING1 mRNA in presenescent fibroblasts extends
their replicative life span is strong evidence that another function of p33INGI is as a
prosenescence gene (Garkavtsev & Riabowol, 1997).
1.5.3.3. Anti-senescence Genes
The above sections have focussed on genes whose actions are considered as pro-
senescence. However, the existence of anti-senescence genes has also been
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postulated. Werner's syndrome (WS) is a rare autosomal recessive genetic disorder
characterised by symptoms of premature ageing (Epstein et al, 1966) and the
development of rare cancers (Goto et al, 1996). Fibroblast cell strains established
from individuals with WS display precocious senescence (Goldstein et al, 1989).
The gene responsible for WS, WRN, has been mapped to human chromosome 8pl 1-
12 (Yu et al, 1996) and shown to function as a DNA helicase (Suzuki et al, 1997)
although it is still unclear how the WRN gene product acts to regulate the onset of
replicative senescence.
1.5.4. Cellular Immortality - Bypassing M2
Human cells undergo spontaneous immortalisation in culture at almost undetectable
frequencies but such cells can be immortalised, albeit at low frequencies, by stable
transfection with SV40 TAg (Shay & Wright, 1989). As already mentioned, any
TAg-expressing immortal clones which arise must have bypassed both the Ml and
M2 checkpoints. Although genes such as p53 and RB are thought to be involved in
Ml regulation, the genetics of the M2 checkpoint are less well understood. However,
one candidate location for an M2 checkpoint gene is human chromosome 6 (see also
Section 1.5.3.1). Cells that have escaped senescence and bypassed M2 display non-
random losses of this chromosome (Hubbard-Smith et al, 1992) and the introduction
of chromosome 6 into post-crisis cells is sufficient to restore M2 and induce
senescence (Sandhu et al, 1994).
The majority of the experiments relating to the M1/M2 model of senescence
regulation discussed above have been done in human cells. While a checkpoint
analogous to Ml is thought to exist in murine cells, the existence of a murine M2
checkpoint is still under debate. For example, human cells undergo spontaneous
immortalisation in culture at almost undetectable frequencies (Shay & Wright, 1989)
and are rarely immortalised by chemical carcinogens (McCormick & Maher, 1988).
In direct contrast, murine cells are readily immortalised by chemical carcinogens and
also undergo spontaneous immortalisation at a high frequency (McCormick &
116
Maher, 1988). The simplest interpretation of these observations is that mouse cells
lack a functionally important M2, or that M2 can be inactivated by both genetic and
epigenetic mechanisms (Wright et al, 1989). Further characterisation of the human
M2 checkpoint should facilitate a fuller understanding of related mechanisms in the
mouse.
In conclusion, a single mutation in any of the multiple senescence pathways is
insufficient to permit escape from cellular replicative senescence. Immortality can
only be achieved by the complete loss of function of all of these pathways and a
senescent phenotype can be induced by the restoration of any single senescent
pathway.
1.5.5, Senescence Activation
Activation of senescence pathways is likely to involve complex regulatory
mechanisms. One such mechanism is thought to be a counting system which records
the number of cell divisions, this was proposed to explain the observation that the
proliferative life span of a cell correlates with the total number of divisions,
independent of chronological time (Hayflick, 1976). To determine how a cell records
the number of cell divisions that it has undergone, several studies were undertaken to
compare specific physical parameters between young and near-senescent cells. One
such study reported that telomere length shortens in normal cells as they approach
senescence (Harley et al, 1990). Subsequent work has confirmed a strong correlation
between telomere length and proliferative capacity (Allsopp et al, 1992).
Telomerase is the enzyme responsible for the extension of telomeres and is active in
germline tissues and the majority of immortal cell lines but is undetectable in normal
tissue (Kim et al, 1994). The correlation of both advanced stage malignancy and in
vitro cellular immortality with telomerase activity provides additional support for the
hypothesis that cellular immortalisation is required for extended tumour cell
proliferation in vivo. Interestingly, it has recently been demonstrated that the
restoration of RB expression in an immortal cell line is sufficient to induce
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replicative senescence and that this correlates with an inhibition of telomerase
activity (Xu et al, 1997). However, the role of telomerase and telomere length in the
regulation of senescence in vivo is more complex, as evidenced by the generation of
viable telomerase null mice (Blasco et al, 1997).
Another physical parameter that varies with cellular proliferation is DNA
methylation. The level of methylated cytosine residues decreases in normal
fibroblasts as they reach the end of their life span in culture. However, exposure of
normal cells to 5-azacytidine doses which are sufficient to reduce methylation levels
to lower than those seen in senescent cells is insufficient to induce growth arrest
(Gray et al, 1991). The favoured interpretation of these results is that the
demethylation that occurs in ageing cells must be site specific, not random as would
be induced by 5-azacytidine. A potential target for site-specific demethylation in
ageing cells is the CpG island in the pl6INK4a gene (Merlo et al, 1995). As cells
approach replicative senescence this site is demethylated and the result is an increase
in pl6INK4a expression (Vogt et al, 1998).
A possible mechanism for senescence-dependent demethylation has also become
apparent. The methyltransferase enzyme and p21 both form separate and mutually
exclusive complexes with PCNA (Chuang et al, 1996). Hence the accumulation of
p21 in cells as they approach senescence could lead to the down-regulation of
methyltransferase and explain the activation of pl6INK4a during late senescence.
1.5.6. Summary
A substantial body of evidence now exists which supports the genetic hypothesis of
replicative cellular senescence, which states that the process is regulated by an
internal cellular program. It is probable that the onset of senescence can be triggered
by several signals, of which telomere erosion and methylation status are examples.
Cells are also able to use multiple pathways to reach the same endpoint, terminal
growth cessation and immortality can only be achieved after the acquisition of
mutations in all of the senescence pathways. While some of the senescence
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regulatory genes and the pathways they function in have been identified many more
are still unknown. Significant advances in our understanding of senescence will
undoubtedly follow the cloning and analysis of the as yet unidentified gene products.
Further in depth study of the better characterised senescence pathways should also
facilitate a more in depth understanding. All of these lines of research should yield







Recombinase Activated Gene Expression
2.1. Introduction
The basic strategy of recombinase activated gene expression (RAGE) has now been
used by several different research groups, and although the exact molecular details
differ between individual groups, the approach remains very similar.
RAGE strategies are closely related to the promoter-trap system (Figure 2.1). This
approach takes advantage of the fact that linear pieces ofDNA introduced into
mammalian cells are capable of stably integrating into the genome. If the introduced
DNA encodes a selectable marker gene, clones that have undergone an insertion
event can be selected for. For example, cells transfected with the neomycin
phosphotransferase gene (neo) will survive selection with the antibiotic G418
(Southern & Berg, 1982). In the promoter-trap strategy promoter-less selectable
marker genes are transfected into mammalian cells and selected for on the basis of
marker gene expression. As the introduced marker gene was promoter-less,
expression can only result from the activity of an endogenous promoter adjacent to
the site of integration (Gossler et al, 1989). Clones that survive selection are
therefore predicted to represent integration events into the coding sequence of an
endogenous gene. Such an integration event has two consequences; first, it places
the selectable marker gene under the control of the endogenous promoter and second,
it disrupts the regulation of the endogenous gene. As such, the downstream gene
may no longer be transcribed or expressed because the insertion event renders it
effectively promoter-less, so-called insertional mutagenesis (Figure 2.1).
It is this simple idea, that the insertion of a piece of DNA between the promoter and
coding sequence of a gene will prevent the expression of that gene, which has been
developed into novel floxed STOP technology.
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Figure 2.1 - Mechanism ofAction ofPromoter Traps and Floxed STOP
Cassettes
A) If a constitutive promoter (black oval) is placed upstream of a marker gene
(blue box) high levels of marker gene expression will result. This is represented
by the graph at the left-hand side of the figure.
B) If a promoter trap construct (red box) is inserted between the promoter and
coding sequence of the marker gene, marker gene expression is inhibited.
C) As with the promoter trap strategy represented in B), the insertion of a tloxed
STOP between the promoter and coding sequence of the marker gene inhibits
expression.
D) In the presence of Cre recombinase the construct represented in C) will
undergo excisive recombination. The outcome will be loss of the STOP
sequence and one loxP site will be retained. Marker gene expression will be
restored.
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Normally, a promoter-trap insertion confers a total and irreversible block upon
downstream gene expression, whereas the use of a floxed STOP strategy should
permit conditional gene expression. This approach still relies on the insertion of
DNA encoding a STOP sequence acting to abolish downstream gene expression, but
additionally uses two directly repeated loxP sites on either side of the STOP
sequence (i.e. floxed) to render the promoter-trap conditional. After expression of
Cre recombinase, recombination will occur at the loxP sites resulting in excision of
the STOP cassette with only one loxP site remaining. As the 34bp of DNA that
comprise a loxP site are unlikely to affect transcription, the regulatory relationship
between the promoter and downstream gene should be restored and expression of the
downstream gene stimulated (see Figure 2.1).
2.2. Conditional Gene Expression - The Floxed STOP Approach
One of the earliest reports of the application of floxed STOP technology to achieve
conditional gene expression in vivo was in 1992 (Lakso et al, 1992). A transgene
was designed which contained the SV40 large tumour antigen (TAg), the lens-
specific murine a-crystallin promoter (maA) and a floxed STOP cassette. The
floxed STOP cassette used in this work consisted of two loxP sites, stuffer DNA (a
segment of the Yeast His3 gene, included to increase the size of the construct rather
than to encode an important function) and a polyadenylation signal (poly A). This
floxed STOP cassette was inserted between the maA and TAg sequences of the
transgene and Cre-mediated excision was used to control the expression of TAg. In
transgenic mice which carried the floxed STOP-TAg construct no TAg expression
could be detected indicating that any transcripts which initiated from the upstream
maA promoter were being efficiently terminated within the STOP sequence.
However, when these mice were mated with Cre-expressing mice efficient Cre-
mediated excision was observed in the doubly transgenic progeny. This resulted in
loss of the floxed STOP sequence and subsequent lens-specific expression of the
TAg gene driven by the maA promoter (Lakso et al, 1992). This paper demonstrated
the feasibility of using of the Cre/loxP system in mammals as well as demonstrating
Cre-mediated control of gene expression in vivo.
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In more recent examples of floxed STOP cassettes the stuffer DNA has been replaced
with promoter-less marker genes. This type of construct has several advantages,
marker gene expression can allow direct selection of cells that contain the floxed
STOP cassette and can also be used to assay the activity of the trapped promoter.
Furthermore, this type of construct has been demonstrated to work efficiently by
several research groups. Examples of promoter-less marker genes used in floxed
STOP cassettes include the chloramphenicol acetylase transferase (CAT) gene
(Araki et al, 1995), the neo gene (Kellendonk et al, 1996; Feil et al, 1997), the neotk
fusion gene (Russ et al, 1996) and the puromycin N-acetyltransferase (pac) gene
(Dias et al, 1998).
While the inclusion of a promoter-less marker gene within floxed STOP cassettes is
now standard, the success of Lakso et al (Lakso et al, 1992) has demonstrated that it
is not essential for the function of these constructs. As such the basic requirements
of a functional floxed STOP cassette are a poly A to efficiently terminate
transcription and two directly repeated loxP sites. This minimal floxed STOP
cassette lacking a marker gene or stuffer DNA and comprising of only a poly A and
loxP sites has been used successfully (Wagner et al, 1997; Gagneten et al, 1997).
There are two major concerns that must be addressed when using a floxed STOP.
The first is how efficiently the floxed DNA will be excised from the genome and the
second is how well the STOP sequence will function in abolishing downstream gene
expression. Notably, of the several groups that have used this approach few have
reported problems in either of these two areas. The efficiency of Cre-mediated
excisive recombination is not quantified by all authors as the process is normally very
efficient. In support of this, two published reports cite recombination frequencies of
over 90% for floxed STOP-containing transgenes as determined by Southern blot
analysis (O'Gorman et al, 1997; Orban et al, 1992). Several publications have also
reported the successful control of gene expression using various different floxed
STOP cassettes. FDCP1 haematopoietic precursor cells are strictly dependent on
interleukin 3 (IL-3) for survival and as such provide an excellent model system in
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which to study floxed STOP-regulated IL-3 expression (Russ et al, 1996). FDCP1
cells that contain a floxed STOP IL-3 transgene did not express IL-3 in the absence
of Cre recombinase as determined by sensitive survival assays. However, subsequent
expression of Cre within these cells caused excisive recombination and resulted in
the loss of the floxed STOP cassette. Such cells were then able to express high levels
of IL-3 and continued to proliferate despite the withdrawal of IL-3 from the culture
medium. Within the limitations of this assay system, both the absence of leaky
expression, and the efficient induction of expression after Cre recombinase-mediated
excision of the floxed STOP cassette were demonstrated (Russ et al, 1996).
2.3. Aims
a) Design and construct a floxed STOP cassette suitable for the regulation of both
exogenous and endogenous gene expression.
b) Demonstrate that the floxed STOP cassette is a functional substrate for Cre
recombinase.
c) Construct a test plasmid with which to assay the efficiency of floxed STOP-
mediated control of gene expression.
d) Introduce the test plasmid into cells and optimise a Cre delivery strategy
e) Analyse the effects of Cre expression upon floxed STOP-regulation of marker
gene expression.
2.4. Construction of pFloxSTOP
A relatively small body of literature exists concerning the use of floxed STOP
cassettes. Although several authors have reported the successful use of such
cassettes to regulate exogenous gene expression in vitro, there are no published
reports of floxed STOP-mediated control of endogenous gene expression in vivo.
However, when an analogous strategy using Flp recombinase and FRT sites flanking
a STOP cassette was applied to the fgf8 gene, a 45% reduction in gene expression
from the unrecombined targeted allele relative to wild type was observed (Meyers et
al, 1998). Therefore, although this particular STOP cassette was not working with
100% efficiency the experiment has demonstrated the feasibility of this approach.
125
The STOP cassette used by Meyers et al, consisted of a neo gene, a promoter and two
directly repeated FRT sites, "flrted" (Meyers et al, 1998). Although this fulfils the
minimum requirements for floxed or flrted STOP cassettes, one possible way to
increase the efficacy of the approach is to develop a novel STOP cassette that can be
used to control both exogenous and endogenous gene expression. The design,
construction and testing of this cassette, pFloxSTOP, are discussed below.
2.4.1. The pGT1.8IRESPgeo Plasmid
The starting point for the creation of the floxed STOP used in these studies,
pFloxSTOP, was the vector pGT1.8IRES(3geo. This plasmid was constructed by
Peter Mountford and obtained from the Centre For Genome Research, Edinburgh
(Figure 2.2). pGT1.8IRES(3geo was originally designed as a promoter-trap vector and
has five main components, a splice acceptor from the engrailed 2 gene (En-2SA), an
internal ribosomal entry site (IRES), a Bgeo gene which is a fusion of the LacZ
and neo genes, a polyadenylation signal from SV40 and a backbone derived from the
pUC19 plasmid (Mountford et al, 1994).
The En-2SA is a 1.8kb fragment derived from a genomic clone of the mouse
engrailed 2 gene that includes the splice acceptor from exon 7 of this gene (Logan et
al, 1992). The En2SA sequences were present to enable pGT1.8IRES(3geo to be
used as a promoter-trap vector. As discussed in Section 2.1, promoter traps work by
the integration of a reporter construct adjacent to an endogenous promoter whereby
successful promoter trapping is usually dependent upon the integration of the
construct into exonic sequences. The efficiency of promoter trapping can be
increased by the inclusion of a splice acceptor such that, after intronic insertion the
reporter gene, e.g. (3geo, would be expressed following appropriate splicing.
Experiments have shown that constructs lacking a splice acceptor generate 12-fold
less (3geo expressing clones than otherwise identical constructs which carry the splice
acceptor (Gossler et al, 1989).
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The pGTl. SIRES j3geo plasmid was the starting point for the construction of
pFloxSTOP. This plasmid was designed as a promoter-trap vector and was
constructed by Peter Mountford.
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The next functional domain of pGT1.8IRES(3geo is the 600bp Internal Ribosomal
Entry Site (IRES) derived from the 5' UTR of the Encephalomyocarditis virus
(ECMV) (Ghattas et al, 1991). IRES sequences allow the constructs which carry
them to express marker genes such as Pgeo, independently of the translation frame or
the coding/noncoding status of the insertion locus. The marker gene present in
pGT1.8IRES(3geo is the fusion gene Pgeo, generated by placing the neo gene (Beck
et al, 1982) in-frame at the 3' end of the LacZ gene (Kalnins et al, 1983). During the
construction of Pgeo the LacZ gene used was engineered to include an ATG codon
which can serve as an initiator of translation in eukaryotic cells (Friedrich & Soriano,
1991). The final functional element of pGT1.8IRESPgeo is the SV40
polyadenylation signal (polyA) (Mountford et al, 1994).
The following construction strategy was developed to convert the pGTl.8IRES.Pgeo
plasmid into a functional floxed STOP cassette.
a) Retain the En2SA splice acceptor, the Pgeo reporter gene and the SV40 poly A
signal.
b) Delete the IRES sequence (see also Figure 4.2).
c) Replace the plasmid backbone and insert two directly repeated loxP sites.
This work is discussed in subsequent sections.
2,4.1.1. Removal of the IRES From pGT1.8IRESPgeo
IRES removal was achieved via double digestion of pGT1.8IRESPgeo with the
restriction enzymes Bgl II and Hind III (Figure 2.3). After this digest had gone to
completion a 596bp fragment spanning the IRES was lost and non-compatible single
strand DNA (ssDNA) overhangs are generated. To permit the recircularisation of the
linearised plasmid the 5' ssDNA overhangs were blunted with Klenow fragment and
then ligated. The ligation reaction was used to transform competent bacteria and
resultant clones were screened for successful deletion of the IRES sequence by
restriction digest analysis (Figure 2.3).
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1.0% agarose/ethidium bromide gel.
Lane 1, molecular weight markers. Lane
2, pGT1.8IRESPgeo cut with Bgl II and
Hind III generates two products, 8849bp
and 569bp. Lane 3, the products of
pGT1.8IRESPgeo cleavage by Sac I,
2559bp and 6886bp. Lane 4, the
products of Xba I cleavage of
pGT1.8IRESPgeo, 4657bp and 4788bp.
These bands are so close in size that on





1.0% agarose/ethidium bromide gel.
Lane 1, molecular weight markers. Lane
2, Sac I digestion of pGT1.8(-
IRES)pgeo. The removal of the IRES
sequence brings the two Sac I sites closer
together hence one cleavage product,
1963bp, is 596bp shorter than in the
parental plasmid pGT1.8IRESPgeo
(parental product is 2559bp). The other
Sac I digest product of this plasmid,
6886bp, is unaffected by the IRES
deletion. Lane 3, Xba I digestion of
pGT1.8(-IRES)3geo. The deletion of the
IRES removes one Xba I site from this
plasmid so this enzyme now cuts once
only generating a single band at 8853bp.
Lane 4, Sal / cleavage of pGT1.8(-
IRES)Pgeo. This enzyme cuts twice in
this plasmid generating two cleavage
products of 2652bp and 620 lbp. The
latter of these products contains all the
components of a STOP cassette and was
subcloned during the construction of
pFloxSTOP.
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The pGTI 8(-IRES){3geo plasmid shown above is the end result after the IRES
sequence was deleted from the parental pGTl.SIRESpgeo plasmid (Figure 2.2)
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Having successfully deleted the IRES sequence, pGT1.8(-IRES)(3geo has all the basic
components of a STOP cassette (Figure 2.4). The final stage in the construction of a
floxed STOP from this plasmid was the insertion of two directly
repeated loxP sites flanking the STOP cassette. This was achieved by the
replacement of the pUC19 backbone of pGT1.8(-IRES)(3geo with a modified pTAg
backbone.
2.4,2. The pTAg Plasmid
The pTAg plasmid is a commercially available plasmid designed for the cloning of
PCR products (R&D Systems). It was supplied as a linear molecule with 3'
overhangs of one molecule of the base thymine. Conversely, PCR products
generated using standard Taq polymerase have 3' overhangs of one adenine molecule
added in a template-independent manner by the polymerase. These complementary
ssDNA overhangs allow PCR products to insert efficiently into the pTAg vector.
Because of the 3' overhangs on the linear pTAg plasmid it cannot recircularise
except in the presence of PCR derived inserts. However, the extremely useful
polylinker of the pTAg plasmid makes this molecule an attractive substrate for
cloning reactions involving none-PCR derived inserts. In order to obtain sufficient
pTAg plasmid for frequent use in standard cloning reactions it was necessary to
construct a circular form of the plasmid as the linearised molecule supplied
commercially cannot be propagated in bacteria. Because the pTAg plasmid had been
specifically designed not to circularise in the absence of insert, the non-
complementary 3' overhangs were blunted with T4 DNA polymerase and then
ligated. This blunting reaction altered none of the restriction sites within pTAg and
the result was a plasmid with a very useful polylinker used in several of the cloning
steps described in this thesis (Figure 2.5).
Once the pTAg plasmid had been circularised two other modifications were needed
to produce the floxed plasmid backbone used in the construction of pFloxSTOP. The
first was the insertion of two directly repeated loxP sites and the second was the
disruption of a Not I site in the polylinker to facilitate later subcloning steps.
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Figure 2.5 - The pTAg Plasmid
T7 promoter
Eco R I (92)








The circular form of the pTAg plasmid generated after the use of T4 polymerase to
blunt the commercially supplied linear molecule. Relevant restriction sites within
the polylinker are shown.
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2.4.2.1. Introducing the LoxP Sites
Two directly repeated loxP sites were introduced into the polylinker of pTAg in two
separate cloning steps. Both loxP sites were obtained as pairs of HPLC purified
oligonucleotides that were 5' phosphorylated during manufacture (Cruachem). All
four oligonucleotides were 40 bases in length, 34 bases of which encoded one strand
of a standard loxP site and 6 bases of which comprised one half of a specific
restriction enzyme recognition sequence. The full sequences of all four
oligonucleotides are shown in Figure 2.6.
The loxP sites were introduced sequentially and each pair of component oligos was
annealed prior to ligation. To insert the first loxP site, pTAg was digested with the
restriction enzymes EcoRI and Sal I. In case of incomplete double digestion the
linearised plasmid was also dephosphorylated using Shrimp Alkaline Phosphatase
(SAP, Amersham) to reduce background due to vector recircularisation. The SAP
treated linearised plasmid was then mixed with the appropriate pair of annealed
oligos, ligated and transformed into competent bacteria. As the insertion of a pair of
loxP oligonucleotides into the pTAg backbone introduced no new restriction sites
and the presence of an extra 40bp of DNA is not readily detectable on a standard
agarose gel, all clones were sequenced. DNA sequencing was also important to
identify and rule out any clones with concatemeric insertion events.
When one clone had been identified which contained the correctly inserted loxP
sequence, pTAg(ESloxP), the second loxP site was then cloned in. This was
achieved using a direct repeat of the process above except that the substrate plasmid,
pTAg(ESloxP) was digested with the restriction enzymes Sal I and Xba I and then
SAP dephosphorylated. As before, DNA sequencing was used to screen recombinant
plasmids resulting from this cloning step. The outcome of these cloning steps was
the production of a pTAg-derived plasmid that contained two directly repeated loxP
sites separated by one Sal I site, this plasmid was named pFloxpTAg (Figure 2.6).
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Figure 2.6 - Inserting LoxP Sites into the Backbone ofthe pTAg Plasmid
LoxP Pair 1
Eco RI
AAT TCA TAA CTT CGT ATA GCA TAC ATT ATA CGA AGT TAT G




TCG ACA TAA CTT CGT ATA GCA TAC ATT ATA CGA AGT TAT T
GT ATT GAA GCA TAT CGA ATG TAA TAT GCT TCA ATA AGA TC
Xbal
Each loxP site was composed of two 40 bp oligonucleotides. The oligos annealed in
a staggered fashion generating 4bp 5' ssDNA overhangs. Each 5' overhang was
designed as one half of a restriction digest cleavage site, the relevant sequences are in
bold text with the specific restriction enzyme site indicated. The two loxP sites were
cloned into the pTAg backbone sequentially, generating the pFloxpTAg plasmid with
a polylinker structure as shown below.



























Figure 2.7- Destruction of the Unique NotI Site in the pTAg Polylinker
A) Not I Linkers
Bgl II Sna BI Hind
5' GGC CAG ATC 7TA CGT AAA GCT T 3'
II III III I II II II II I
3' TC TAG AAT GCA T7T CGA ACC GG 5.
B) pFloxpTAg(25na BI)
2 3 4
Lane 1, molecular weight markers. Lane 2, Bgl II cleavage of pFloxpTAg(25'na BI).
The correctly inserted Not I linkers into the pFloxpTAg plasmid introduce a novel
Bgl II site, the linearised plasmid is 3876bp in size. The destruction of the Not I site
in the polylinker is confirmed by resistance to Not I digestion, the supercoiled
pFloxpTAg(25na BI) plasmid has a greatly increased mobility running at about the
2kb marker (Lane 3). Lane 4, molecular weight markers.
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The pFloxpTAg(2Sna BI) plasmid shown above is the product of the cloning steps
described in Sections 2.3.2.1 and 2.3.2.2. The plasmid contains two directly repeated
loxP sites and contains the Not! linkers thereby introducing a second Sna BI site in
the polylinker.
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2.4.2.2. Modifying the pFloxpTAg Polylinker
The unique Sal I site between the two loxP sites was designed to allow the
subcloning of selected DNA segments. The two directly repeated loxP sites will then
flank or "flox " the inserted DNA. To allow easy removal of the floxed DNA
sequences a simple digest strategy was needed to cut outwith the two loxP sites. It
was originally intended to use a double digest of Sua BI and Not I but while the blunt
end generated by Sua Bl is ideal for further subcloning reactions the overhangs
generated by Not I cleavage are more difficult to work with. To remove the Not I
site and replace it with a more useful cleavage site a pair of oligonucleotides were
designed (see Figure 2.7). As with the loxP oligonucleotides these were also
supplied with 5'phosphate groups (Cruachem) and were annealed prior to
subcloning. To insert the oligonucleotide pair into the Not I site the pFloxpTAg
plasmid was digested to completion with Not I, dephosphorylated and then ligated
with the annealed oligonucleotides. The insertion event was designed to destroy the
Not I site and replace it with a Bgl 77, a Hindlll and a second Sna BI site (Figure
2.1A). The correct integration of the oligonucleotides into the Not I site was
demonstrated by the acquisition of a novel Bgl II cleavage site and resistance to Not I
digestion (Figure 2.7B) generating pFloxpTAg(2Sna 57) (Figure 2.8).
2.4.3. Inserting the STOP Cassette into pFIoxpTAg(2Sna BI)
The final cloning step in the construction of pFloxSTOP was the insertion of the
STOP sequence derived from pGT1.8(-IRES)Pgeo into the pFloxpTAg(25na 57)
polylinker. The pFloxpTAg(2Sn<3 57) vector was linearised by Sal I digestion and the
STOP cassette-containing insert was also prepared by Sal I digestion of
pGT1.8(IRES)[3geo. These two components were ligated, transformed into bacteria
and resultant clones screened by restriction digest analysis. Insertion of the STOP
cassette was demonstrated via digestion with Sal I and the orientation of the insert
was established with Sac I digestion (Figure 2.9). The resultant plasmid was termed
pFloxSTOP (Figure 2.10a). The complete floxed STOP cassette in pFloxSTOP can
subsequently be excised with a single Sna BI (Figure 2.10b). Two blunt ended
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Figure 2.9 - Constructing pFloxSTOP; Inserting the STOP Cassette into the
pFloxpTAg(2Sna BI) Backbone







1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2, Sal
I digestion of pFloxpTAg(2Sna BI) generating a linear 3875bp vector backbone.
Lane 3, Sal I digestion of pGT 1.8(-IRES)Pgeo generates two products a 2652bp and
a 6201 bp STOP sequence-containing fragment. To construct pFloxSTOP the 6201bp
STOP fragment was subcloned into the pFloxpTAg(2Sna BI) plasmid. Sal I
digestion was used to screen the resultant clones. Sal I digestion of the pFloxSTOP
plasmid generates two cleavage products. A 3875bp pTAg backbone-derived
fragment and a 620lbp STOP cassette-derived fragment (Lane 4). Lane 6, Sac I
digestion was used to determine the orientation of the STOP cassette. The sample
shown in lane 6 has the STOP in the reverse orientation giving Sac / cleavage
products of 6197bp, 1967bp and 1912bp. The latter two products run as an
unresolved doublet. The pFloxSTOP plasmid and corresponding Sac I sites are
illustrated in Figure 2.11. Lane 7, Sna BI cleavage of pFloxSTOP results in two
products, a 3738bp product derived from the pTAg backbone and a 6338bp product
which includes the complete floxed STOP cassette.
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b) Below is a linear representation of the floxed STOP cassette which is excised

















cleavage products are generated; a 3738bp derived from the pTAg backbone and a
6338bp band that includes the complete floxed STOP (Figure 2.9).
2.5. Is pFloxSTOP a Functional Substrate For Cre Recombinase ?
2.5.1. Excisive Recombination in BNN 132 Cells
The availability of bacterial strains that constitutively express Cre recombinase
allows loxP site containing plasmids to be tested for recombination competence prior
to any lengthy in vitro or in vivo characterisation (Buchholz et al, 1996b). One such
commercially available Cre-expressing bacterial strains, BNN 132 (MoBiTec), was
used to test pFloxSTOP and related plasmids. Cultures of BNN132 cells were grown
up and competent cells generated using a standard calcium chloride protocol
(Sambrook et al, 1989). Competent BNN 132 bacteria were transformed with the
pFloxSTOP plasmid and plated onto LB-agar plates supplemented with the antibiotic
ampicillin (50pg/ml). The predicted outcome of Cre-mediated recombination will be
the generation of two plasmid species from the parental pFloxSTOP plasmid. First,
pTAg(BNN) which will be derived from the pFloxpTAg(2Sna BI) backbone and
contain one loxP site and second, pSTOP(BNN) which will be derived from the
STOP cassette and also contain one loxP site (Figure 2.11). However, as the
ampicillin resistance gene is present only on the pTAg(BNN) plasmid, only this
species will be represented in clones produced from the transformation of BNN 132
cells after selection with ampicillin. These predicted results were confirmed by
restriction digest analysis of ampicillin resistant (ampR) clones arising after the
transformation of BNN 132 cells with pFloxSTOP. Figure 2.12, lane 2 shows the
products of Sua BI digestion of pFloxSTOP, a 6338bp band containing the floxed
STOP cassette and a 3738bp band derived from pTAg backbone. Sna BI digestion of
plasmid DNA isolated from clones that resulted from the transformation of BNN 132
cells with pFloxSTOP generated only two cleavage products of 3738bp and 97bp,
only the former is visible in Figure 2.12, lane 3. This result is consistent with Cre-
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When the pFIoxSTOP plasmid is transformed into BNN 132 cells Cre-mediated
excisive recombination occurs. The result of this is two plasmid species, the first,
pSTOP(BNN), contains one loxP site and all of the STOP cassette. The second
species, pTAg(BNN), is derived from the plasmid backbone and also contains one
loxP site. Only pTAg(BNN) contains an ampicillin resistance gene so this should be
the only plasmid species represented in clones arising from the transformation.
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Figure 2.12 - Restriction Digest Analysis To Confirm That The pFloxSTOP





1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2, Sna
Bl digestion of pFloxSTOP. Two products are seen, a 6338bp band which
constitutes the floxed STOP cassette and a 3738bp band comprising the pTAg
backbone. Lane 3, Sna Bl digestion of pTAg(BNN) results in one band of 3835bp.
This plasmid is the outcome of pFloxSTOP transformation into BNN 132 cells. The




The work discussed above has reported the successful completion of the first two
aims of this chapter. First, the design and construction of a novel floxed STOP
cassette, pFloxSTOP. Second, the demonstration pFloxSTOP is a functional
substrate for Cre recombinase and undergoes excisive recombination in BNN 132
bacteria. The next sections of work focus on testing the capabilities of pFloxSTOP to
regulate exogenous gene expression in vitro.
2.7. Inducible Control of Gene Expression in vitro
In order to investigate the transcriptional control functions of the floxed STOP
cassette derived from pFloxSTOP a test construct, pFloxEGFP, was designed and
built. In the pFloxEGFP plasmid the floxed STOP cassette from pFloxSTOP was
inserted between the promoter and downstream coding sequence of a marker gene
thereby permitting an analysis of Cre recombinase-mediated conditional marker gene
expression (see Figure 2.13). The marker gene used in pFloxEGFP was the Enhanced
Green Fluorescent Protein gene (EGFP) and the basic experimental strategy is
illustrated in Figure 2.13.
The presence of the floxed STOP cassette in pFloxEGFP should block expression of
the EGFP marker gene in the absence of Cre recombinase. Transcription will initiate
from the upstream CMVie promoter and read through the floxed STOP cassette
before hitting the SV40 polyadenylation signal and terminating. While this should
prevent EGFP expression, the (3geo gene within the floxed STOP will be transcribed
and expressed. As a result cells that contain the unrecombined plasmid will be neoR
and should stain positively for (3-galactosidase expression (Friedrich & Soriano,
1991). After Cre mediated excisive recombination the (3geo containing-floxed STOP
cassette should be lost from both constructs. Cells that contain a recombined form of
the pFloxEGFP plasmid will no longer be neoR or stain positively for (3-galactosidase
but should now express the EGFP marker gene.
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Figure 2.13 - Research Strategy For the pFloxEGFP Plasmid
CMV loxP EGFP gene
Gene expression
The pFloxEGFP plasmid. In the unrecombined state the CMVie promoter (black
oval) is positioned upstream of the floxed STOP cassette (black arrows flanking the
red and blue boxes). This arrangement is predicted to prevent the expression of the
EGFP marker gene (green box) although the j3geo gene should be expressed from
within the floxed STOP cassette (dark blue box within red box). The relative levels
of gene expression are represented in the bar chart to the right of the figure.
The second figure illustrates the pFloxEGFP plasmid structure after Cre-mediated
excision of the floxed STOP cassette. The loss of the floxed STOP cassette is
predicted to abolish expression of Pgeo and stimulate expression of the second
marker gene, EGFP.
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2.7.1. The Enhanced Green Fluorescent Protein Gene
The EGFP gene (Cormack et al, 1996) is derived from the green fluorescent protein
(GFP) gene of the jellyfish Aequorea victoria (Prasher et al, 1992). The GFP gene
encodes a 238 amino acid protein able to fluoresce in a wide variety of cell types
without the need of any co-factors. The fluorescence is emitted from a chromophore
consisting of a cyclic tripeptide derived from Ser-Tyr-Gly in the primary protein
sequence of GFP (Cody et al, 1993). Nascent GFP is not fluorescent as chromophore
formation occurs post-translationally during cyclization and oxidation reactions
(Heim et al, 1994). GFP emits a green fluorescence (Xmax 508nm) in living cells after
stimulation with UV light (major absorbance peak 395nm, minor peak at 470nm).
Another significant property of the GFP protein is that fusions can be made to either
its C- or N- termini without affecting its fluorescent properties (Wang & Hazelrigg,
1994) and indeed commercial vectors are now available with this aim in mind
(Clontech).
Since the original GFP gene became widely available it has undergone several
refinements and improvements the result of which is the EGFP gene. EGFP encodes
a red-shifted variant of wild type GFP achieved by introducing two amino acid
substitutions, Phe64 to leucine and Ser65 to threonine into the wild type primary
sequence (Cormack et al, 1996). EGFP has an excitation peak at 488nm and an
emission maximum at 507nm making it ideally suited to the argon lasers used in flow
cytometry and for use with FITC filter sets for UV microscopy. These mutations
also confer other advantages, the fluorescence is brighter and the altered excitation
wavelengths mean that the fluorescence is more stable and less susceptible to
photobleaching. In addition to the two amino acid substitutions in the EGFP
sequence more than 190 silent base changes have been made which correspond to
human codon-usage preferences (Haas et al, 1996). This and the addition of a Kozak
sequence (Kozak, 1987) were designed to increase the expression of EGFP in
mammalian cells.
2.7.2. Construction of pFloxEGFP
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The pFloxEGFP vector was built with a simple one-step cloning reaction. The
pEGFP expression vector, pEGFP-Cl (Clontech, Figure 2.14), was linearised with
the blunt cutting restriction enzyme, Eco 47111 and dephosphorylated with SAP. The
aim was to insert the floxed STOP cassette excised from pFloxSTOP into the
Eco47111 site. The linear floxed STOP insert was prepared by digestion of the
pFloxSTOP plasmid with the restriction enzyme Sua BI. This generates two
cleavage products, a 3738bp pTAg backbone-derived fragment and a 6338bp
fragment that includes the floxed STOP cassette. The higher molecular weight
fragment comprising the floxed STOP cassette was then excised from the gel,
purified and ligated into the blunt, dephosphorylated pEGFP-Cl vector. Competent
bacteria were transformed with the ligation reaction mix and restriction digest
analysis used to identify those clones which contained the recombinant pFloxEGFP
plasmid (Figure 2.15).
Having successfully constructed pFloxEGFP (Figure 2.16) the next step was to
introduce it into mammalian cells and assay the effects of Cre recombinase on
marker gene expression.
2.7.3. Introduction of pFloxEGFP into ES Cells
ES cells were chosen as the test system for this plasmid for several reasons.
Extensive culture experience was available locally, standardised protocols for
electroporation and transient transfection ofDNA were already in existence and
published work had shown that the Cre/loxP system worked well in this cell type (for
example, Smith et al, 1995).
The pFloxEGFP plasmid was electroporated into passage 19 HM-1 ES cells (Magin
et al, 1992). Prior to electroporation the pFloxEGFP plasmid was linearised via
digestion with the restriction enzyme Sfi I. This enzyme cuts at a unique site within
the plasmid backbone of pFloxEGFP, distal to important functional domains of the
plasmid such as the CMVie promoter or EGFP coding sequence (Figure 2.16). This
146







pEGFP-Cl, the commercially supplied EGFP expression vector (Clontech). The Eco
47111 site into which the floxed STOP cassette was inserted is indicated as is the
unique Sfi 1 site.
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Figure 2.15 - Construction of the pFloxEGFP Plasmid
A)
3.0kb
1.0% agarose/ethidium bromide gel.
Lane 1, Eco 47III digestion of the
pEGFP-Cl plasmid generates a single
473 lbp cleavage product. Lane 2, Sna
BI digestion of the pFloxSTOP plasmid
generates two cleavage products, 3738bp









1.0% agarose/ethidium bromide gel.
Lane 1, Sac I digestion of pFloxEGFP
was used to orientate the floxed STOP
cassette insert. In the correct orientation
four cleavage products should be seen,
3998bp, 3193bp, 1912bp and 1967bp
(last two are seen as an unresolved
doublet). Lane 2, Sal 1 digestion of
pFloxEGFP. Three cleavage products
are observed, 620lbp, 4039bp and
830bp. Lane 3, blank. Lane 4,
molecular weight markers.
The Sal I and Sac I digests both
confirmed that the floxed STOP cassette
was in the correct orientation in
pFloxEGFP. The complete plasmid is
shown in Figure 2.16.
<-1 Okb
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The pFloxEGFP vector in which a floxed STOP cassette has been inserted between
the promoter, CMVif, and the EGFP marker gene. The orientation of the floxed STOP
cassette was confirmed by restriction digest analysis (Figure 2.15b) as it will function
correctly only in the orientation shown above. The Sfi I site used to linearise this
plasmid prior to introduction into mammalian cells is also shown.
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is significant as during the electroporation procedure linearised plasmids maybe
subject to degradation at the ends of the molecule.
Following electroporation the cells were put into medium containing 200|Xg/ml G418
and G418r clones became visible to the naked eye after 10-14 days. Over two
hundred clones were picked and expanded prior to analysis.
2.7.3.1. Analysis of G418R Clones
2.7.3.1.a. (3-galactosidase Expression
Of the first 64 G418R clones analysed, p-gal activity was only detectable in 14 (22%).
Of the 14 clones, 10 expressed high levels of (3-gal while the remaining 4 expressed
only low levels with a high degree of mosaicism. However, the successful
identification of 10 (3-gal positive clones meant that the remaining G418R clones
were not subjected to further analysis.
2.7.3.1.b. EGFP Marker Gene Status
Integration of the linear pFloxEGFP construct into the genome of HM-1 ES cells
introduces two novel marker genes. The first of these is the (3geo fusion gene that
confers resistance to the antibiotic G418 and expression of (3-gal. As the clones
arising from electroporation of HM-1 cells with pFloxEGFP had survived exposure
to 200pg/ml of G418 and 14 of the 64 clones analysed expressed histochemically
detectable (3-gal, the only marker gene which could not be assayed directly at this
stage was the EGFP gene. The presence of the floxed STOP cassette in pFloxEGFP
abolishes EGFP expression but it was vital to establish whether or not the full length
EGFP coding sequence was present in the (3geo positive clones.
With this aim in mind a PCR was designed with primers that anneal within the |3geo
gene of the floxed STOP and at the extreme 3' end of the EGFP gene (Figure 2.17a).
Genomic DNA samples were prepared from the 10 G418R/(3gal positive clones and
subjected to PCR analysis, the results are shown in Figure 2.17b. The presence of
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The structure of the intact pFloxEGFP-derived transgene. The respective positions of
the neo and EGFP PCR primers and predicted product size are indicated.
b)
1.0% agarose/ethidium bromide gel showing the neo-EGFP PCR results. Lanes 1 and
14, MW, molecular weight markers. Lanes 2-11 each represent one clone, the
number ofwhich is listed above. All clones except FE62 and FE63 contain the full
length EGFP sequence as determined by PCR Lane 12, PCR blank. Lane 13, PCR
positive control (1.10,000 dilution of pFloxEGFP plasmid).
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the 1213bp PCR product identified those clones that contained the full-length EGFP
sequence and of the 10 clones examined the full-length EGFP coding sequence could
be detected in 8. One such clone, FE13 which was PCR positive and expressed high
levels of (3-gal was selected for further analysis.
2.8. Clone FE13 - Introducing Cre Recombinase
The aim of this next section of work was to develop a strategy to express Cre
recombinase within FE13 cells and to analyse the effects upon marker gene
expression. The first method considered was the transient transfection of FE13 cells
with Cre-encoding plasmids. However, only relatively low transfection efficiencies
were achieved, using both lipofection and electroporation, and Cre-mediated
recombination could not be detected (data not shown). Another reason for the poor
results obtained with transient transfection could be low levels of Cre expression
from the introduced plasmid, Cre-5 a gift from Dr. T. Gardner (see Appendix 1).
Two alternatives were considered in parallel in an attempt to overcome this problem,
first, the construction of another Cre expression vector with an alternative promoter
sequence (Section 2.8.1) and second, the use of replication-defective recombinant
adenoviridae (Section 2.8.2).
2.8.1. Characterisation of an ES Cell Differentiation State-Specific Promoter
Sequence
2.8.1.1. Background
As discussed above, one approach to permit the expression of Cre recombinase in
FE13 cells was to develop a new vector that would drive high levels of Cre
expression in ES cells. As part of this work, in collaboration with Dr. J. Quinn and
Dr. C. Fiskerstrand from the Department of Veterinary Pathology, Edinburgh
University, the promoter activity of a novel region of the rat preprotachykinin gene
(rPPT) was characterised in murine ES cells. Dr. C. Fiskerstrand constructed and
supplied all plasmids and prepared the protein extracts from transfected cells,
however the ES cell culture was carried out by myself.
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The rPPT gene encodes the neuropeptides substance P, neurokinin A, neuropeptide K
and neuropeptide y, which are derived by alternative splicing and post translational
processing of the peptide precursors (Maggio, 1988). Sequences derived from the
promoter of this gene have already been demonstrated to restrict expression to
neuronal cells in vitro but do not support transgene expression in vivo (Mulderry et
al, 1993). Therefore, it was of interest to characterise the enhancer activity of a novel
intronic domain within the rPPT gene, consisting of a CCCT repeat motif, which had
not been previously characterised due to a high level of genetic instability. This
domain was cloned upstream of a luciferase marker gene and basal promoter (pGL3p,
Promega) and the resultant plasmid, CCCT-pGL3p, was then transfected into HeLa
and ES cells and the levels of luciferase expression quantified.
ES cells are pluripotent and undifferentiated however, the maintenance of this stem
cell phenotype is an active process. Several protocols have been developed which
promote the differentiation ofES cells (reviewed in Hooper, 1982). As certain
elements of the rPPT promoter had already been shown to restrict marker gene
expression to differentiated cells it was of interest to compare the enhancer activity of
the novel CCCT repeat motif in undifferentiated and differentiating ES cells. There
are two basic protocols to stimulate ES cell differentiation, first, the withdrawal of
LIF and second, the addition of retinoic acid (RA). The withdrawal ofLIF induces the
differentiation ofES cells into a mixture of visceral and parietal endoderm-like and
mesoderm-like cells (Mummery et al, 1990). Neuronal cells constitute only a small
percentage of the cell types observed after LIF withdrawal, although this yield can be
increased by exposure to RA (Gajovic et al, 1997). Hence, ES cells were transfected
in the presence or absence ofLIF and RA (all trans RA, dissolved in ethanol, over the
range 0-500pM) and luciferase expression quantified.
2.8.1,2. Results
As shown in Figure 2.18A the level of luciferase expression driven from both the
pGL3p and CCCT-pGL3p plasmids was cell type specific. Low levels of luciferase
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Figure 2.18 - Investigation of the Enhancer Activity of the CCCT RepeatMotif











HeLa ES + lif ES - lif
^ pGL3p
I—| CCCT-pGL3p
Luciferase expression from cells transfected with either the basal luciferase
expression vector (pGL3p) or the vector with the CCCT putative enhancer present
(CCCT-pGL3p). Luciferase units are normalised using RSVCAT expression in each
sample to correct for transfection efficiencies. A similar number of HeLa and ES
cells were used in each experiment and transfections were carried out in triplicate
(error bars are standard error of the mean).
B)
The enhancer activity of the rPPT Intron 2 CCCT element is shown as the increase in
luciferase units over the basal activity of the expression vector. Results are corrected
for transfection efficiencies. Data is shown as + and - LIF at increasing retinoic acid
concentrations from 0-500pM (error bars are standard error of the mean).
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were expressed from both plasmids after transfection into HeLa cells. Higher, but
not significantly different levels of luciferase expression were detected when both
plasmids were transfected into undifferentiated ES cells cultured in the presence of
LIF. However, the withdrawal of LIF over the 64-hour period of transient
transfection resulted in a 150-fold increase of luciferase expression from the CCCT-
pGL3p plasmid relative to the control plasmid. Hence the molecular changes
initiated in ES cells by the withdrawal of LIF were sufficient to permit the CCCT
repeat motif to prevent the inhibition of luciferase expression observed with the
control plasmid. One interpretation of these data is that the CCCT element is able to
act as a transcriptional enhancer, an effect not further enhanced by exposure of
transfected cells to a variety of RA doses.
In conclusion, the rPPT-derived CCCT element can permit high levels of marker
gene expression in differentiating ES cells. However, no attempts were made to
utilise this enhancer for the expression of Cre recombinase as the recombinant
adenovirus approach, investigated in parallel, yielded encouraging results. This work
is discussed in the following section.
2.8.2. Replication-defective Recombinant Adenoviridae
Several groups have developed replication-defective recombinant adenoviridae and
all are constructed along similar lines but differ in the heterologous protein that they
have been engineered to express. The virus is rendered replication-defective by the
insertion of an expression cassette and simultaneous deletion of endogenous genes
that are essential for replication. One such virus in which the El region has been
replaced with a Cre recombinase expression cassette, AdCre, was obtained from M.
Anton and FL. Graham (Anton & Graham, 1995).
The adenovirus approach has several advantages, the virus is able to efficiently infect
a wide variety of cell types, both replicating and quiescent, at a high efficiency. Once
inside cells the constitutive promoter, human CMVje drives high levels of Cre
recombinase expression from the expression cassette present in AdCre. Because
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AdCre is non-replicating the virus behaves as an episomal molecule and will be
gradually lost from dividing cells and in this respect AdCre acts as a high efficiency
method of transiently transfecting mammalian cells with Cre recombinase.
At the time of this work only one publication had reported the successful use of
adenovirus to infect murine ES cells (Aladjem et al, 1998). The authors had
indicated that very high titres of virus were needed to infect undifferentiated ES cells
(at least 5 x 109 particles per 5 x 105 cells) but no data were included in this paper
about the actual multiplicity of infection (m.o.i.) used. For this reason it was
necessary to determine an optimal adenovirus m.o.i that resulted in a high level of
infection without any obvious cytopathic effects.
2.8.2.1. Determination of the Optimum Adenovirus Titre for ES Cell Infection
Because the AdCre recombinant adenovirus does not express any readily detectable
marker genes, the optimum titre of adenovirus for efficient infection of ES cells was
determined using an alternative recombinant adenovirus, AdLacZ which expresses (3-
gal, also obtained from M. Anton and FL. Graham (Anton & Graham, 1995).
Undifferentiated HM-1 ES cells were plated out at identical densities and each
sample was then infected with a different titre of AdLacZ, either 50 m.o.i, 200 m.o.i
or 1000 m.o.i. Twenty-four hours after infection the cells were fixed and stained for
(3-gal expression (Figure 2.19). At both 50 m.o.i. and 1000 m.o.i, a similar number
of (3-gal positive cells were present. However, the majority of (3-gal positive cells
were in fact differentiated ES cells that make up a percentage of the ES cell
population in any given culture. It is only when the efficiency of infection of
undifferentiated ES cells was examined that differences between the AdLacZ titres
become apparent. No undifferentiated ES cell infection was seen in the two lower
titres used in this experiment (Figure 2.19A). It is only at 1000m.o.i. AdLacZ that
small numbers of (3-gal positive undifferentiated ES cells can be visualised (Figure
2.19B). In support of this observation, the preferential infection of differentiated ES
cells has been reported elsewhere (Aladjem et al, 1998). However, rather than use
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Figure 2.19 - Histochemical Detection offi-gal Activity; Results ofAdLacZ-
infection of Undifferentiated ES Cells
1) B-gal staining results after undifferentiated ES cells exposed to 50 m.o.i. of
AdLacZ.
A) Photograph taken without phase at xlOO magnification. Blue staining cells are
clearly visible.
B) Duplicate photograph of the cells shown in 1A) but taken here with phase at xlOO
magnification. In this image morphological details of the cells can be seen. In the
centre of the image a group of undifferentiated ES cells can be seen. By
comparison with image 1A), such cells do not express histochemically detectable
B-gal activity and have therefore not been infected with AdLacZ. At the
extremities of the photograph large cells with irregular size and morphology are
seen, these are differentiated ES cells. By comparison with image LA), such cells
express high levels ofB-ga! and have therefore been infected by AdLacZ.
Therefore, at 50 m.o.i., only differentiated ES cells are infected by the recombinant
adenovirus, AdLacZ.
2) B-gal staining results after undifferentiated ES cells exposed to 1000 m.o.i. of
AdLacZ.
A) Photograph taken without phase at xlOO magnification. Blue staining cells are
clearly visible.
B) Duplicate photograph of the cells shown in 2A) but taken here with phase at xlOO
magnification. In this image morphological details of the cells can be seen. In the
centre of the image a group ofundifferentiated ES cells can be seen. By
comparison with image 2A), a percentage of such cells do express histochemically
detectable B-gal activity and have therefore been infected with AdLacZ. At the
extremities of the photograph large cells with irregular size and morphology are
seen, these are differentiated ES cells. By comparison with image 2A), such cells
express high levels of B-gal and have therefore been infected by AdLacZ.
Therefore, at 1000 m.o.i., both differentiated and undifferentiated ES cells are
infected by the recombinant adenovirus, AdLacZ. However, even at this relatively
high viral titre a low efficiency of undifferentiated ES cell infection is observed.
Figure 2.19 - Histochemical Detection offi-galActivity; Results ofAdLacZ-
infection ofUndifferentiated ES Cells
1) With 50 m.o.i AdLacZ (xlOO)
A) (Bright field) B) (With phase)
B) (With phase)
2) With 1000 m.o.i. AdLacZ (xlOO)
A) (Bright field)
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extremely high titres of adenovirus to infect undifferentiated FE13 cells it was
decided to deliberately differentiate ES cells in culture prior to adenovirus infection.
2.8.2.2. AdCre Infection of Differentiated of FE13 ES Cells
FE13 cells were differentiated according to standard procedures (reviewed in Keller,
1995). The cells were then infected with 50 m.o.i of AdCre and control plates of
differentiated HM-1 and FE13 ES cells and were mock-infected. Immediately after
infection zero hour time-points of mock infected HM-1 and FE13 cells were
harvested. Seventy-two hours after infection, the infected cells and the mock-
infected control samples were also harvested. At each time-point the harvested cells
were divided into multiple samples for analysis including protein extract preparation,
samples for FACS and UV microscopy, preparation of genomic DNA and total RNA.
2.8.2.2.a. Episomal AdCre Detection
Adenoviridae only rarely integrate into the host genome and are instead thought to
persist as extrachromosomal molecules (Stratford-Perricaudet et al, 1992). The
presence of these episomal molecules in DNA extracts prepared from infected cells
can be detected by PCR, using primers that anneal within the Cre expression cassette
of AdCre (designed by Dominic Rannie). The 660bp band visible in Figure 2.20,
lane 4 suggests the successful infection of differentiated FE13 cells.
Having demonstrated that AdCre is capable of infecting FE13 cells the next step was
to demonstrate that the recombinant virus was expressing functional Cre
recombinase. This was achieved by examining the recombination status of the
pFloxEGFP transgene in FE13 cells.
2.8.2.2.b. pFloxEGFP Recombination Status
Genomic DNA was prepared from FE13 cells harvested at Ohrs, 72hrs(mock
infected) and finally 72hrs(AdCre-infected) and the recombination status of the
transgene present in the genome of FE13 cells was analysed by both PCR and
Southern blot.
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Figure 2.20 - PCR Detection ofEpisomal Adenovirus Molecules
2.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
DNA sample from uninfected FE13 cells. Lane 3, positive control sample supplied
by D. Rannie ofDNA extracted from cells known to be infected with AdCre. Lane
4, DNA sample prepared from AdCre infected FE13 cells (72hr timepoint). The
660bp band diagnostic of the presence of episomal AdCre molecules within genomic
DNA can be seen in both lanes 3 and 4.
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En-2 intron + SA SV40 pA
Sal I (2881) Sal I (9082)
1 I
Lox2 loxl
CMV IE promoter EGFP gene
Kan R pUC ori Lac-Z-Neo Neo Sal I (9912
#
CMV neo -►<- EGFP
pFloxEGFP transgene I213bp
11070 bp
The structure of the complete pFloxEGFP transgene with the relative positions of the
CMV, neo and EGFP primers indicated. Prior to Cre-mediated excisive





Kan R pUCori loxl Sal I (3671)
CMV "► EGFP, 1325bp
Recombined pFloxEGFP transgene
4829 bp
After excisive recombination has occurred the neo primer binding site is lost and the
alternative upstream primer, CMV together with the EGFP primer, generates= a
recombination specific 1325bp product.
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Figure 2.22 - Results ofthe pFloxEGFP Recombination Status-Specific PCR
1 Okb—^
1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2, the
1213bp PCR product amplified from genomic DNA harvested from cells at the Ohrs.
uninfected timepoint. Lane 3, the 1213bp PCR product amplified from genomic DNA
harvested from cells at the 72hrs. uninfected timepoint. Lane 4, the 1213bp PCR
product amplified from genomic DNA harvested from cells at the 72hrs. AdCre
infected timepoint. Lane 5, negative control (water). Lane 6, molecular weight
markers. Lane 7, blank, no 1325bp recombination-specific is amplified from genomic
DNA harvested from cells at the Ohrs. uninfected timepoint. Lane 8, blank, no
1325bp recombination-specific is amplified from genomic DNA harvested from cells
at the 72hrs. uninfected timepoint. Lane 9, the 1325bp recombination-specific PCR
product amplified from genomic DNA harvested from the 72hrs AdCre infected
timepoint. Lane 10, negative control (water).
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i) PCR Strategy
A PCR strategy was designed which generated recombination status-specific
products (Figure 2.21). In the unrecombined state, the primer pair neo and EGFP are
predicted to generate a 1213bp product from the integrated transgene present in FE13
cells (Figure 2.21). However, after Cre-mediated recombination has occurred the
floxed STOP cassette is excised and the neo primer binding site lost. The third
primer CMV then pairs with EGFP to generate a recombination specific 1325bp PCR
product.
These two PCR reactions were carried out on genomic DNA harvested from AdCre-
or mock-infected FE13 cells and the results are shown in Figure 2.22. The
neo/EGFP primer pair gives rise to a 1213bp band from all DNA samples indicating
that the unrecombined transgene is still present even in AdCre-infected FE13 cells.
However, the 1325bp recombination-specific CMV/EGFP product is only amplified
from genomic DNA prepared from AdCre-infected cells (Figure 2.22, lane 9). The
presence of this 1325bp PCR product is diagnostic that Cre-mediated excisive
recombination has occurred only in AdCre-infected cells and demonstrates the
production of functional Cre recombinase by AdCre. However, this PCR reaction is
not quantitative and cannot be used to assess the efficiency of Cre-mediated
recombination in FE13 cells.
ii) Southern Blot Strategy
FE13 genomic DNA was digested with the restriction enzyme Hind 111. This enzyme
was selected as it generates recombination status-specific cleavage products, a
7090bp product from the unrecombined transgene (Figure 2.23A) and an 849bp
digest product from the recombined transgene (Figure 2.23B). These digest products
were detected by hybridisation with a radiolabeled EGFP-derived probe, the relative
location of the probe sequence is shown on Figure 2.23. The EGFP probe used was a
600bp PCR product amplified from the EGFP gene using the primers CAP and
EGFP (see Chapter 6, Section 6.1.14.3.b). The result of this Southern blot strategy is
shown in Figure 2.24.
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Figure 2.23 - Southern Strategy for the pFloxEGFP Plasmid
A) ATG site













Diagram to illustrate the Southern blot strategy to monitor Cre-mediated excisive
recombination in FE13 cells. Digestion of genomic DNA from FE13 cells with Hind
III should generate a 7090bp band which will hybridise with the EGFP probe
indicated (thick black line).
B)









After Cre-mediated excisive recombination has occurred, digestion of FE13 genomic
DNA with Hind III is predicted to yield an 849bp band which will hybridise with the
EGFP Southern probe indicated.
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Figure 2.24 - FE13 Southern Blot Result
Photograph of autoradiograph obtained from Hind Ill-digested FE13 genomic DNA,
transferred onto a filter and than probed with a radiolabeled EGFP probe. Lane 1,
genomic DNA harvested from control uninfected FE13 cells. Two bands are visible, the
7090bp digest product derived from the unrecombined pFloxEGFP transgene and a +8
kb digest product which presumably represents incomplete digestion of the genomic
DNA. Lane 2, genomic DNA harvested from AdCre-infected (50 m.o.i) FE13 cells. As
in lane 1, two bands are visible, the 7090bp digest product derived from the
unrecombined pFloxEGFP transgene and the +8kb incomplete digest product. However,
the 849bp digest product derived from the recombined pFloxEGFP transgene was not
detected in this lane. Approximate size markers are shown at the left-hand side of the
photograph, these were calculated from the positions of molecular weight markers on the
original agarose gel (not shown).
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The 7090bp digest product generated from the unrecombined pFloxEGFP transgene
was detected in both the FE13 mock-infected and FE13 AdCre-infected genomic
DNA samples (indicated on Figure 2.24). Both lanes also contain a higher molecular
weight band (approximately 8-9kb) which probably represents incomplete digestion
of the genomic DNA. However, the 849bp digest product diagnostic of Cre-
mediated excisive recombination was not detected in genomic DNA isolated from
AdCre-infected FE13 cells. The possible reasons for this are discussed further in
Section 2.9.
2.8.2.2.C. EGFP Expression Data
If the floxed STOP cassette present in pFloxEGFP functions as predicted, in the
absence of Cre recombinase EGFP expression should be inhibited. However, after
Cre-mediated loss of the floxed STOP cassette high levels of EGFP should be
expressed (see Figure 2.13). Three methods were used to monitor levels of EGFP
expression, Fluorescence Activated Cell Sorting (FACS), UV microscopy and RT-
PCR.
i) FACS and UV Microscopy Data
As already mentioned FE13 cells were infected with AdCre and control FE13 and
HM-1 cells were simultaneously mock infected. Cell samples were harvested at Ohr
and 72hr timepoints, and were transferred to storage at -70°C. Prior to FACS
analysis all cell samples were defrosted simultaneously, washed in PBS and then
resuspended in PBS. A small aliquot of cells from each sample were transferred onto
chamber slides and visualised by UV microscopy (FITC filter set). Positive control
cells transiently transfected with the pEGFP-Cl plasmid (Figure 2.14) were
immediately obvious when viewed using a UV microscope, however, no fluorescent
cells were seen in the FE13 samples. This observation was supported by FACS data.
The remaining cells from each sample were not fixed and so were subjected to FACS
analysis immediately. Ten thousand cells from each sample were analysed in
triplicate using a Coulter EPICS XL-MCS flow cytometer measuring the
166
Figure 2.25 - EGFP Expression Data
A) FACS data
B) Bar chart of the MnIX values from triplicate samples of HM-1 control AdCre
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fluorescence emitted by each cell in a 488nm argon laser. The forward scatter (FS),
side scatter (SS) and fluorescent light emissions of the samples were measured
between the wavelengths of 489nm-700nm. The data was then presented as a scatter
plot and histogram as shown in Figure 2.25A.
The excitation maximum of the EGFP protein is 488nm and the emission maximum
is 507nm, these characteristics make it an ideal fluorescent marker gene for use in
flow cytometry. However, when the mean fluorescence (MnIX value) of the three
cell populations represented in Figure 2.25A, HM-1 mock infected, FE13 mock-
infected and FE13 AdCre-infected, is plotted as in Figure 2.25B no increase in MnIX
value is observed in the FE13 AdCre-infected cell population. There is no significant
difference between the MnIX values of any of the cell populations shown in Figure
2.25 (p>0.05, Mann-Whitney U test, two-tailed).
ii) Semi-quantitative RT-PCR Detection of EGFP mRNA
As expression of the EGFP protein from the recombined pFloxEGFP transgene could
not be demonstrated by UV microscopy or FACS analysis an RT-PCR strategy was
designed in an attempt to quantify, within the limitations of this technique, the levels
of EGFP transcription. Two pairs of PCR primers were used, firstly, BA4 and BA15
which generate a 440bp band from the mouse (3-actin cDNA and secondly CAP and
EGFP which generate a 600bp band from the EGFP cDNA.
In order for PCR to be quantitative the reaction must terminate during the log phase
of product amplification. During this phase, the product concentration has a log
linear relationship with the original template concentration. To determine the log
phase of the EGFP PCR reaction, 21 reaction mixes were prepared as described in
Chapter 6, Section 6.1.14.3.b and three tubes were removed after 20, 23, 25, 27, 30,
32 and 35 of the programme thermal cycles had been completed. The PCR products
were then electrophoresed through a 2% agarose gel and the relative intensity of all
of the products analysed with EASY Analysis gel documentation software. In
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2.0% agarose/ethidium bromide gel. Three sample tubes were removed from the
thermal cycler at each of the cycle numbers indicated above the gel. lOpl of each
product for cycles 20-27 and 5ptl for cycles 30-35, was then loaded on the above gel.
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Linear and logarithmic plots of the relative intensities of the PCR products shown in
the above gel after standardisation for gel loading.
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log phase, these results are shown in Figure 2.26A and B. As the log phase for the (3-
actin PCR had already been determined as cycle number 31 it was unnecessary to
repeat this process for this PCR reaction (Wallace, 1997).
Total RNA was harvested from FE13 AdCre-infected and control cells and equal
amounts of RNA from each sample were converted to cDNA via reverse
transcription. The cDNA produced in these reactions was then used as a template for
both the p-actin and EGFP PCR reactions. The thermal cycler programmes for each
reaction were amended to terminate within the pre-determined log phase cycle
number. PCR products were then electrophoresed through a 2.0% agarose gel and
the relative intensity of the products was quantified using EASY Analysis gel
documentation software. Triplicate samples of RNA harvested from FE13 mock-
infected cells (Ohr and 72hr timepoints) and AdCre-infected FE13 cells (72 hr
timepoint) were analysed in this manner and the results are shown in Figure 2.27.
A 440bp p-actin PCR product was amplified efficiently from all cDNA samples.
However, the 600bp EGFP PCR product can was also detected in all cDNA samples
irrespective of the exposure of the cells to AdCre. This result indicates that the
floxed STOP cassette present in the pFloxEGFP transgene within EE 13 cells does not
block transcription of the EGFP marker gene with 100% efficiency. If the ratio of P-
actin to EGFP PCR products present in Figure 2.21A is calculated an approximate
two-fold induction of EGFP mRNA is seen in the AdCre infected cells (Figure
2.27B, p<0.05, Mann-Whitney U test, two-tailed).
iii) Confirmation of the Absence of EGFP protein
As discussed above, the infection of FE13 cells with AdCre resulted in Cre-mediated
excisive recombination, as detected by PCR, and a small but significant upregulation
of EGFP mRNA. However, no fluorescent EGFP protein was detected by FACS
analysis or UV microscopy. To confirm this surprising observation a repeat AdCre-
infection (50 m.o.i) using a new viral stock, was carried out on differentiated FE13
cells. Twenty-four hours after infection cells were harvested and half of the sample
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Figure 2.27 - qRT-PCR Data on fi-actin and EGFP Expression
A)
OUN 72 UN 72 CRE








Top gel, lOul of the 440bp (3-actin PCR product amplified from cDNA templates
prepared from three cell samples, FE13 Ohr uninfected, Fel3 72 hr uninfected and
FE13 72hr AdCre infected. Lower gel, 10pl of the 600bp PCR product amplified
from cDNA templates prepared from three cell samples, FE13 Ohr uninfected, Fel3
72 hr uninfected and FE13 72hr AdCre infected.
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B) Bar chart illustrating the mean relative intensities of the p-actin and EGFP PCR













C) Bar chart illustrating the ratio of the relative intensities of the P-actin and EGFP
PCR products amplified from cDNA prepared from the three timepoints, FE13 Ohrs















used for protein extract preparation while the remaining cells were examined by UV
microscopy. A comparable decrease in P-gal activity was seen between the AdCre-
and mock-infected cells (from 57pU/pg to 20jLtU/ptg after AdCre infection, detailed
data not shown) as shown in Figure 2.28 indicating a similar efficiency of infection
had occurred. However, when samples from both populations of cells were
examined under UV light no fluorescent cells were visible. This experiment
confirmed the observation that Cre-mediated excision of the floxed STOP cassette
from pFloxEGFP plasmid is insufficient to permit the upregulation of EGFP protein.
2.8.2.2.d. p-galactosidase Expression Data
As shown in Figure 2.13, the recombination status of pFloxEGFP influences the
expression of two maker genes, the fusion gene Pgeo, encoding the P-gal and neo
genes, and EGFP. In the absence of Cre-mediated recombination, the constitutive
CMVie promoter should drive high levels of expression of the Pgeo fusion gene.
After excisive recombination, the floxed STOP cassette will be lost, the Pgeo gene
deleted, and expression abolished. The P-galactosidase Enzyme Assay Kit
(Promega) was used to quantify the levels of P-gal activity in protein extracts
prepared from FE13 cells exposed to or mock treated with AdCre. However, a
comparison of P-gal activity levels in protein extracts prepared from uninfected
control cells and those from AdCre-infected cells revealed only a small decrease
(data not shown). There were two possible explanations, first that Cre-mediated
recombination had occurred at a low frequency within the FE13 cells or second, that
the stability of the bacterial P-gal protein in mammalian cells resulted in its retention
in cells even after expression had been abolished (Yang et al, 1995). To determine
which of these factors was responsible a second AdCre infection was set up and the
levels of P-gal activity in FE13 cells were analysed daily for one week after infection.
i) P-gal Activity
The amount of P-gal activity present in the total protein extracts prepared from FE13
cells exposed to AdCre or mock-infected was measured using the P-galactosidase
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Figure 2.28 - fi-galactosidase Expression Data Over a 7 day Timecourse
Graph illustrating the levels of (3-gal activity (microunits/ng of total protein) in
control uninfected FE13 cells and FE13 cells infected with AdCre. P-gal activity
was determined using a (3-galactosidase Enzyme Assay Kit (Promega) and
standardised for protein concentration. Triplicate samples were analysed and mean
(3-gal activity values are plotted.
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Enzyme Assay Kit (Promega). The results are shown in Figure 2.28. The average
level of P-gal activity in the control cells remains at approximately 53pU/pg over 7
days. However, a significant decrease in P-gal activity was seen in the AdCre-
infected cells. Twenty four hours after infection the level of P-gal activity has
decreased from 47.9pU/pg to 5.12|iU/pg (approx. 90% decrease). This significantly
reduced level of expression was maintained over 7 days (p<0.05, Mann-Whitney U
test, two-tailed). Note, AdCre-infected cells displayed a slight growth impairment
and therefore a minimum number of timepoints were analysed (Days 1, 5 and 7). In
the mock treated sample it was possible to harvest material daily.
ii) Histochemical 3-gal Detection and Scoring
As well as quantifying the level of P-gal expression in FE13 cells using the above
protein assay, P-gal expression was also monitored via histochemical visualisation
and scoring. Cells harvested over the 7-day period were transferred onto 100mm
culture dishes and allowed to grow until small, discrete clones (approximately 50-
100 cells) became visible. These were then fixed and stained. A 5-Bromo-4-chloro-
3-indolyl galactopyranoside (X-gal) based stain was used as the cleavage of the X-gal
substrate by the P-gal enzyme produces a local blue precipitate. The number of blue
clones and white clones visible on each culture dish was then scored. It should be
noted that mosaicism was observed in all cultures of FE13 cells. Other groups using
the pgeo marker gene have also reported this observation (Friedrich & Soriano,
1991). For this reason the stained populations of clones were divided into four
groups, those which were uniformly dark blue staining, those which were uniformly
pale blue staining, those which displayed mosaic staining and finally clones which
were completely white. Photographs of a representative clone from each of these
groups are shown in Figure 2.29.
The number of each of the above four clone types in the AdCre-infected, and mock
treated FE13 cultures, was scored in order to determine their relative proportions. It
was necessary to establish a running mean to determine the minimum number of
clones to count in order to produce accurate data. As shown in Figure 2.30, the
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Figure 2.29 - Photographs of the Four Clone Types Scored After fi-gal Staining of
FEB Cells
1) Navy Blue (xlOO) 2) Pale Blue (xlOO)
3) Mosaic (xlOO) 4) White (xlOO)



















An example of the data generated when the numbers of navy blue, pale blue, mosaic
and white clones present in FE13 cells 2 days after infection with AdCre were scored
as a running mean. Each point represents the running mean (%) of that clone type
when 50-60 clones were scored. When the mean value stabilised, i.e. when the
inclusion of counts from the next set of 50-60 clones were included and the mean
remained unchanged, no further clones were scored.
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Figure 2.31 - Percentage ofClone Subtypes in Control andAdCre-infected
FE13 Cells
A)
This graph shows the % of each clone type (see legend) present in samples from
control mock infected FE13 cells over a 7 day period. The numbers of each clone










This graph illustrates the % of each clone type (see legend) present in samples from
FE13 cells infected with AdCre at Day 0. The numbers of each clone type were
scored as explained in Figure 2.30.
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running mean value for each clone type stabilised after 500 clones had been scored,
therefore a minimum of 500 clones were counted from each subsequent sample.
Figure 2.31A illustrates the characteristic staining pattern of mock treated FE13
clones, consisting of approximately 5% navy blue, 58% pale blue, 36% mosaic and
1% white clones, this remains essentially unchanged over the 7 day period of
analysis.
However, as shown in Figure 2.3 IB, a notable change in the relative proportions of
the four clone types was seen in FE13 cells infected with the AdCre virus. A gradual
shift can be seen, navy blue clones are no longer apparent by 48 hours after AdCre
infection. While the level of mosaic clones did not change dramatically, a steady
decrease in pale blue clones and concomitant increase in white clones was observed.
These data suggest that Cre-mediated excision of the floxed STOP abolishes Pgeo
expression, leading to progressively lower levels of histochemically detectable (3-gal
in AdCre-infected FE13 cells.
2.9. Discussion
A relatively small body of literature exists on the application of floxed STOP-based
technology to achieve conditional gene expression. However, many of these
publications report that floxed STOP cassettes function well and allow the efficient
and tight regulation of exogenous gene expression (reviewed in Section 2.2).
Because of these reports it was decided to develop a novel floxed STOP cassette
designed to regulate both endogenous and exogenous gene expression in vitro and in
vivo. As discussed in Section 2.1, floxed STOP cassettes are analogous to promoter
traps, hence the logical starting point for the construction of a floxed STOP cassette
was a previously characterised promoter trap vector such as pGT1.8IRES|3geo
(Mountford et al, 1994).
To generate an effective floxed STOP cassette from pGT1.8IRES(3geo the IRES
sequence was removed and two directly repeated loxP sites were introduced. Before
the pFloxSTOP plasmid was introduced into cells it was necessary to determine
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whether the introduced loxP sites were functional substrates for Cre recombinase.
The pFloxSTOP plasmid was transformed into cells of the bacterial strain BNN132
that had been engineered to constitutively express Cre recombinase (Clontech).
Restriction digest analysis of resultant transformants indicated that the pFloxSTOP
plasmid underwent efficient Cre-mediated excisive recombination.
To determine the ability of the floxed STOP cassette to regulate downstream gene
expression the test plasmid pFloxEGFP was built. This plasmid contained the
CMVie promoter and the EGFP marker gene separated by the floxed STOP cassette.
In theory, the (3geo marker gene present within the floxed STOP cassette should only
be expressed from the unrecombined plasmid whereas expression of the EGFP
marker gene should be dependent upon Cre-mediated excisive recombination. To
test this theory the plasmid was linearised and electroporated into HM-1 ES cells.
Clones that arose were then analysed to determine whether the complete pFloxEGFP
plasmid had stably integrated. First, the ability of clones to survive selection in
200pg/ml of G418 demonstrated that the neo component of the (3geo fusion gene was
being expressed at a level commensurate with function. However, not all such
G418R clones also expressed [3-gal, of 64 clones screened, (3-gal expression was
histochemically detectable in 14 (22%) only 10 of which expressed significant levels
(16%). As the (3geo gene is a fusion gene it is perhaps surprising that all G418R
clones do not also stain positively for (3gal expression, however this observation is in
agreement with earlier work on the (3geo gene (Friedrich & Soriano, 1991). These
authors suggested that differences in the sensitivity of the detection systems, i.e.
clones which express low levels of (3geo will survive G418 selection but the (3-gal
activity may be below threshold detectable with an X-gal based stain, were
responsible for the observed variation (Friedrich & Soriano, 1991). An alternative
explanation for clonal heterogeneity in (3-gal staining is variation in the methylation
status of the integrated transgene (MacGregor et al, 1987).
To determine whether the full-length pFloxEGFP transgene was present in the 10
G418r , (3-gal positive FE clones, a PCR strategy was designed. The full-length
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EGFP gene could be detected in 8 clones and one such clone, FE13 was chosen for
further analysis (Figure 2.17). Two methods were considered for the introduction of
Cre recombinase into FE13 ES cells. First, the transient transfection of Cre-encoding
plasmids into FE13 cells and second, the infection of cells with a recombinant,
replication defective adenovirus engineered to express Cre recombinase (Anton &
Graham, 1995).
As part of the work examining the feasibility of transiently transfecting FE13 cells
with Cre-encoding plasmids a novel ES cell differentiation state-specific enhancer
element was characterised. In collaboration with Dr C. Fiskerstrand from the
Department of Veterinary Pathology, University of Edinburgh the enhancer activity
of a previously unidentified intronic region of the rat preprotachykinin gene was
analysed (Fiskerstrand et al, 1999). The ~lkb of novel sequence was cloned
upstream of a basal promoter and a luciferase marker gene, plasmid pGL3p
(Promega), and the resultant plasmid, pGL3p-CCCT was transiently transfected into
ES cells. When the two plasmids were introduced into undifferentiated ES cells no
significant differences in the levels of luciferase expression were observed.
However, when they were introduced into ES cells cultured in the absence of LLF,
approximately 150-fold more luciferase was expressed from the pGL3p-CCCT
plasmid than the control pGL3p plasmid. These ES cells had been cultured in the
absence of LIF for approximately 64 hours after transfection. While this was
insufficient time for gross morphological changes to be visible, changes at the
molecular level can be detected as early as 36 hours after LIF withdrawal (Nemetz &
Hocke, 1998). These data would seem to indicate that changes in the components of
the intracellular pool of transcription factors, induced by LIF withdrawal, facilitated a
dramatic increase in the enhancer capabilities of the CCCT intronic element.
In conclusion, this work has reported the successful characterisation of a novel
enhancer element isolated from the rPPT gene. This element was shown to permit
high levels of marker gene expression is differentiating, but not undifferentiated, ES
cells. However, this technology was not adapted for use as part of a Cre delivery
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strategy. There are several publications reporting the successful expression of Cre
recombinase using various transient transfection techniques (for example, calcium
phosphate, Bethke & Sauer, 1997; lipofection, Dias et al, 1998). However, attempts
to introduce Cre-encoding plasmids into FE13 cells by both electroporation and
lipofection yielded poor transfection efficiencies and no Cre-mediated recombination
was detected. Furthermore, encouraging results obtained with the adenovirus system
investigated in parallel precluded any further optimisation of transfection protocols.
When using adenovirus it is crucial to determine the optimal titre (multiplicity of
infection, m.o.i) for infection. Too little and a low efficiency of infection will result,
too much and cytopathic effects may occur. To determine the optimal m.o.i for the
infection of ES cells a second recombinant adenovirus, AdLacZ, which had been
engineered to express the bacterial (3-gal enzyme, was used. Cultures of ES cells
were exposed to a range of AdLacZ titres and preferential infection of differentiated
ES cells was observed. This phenomenon has been previously reported (Aladjem et
al, 1998). The efficient infection of differentiated ES cells was observed even at the
lowest adenovirus titre used, 50 m.o.i, whereas the infection of undifferentiated ES
cells was only observed at 1000 m.o.i. Even with this high virus titre a very low
efficiency of infection was seen. For this reason the decision was taken to
deliberately differentiate ES cells in vitro prior to infection with AdCre.
Therefore, in all experiments described below FE13 cells were differentiated in vitro
and then infected with 50 m.o.i of AdCre. A PCR strategy was then used to
determine whether any episomal adenovirus molecules were present in the genomic
DNA extracted from infected cells. The 660bp band amplified from the Cre-
expression cassette within AdCre was produced only from adenovirus-exposed cells
demonstrating that the AdCre was successfully infecting the differentiated FE13 ES
cells (Figure 2.20). A second PCR strategy was used to monitor the recombination
status of the pFloxEGFP transgene integrated within FE13 cells (Figure 2.21). A
1213bp product was amplified from the unrecombined transgene in both AdCre-
infected and uninfected FE13 cells. However, the recombination-specific 1325bp
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product was only amplified from genomic DNA harvested from AdCre-infected
FE13 cells (Figure 2.22). This result demonstrated that Cre-mediated excisive
recombination was occurring specifically within AdCre-infected FE13 cells but
because the PCR reaction was not quantitative, the exact level of recombination
could not be determined.
In order to quantify the amount of Cre-mediated excisive recombination occurring
within AdCre-infected FE13 cells a Southern blot strategy was designed. The
7090bp Hindlll genomic DNA digest product derived from the unrecombined
pFloxEGFP transgene was detected in both AdCre- and mock-infected cells.
However, the 849bp recombination specific Hindlll digest product was not identified
(Figure 2.24). This is in direct contrast with the results obtained from recombination
state-specific PCR discussed above. However, others have observed disparities
between the sensitivity of PCR and Southern blotting for the detection of Cre-
mediated recombination in this research group (D. Rannie, unpublished obs.).
Therefore, although the level of Cre-mediated recombination was sufficient to be
detected by PCR it was below the sensitivity threshold of this specific Southern blot.
The failure to induce high levels of Cre-mediated recombination in response to
AdCre exposure is also in direct contrast with published observations. For example,
when the mouse myoblast cell line C2C12, stably transfected with a floxed STOP/(3-
gal reporter construct, was infected with AdCre upregulation of (3-gal expression was
histochemically detectable in 90-100% of cells (Sakai et al, 1995). Furthermore,
AdCre has been used successfully in vivo, with high recombination frequencies
reported by several authors (for example, Wakita et al, 1998). The most logical
interpretation of the observed low recombination frequency is a low efficiency of
adenovirus infection. The implications of this conclusion are discussed in more
depth at the end of this section.
Having demonstrated that Cre mediated recombination was occurring within AdCre-
infected FE13 cells, albeit at a low frequency, the next step was to analyse its effects
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upon marker gene expression. First, was Cre-mediated excision of the floxed STOP
cassette causing an upregulation of EGFP expression? The level of EGFP expression
was quantified by flow cytometry but no significant difference between the
fluorescence of mock- and AdCre-infected FE13 cells was observed (Figure 2.25).
Because the presence of the full length EGFP gene had been shown by PCR, it was
unclear why it was not being expressed after Cre-mediated recombination. An RT-
PCR strategy was designed to determine whether or not the EGFP gene was
transcriptionally active. Preliminary results indicated that the EGFP mRNA was
present in both mock- and AdCre-infected FE13 cells demonstrating that
transcription was occurring from the unrecombined transgene. The RT-PCR strategy
was then made quantitative in an attempt to determine whether the floxed STOP
cassette exerted any control over EGFP expression. Results from the qRT-PCR
demonstrated that although leaky EGFP expression was occurring from the
unrecombined transgene, an approximate 2-fold induction in EGFP mRNA was seen
in FE13 cells after AdCre infection (Figure 2.27).
The FACS and RT-PCR data discussed above generated three key results. First, the
demonstration that the floxed STOP cassette within the pFloxEGFP plasmid permits
leaky expression of the EGFP gene at the level of transcription. The majority of
floxed STOP cassettes described in the literature are not reported to permit leaky
expression of the target gene. However, others have observed this phenomenon. For
example, two groups (Agah et al, 1997; Anton & Graham, 1995) have reported leaky
expression from a floxed STOP-luciferase vector. Both groups suggested that
spontaneous homologous recombination between the two loxP sites and resultant
excision of the intervening floxed STOP cassette was responsible for leaky
expression in the absence of Cre recombinase although this has not been
demonstrated. Spontaneous recombination would be expected to occur at the same
frequency in both mock- and AdCre-infected FE13 cells. However, the inability to
amplify the 1325bp recombination-specific PCR product from genomic DNA
extracted from mock-infected FE13 cells indicates that if spontaneous recombination
was occurring it was at an undetectably low frequency. It is therefore improbable
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that it was responsible for the leaky EGFP mRNA expression in mock-infected cells.
An alternative suggestion to explain the leaky EGFP expression observed in FE13
cells is position effect. It may be that the linear pFloxEGFP vector has integrated
into a transcriptionally active region of the genome that is preventing maximal
inhibition of transcription by the floxed STOP cassette. One possible way to test this
theory would be the examination of EGFP expression in other FE clones that
presumably represent alternative integration events. Time constraints precluded this
analysis.
The second key result generated by this work is the absence of detectable EGFP
expression at the protein level. Although fluorescent cells could be visualised by UV
microscopy in the positive control sample, none were seen in the mock- or AdCre-
infected FE13 cells. Flow cytometric analysis confirmed this observation.
Interestingly, the inability to upregulate downstream gene expression after Cre-
mediated excision of the floxed STOP cassette has been described elsewhere. For
example, in the floxed STOP-FacZ mouse developed by Agaki et al (Agaki et al,
1997) silencing of the transgenic locus after recombination and juxtaposition of the
FacZ gene adjacent to the promoter was observed (Krimpenfort et al, 1998).
Conversely, the successful upregulation of EGFP expression using constructs
analogous to pFloxEGFP has been reported by two independent research groups (He
& Thomas, 1998; Gaur & Rajewsky, 1998).
The possibility that the EGFP gene had been silenced by methylation was eliminated
after the RT-PCR data shown in Figure 2.27 demonstrated that the gene was
transcriptionally active. Another possibility was that the levels of EGFP mRNA,
although detectable by RT-PCR, may have been too low permit the expression of
sufficient EGFP protein to be detected by UV or FACS analysis. This option cannot
be ruled out and is discussed in more depth at the end of this section. A third option
was that during the construction of pFloxEGFP, or the generation of the FE13 clone,
a point mutation could have arisen within the EGFP coding sequence abolishing the
fluorescence of the protein. No sequencing of the RT-PCR products was undertaken
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so this option cannot be ruled out. The fourth possible explanation is the "Reverse
loxP Problem" which was first suggested by B. Sauer, one of the original Cre/loxP
researchers (reviewed in Sauer, 1998). As shown in Figure 2.32, when a loxP site is
present in the reverse orientation two false translation start signals, ATG codons, are
introduced. This is only problematic if the loxP site lies between a promoter and
downstream coding sequence. In the pFloxEGFP vector the loxP site retained after
Cre-mediated excisive recombination is in the reverse orientation and does lie
between the CMVie promoter and the EGFP gene. Therefore, three translation start
codons lie immediately downstream of the 5' end of the mRNA (numbers 1,2 and 3
on Figure 2.32). If translation is initiated at either codons 1 or 2 (loxP site-derived)
then a frameshift will be introduced into the protein product. Only translation
initiation at codon 3 will give rise to the fluorescent EGFP protein. This is only a
theoretical model and false translation initiation at a loxP-derived start codon has not
been reported, nonetheless it is an attractive hypothesis to explain some of the results
obtained with clone FE13.
The third key result generated from the FACS and RT-PCR data discussed above is
that only a low level of EGFP mRNA induction, 2-fold, was observed in the AdCre-
infected FE13 cells relative to the mock-infected controls. There are two possible
explanations, first, that the low level of induction may be due to the almost complete
failure of the floxed STOP cassette to regulate transcription. Hence, the presence or
absence of the floxed STOP cassette would have little or no effect upon EGFP
transcription. The second possible explanation for the low EGFP mRNA induction
observed, is a low efficiency of AdCre infection that would generate a concomitant
low level of Cre-mediated recombination. Therefore, the amount of EGFP
expression being driven from the recombined transgene would be almost
indistinguishable from the leaky expression off the unrecombined pFloxEGFP
transgene. The latter explanation is the most probable as there is a small but
significant (p<0.05, Mann-Whitney U test) increase in EGFP transcription after Cre-
186
Figure 2.32 -The Reverse loxP Problem
A) The structure of the recombined pFloxEGFP transgene
j mRNA
cmv Promoter loxP EGFP gene
Xba I EcoRI
B) Sequence data
5' tca gat ccg cta gcg taa gat ctg gcc gcg agc tcg ggc ccc
3' agt cta ggc gat cgc att cta gac cgg cgc tcg agc ccg ggg
cac acgtgt ggt cta gaA TAA CTTCGTATA ATG 7ATGCT
gtg tgc aca cca gat CT TATT GAA GCA TAT TAC ATA CGA
Eco ri
ATA CGA AGT TAT gaa ttc tgg atc cga tac gctacc ggt
TA T GCT TCA A TA ctt aag acc gag gct atg cga tgg cca
3
CGC CAC C ATG Gtg 3'
GCG GTG G TAC Cac s*
Above is the sequence from the extreme 5' end of the EGFP mRNA initiated within
the cmv promoter. The loxP sequence is shown in italics. The two restriction sites
which flank the loxP, Xba I and Eco RI are indicated in bold text. The numbers 1-3
mark the multiple translation initiation codons (ATG) present in this mRNA.
Positions 1 and 2 are encoded in the loxP site spacer region, whereas position 3 is the
intended translation initiation signal with surrounding Kozak concensus sequence
underlined.
Xba i 1 2
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mediated excisive recombination and a low efficiency AdCre-infection has been
implied by other data.
Changes in the expression of two marker genes EGFP and (3geo were examined
during the work described in this chapter. As already discussed, Cre-mediated
excision of the floxed STOP cassette in pFloxEGFP did permit a small but
significant upregulation of EGFP mRNA. To determine whether a concomitant
decrease in (3geo expression occurred, two methods were used to quantify (3-gal
activity in FE13 cells, a quantitative (3-gal activity assay and direct histochemical
detection. Differentiated FE13 cells were either mock- or AdCre-infected (50 m.o.i)
and protein extracts prepared 72 hours later. When the levels of (3-gal activity were
compared between the 72 hours mock- and AdCre-infected extracts only a small
decrease was observed. There are two possible explanations for this observation,
first that a low level of infection has occurred or second, that the long half-life of [3-
gal results in its retention within cells. To distinguish these two alternatives a repeat
AdCre-infection was set up and protein extracts and cultures for histochemical
analysis were prepared over the 7 day period after infection.
When the levels of (3-gal activity were analysed in AdCre-infected cells relative to
controls significant differences were observed. Twenty-four hours after infection the
level of [3-gal activity had decreased from 47.9pU/pg to 5.12pU/pg (approx. 90%
decrease) (Figure 2.28). This reduced level of expression was maintained over the 7-
day experimental period but did not decrease any further. The significant decrease in
(3-gal expression after AdCre-infection is also supported by data generated from
scoring FE13 clones after histochemical detection of (3-gal activity. The numbers of
four species of clones, navy blue, pale blue, mosaic and white were scored blind in
cultures arising from mock- and AdCre-infected FE13 cells. In the control cells no
significant alterations are seen in the relative proportions of each clone type over the
seven-day experimental period (Figure 2.31A). However, in the AdCre-infected cells
notable changes are seen (Figure 2.3IB). By 48 hours after infection no navy blue
clones are seen and a large increase in mosaic clones is seen. Over the seven-day
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period, the number of pale blue clones in the AdCre-infected cultures also decreases
but there is a gradual increase in the proportion of white clones until they constitute
over 50% of the total. These data indicate that Cre-mediated excisive recombination
of the floxed STOP cassette does indeed efficiently abolish expression of [3-gal from
the (3geo marker gene. The successful abolition of floxed gene expression after Cre-
mediated excision has been reported by numerous other groups using floxed STOP
technology (for example, O'Gorman et al, 1997). In all cases the efficiency is
proportional to the efficiency of Cre-mediated excisive recombination.
In the data reviewed above one recurring explanation for some of the results is a low
efficiency of AdCre-infection. For example, the difficulty in detecting the
recombination-specific Hindlll genomic digest product by Southern blot, the small
increase in EGFP mRNA in AdCre-infected cells and the small decrease in (3-gal
activity in AdCre-infected relative to mock-infected control cells over the original
seventy two-hour timecourse. When the AdCre-infection was repeated using a fresh
stock of recently titred adenovirus and (3-gal levels assayed over one week, a much
larger decrease in (3-gal activity was detected in both protein assays and with the use
of histochemical staining techniques. Therefore, these data would seem to suggest
that the levels of (3-gal activity within differentiated FE13 ES cells decrease in
proportion with efficiency of Cre-mediated excision of the floxed STOP cassette,
exactly as reported in other publications (for example, O'Gorman et al, 1997).
As already mentioned, one possible explanation for the absence of EGFP protein in
AdCre-infected FE13 cells was a low level of mRNA. Therefore, even if translation
was occurring normally the level of EGFP protein in such cells may remain below
the threshold detectable by FACS analysis or UV microscopy. This would be a
particular problem if AdCre-infection was submaximal giving a concurrent low
efficiency of Cre-mediated recombination. To establish if this problem had occurred
in FE13 cells, in parallel with the repeat infection for (3-gal activity analysis
discussed above, a second AdCre-infection (50 m.o.i) was also carried out to confirm
the EGFP data. The second adenovirus infection was carried out using a fresh stock
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of recently titred virus and twenty four hours after infection a cell sample was
removed for UV microscopy and a protein extract prepared for use in determining (3-
gal activity. This timepoint was chosen as the data illustrated in Figure 2.28
demonstrated that a significant decrease in (3-gal activity within FE13 cells occurred
twenty four hours after AdCre-infection. However, despite a sizeable reduction in (3-
gal activity within the repeat infected FE13 cells, when they were examined by UV
microscopy no fluorescent cells were seen.
In conclusion, it is probable that the first time the EGFP status of FE13 cells was
examined only a small percentage of cells had been successfully infected with AdCre
hence the small scale of EGFP mRNA induction, the inability to identify the 849bp
recombination-specific Hind III digest product by Southern and the low level of (3-gal
activity decrease over the original seventy two hour time course. However, in the
repeat experiment a higher efficiency of Cre-mediated recombination was almost
certainly induced as evidenced by the concurrent decrease of |3-gal activity. Yet in
both experiments no fluorescent cells were detected. This observation sheds further
light on the question of why no EGFP protein could be detected in FE13 cells. Three
hypotheses were originally proposed, first that the levels of EGFP mRNA, even in
the AdCre-exposed cells, were too low to permit the expression of sufficient EGFP
protein to be detected by UV or FACS analysis. This hypothesis has become less
probable due to the absence of detectable EGFP protein in cells that have almost
certainly undergone a high efficiency of AdCre-infection. Instead either the
acquisition of a mutation in the EGFP gene or the Reverse loxP Problem discussed
above may better explain the absence of fluorescent cells.
These proposed variations in adenovirus infection efficiencies can be most simply
explained by variations in the viability and titre of the virus. Therefore, although all
AdCre infections were apparently carried out using a titre of 50 m.o.i in reality, cells
were probably exposed to different viral titres. Errors could have been introduced at
several stages including the initial titration of the stock. Furthermore, repeat freeze-
thaw cycles are known to significantly affect viral titres (Croyle et al, 1998).
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Nonetheless, this work did indicate a potential problem with the pFloxEGFP vector,
that is the absence of EGFP protein expression. As this vector was originally
designed to provide a simple, visual indicator of Cre-mediated excisive
recombination no further experiments were carried out using it. Instead, bearing in
mind the problems with encountered during the construction and testing of
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Chapter 3
RAGE-Based Strategies to Achieve Conditional Upregulation of the
Murine p53 Gene in vitro
3.1. Introduction
Replicative cellular senescence has been reviewed in depth elsewhere in this thesis
(Section 1.5). Briefly, at the end of a cells replicative lifespan it enters a state of
terminal G1 arrest. This event is thought to be regulated by an internal genetic
program via two regulatory mortality checkpoints, Ml and M2 (Wright & Shay,
1992). Immortality can only be achieved by cells able to overcome both Ml and M2,
therefore escaping the constraints of replicative cellular senescence.
A key molecule involved in the regulation of senescence and in particular, the Ml
checkpoint is the tumour suppressor gene p53. The majority of the work
investigating the role of p53 in this process has been carried out using the SV40 TAg
protein (see Section 1.5.3.2). A significant drawback to this approach is the
pleiotropic nature of TAg function. First, SV40 TAg binds to RB, dissociating RB-
E2F complexes within cells (Stein et al, 1990), and the RB-related proteins pl07 and
pl30 (Knudsen & Wang, 1998). Second, a novel anti-apoptotic domain has been
identified within TAg (amino acids 525-541) with uncharacterised cellular binding
partners (Conzen et al, 1997). Third, the C-terminal (amino acids 351-450 and 533-
626) of TAg binds to the core domain of p53 (amino acids 94-293) (Ruppert et al,
1993) and inhibits the sequence-specific DNA binding activity of p53 (Bargonetti et
al, 1991). Each of these functional domains has the ability to transiently bypass
senescence but individually, are insufficient to permit immortality (Jha et al, 1998).
Therefore when using SV40 TAg it may be difficult to separate the individual
contributions of these domains to the abrogation of senescence.
Antisense technology is a second approach that has been much used during the
investigation of the genetic regulation of senescence. The culturing of FIDFs in the
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presence of RB or p53 antisense oligonucleotides was shown to have functional
consequences in terms of the onset of senescence (Hara et al, 1991). However, in all
of these experiments the precise extent of reduction of target gene expression is
unclear, for example, it is highly unlikely that p53 expression has been completely
abolished in cells exposed to p53 antisense oligonucleotides. Therefore experiments
based on antisense technology need careful interpretation.
One way around the problems inherent in TAg- or antisense-based experiments is to
approach it from the opposite direction namely, to directly regulate target gene
expression. The power of this approach was demonstrated when a tetracycline
inducible p53 construct was introduced into a p53 null bladder carcinoma cell line.
Re-expression of p53 was sufficient to induce the onset of replicative senescence in
these cells (Sugrue et al, 1997).
Several different strategies for the regulated expression of p53 have been reported
including inducible promoters (Sugrue et al, 1997) and recombinant adenoviridae
(Aladjem et al, 1998). There are several important considerations when using such
approaches including the stability, delivery or toxicity of inducing agents for some
inducible promoters, differences in the sensitivity to adenovirus and potential
cytopathic cellular response to infection. To provide an alternative tool for the
regulation of p53 expression, it was decided to construct a floxed STOP-regulated
p53 expression vector, pICDP(for).
A large proportion of the work investigating replicative cellular senescence has been
done in human diploid fibroblasts (HDFs). However, the availability of numerous
knock-out mouse strains with targeted null mutations in potential senescence
regulatory genes makes murine cells an attractive model system. One possible reason
why full advantage has not been taken of the mouse system is the absence of a
convenient senescence-specific biomarker. In contrast, expression of the novel
biomarker Senescence Associated (3-galactosidase (SA(3-gal) has been reported in
human cells (Dimri et al, 1995). Previously senescent cells, such as primary
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fibroblasts, were distinguished in vitro using morphological criteria. Senescent
fibroblasts have enlarged nuclei, elongated cellular processes, increased size and a
flattened appearance (Hayflick & Moorehead, 1961). However, these criteria were
very difficult to apply in vivo making the identification of such cells very difficult.
The discovery of SA(3-gal permitted an analysis of human cell senescence in vitro
and in vivo for the first time. To facilitate an analysis of senescence in murine cells
an analogous biomarker was required however, no SAP-gal expression was originally
detected in rodent cells (Dimri et al, 1995). This is discussed further in Section 3.3.
3.2.Aims
a) Identify and characterise SAP-gal expression in primary mouse fibroblasts and
mouse skin sections.
b) Design and construct a vector in which expression of the p53 cDNA can be
upregulated in response to Cre-mediated excision of the floxed STOP cassette
from the pFloxSTOP plasmid.
c) Develop a method for the stable transfection of p53 null primary mouse
fibroblasts.
d) Characterise primary mouse fibroblast system in terms of feasibility of Cre-
mediated upregulation of p53 expression and effects on SAP-gal expression.
3.3. Do Primary Mouse Fibroblasts Express SAP-gal ?
3.3.1. Human Senescence Associated P-galactosidase
p-galactosidase (p-gal) activity can be detected histochemically using the synthetic
substrate 5-Bromo-4-chloro-3-indolyl galactopyranoside (X-gal), which forms a local
blue precipitate upon cleavage (Miller, 1972). All human cells express a lysozomal
P-galactosidase enzyme with a pH optimum of 4 (Moreau et al, 1989). A neutral, pH
7, P-gal activity has also been described in mammalian tissues (Kuo & Wells, 1978).
However, no change in the activity of either of these enzymes has been reported as
cells approach replicative senescence. In contrast, SAp-gal has a pH optimum of 6
and is detected primarily in senescent human cells with a perinuclear staining pattern
(Dimri et al, 1995).
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3.3.2. Murine (3-galactosidases
SA(3-gal was originally described in human cells and indeed the original authors
stated that SAP-gal activity could not be detected in murine fibroblasts (Dimri et al,
1995). Because the availability of a murine senescence-specific biomarker was such
a desirable tool it was decided to re-examine the possibility of mouse SAP-gal.
Detailed SAP-gal and lysozomal P-gal protocols were kindly supplied by J. Campisi
(J. Campisi, pers. comm.) and tested on mouse embryonic fibroblasts (MEFs).
However, in line with previous work (Dimri et al, 1995), no positively staining cells
were detected. It should be noted that SAP-gal histochemical visualisation was
attempted with MEFs that had been maintained in vitro for a range of different times
and no positive cells were observed even in the oldest cultures (data not shown).
However, when MEFs were treated with the lysozomal p-gal stain solution, prepared
as described by J. Campisi, all cells were positive independent of length of time in
culture. A typical MEF that stained positively for lysozomal P-gal activity is shown
in Figure 3.1A.
However, a second novel SA-Pgal stain solution was also used in parallel with that
recommended by J. Campisi. When MEF cultures were exposed to this stain
solution positively staining cells were observed. The vast majority of positively
staining cells also displayed morphological changes characteristic of replicative
cellular senescence (see Section 3.1). Typical SAP-gal positive MEFs are shown in
Figure 3.l.B and C. The perinuclear staining pattern observed in SAP-gal positive
MEFs is identical to that described in human cells (Dimri et al, 1995) and obviously
distinct to that observed in lysozomal P-gal positive cells (compare the three
morphologically senescent cells in Figure 3.1).
Also in agreement with the original report of Dimri et al, was the observation of
SAP-gal positive cells that were not morphologically senescent. Such cells are rare
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Figure 3.1 - Histochemical Detection ofLysozomal and Senescence-Associated
fi-ga!actosidase Expression
A) Photograph taken at x400 magnification of a morphologically senescent cell
showing positive staining for lysozomal B-gal expression (pH 4.0) and
counterstained with Neutral R.ed. The dispersed, granular blue deposits are
characteristic of lysozomal B-ga! activity.
B) Photograph taken at x400 magnification of a morphologically senescent cell
showing positive staining for Senescence-Associated B-gal (pH 6.0) expression and
counterstained with Neutral R.ed. The intense perinuclear blue deposit is identical
to that described by Dimri et at, in senescent human cells (Dimri et al, 1995).
C) Another example of the staining pattern charactersitic of SA B-gal expression as
described in B).






in both human (Dimri et al, 1995) and mouse early passage cultures and an
explanation for this observation has yet to be proposed.
3.3.3. Does The Expression of SA[3-gal Correlate With Passage Number ?
In an attempt to further characterise the SA(3-gal positivity observed in MEFs in
vitro, a continuous culture experiment was set up from which cell samples from wild
type and p53 null cultures were removed at regular intervals and stained for SA(3-gal
activity.
3.3.3.1. Continuous Passaging ofMEFs
Embryos were harvested from p53 +/- and -/- matings and embryonic fibroblasts
were prepared as described (Todaro & Green ,1963). The following day cells were
harvested by trypsinisation and transferred to storage at -80°C, such cells were
referred to as passage 1 (PI). A small aliquot of cells was removed and genomic
DNA prepared. This DNA was used as a template for a PCR reaction to determine
the p53 genotype of the individual cultures (Figure 3.2).
The standard EF culture regime is referred to as 3T3, in which lxlO6 cells are plated
per 100mm tissue culture dish and passaged every 3 days (Todaro & Green, 1963).
Once the p53 genotype of the cells had been established, wild type and p53 null
MEFs were seeded at lxlO6 cells per 100mm dish and maintained in approximate
accordance to the 3T3 regime such that cells were plated at 40% confluence every
three days as this corresponded to the cell density observed when lxlO6 cells were
originally plated out per 100mm dish. Cell samples were removed regularly and
stained for SA(3-gal expression, counterstained with Neutral Red and mounted. SA-
(3gal positivity was then scored via a running mean method and the results are
illustrated in Figure 3.3.
3.3.3.2. SA|3-galactosidase Timecourse Results
Wild type MEFs were maintained in culture according to the passaging regime
described above for 11 passages (PI 1). During this culture period the level of SA-
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Figure 3.2 — PCR Genotyping ofPrimary Mouse Embryonic Fibroblasts
4.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2, the
642bp PCR product amplified from the wild type p53 allele. Lane 3, the 642bp PCR
product amplified from the wild type allele and the 510bp PCR product amplified
from the targeted allele of p53, therefore this embryo was heterozygous for p53.
Lane 4, the 510bp PCR product amplified from the targeted allele of p53, therefore
this embryo was homozygous null for p53. Lane 5, molecular weight markers.
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Figure 3.3 - Graph Illustrating the Number ofSA-figal Positive Cells in p53 Null
and Wild TypeMEF Cultures After Repeat Passaging




This graph illustrates the changes in SA-pgal positivity in wild type and p53 null
MEFs after repeat passaging in culture. All samples were scored using a running
mean method.
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(3gal positivity increased from 17% at PI to 60% at Pll. At this point there were no
overt signs of proliferation as no change in cell density was observed in the three
days subsequent to passaging and the majority of cells displayed the morphological
changes characteristic of senescence. In contrast, p53 null MEFs were maintained in
culture for over 30 passages. Even at this late passage the cells were actively
proliferating and had not entered replicative cellular senescence. A substantially
reduced number of SA-(3gal positive cells were observed in the p53 null cultures
relative to wild type at all timepoints. For example, at PI only 2% of p53 null cells
expressed detectable levels of SA-(3gal and this increased to 50% by P20.
Interestingly, two peaks of SA-(3gal expression are seen in the p53 null cultures, at
P20 and at P33. These results are discussed further in Section 3.7.
3.3.4. Murine SA|3-gal in vivo
When the discovery of SA(3-gal was originally reported, positively staining human
cells were detected in vitro and in vivo (Dimri et al, 1995). Having successfully
demonstrated the existence of murine SA(3-gal in vitro the next step was to
investigate whether this enzyme activity could also be detected in vivo. Two mice
were killed, one was six weeks of age and the second was 2 years of age. A patch of
skin on the back of the mice was shaved and a skin sample removed. The tissue
sample was then snap frozen in liquid nitrogen. Frozen sections from the two skin
samples were then fixed and incubated with SA(3-gal staining solutions. Duplicate
sections were incubated with both the stain solution described by J. Campisi and the
stain developed by myself. After 24 hours the sections were counterstained with
eosin, mounted and viewed. A frozen section of mouse skin stained with
haematoxylin and eosin is shown in Figure 3.4. Relevant structures within the
section are indicated. Typical SA(3-gal staining results from frozen skin sections are
shown in Figure 3.5.
No SA-Pgal positive cells were seen in the sections of skin harvested from the 6
week old mouse exposed to either stain solution. However, in the old mouse positive
staining is associated with hair follicles, sebaceous glands and eccrine glands. This
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Figure 3.4 - Haematoxylin and Eosin Counterstained Mouse Skin Section (x200)
A mouse was killed, an area of back skin exposed by shaving and a sample removed
and snap frozen. The skin sample was then mounted and frozen sections cut. The
sections were transferred onto poly-lysine coated microscope slides and fixed with




C - collagenous layer
HF - hair follicles
SDF - subdermal fat layer
ED - eccrine duct
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Figure 3.5 - SA-dgal Staining in Mouse Skin Sections Counterstained With
Eosin (x400)
Two mice were killed, the first six weeks of age and the second, two years of age.
An area of skin on the back of each mouse was shaved, a sample removed,
transferred into a sterile eppendorf and then snap frozen. The skin samples were
mounted in OCT and frozen sections cut which were then transferred onto poly-
lysine coated microscope slides. Immediately after cutting the sections were
immersed into SA-Pgal stain solution and incubated at 37°C overnight. The
following day the sections were rinsed, fixed with Macrodex, counterstained with
eosin, mounted, viewed microscopically and photographed.
A) SA-Pgal staining in an eccrine gland within the skin of the two year old mouse
(x400).
B) SA-Pgal staining within a hair follicle and associated gland structure within the
skin of the two year old mouse (x400).
C) SA-Pgal staining in two hair follicle structures within the skin of the two year old
mouse (x400).
D) Skin section taken from six week old mouse. The photograph includes several
hair follicles and associated ducts, notice the absence of SA-Pgal staining in these
structures (x400).




staining pattern was seen in sections exposed to both staining solutions. Intriguingly,
this is similar to observations reported by Dimri et al (Dimri et al, 1995). In human
skin sections positive cells were always observed in hair follicles and associated
sebaceous glands and in eccrine glands and ducts. However, in human skin samples,
this staining occurred independently of donor age. A second pattern, which was
absent in the mouse, was positively staining cells within the dermis and epidermis of
skin sections taken from old donors only (Dimri et al, 1995).
3.3.5. Summary
The first aim of this section of work was to determine whether SA[3-gal expression
could be detected in murine cells. A novel SA(3-gal stain solution was developed
which permitted the detection of murine SA(3-gal positive cells in vitro for the first
time. SA(3-gal positive cells were not detected in vivo.
3.4. Design of a Conditional p53 Expression Vector
3.4.1. Basic Strategy
The second aim of this section of work was to design and construct a vector in which
expression of the p53 cDNA is upregulated in response to Cre-mediated excision of
the floxed STOP cassette from the pFloxSTOP plasmid. To achieve this the
pICDP(for) plasmid was developed.
The pICDP(for) plasmid has three key functional domains that are represented in
Figure 3.6. Firstly, the constitutive promoter, PGK, secondly, the floxed STOP
cassette subcloned from the pFloxSTOP vector (Section 2.4, Figure 2.10) and finally
the mouse wild type p53 cDNA. When the pICDP(for) plasmid is in the
unrecombined state as represented in Figure 3.6.A, the floxed STOP cassette should
block expression of p53. Instead, the constitutive PGK promoter should drive high
levels of expression of the (3geo fusion gene present in the floxed STOP cassette.
After Cre-mediated recombination has occurred the floxed STOP cassette should be
excised. The structure of the recombined pICDP(for) plasmid is shown in Figure
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PGK p53 cDNA LacZ p53
Gene Expression
The pICDP(for) plasmid.
A) In the absence of Cre recombinase the floxed STOP is predicted to prevent the
expression of the p53 cDNA (pale blue box). However, the |3geo gene is expressed
from within the floxed STOP cassette (dark blue box within red box). The relative
expression levels of both of these genes from the unrecombined plasmid are
represented in the bar chart at the right hand side of the figure.
B) The structure of the pICDP(for) plasmid after Cre-mediated excisive
recombination has occurred. The floxed STOP cassette has been excised abolishing
expression of the (igeo gene and the p53 cDNA, is now directly downstream of the
PGK promoter. This plasmid structure is predicted to drive high levels of p53
expression. The relative levels of"gene expression after Cre-mediated recombination
are represented in the bar chart to the right of the figure.
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3.6B. As the (3geo gene has been lost, LacZ expression is abolished and the PGK
promoter should instead drive high levels of p53 expression.
3.5. Construction of pICDP(for)
3.5.1. The p53 cDNA
The p53 cDNA used in the construction of pICDP(for) was constructed by Dr. R.
Malcolmson (Malcomson, 1996). The cDNA encodes the wild type sequence of the
mouse p53 protein with the only alterations being the inclusion of an SV40 intron
sequence and associated splice donor and acceptor sites and the replacement of the
endogenous polyadenylation signal with an SV40 polyadenylation signal (Figure
3.7). The full length cDNA was sequenced after construction to confirm that it
encoded the wild type p53 protein.
The p53 cDNA was originally subcloned into the pTETOp53HYG vector constructed
by Dr. S. Lyons (Lyons, 1999) and this vector was used as the starting point for the
construction of pICDP(for). Digestion of the pTETOp53HYG plasmid with the
restriction enzyme Eco RI releases a 1.9kb cleavage product that includes the p53
cDNA sequence. The 1.9kb band was gel extracted, purified and ligated into an Eco
RI site within the polylinker of the pTAg plasmid (see Section 2.4.2, Figure 2.5) to
generate the recombinant p53pTAG plasmid (Figure 3.8B). Several recombinant
clones were identified as a result of this approach and the orientation of the cDNA
insert was determined by digestion of the plasmids with the restriction enzyme Bam
HI (Figure 3.8.A).
Having successfully identified a clone in which the p53 cDNA had been inserted in
the reverse orientation within the pTAg polylinker the next step was to insert the
constitutive promoter, PGK into the p53pTAg plasmid (Figure 3.8B).
3.5.2. Inserting PGK Promoter into p53pTAg
The PGK promoter used for the construction of the pICDP(for) vector was subcloned
from a vector constructed by Dr. C. Cooper, pPGK (Cooper, 1999). The polylinker
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Figure 3.7 - Structure ofthe p53 cDNA
Sac I(199)
Sac I(45) \ p53wt 5' splice 3'splice SV40 pi
p53 cDNA
1813 bp
The p53 cDNA cassette. The relative positions of the mouse wild type p53 cDNA
sequence, splice sites and polyadenylation signal are shown. This cDNA sequence
was constructed by Dr. R. Malcomson.
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gel. Lane 1, Eco R1 digestion of
the p53pTAg plasmid generates
two cleavage products, 1918bp
and 3801 bp demonstrating the
correct insertion of the cDNA
into pTAg. Lane 2, the insert is
confirmed as being in the reverse
orientation as Bam HI digestion
also generates two cleavage
products, 1934bp and 3785bp.

















The p53pTAg plasmid with the cDNA (p53wt) inserted in the reverse orientation as
determined by Bam HI digestion.
211
of the pPGK plasmid had been modified to allow excision of the PGK promoter with
a single Apa I digest. Digestion of pPGK with this restriction enzyme generates two
cleavage products, a 903bp fragment which includes the PGK sequence and a 2745bp
fragment derived from the plasmid backbone (lane 3, Figure 3.9). The 903bp Apa I
fragment was excised from the gel, purified and ligated into Apa I linearised
p53pTAg (lane 4, Figure 3.9). Several clones were identified as a result of this
approach and screened for the correct insertion event via digestion with the
restriction enzyme Bam HI (lane 5, Figure 3.9). The recombinant plasmid, pPGKp53
is shown in Figure 3.9.B.
3.5.3. Inserting the Floxed STOP into pPGKp53
The next step was the insertion of the floxed STOP cassette from pFloxSTOP
between the PGK promoter and downstream p53 cDNA present in pPGKp53. The
pPGKp53 plasmid was linearised via digestion with the restriction enzyme BstXl
(Figure 3.9.B) which cleaves at a site between the promoter and cDNA sequences.
The 3' single stranded DNA overhangs generated by Bst XI digestion of pPGKp53
were removed using T4 DNA polymerase. The 6338bp floxed STOP cassette
excised from pFloxSTOP via digestion with the restriction enzyme Sna BI (lane 4,
Figure 3.10A) was then cloned into the linear, blunt ended pPGKp53 plasmid.
Resultant clones were screened and insertion and orientation of the floxed STOP
cassette was confirmed by Sac I digestion of recombinant plasmids (lane 5, Figure
3.10A). The outcome of this cloning step was the vector pIcDNA(rev) as shown in
Figure 3.1OB.
3.5.4. Testing pIcDNA(rev) in BNN 132 Cells
Having inserted the floxed STOP cassette from pFloxSTOP into the pPGKp53 vector
to produce the plasmid pIcDNA(rev), the ability of the plasmid to act as a substrate
for Cre recombinase was tested in BNN 132 bacteria (see also Section 2.4.1).
Bacteria of the strain BNN 132 have been engineered to constitutively express Cre
recombinase (MoBiTech) and can be used as a convenient test system in which to
assay the functionality of loxP-site containing vectors (Bucholz et al, 1996).
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1.0% agarose/ethidium bromide ge!. Lane 1, molecular weight marker. Lane 2,
blank. Lane 3, Apa I digestion of the pPGK plasmid generates two cleavage products,
a 903bp fragment which encompasses the PGK promoter and a 2745bp backbone-
derived fragment. Lane 4, Apa I digestion of the p53pTAg plasmid linearises the
molecule generating a 5719bp band. Lane 5, Bam HI digestion was used to orientate
the PGK insert introduced into p53pTAg. In the orientation as shown in Figure 2.32b





















- Inserting the Floxed STOP Cassette into the pPGKp53 Plasmid









1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
blank. Lane 3, Bst XI linearisation of the pPGKp53 plasmid generates a 6630bp
band. Lane 4, Sna BI digestion of pFloxSTOP generates two cleavage products, the
floxed STOP encompassing 6338bp fragment and the 3738bp plasmid backbone-
derived fragment. Lane 5, Sac 1 digestion of the plcDNA(rev) plasmid generates 6
cleavage products of 5368bp, 2621bp, 1967bp, 1912bp, 942bp and 154bp. All but


























































When the pIcDNA(rev) plasmid is transformed into BNN 132 cells Cre-mediated
excisive recombination occurs. The result of this is two plasmid species, the first,
pSTOP(BNN), contains one loxP site and all of the STOP cassette. The second
species, plC(BNN), is derived from the plasmid backbone and also contains one loxP
site. Only pIC(BNN) contains an ampicillin resistance gene so this is the only









Figure 3.12 - Restriction Digest Analysis to Demonstrate That the pIcDNA(rev)







1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
blank. Lane 3, Sac I digestion of pIcDNA(rev) generates six cleavage products of
5368bp, 2621bp, 1967bp, 1912bp, 942bp and 154bp(the latter is too small to be seen
above). Lane 4, Sac I digestion of the pIC(BNN) plasmid generates four cleavage
products of 5368bp, 942bp, 280bp and 154bp (the latter are too small to be seen
above). Lane 5, molecular weight markers.
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The bacteria were grown up to an appropriate volume, made competent using a
standard calcium chloride-based protocol (Sambrook et al, 1989) and transformed
with the pIcDNA(rev) plasmid. Clones that resulted from this transformation were
grown up as minipreps and plasmid DNA subjected to restriction digest analysis.
Cre-mediated recombination would be expected to generate two plasmid species,
first, the excised and circularised floxed STOP component, pSTOP(BNN) and
second, the pIcDNA(rev) backbone-derived pIC(BNN) plasmid (Figure 3.11). As the
BNN132 cells are selected in ampicillin after transformation only the second plasmid
species will be represented in surviving clones. Sac I digestion of plasmid DNA
n
extracted from Amp clones confirmed this prediction (Figure 3.12).
3.5.5. Substitution of the Floxed STOP Cassette Within pIcDNA(rev)
After the construction of pIcDNA(rev) had been completed it was decided to replace
the floxed STOP cassette present in this plasmid. The original floxed STOP cassette
present, subcloned from the pFloxSTOP plasmid (Chapter 2, Figure 2.10) contains
two directly repeated loxP sites that are in the reverse orientation according to
standard nomenclature. The possible implications of leaving a reverse loxP site
between a promoter and coding sequence have been discussed in Chapter 2 and to
avoid this problem it was considered necessary to rebuild the floxed STOP cassette
and the pIcDNA(rev) plasmids.
3.5.5.1. Construction of pFloxSTOP(for)
The relative orientations of the functional components of the pFloxSTOP and
pFloxSTOP(for) plasmids are shown in Figure 3.13.
The pFloxSTOP(for) plasmid was constructed from the parental pFloxSTOP
plasmid. As shown in Figure 3.13, digestion of pFloxSTOP with the restriction
enzyme Sal I excises the STOP cassette from the floxed pTAg backbone. Therefore,
to reverse the orientation of the loxP sites relative to the STOP cassette pFloxSTOP
was digested with Sal I and then re-ligated. The ligation reaction was then
transformed into bacteria and plasmid DNA extracted from resultant clones
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Figure 3.13 - Relative orientations of the STOP Cassettes Within the
pFloxSTOP andpFloxSTOP(for) Plasrnids
SA Bgeo poly A
A) pFloxSTOP
B) pFloxSTOP(for)
Sua BI Sal I Sail SnaBI
Schematic representation of the two plasmids pFloxSTOP and pFloxSTOP(for).
A) The original plasmid, pFloxSTOP contains the STOP cassette in the opposite
orientation to the loxP sites (black arrows). This was the tloxed STOP cassette
structure used for the construction of pFloxEGFP and plcDNA(rev).
B) The pFloxSTOP(for) plasmid contains the STOP cassette in the same, forward
orientation as the loxP sites. This plasmid was used for the construction of
pIcDNA(for).
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Figure 3.14 - Construction ofpFloxST()P(for); Restriction Digest Analysis to








gel. Lane 1, molecular weight
markers. Lane 2, Sac I digestion
of pFloxSTOP generates
cleavage products of 6197bp,
1967bp and 1912bp. Lane 3, sac
1 digestion of pFloxSTOP(for)












The pFloxSTOP(for) plasmid in which both the directly repeated loxP sites and the
STOP cassette are in the forward orientation. The floxed STOP cassette can be
excised from this plasmid via digestion with the restriction enzyme, Sna BI.
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subjected to restriction digest analysis. Three plasmid species were predicted to arise
after Sal I digestion and re-ligation of the pFloxSTOP plasmid. Firstly, a 3875bp
plasmid species derived from the floxed plasmid backbone (the pFloxpTAg(2
SnaBI), Figure 2.8), secondly, a 10076bp species in which the STOP cassette has
inserted into the floxed plasmid backbone in the reverse orientation (equivalent to the
parental plasmid, pFloxSTOP, Figure 3.13.A) and finally a 10076bp species in which
the STOP cassette has inserted into the floxed plasmid backbone in the forward
orientation (the desired outcome, Figure 3.13B). These three alternatives were
distinguished by digestion of plasmid DNA with the restriction enzyme Sac I (Figure
3.14).
As with the parental plasmid, pFloxSTOP, the floxed STOP cassette present in
pFloxSTOP(for) can be excised from its plasmid backbones via digestion with the
restriction enzyme, Sna Bl (Figure 3.13).
3.5.5.2, Inserting the Floxed STOP Cassette From pFloxSTOP(for) into
pPGKp53
The pPGKp53 plasmid was linearised via digestion with the restriction enzyme Bst
XI (Figure 3.9B) which cleaves at a site between the PGK promoter and p53 cDNA.
The 3' single stranded DNA overhangs generated by Bst XI digestion of pPGKp53
were removed using T4 DNA polymerase. The 6338bp floxed STOP cassette
excised from pFloxSTOP(for) via digestion with the restriction enzyme Sna Bl was
then ligated into the linear, blunt ended pPGKp53 plasmid. The ligation reaction was
then used to transform bacteria and plasmid DNA isolated from resultant clones was
screened for insertion and orientation of the floxed STOP cassette by digestion with
the restriction enzyme Sac I. The outcome of this cloning step was the vector
pIcDNA(for) as shown in Figure 3.15.B.
3.5.6. Inserting the Puromycin Resistance Gene ipac) into pIcDNA(for)
The presence of the (3geo gene within the floxed STOP cassette of pIcDNA(for)
would normally have been sufficient to allow the selection of cells that contain
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1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2, Est
XI digestion of pPGKp53 linearises the plasmid giving a single digest product of
6630bp. Lane 3, Sua BI digestion of pFloxSTOP(for) generates two digest products
of 6338bp and 3738bp. Lane 4, Sac I digestion ofpIcDNA(for) with the floxed
STOP cassette inserted in the correct orientation generates seven digest products of
5368bp, 2827bp, 2450bp, I967bp, 1912bp, !98bp and 154bp. The latter two















stably integrated copies of pIcDNA(for). However, the aim was to introduce the
pIcDNA(for) vector into p53 null cells generated by gene targeting which are already
G418r as a consequence of the targeting event (Purdie et al, 1994). For this reason it
was necessary to introduce a second selectable marker into the construct and the
puromycin N-acetyltransferase gene, pac, from the commercially available pPUR
plasmid (Clontech) was chosen (Figure 3.16).
The pIcDNA(for) plasmid was linearised via digestion with the restriction enzyme
Sna BI. The pac expression cassette was excised from pPUR (Figure 3.16) using a
double digest, with the enzymes Xmn I and Pvu 11, that generated two cleavage
products, a 1716bp backbone-derived fragment and a 2541bp fragment which
encompassed the pac cassette. All of the restriction enzymes used in this cloning
step generate blunt ended cleavage fragments so that the 2541bp pac fragment was
ligated directly into the Sna 57-linearised pIcDNA(for) plasmid. The ligation
reaction was used to transform bacteria and plasmid DNA isolated from resultant
clones was screened by restriction digestion analysis. The pac cassette can insert into
the pIcDNA(for) plasmid in two possible orientations, these two plasmid species,
pICDP(for) and pICDP(rev), were differentiated by digestion with the restriction
enzyme Sal I (Figure 3.17A) and both outcomes are illustrated in Figure 3.17C.
3.5.7. Summary
This section has described the successful construction of the pICDP(for) plasmid that
has been designed to permit the conditional upregulation of p53 expression. The first
version of the plasmid, pIcDNA(rev) contained the floxed STOP cassette derived
from the pFloxSTOP plasmid which was the same as that used for the construction of
the pFloxEGFP plasmid described in Chapter 2. As one possible explanation for the
results obtained with the pFloxEGFP plasmid was the orientation of the loxP sites, it
was decided to rebuild both the floxed STOP cassette and pIcDNA(rev). The
outcome was pICDP(for) in which, after Cre-mediated
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The pPUR plasmid was obtained from a commercial supplier (Clontech). The puro
expression cassette was excised via double digestion with the restriction enzymes,
Xmn I and Pvu II (cleavage sites indicated above).
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Figure 3.17 - Constructing ofpICDP(for); Inserting the pac Gene Into the
plcDNA (for) PlasmiU
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recombination has occurred, one loxP site will be retained but in the forward
orientation.
3.6. Introducing pICDP(for) Into p53 Null Mouse Embryonic Fibroblasts by
Calcium Phosphate Transfection
Previous sections of this chapter have described the generation of two useful tools,
the identification of a novel murine senescence-specific biomarker and the design
and construction of a p53 conditional expression. This next section of work
examines the feasibility of combining these two tools, i.e. stably introducing the
pICDP(for) plasmid into EFs, expressing Cre in the transfected cells, quantifying p53
upregulation and examining its effect on senescence and SA(Tgal expression.
3.6.1. Determination of Puromycin Sensitivity of p53 Null EFs
As no data were available, it was necessary to determine the puromycin sensitivity of
p53 null MEFs. Equal numbers of the cells were plated ontolOOmm culture dishes
and exposed to doses of puromycin over the range of 0.5pg/ml to 2.5pg/ml for 14
days. At the end of this time the surviving clones at each dose were stained with
GIEMSA (Sigma) and then scored (data not shown). This work established that the
optimal concentration of puromycin with which to select stable pac transformants of
p53 null MEFs is 2.5pg/ml.
3.6.2. Stable Transfection ofMEFs
There are no publications reporting the stable introduction of plasmid DNA into
primary MEFs. One significant reason for this is the short replicative lifespan of the
cells, usually between 15 and 20 passages in culture (Harvey et al, 1993) hence the
cultures will have reached senescence before the selection period (10-14 days) after
stable transfection has elapsed. However, because I intended to work with p53 null
EFs, which had been reported not to enter senescence (Harvey et al, 1993) stable
transfection was a realistic option. It was decided to attempt to introduce DNA into
these cells using a modified calcium phosphate precipitation protocol (Chen &
Okayama, 1987). For two days after transfection the cells were maintained in non-
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Figure 3.18 - GIEMSA Visualisation ofStably TransfectedMEF Clones
A) Untransfected control MEFs exposed to 2.5ug/ml of puromycin for 18 days. Cells
then stained with GIEMSA (100mm culture dish).
B) MEFs transfected with the pPUR vector (Clontech) and cultured in the presence
of 2.5ug/ml of puromycin for 18 days. Cells then stained with GIEMSA (100mm
culture dish).
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selective medium, after which they were transferred into medium containing
2.5pg/ml puromycin. Clones became visible after 15-20 days in selection and were
then harvested and subjected to further analysis. Figure 3.18 illustrates the number
of clones visible on a control and a transfected plate after 15 days in selection
(visualised with GIEMSA).
3.6.3. Introduction of Cre Recombinase into MEF/pICDP(for) Clones
As with the pFloxEGFP system already described, expression of Cre in MEFs was
achieved by their infection with a recombinant adenovirus engineered to express Cre
recombinase, AdCre (Anton & Graham, 1995; also Section 2.5.4). At the time of
this experiment no data had been published relating to the feasibility of infecting
MEFs with adenovirus. For this reason it was necessary to establish the optimal titre
(measured in multiplicity of infection, m.o.i, units) for infection as described below.
3.6.3.1. Determination of Optimal Adenovirus Titre For MEF Infection
Equal numbers of p53 null MEFs were plated out into three wells, each sample of
cells were then infected with either 1 m.o.i, 10 m.o.i or 50 m.o.i of AdLacZ (Anton &
Graham, 1995). Twenty-four hours after infection the cells were fixed and P-
galactosidase activity was visualised histochemically (Figure 3.19). Infection of
MEFs with lm.o.i of AdLacZ resulted in the successful infection of 1-5% of cells, in
contrast, at 50m.o.i almost 100% of cells are infected and no obvious
cytopathological side-effects were observed. After this preliminary experiment all
subsequent adenovirus infections of MEF cells were carried out using 50 m.o.i of
virus.
3.6.3.2. Infection ofMEF/pICDP(for) Cells With AdCre
p53 null MEF cells, which had been stably transfected with the pICDP (for) plasmid,
were plated onto chamber slides. The slides of cells were then divided into two
groups, one group were infected with AdCre at 50 m.o.i, and the other half were
infected with the control adenovirus DL-70 at 50 m.o.i.(Sallenave et al, 1998). The
DL-70 adenovirus has been engineered to be replication defective but does not
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Figure 3.19 - Infection ofPrimary MEFs With a Range ofAdLacZ Titres
A) 1 m.o.i (taken without phase at x 100 magnification)
C) 50 m.o.i (taken without phase at x 100 magnification)
express any heterologous proteins and is referred to as "empty" (Sallenave et al,
1998). Forty-eight hours after infection, 1 slide from each group was UV irradiated
(10 j/m2) to facilitate the immunohistochemical detection of p53. This was necessary
as the p53 protein has a very short half-life within normal cells and is not readily
detectable by immunohistochemistry in the un-induced state (half-life approximately
15 minutes, Kamijo et al, 1998). Six hours after UV irradiation all cells were
harvested. Genomic DNA was isolated from cells infected with either DL-70 or
AdCre and the remaining cells were fixed and stored at -70°C prior to
immunohistochemical visualisation of p53 status.
3.6.4. PCR-Based Analysis ofMEF Clones
3.6.4.1. PCR Detection of Episomal Adenovirus Molecules
Adenoviridae only rarely integrate into the host genome and are instead thought to
persist as extrachromosomal molecules (Stratford-Perricaudet et al, 1992). The
presence of these episomal molecules in DNA extracts prepared from infected cells
can be detected by PCR, using primers that anneal within the Cre expression cassette
of AdCre (designed by Dominic Rannie). The 660bp band visible in Figure 3.20,
confirms the successful infection ofMEF cells.
3.6.4.2. Recombination-Specific PCR Strategy
A PCR strategy was designed which generated recombination-specific PCR products
from the pICDP(for)-derived transgene present in the MEF cells (Figure 3.21). In the
unrecombined state the neo and SENII1 primers anneal to the transgene and generate
a 2291 bp product. However, after Cre-mediated recombination, the floxed STOP is
excised from the transgene, deleting the neo primer binding site and a novel upstream
primer, PGK, is needed. The PGK/SEN III primer combination cannot generate a
product from the unrecombined transgene but in the presence of the recombined
transgene a 1887bp product is produced.
As shown in Figure 3.22, the 2291bp product generated from the unrecombined
pICDP(for) construct can be amplified from genomic DNA harvested from control
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Figure 3.20 - PCR Detection ofEpisomal AdCre Molecules
1.0 kb
<— 5()0bp
4% agarose/ethidium bromide gel. Lane 1, blank. Lane 2, the 660bp PCR product
amplified from genomic DNA harvested from AdCre-infected EF cells. Lane 3,
molecular weight markers.
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Figure 3.21 - Recombination Status-Specific PCR Strategy For the pICDP(for)
Plasmid
A) Structure of the unrecombined pICDP(tbr) plasmid in EF cells and relative PCR
primer positions.
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B) Structure of the p53 transgene in EF cells after Cre-mediated recombination has















5' splice PGK promoter




a A r -) i- —
2.31
Figure 3.22 - Recombination Status-Specific PCR Results
A)
1.0% agarose/ethidium bromide gel. Lane 1, the 2291bp product amplified from
genomic DNA harvested from DL-70-infected EF cells. Lane 2, the 2291bp product
amplified from genomic DNA harvested from AdCre-infected EF cells. Lane 3,
blank. Lane 4, molecular weight markers.
B)
6 7
1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
PCR result when genomic DNA harvested from DL-70-infected EF cells was used as
the template for the PGK/SENIII PCR reaction. Lane 3, PCR result when genomic
DNA harvested from AdCre-infected EF cells was used as the template for the
PGK/SENIII PCR reaction. Lane 4, blank. Lane 5, the 1887bp recombination status-
specific PCR product amplified from a positive control plasmid.
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DL-70 and AdCre-infected MEF cells. This confirms that the plasmid has been
stably integrated into the genome of these cells. However, when the recombination-
specific PGK/SENIII primer pair were used the characteristic 1877bp band was
amplified from the positive control DNA but not the MEF genomic DNA (Figure
3.22B).
3.6.5. Immunohistochemical Detection of p53 Status
The successful detection of episomal adenovirus molecules in genomic DNA from
AdCre-infected MEF cells confirms that the virus was entering these cells.
Furthermore the PCR results shown in Figure 3.22A demonstrate that the pICDP(for)
plasmid has stably integrated into the genome of the transfected MEFs. However,
thel887bp recombination-specific PCR product could not be amplified from the
same genomic DNA samples. Therefore, the predicted recombined plasmid structure
shown in Figure 3.21 was not present and so low levels of p53 upregulation are
expected in these cells. Nevertheless, p53 immunohistochemistry was undertaken on
the various transfected MEF samples to provide data on two aspects of the
pICDP(for) plasmid. First, whether any leaky expression from the integrated, but
unrecombined pICDP(for) plasmid, be detected in transfected but DF-70 infected
cells as was indicated by the analogous pFloxEGFP system. Second, whether the
predicted low level of p53 upregulation can be detected in the AdCre-infected
population of cells. Immunohistochemistry was carried out on AdCre- and DL-70-
infected cell samples, one unirradiated and a second UV irradiated (lOJ/m ) sample,
as well as appropriate positive and negative controls.
An example of the typical nuclear staining pattern observed after p53 has been UV
stabilised in a wild type EF is shown in Figure 3.23A. In comparison, no p53
expression can be detected in p53 null MEFs after UV irradiation (Figure 3.23B).
However, rare p53 positive cells were seen in the pICDP(for) transfected-MEF cells
that had been infected with AdCre and UV irradiated (approximately 1-2%). Two
examples are shown in Figure 3.23C and 3.23D. No positive cells were observed in
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Figure 3.23 - Immunohistochemical Detection ofp53 in MEFs
A) Positive staining wild type cell B) Negative staining in p53 null
demonstrating nuclear p53 MEFs after UV irradiation
accumulation after UV irradiation (x400, haematoxylin
(x400, haematoxylin counterstaining). counterstaining).
MHBK. **
.
C) Positive staining p53 null MEF cells after stable transfection with plCDP(for),
infection with AdCre and subsequent UV irradiation (x400, haematoxylin
counterstaining).
Figure 3.24 - SAfi-gal Scoring in AdCre-infected, pICDP(for) transfectedMEFs
A) Typical SAB-gal Positive Cell (x400)
B) Numbers of SAB-gal positive cells in control DL70-infected and AdCre-infected


















the control DL-70-infected cells or in the unirradiated AdCre-infected cells (data not
shown).
3.6.6. SA-Pgal Detection
After adenoviral infection of the transfected MEF cells samples were removed for
both immunohistochemistry and the histochemical detection of SAP-gal expression.
The low level of p53 upregulation in the AdCre-infected cell population would be
predicted to have no significant effect on the level of SAP-gal expression. In line
with this prediction, when the numbers of SAP-gal positive cells in both the AdCre-
and DL-70-infected samples was scored no significant difference was observed
(Figure 3.24).
3.7. Discussion
The availability of a senescence-specific biomarker for use in murine cells was such a
desirable tool it was decided to re-examine the possibility of SAP-gal expression in
MEFs. A novel stain solution was developed which, for the first time, permitted the
visualisation of SAP-gal expression in MEFs in vitro (Figure 3.1). However, unlike
the system developed by Dr. J. Campisi and colleagues for use with human samples
(Dimri et al, 1995), the murine stain solution failed to identify SAP-gal positive cells
in vivo (Figure 3.5).
To check the validity of the murine SAP-gal detection system in vitro a continuous
culture experiment was initiated. Wild type and p53 null MEFs were maintained
according to the 3T3 culture regime (Todaro & Green, 1963). Cells samples were
removed at regular intervals, fixed, stained and scored via a running mean for SAP-
gal expression. As shown in Figure 3.3 substantial differences became apparent in
the SA-pgal positivity detectable in p53 null and wild type cultures. At passage 1,
SA-Pgal expression was detectable in 17% of wild type MEFs but in only 2% of p53
null MEFs. The consistently higher level of SA-Pgal expression in the wild type
cells was maintained up to passage 11, at which point the culture was not obviously
proliferating and was judged to have entered replicative cellular senescence. This
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conclusion was supported by the observation that 60% of such cells expressed
histochemically detectable SA-Pgal activity. In contrast, at passage 11 only 8% of
p53 null MEFs were SA-Pgal positive. Interestingly, two peaks of SA-Pgal positivity
were observed in the p53 null cultures, the first at P20 with 50% staining and the
second at P33 with 52% of cells staining positively for SA-Pgal expression. No
changes in cell proliferation, such as a crisis phase, or morphology were noticed that
correlated with the increased SAP-gal positivity at P20 and the correct interpretation
of this observation is at present unclear and at P33 the p53 null MEFs were still
actively proliferating.
The successful development of a murine SA-Pgal detection system arose fortuitously.
Having unsuccessfully tried the protocol provided by J. Campisi on primary MEFs, it
was decided to vary individual components of the stain solution. The basic
ingredients of all P-gal stain solutions are, X-gal which acts as a visible indicator of
enzyme activity, the potassium ferro- and ferricyanide mixture which acts as an
oxidation catalyst to help localise the stain and intensify the colour of the reaction, a
buffer to maintain pH, and sodium and magnesium ions which act as activator and
co-factor, respectively, of the P-gal enzyme (Yarborough et al, 1967). The first
component varied in the new stain was the magnesium ion concentration, this was
increased 100 fold. When this new stain was tested on primary MEFs, cells that
stained positively for SA-Pgal expression were detected. Therefore, the only
significant difference between the SA-Pgal stain protocol developed by J. Campisi
and colleagues and the one developed during the course of this PhD is the
concentration of magnesium. This may reflect an underlying biochemical difference
in the requirement for the magnesium ion co-factor between the human and murine
forms of the P-galactosidase enzyme.
The experimental data illustrated in Figure 3.3 also highlighted the different
proliferative capacities of the wild type and p53 null MEFs. Wild type MEFs could
only be maintained in culture for 11 passages. With other authors reporting vastly
different MEF replicative lifespan values, from 20 passages (Harvey et al, 1993) to 4
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passages (Jha et al, 1998) there is obviously significant variation in this value. This
may be due to differences between the mouse strain from which the primary MEFs
were established or culture conditions. However, the continued proliferation and
failure of p53 null MEFs to enter senescence is exactly in line with previous reports
(Harvey et al, 1993). p53 null MEFs were maintained according to the 3T3 regime
for over 30 passages and even at this point displayed no signs of reduced
proliferation.
As p53 status conferred such different growth capabilities on MEFs it was decided to
generate tools to facilitate the understanding of the role of p53 in the regulation of
replicative senescence. The first such tool was the pICDP(for) vector, designed to
permit Cre-mediated conditional upregulation of p53 expression. This vector was
initially constructed using the floxed STOP cassette from the pFloxSTOP plasmid.
However, in the light of results obtained with the pFloxEGFP vector (Chapter 2), it
was decided to rebuild both the floxed STOP cassette and the p53 expression vector.
The outcome of these cloning steps was the pICDP(for) vector.
Having built the conditional p53 expression vector it was then necessary to develop
and optimise a protocol for the introduction of plasmid DNA into primary MEFs.
This had not previously been reported. Techniques including electroporation were
tried, although eventual success was achieved when stable transformants were
generated using a modified calcium phosphate protocol (Chen & Okayama, 1987).
The successful amplification of a vector-derived 229lbp PCR product from the
genomic DNA of transfected MEFs confirmed that the pICDP(for) plasmid had
indeed stably integrated into these clones (Figure 3.22).
The Cre delivery method selected for use with the MEFs was the recombinant
adenovirus, AdCre (Anton & Graham, 1995). However, no publications had reported
the use of adenoviridae with this cell type so it was necessary to determine the
optimal virus titre for infection. MEFs were infected with a range of three viral
titres, 1 m.o.i, 5 m.o.i and 50 m.o.i of the AdLacZ virus (Anton & Graham, 1995)
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and (3-gal expression was detected histochemically (Figure 3.19). The infection
efficiency with 1 m.o.i of virus was less than 5%, however, when MEFs were
exposed to 50 m.o.i. of AdLacZ 100% of cells were infected with no obvious
cytopathic effects. Therefore, all further adenovirus infections of MEF cells were
carried out at this titre.
After the successful infection ofMEFs with AdCre was confirmed by the PCR
detection of episomal adenovirus molecules, the next step was to analyse the
consequences of Cre expression. First, a recombination status-specific PCR strategy
was designed and implemented. The presence of the unrecombined pICDP(for)
plasmid in MEFs was confirmed, but the predicted recombination-specific PCR
product could not be amplified from genomic DNA harvested from AdCre-infected
MEFs (Figure 3.22).
There are several possible explanations for this result. First, that Cre-mediated
excisive recombination was not actually occurring within these cells. This is
improbable as episomal adenovirus molecules were detected by PCR in the genomic
DNA of AdCre-infected MEFs indicating successful infection. Furthermore, the
virus stock used was freshly prepared and its ability to express Cre recombinase had
been confirmed by other research workers (D. Rannie, data not shown).
Alternatively, a mutation may have arisen in one of the loxP sites in pICDP(for)
which could prevent Cre-mediated excisional recombination. This is also
improbable as the integrity of the loxP sites in pICDP(for) were confirmed by DNA
sequencing. Therefore, it is probable that Cre-mediated excisive recombination was
occurring within these cells, and that the failure to detect it, was due to the
transfection method used.
When high concentrations of plasmid DNA are introduced into cells,
extrachromosomal homologous recombination (ECR) results in the production of
large tandem arrays in which the DNA molecules are joined in a head-to-tail
arrangement. Tandem arrays can only be formed by ECR taking place between
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Figure 3.25 - Mechanisms ofChromosomal Integration ofCalcium Phosphate
TransfectedDNA
A) Productive Insertion Events
i) A schematic representation of the pICDP(for) plasmid. ii) When this plasmid is
introduced into cells it undergoes random linearisation, in this example at a site within
the plasmid backbone, iii) ECR between the linear and circular species of the plasmid
then results in the production of large tandem arrays. The tandem arrays then integrate
into the genome of the transfected cell. Dotted lines in iii) delineate the individual
repeat units that comprise this tandem array, iv) After cre-mediated recombination all
floxed DNA is excised and the result is the transgene structure shown. This transgene
structure can be detected using a recombination state-specific PCR reaction which
amplifies a 1887bp product and should permit the upregulation of p53 expression.
B) Non-productive insertion events
i) A schematic representation of the pICDP(for) plasmid. ii) When this plasmid is
introduced into cells it undergoes random linearisation, in this example at a site within
the functional domains of the plasmid. iii) ECR between the linear and circular species
of the plasmid then results in the production of large tandem arrays. The tandem arrays
then integrate into the genome of the transfected cell. Dotted lines in iii) delineate the
individual repeat units that comprise this tandem array, iv) After cre-mediated
recombination all floxed DNA is excised and the result is the transgene structure shown
The 1887bp recombination-specific PCR product cannot be amplified from this
transgenes of this structure, furthermore, they will not support the upregulation of p53
expression.
Figure 3.25A - Mechanism ofChromosomal Integration ofCalcium Phosphate
Transfected DNA; Productive Insertion
i) Simplified pICDP(for) Structure
ii) After Random Linearisation
iii) Tandem Array (Head-to-Tai! Structure)











Figure 3.25B - Mechanism ofChromosomal Integration ofCalcium Phosphate
Transfected DNA; Non-productive Insertion
i) Simplified pICDP(for) Structure
ii) After Random Linearisation
iii) Tandem Array (Head-to-Taii Structure)
■ft
iv) Tandem Array After Cre-mediateu Excisive Recombination










linear and circular forms of the introduced plasmid DNA (reviewed in Bishop &
Smith, 1989). However, as the DNA used for calcium phosphate transfection is
circular, linearisation occurs randomly. The results of random pICDP(for)
linearisation can be divided into two groups. First, productive insertion which occurs
as a result of linearisation within the plasmid backbone as shown in Figure 3.25. If
ECR occurs between the linear and circular plasmid forms shown in Figure 3.25A a
tandem array will be formed (Figure 3.25A, iii), dotted lines on the diagram delineate
the functional domains within the array). Such arrays then integrate randomly into
host chromosomes. After Cre-mediated excisive recombination has occurred all
floxed sequences are deleted and the functional plasmid structure is reconstituted
(Figure 3.25A, iv). The recombined structure should then be detectable by PCR and
should support p53 upregulation.
The second type of insertion event that occurs after the random linearisation of
plasmids introduced into cells by calcium phosphate transfection is non-productive
(see Figure 3.25B). Such events are due to linearisation occurring within a functional
domain of the plasmid (see Figure 3.25B, ii). If the pICDP(for) plasmid is randomly
linearised, forms tandem arrays and then undergoes Cre-mediated excisive
recombination, the outcome is the structure as shown in Figure 3.25B, iii). In this
example, the recombined plasmid structure will not be detectable by PCR and will
not permit the upregulation of p53 expression (Figure 3.25B, iv).
The probability of productive and non-productive events can be estimated by
comparing the relative length of functional plasmid domains to the length of the
plasmid backbone. pICDP(for) is 15kb, key functional domains span llkb and the
remaining 4kb are plasmid backbone structures. Therefore, if linearisation occurs
randomly, approximately 24% of linearisation sites will result in productive insertion
events and 76% of linearisation sites will generate non-productive transgenes after
Cre-mediated excisive recombination. However, the exact percentage of pICDP(for)-
transfected MEFs that can upregulate p53 expression in response to AdCre-infection
is dependent upon the AdCre-infection efficiency. For example, the predicted 24%
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maximal induction is dependent upon 100% infection efficiency. As shown in Figure
3.19, at 50 m.o.i. up to 100% infection efficiencies were seen when MEFs were
infected with AdLacZ. However, variations in the viability of viral stocks could
result in lower infection efficiencies. For example, repeated freeze/thaw cycles are
known to be deleterious to virus viability (Croyle et al, 1998).
The failure to detect recombined plasmid structures that have arisen from productive
insertion events may also be explained by non-random plasmid linearisation. If
linearisation events were occurring preferentially within the functional domain-
containing regions of pICDP(for) then substantially fewer productive insertion events
would be observed. The recombination state-specific PGK/SEN III PCR can only
amplify a 1887bp product from the recombined pICDP(for) plasmid structures that
result from productive insertion events (Figure 3.25). The failure to amplify this
PCR product from genomic DNA isolated from AdCre-infected MEFs (Figure 3.22)
may suggest that significantly fewer than predicted productive insertion events have
occurred within the transfected MEFs. The presence of non-productive insertion
events could not be confirmed by either Southern blot analysis, due to limitations on
experimental material availability or, by PCR, due to the multiple possible
linearisation sites and subsequent tandem array structures.
In concordance with the failure to detect Cre-mediated recombination products by
PCR, when the AdCre- and control DL70-infected MEFs were subject to p53
immunohistochemistry a very low level of p53 upregulation was observed
(approximately 1-2%). As the pICDP(for) plasmid was specifically rebuilt to avoid
the potential Reverse loxP Problem, this is not a valid explanation for these data.
Furthermore, it is improbable that a mutation has arisen within the coding sequence
of the p53 gene as some p53 expressing cells were successfully detected by
immunohistochemistry (Figure 3.23). However, a contributory factor to the low level
of p53 upregulation may be the potential for a small number of untransfected clones
to survive selection in 2.5pg/ml of puromycin. As shown in Figure 3.18 a small
minority of untransfected MEF cells can survive puromycin selection. The continued
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survival of such cells would further reduce the percentage of MEFs capable of p53
upregulation after AdCre-infection. Unfortunately, higher doses of puromycin could
not be used as they compromised the survival of pac expressing cells (data not
shown); furthermore, a puromycin concentration of 2.5pg/ml was already
significantly higher than the maximum recommended by the manufacturer
(Boehringer Mannheim).
In conclusion, the failure to detect recombined pICDP(for) transgene structures and
the low level of p53 upregulation are interrelated observations. Minor variations in
AdCre titre, and a small number of untransfected MEFs surviving puromycin
selection may have contributed to a lower frequency of p53 upregulation than
predicted. However, these data may also be explained as artefacts of the calcium
phosphate precipitation method used to stably transfect the p53 null MEFs, if for
example non-random plasmid linearisation was occurring.
Despite the low level of p53 upregulation observed after AdCre-infection of
transfected MEFs, a key result was obtained with the pICDP(for)/MEF system. That
is the absence of detectable leaky p53 expression from the unrecombined tandem
arrays. For example, a maximum of 24% of all linearisation events would be
predicted to result in the reconstitution of productive plasmid structures after Cre-
mediated recombination. However, independent of the linearisation site all tandem
arrays, which are predicted to comprise up to 100% of calcium phosphate-mediated
insertion events (reviewed in Bishop & Smith, 1988), should contain functional units.
Therefore, if leaky expression was occurring from the unrecombined plasmid arrays,
as suggested by data from the pFloxEGFP plasmid, then p53 expression should be
immunohistochemically detectable in the UV irradiated, DL70-infected control cells.
This was not observed which would seem to indicate that the floxed STOP cassette
was efficiently stopping marker gene expression.
Another explanation for the absence of leaky expression from the proposed
unrecombined tandem arrays is the phenomenon of repeat-induced gene silencing
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(Garrick et al, 1998). These authors demonstrated that the presence of multiple
homologous copies of a transgene within a tandem array can have a repressive effect
upon gene expression. Therefore, the introduction of the pFloxEGFP plasmid into
ES cells via electroporation probably resulted in single-copy insertion at a unique
locus (reviewed in Hooper, 1992), a situation which may permit leaky expression. In
contrast the pICDP(for) plasmid is probably present in MEFs as a tandem array in
which leaky expression could be limited by repeat-induced gene silencing (Garrick et
al, 1998). Unfortunately, as already mentioned, the limited availability of
experimental material prevented a Southern analysis of the nature of the integration
events occurring within pICDP(for)-transfected MEFs.
As well as attempting to develop tools for the conditional upregulation of p53
expression, this section of work has also addressed the phenomenon of replicative
cellular senescence. One area of particular interest was the role of p53 in regulating
the onset of senescence and coincident expression of the novel murine senescence-
specific biomarker, SAP-gal. Therefore, as well as examining the p53 status of
pICDP(for)-transfected MEFs after DL70- or AdCre-infection, SA(3-gal expression
was also quantified. As shown in Figure 3.24, there was no significant difference in
the number of SAp-gal positive cells in the DL70- and AdCre-infected samples
(-10% in both). This was expected as only a low level of p53 upregulation was
achieved in the AdCre-infected cells. Hence, the levels of SA-Pgal expression are
below any of those recorded in wild type MEFs (Figure 3.3), therefore independent
of AdCre exposure, the pICDP(for)-transfected MEFs are effectively still p53 null.
The problem of both productive and non-productive insertion events occurring within
calcium phosphate transfected cells could have been overcome if a method were
developed to permit the introduction of linear, rather than supercoiled DNA. The
plasmid could then be linearised by digestion with a restriction enzyme that cuts at a
known position within the backbone, for example, Eco N1 for the pICDP(for)
plasmid. In theory, all integration events that arise from the transfection should then
be productive.
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Several alternative transfection strategies were considered. First, lipofection, but this
was not attempted as no publications or technical literature from various suppliers
had reported the successful application of this technology to the stable transfection of
primary cells. Second, the use of a calcium phosphate protocol to introduce the
pICDP(for) plasmid after linearisation by digestion with the restriction enzyme Eco
Nl. However, after transfection with the linear DNA no MEF clones were observed
after 18 days in selection with 2.5|Lig/ml of puromycin (data not shown). This
observation is in agreement with other reports stating that linear DNA cannot be used
in calcium phosphate precipitation (Chen & Okayama, 1987). The third strategy
used in an attempt to introduce linear DNA into MEFs was electroporation. Using
conditions recommended by the manufacturer of the electroporation equipment
(BioRad), MEFs were electroporated with linear pICDP(for) plasmid DNA.
However, following the electroporation, no MEF clones became visible after 18 days
in selection with 2.5|U,g/ml of puromycin (data not shown).
In conclusion, the only successful strategy for the stable transfection of primary
MEFs was the calcium phosphate protocol using supercoiled DNA (Chen &
Okayama, 1987). Unfortunately, this method brings with it the potential for both
productive and non-productive insertion events. One final option for the introduction
of pICDP(for) into MEFs is the generation of transgenic mice. The conditional p53
expression transgene could then be bred onto a p53 null background and primary
cultures established from embryos. This method has the advantage that the
pICDP(for) plasmid would be present in all cells within the culture avoiding the need
for transfection. Furthermore, this section of work has demonstrated the simplicity of
using AdCre to infect MEF cultures. Transgene positive cultures could be infected at
approximately 100% efficiency allowing maximal induction of p53 expression and a
thorough analysis of the effects of p53 expression on the onset of replicative
senescence. Unfortunately, time and budget constraints rendered such an approach
unfeasible within the duration of this project.
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Inducible Gene Targeting of the Murine p53 Gene
4.1. Introduction - Inducible Gene Targeting
Standard gene targeting allows the generation of knockout mice, that is mice with
engineered deletions introduced into specific endogenous genes. While this type of
approach has resulted in significant advances in the field of reverse genetics the
technique does have limitations. One of the most significant problems is that target
gene function is ablated or at least modulated in all tissues of the mouse throughout
development. Furthermore, not all knockout mice are viable; the absence of
expression of certain gene products is incompatible with the successful completion of
normal embryogenesis and development, hence precluding further analysis of target
gene function (reviewed in Copp, 1995). The ability to spatially and temporally
regulate endogenous gene expression within transgenic mice, so-called inducible
gene targeting (IGT), should allow a more informative analysis of gene function. It
was with this aim in mind that the two technologies of gene targeting and the
Cre/loxP system have been brought together. Both of these systems have been
described in detail elsewhere in this thesis (see Sections 1.1-1.3) and the aim of this
introduction is to explain how they can be combined to generate an allele of a target
gene from which conditional expression can be achieved.
The minimum components of a replacement type targeting vector are a substantial
length ofDNA homologous to the target locus, a positive selectable marker and a
unique restriction site outwith the region of homology with which to linearise the
vector. Replacement targeting strategies utilise the intracellular homologous
recombination machinery to replace sections of the endogenous target gene with
sequences from the linearised targeting vector. The vector-derived sequences may
encode selectable markers or mutated versions of the target gene depending on the
type of replacement strategy used. The outcome is either the creation of a null allele,
249









Strategy to achieve conditional inactivation of gene expression. A) The insertion of
two directly repeated loxP sites (blue arrows) within the intronic sequence (narrow
black line) of a gene should not affect expression as shown by normal mRNA
production (broken red line) and protein expression (green line). B) After Cre-
mediated excisive recombination the floxed segment of DNA, including two exons
(solid black boxes) is deleted. A truncated mRNA and protein product are expressed
from this allele.
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if for example wild type sequences are deleted and replaced with an exogenous
selectable marker, or the creation of a subtle mutant allele (see Section 1.2.2.4.b).
The basic replacement gene targeting strategy can be adapted for use in IGT. The
only significant design consideration is whether the desired outcome of the IGT
strategy is conditional activation or inactivation of target gene expression. The
method of choice to achieve conditional inactivation of target gene expression is to
use a replacement targeting vector to remove an area of the target gene and replace it
with a copy that includes two directly repeated loxP sites (Figure 4.1). This type of
approach has been used successfully by several groups to achieve conditional
inactivation of endogenous gene expression (discussed in more detail in Section
1.3.3.2.C).
In contrast to conditional gene inactivation, no publications have reported the use of
the Cre/loxP system to achieve conditional activation of endogenous gene
expression. Yet in theory the same replacement targeting strategies used above can
be modified to allow the insertion of a floxed STOP cassette within the coding
sequence of an endogenous gene. In the absence of Cre expression the floxed STOP
cassette should prevent target gene expression. After Cre-mediated excisive
recombination has occurred only one 34bp loxP site will be retained within the target
gene. To allow gene expression from the recombined allele it is vital that the
retained loxP site does not lie within the coding sequence of the target gene. The
simplest way to ensure this is to insert the floxed STOP cassette within an intron.
Two types of insertion event can be envisaged with this approach, directly
downstream of the target gene promoter or alternatively within a more 3' intron.
Both of these strategies and their predicted effects on gene expression are shown in
Figure 4.2.
Recently, the application of an analogous strategy using Flp recombinase and a STOP
cassette flanked by FRT sites has been reported (Meyers et al, 1998). These authors
inserted a flrted STOP cassette, a neo gene and polyA signal, into intron 1 of
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Figure 4.2 - The Predicted Effects ofFloxed STOP Insertion and Subsequent
Excision on Gene Expression
A) The insertion of a floxed STOP cassette between the promoter (grey circle) and
downstream coding sequence of a gene (black boxes) blocks target gene
expression. However, any marker genes present within the floxed STOP cassette
should be transcribed (broken red line) and translated (blue line).
Note that both the transcription and translation of the exogenous marker gene are
under the control of the trapped endogenous promoter. However, latent p53
negatively regulates the translation of its own mRNA (Mosner et al, 1995).
Therefore to place the (3geo marker gene under both the transcriptional and
translational control of p53 it was necessary to delete the IRES cassette from the
original pGT1.8IRESPgeo vector (described in Sections 2.4.1 and 2.4.1.1.). Had
the IRES cassette been retained it may have permitted IRES-mediated translation
initiation of the p53/(3geo fusion transcript under conditions when latent p53 was
inhibiting CAP-mediated translation of this mRNA.
B) Cre-mediated excisive recombination results in the excision of the floxed STOP
cassette and the retention of one loxP site. Normal transcription of the target gene
is restored and the full-length protein product should be expressed (green line).
C) The insertion of a floxed STOP cassette within a more 3' intron of the target gene
also disrupts transcription (broken red line) and protein expression. A fusion
protein is produced (blue/green line) made up of target gene-derived sequence and
any marker genes present within the floxed STOP. The possible expression of a
truncated target gene is an important consideration when choosing between this
strategy and that shown in A).
D) Cre-mediated excisive recombination results in the excision of the floxed STOP
cassette and the retention of one loxP site in the third intron. Normal transcription
is restored and the full-length protein product is expressed.
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the mousefgf8 gene via homologous recombination. Gene expression was reduced
by over 50% from the targeted allele relative to wild type but was restored to normal
after Flp-mediated excisive recombination (Meyers et al, 1998). This confirms that
STOP cassettes can be used to regulate both exogenous and endogenous gene
expression in vivo and demonstrates the feasibility of this approach.
4.2. Inducible Gene Targeting Of The Murine p53 Gene
The central objective of this chapter was to apply IGT technology to the murine p53
gene. Details on the target locus and the design and implementation of an IGT
strategy are discussed in the following sections.
4.2.1. Structure of the p53 Locus
The mouse p53 gene spans 12kb and lies on chromosome 11 (Rotter et al, 1984;
Czosnek et al, 1984). It consists of 11 exons of which 10 contribute to the translation
product as exon 1 is transcribed but not translated (Bienz et al, 1984). The structure
of the endogenous promoter and genomic organisation of the murine p53 locus are
represented in Figure 4.3.
4.2.2. Targeting Strategy
As shown in Figure 4.2 the floxed STOP insertion site can have significant effects on
target gene expression from the unrecombined allele. To avoid the possibility of
expression of a truncated p53 protein from the unrecombined targeted allele it was
decided to target the floxed STOP cassette into intron 1, directly downstream of exon
1 and the promoter. The chosen floxed STOP cassette-insertion site lies downstream
of the transcription start site but upstream of the translation initiation point. This has
the advantage that the Pgeo marker gene present in the floxed STOP cassette should
be expressed under the control of the endogenous murine p53 promoter while
simultaneously abolishing expression of the p53 gene itself.
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Figure 4.3 - The Promoter Structure and Genomic Organisation of the Murine
p53 Gene
A) Detailed p53 promoter structure (not to scale). The p53 promoter spans 41 lbp
and includes numerous protein binding sites (thick black lines). Transcription is
initiated within the Initiator element (In) (-2 bp +5bp) (O'Shea-Greenfield &
Smale, 1992) as indicated by the red arrow. To the 5' of the In element lie three
protein binding sites, PF-2 (Hale & Braithwaite, 1995), PF-1 (Ginsberg et al,
1990) and Sp-1 (Bienz-Tadmor et al, 1985; Dynan, 1986). A further three protein
binding sites lie downstream of the In, NF-1 (Ginsberg et al, 1990), ETF (Hale &
Braithwaite, 1995) and bHLH (Ronen et al, 1991). The position of the proposed
dyad symmetry element present in the 5' region of the p53mRNA is also indicated
(+5-+108bp) (Bienz et al, 1984).
The aim of this diagram is only to provide an overview of the p53 promoter structure,
a detailed discussion can be found elsewhere (Section 1.3.1).
B) Schematic representation of the murine p53 genomic locus (not to scale). The
promoter region is indicated (blue line) as are the 11 exons (black boxes) and 10
intervening introns (thin black line). The mRNA (red line) and protein products
(green line) expressed from this locus are also shown.
Figure 4.3 — Genomic Organisation and Promoter Structure of the Murine p53
Locus
A) Detailed p53 Promoter Structure (not to scale)
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a) The isolation and/or construction of a genomic clone spanning the promoter
region of p53.
b) The construction of a targeting vector, pIGTV, designed to permit the insertion of
the floxed STOP cassette from pFloxSTOP into intron 1 of the murine p53 gene.
c) Demonstration that pIGTV is a functional substrate for Cre recombinase.
d) The introduction of pIGTV into ES cells and the development of a screening
strategy allowing the identification of successfully targeted clones.
4.4. IGT Vector Construction
4.4.1. Obtaining a Genomic Clone Homologous to the Target Locus
The variables which affect targeting efficiency at a given locus have been discussed
in depth elsewhere (Section 1.2.2.5.). The only one of these factors relevant to this
discussion is the extent of homology between the target locus and the targeting vector
as this is roughly proportional to the recombination frequency observed (reviewed in
Capecchi, 1989). For this reason it is desirable to use regions of homology in
targeting vectors which are as long as reasonably practical. The standard method of
obtaining genomic clones that are homologous to specific loci is via the screening of
genomic libraries. However, a suitable genomic clone spanning the 5' end of the p53
gene was not successfully identified after the screening of two genomic libraries (see
Lyons, 1999). Therefore, it was decided to try to obtain a genomic clone by PCR.
Three PCR reactions were designed, the products of which span the site to be
targeted in the p53 genomic locus (see Figure 4.4). Two of the three PCR reactions,
FX and F3K were designed and optimised by Dr. S. Lyons (Lyons, 1999). These two
PCR products were cloned into the Bluescript plasmid backbone generating the
pFXF3K plasmid which was obtained as a kind gift from Dr. S. Lyons (Figure 4.5).
All PCR products were amplified from genomic DNA harvested from HM-1 ES cells
as the completed IGT vector was to be introduced into that ES cell strain.
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Figure 4.4 - The Relative Sizes and Locations of the FX, SR and F3K PCR
Products
A)









A diagram of the 5' end of the mouse p53 locus (black line and box, not to scale)
with the three overlapping PCR products also shown (arrows). The construction of
the complete genomic clone is discussed in Section 4.5.1.
B)






1.0% agarose/ethidium bromide gel. Lane 1, the 1158bp band generated during the
FX PCR reaction. Lane 2, blank. Lane 3, the 2300bp band generated during the
SR PCR reaction. Lane 4, blank. Lane 5, 3200bp band generated during the F3K
PCR reaction. Lane 6, blank. Lane 7, molecular weight markers.
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The pFXF3K plasmid was obtained as a kind gift from Dr. S. Lyons. This plasmid
contains both the FX and F3K PCR. products and these are indicated on the above
diagram. The Sma I site was used during the in vivo cloning and this work is
discussed in more detail in Section 3.3.1.1.
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The pFXF3K vector was the starting point for the construction of a continuous
genomic clone spanning the promoter, exon 1 and the 5' end of intron 1 of the mouse
p53 gene. However, while the FX and F3K PCR products are separated by only a
few base pairs in the pFXF3K plasmid their genomic homologues are actually
separated by over 2 kilobases in the p53 locus (Figure 4.4.A). To generate a
continuous genomic clone spanning the region of interest it was necessary to insert a
third PCR product, SR between FX and F3K. However, the absence of suitable
restriction enzyme cleavage sites meant that this could not be accomplished using
standard cloning techniques, therefore the relatively new technique of In Vivo
Cloning (IVC) was used.
4.4.1.1. In Vivo Cloning
The standard method used to construct recombinant plasmids from multiple DNA
molecules involves restriction digestion of parental molecules and subsequent
ligation of component fragments. However, appropriate restriction enzyme cleavage
sites cannot always be found for every cloning step and this was the case with the
SR/pFXF3K step. Conventional cloning techniques would not have permitted the
seamless joining of the SR PCR product between the cloned FX and F3K products in
the pFXF3K vector. For this reason the continuous genomic clone was generated
using IVC (Oliner et al, 1993; Bubeck et al, 1993).
Specific E. coli strains can repair gapped plasmids via intramolecular homologous
recombination (Kobayashi & Takahashi, 1988) and the IVC technique is based on the
subsequent demonstration that certain of these strains can also perform
intermolecular homologous recombination (Oliner et al, 1993; Bubeck et al, 1993).
If two pieces of linear DNA are co-transformed in to the bacteria homologous
recombination can occur between the two to generate one circular molecule, provided
there is sufficient homology at the ends of both molecules. Cloning efficiency is
roughly proportional to the extent of homology between the components with 10 base
pair overlaps being a practical minimum (Bubeck et al, 1993).
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Figure 4.6 - Construction of the pIVC4 Plasmid and Restriction Digest Analysis
ofthe p53 Genomic Clone
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1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
Hind III digestion of pFXF3K plasmid generates two cleavage products of 5392bp
and 1998bp. Lane 3, Hind III digestion of the pIVC plasmid generates three
products, 1998bp, 2790bp and 4556bp. Lane 4, blank. Lane 5, Kpn I digestion of
pIVC gives a 103bp fragment (too small to be visible), a 1512bp,a 2883bp and
4846bp cleavage products. Lane 6, Sac I digestion of pIVC. Six cleavage products
are generated, two of 62bp and 33bp are too small to be visible on this gel. The other
four products of 1173bp, 1225bp, 3158bp and 3693bp are all seen. Lane 7, Sma I
cleaves the pIVC plasmid at one unique site generating a single band of 9344bp.
Lane 8, Xho I digestion of pIVC generates three cleavage products of 744bp, 2177bp
and 6423bp. Lane 8, molecular weight markers.
The relative positions of cleavage sites for the above restriction enzymes are shown
in the 6354bp genomic clone below (Figure 4.6.A) and in the complete pIVC
plasmid in Figure 4.7.
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Taking this into consideration the SR PCR reaction was designed to generate a
product that overlapped the cloned FX and F3K PCR products by a minimum of 40bp
at both ends. The SR PCR reaction was carried out using a blend of high fidelity Taq
polymerases (the Expand™ system, Boehringer Mannheim). The Pwo polymerase in
this blend possesses a 3'-5' exonuclease proof-reading activity which has been
6
reported to result in a 3-fold increased fidelity ofDNA synthesis (8.5 x 10" error
rate) compared to normal Taq DNA polymerase (2.6 x 10""' error rate) (Barnes,
1994). This reduced error rate was significant as the SR PCR product includes exonic
sequences whereas the FX and F3K products are composed of intronic sequences
only. The pFXF3K plasmid was linearised by overnight digestion with the restriction
enzyme Sma I. This digest was used as Sma I cleaves the pFXF3K plasmid at a
unique site within the polylinker between the cloned PCR products (site indicated on
Figure 4.5). The digest reaction was then electrophoresed through a 0.8% agarose
gel and the linear 7.3kb plasmid band excised and purified from the gel. The SR PCR
product was also prepared for IVC via gel electrophoresis and subsequent excision
and purification of the 2.3kb band. Both of the linear DNA molecules were mixed
and then used to transform competent bacteria of the strain DH5a (Life
Technologies). The transformed bacteria were plated onto L-amp plates (50p.g/ml of
ampicillin) and resultant clones screened by restriction digest analysis. Hind 111
digestion of the parental pFXF3K plasmid generates two cleavage products of 1998bp
and 5392bp in size (Figure 4.6, lane 2). However, if the SR PCR product has been
inserted into this plasmid via IVC, generating the plasmid pIVC, the Hind III cleavage
pattern is altered and three cleavage products are seen (Figure 4.6, lane 3). To
confirm that the SR PCR product had been correctly introduced into the pFXF3K
plasmid in the predicted location, the pIVC plasmid was subjected to digestion with
numerous restriction enzymes (Figure 4 .6, lanes 5-8). All of these restriction digest
analyses yielded products of exactly the sizes predicted from Figure 4.7 suggesting
that the pIVC plasmid did contain a 6354bp continuous genomic clone spanning the
5' end of the murine p53 gene although this was not confirmed by direct DNA
sequencing.
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Figure 4.7 - Plasmid Maps of the p53 Genomic Clone Contained in the pIVC4
Plasmid
A) A map of the 6354bp continuous genomic clone created by In Vivo Cloning
Hind 01 (1585)
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4.4.2. Inserting the Floxed STOP Cassette into pIVC
To generate the complete targeting vector the final construction step was the insertion
of the floxed STOP cassette from pFloxSTOP into pIVC. The pIVC plasmid was
linearised using the restriction enzyme Sma I (Figure 4.8, lane 2). Digestion of pIVC
with Sma / has several advantages, cleavage with Sma I generates blunt ends which
facilitates insertion of the floxed STOP cassette and the unique cleavage site lies
downstream of exon 1 within intron 1-derived sequences in the p53 genomic clone
present in pIVC. As already discussed in Section 4.2.2, the desired insertion site of a
floxed STOP cassette is downstream of the target promoter and within intronic
sequences. The correct insertion and orientation of the floxed STOP cassette into
pIVC was confirmed by Sac I restriction digest analysis (Figure 4.8, lane 5). The
completed targeting vector, pIGTV, is shown in Figure 4.9. A linear representation
of the p53 genomic clone containing the correctly inserted floxed STOP cassette is
also shown in Figure 4.9.
4.4.3. Testing pIGTV in BNN 132 Cells
Before the pIGTV vector was introduced into mammalian cells the ability of the
vector to undergo Cre-mediated excisive recombination was tested using the bacterial
strain BNN 132 (Clontech, see also Section 2.5.1.). Cultures of BNN 132 cells were
grown and competent cells generated using a standard calcium chloride protocol
(Sambrook et al, 1989). Competent BNN 132 bacteria were transformed with the
pIGTV plasmid and plated onto LB-agar plates supplemented with the antibiotic
ampicillin (50pg/ml). The predicted outcome of Cre-mediated recombination will be
the generation of two plasmid species from the parental pIGTV plasmid. First, the
pBluescript(BNN) plasmid which should be derived from the pBluescript backbone
and contain the p53 genomic clone and one retained loxP site. Second, the
pSTOP(BNN) plasmid which should be derived from the STOP cassette and contain
the second loxP site (Figure 4.10). However, as the ampicillin resistance gene is
present only in the pBluescript(BNN) plasmid only this species will be represented in
clones produced from the transformation of BNN 132 cells after selection with
ampicillin. These predicted results were confirmed by restriction
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1% agarose gel with ethidium bromide. Lane 1, molecular weight markers. Lane 2,
Sma I digestion of the pIVC plasmid generates one band of 9344bp. Lane 3, Sna BI
digestion of pFloxSTOP produces two cleavage products of 3738bp and 6339bp.
Lane 4, blank. Lane 5, sac I digestion was used to orientate the floxed STOP cassette
present in pIGTV. The cleavage products shown above, 4807bp, 3158bp, 1967bp
and 1913bp (which run as an unresolved doublet), 1345bp, 1225bp and 1173bp are
those obtained when the floxed STOP cassette is inserted in the correct orientation as
shown in Figure 4.9.
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Figure 4.9 - PlasmidMaps ofthe Inducible Gene Targeting Vector, pIGTV
A) A linear representation of the p53 genomic clone and inserted floxed STOP
cassette present in the pIGTV plasmid shown below.
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B) The complete pIGTV vector. The relative positions of all Sac 1 cleavage sites are
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When the pIGTV plasmid is transformed into BNN 132 cells Cre-mediated excisive
recombination occurs. The result of this is two plasmid species, the first,
pSTOP(BNN), contains one loxP site and all of the STOP cassette. The second
species, pBluescript(BNN), is derived from the plasmid backbone and p53 genomic
clone and also contains one loxP site. Only pTAg(BNN) contains an ampicillin
resistacnce gene so this should be the only plasmid species represented in clones
arising from the transformation.
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Figure 4.11 - Restriction Digest Analysis to Confirm plGTVHas Undergone
Cre-mediated Excisive Recombination









1.0% agarose/ethidium bromide gel. Lane 1, molecular weight markers. Lane 2,
blank. Lane 3, Sac I digestion of plGTV. Cleavage with this enzyme generates nine
digestion products, 4807bp, 3158bp, 1912bp and 1967bp (which run as an
unresolved doublet), 1345bp, 1225bp, 1173bp, 62bp and 33bp bands, the last two of
which are too small to be seen in the above gel. Lane 4, Sal I digestion of plGTV
generates a single cleavage product of 15682bp. Lane 5, Sac I digestion of the
pBluescript(BNN) plasmid generates seven cleavage products of 3158bp, 2445bp,
1345, 1225bp, 1173bp, 62bp and 33bp. All but the latter two bands are visible
above. Lane 6, Sal I digestion of pBluescript(BNN) generates a single cleavage
product of 9441bp. Lane 7, molecular weight markers.
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digest analysis of ampicillin resistant (AmpR) clones that arose from the
transformation of BNN 132 cells with pIGTV plasmid (Figure 4.10).
4.5. Summary
The work described in the above sections represents the successful completion of the
first three aims of this chapter. A continuous genomic clone spanning the 5' region
of the murine p53 gene has been constructed, furthermore the floxed STOP cassette
from the pFloxSTOP plasmid has been inserted into this clone generating the IGT
vector pIGTV. Finally, the efficient Cre-mediated excisive recombination of this
floxed STOP cassette from pIGTV has been demonstrated in BNN 132 cells.
4.6. Inducible Gene Targeting
4.6.1. Introducing pIGTV Into ES Cells
The completed targeting vector, pIGTV, was linearised by digestion with Sac II
(Figure 4.9B). The linear DNA was then introduced into ES cells by electroporation
(300pF, 0.8Kv, time constant O.lsecs, Biorad Pulse Generator) and the cells selected
in medium containing 200pg/ml of G418 (Southern & Berg, 1982). After 10-14 days
clones were picked into individual wells. The clones were then grown up and
divided into duplicate wells. Genomic DNA was prepared from one well while the
duplicate sample of each clone was transferred into storage at -80°C. The genomic
DNA from each clone was analysed by Southern blot to determine the mechanism of
targeting vector integration, either random or via homologous recombination. This
work is discussed in the following sections.
4.6.2. The Screening Strategy
A screening strategy is needed to allow the differentiation of ES cell clones in which
pIGTV has integrated randomly from those clones in which represent insertion events
mediated by homologous recombination. To determine which of these two outcomes
has occurred a Southern blot-based strategy is required in which the wild type
structure of the target locus can be differentiated from that of a correctly targeted
locus. Ideally two screening strategies should be designed, one for each end of the
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targeting vector to confirm that vector-derived sequences have indeed been inserted
into the target locus by homologous recombination. The Southern blot strategy
designed to identify ES cell clones in which the floxed STOP cassette had been
introduced into intron 1 of the murine p53 gene is discussed below.
4.6.2.1. Southern Blot Analysis
The restriction enzyme used for Southern analysis of clones that arose from the
electroporation of ES cells with linearised pIGTV was Bst XI. In the wild type p53
allele, digestion with Bst XI generates a 4894bp product whereas the digestion of the
targeted allele is predicted to yield a 5699bp product. Both of these digest products
share the same 3' sequences and it is to this region that the probe hybridises. The
probe designed for use in this strategy was a 224bp PCR product amplified from
within intron 1 of the p53 gene. Importantly, the intronic sequence from which the
probe is amplified lies beyond the 3' end of sequences incorporated into the targeting
vector.
The PCR primers and reaction conditions were designed and optimised by Dr. S.
Lyons (Lyons, 1999). The PCR product was then cloned into the commercial pCR
2.1 vector (Invitrogen) generating the plasmid pProbe. The p53 probe was excised
from pProbe by digestion with the restriction enzyme Eco RI. The reaction mixture
was then electrophoresed through a 2% agarose gel and the 241bp band containing
the probe sequence was excised from the gel and the DNA extracted. Southern blots
were hybridised with probe overnight, washed and then exposed to X-ray film for 10-
14days at -80°C before developing (Kodak Hyperprocessor). A typical blot is shown
in Figure 4.13.
4.6.2.2. Targeting Frequency
Over 200 G418R clones which arose after the electroporation of HM-1 ES cells with
the linearised pIGTV vector were picked and expanded for further analysis.
Genomic DNA prepared from individual clones was subjected to the Southern
blotting regime described above. The numbers of clones with wild type or targeted
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Figure 4.12 - Southern Blot Screening Strategyfor the Identification of
Targeted Clones
A) Structure of the exonl and intronl region of the wild type p53 genomic locus.
The positions of the relevant Bst XI sites, boundary of targeting vector-derived
sequences (dotted line) and probe (blue line) are all indicated.
Sequence present in targeting vector
firt XI (1719)
Exon 1 \








B) Structure of the targeted locus after the floxed STOP cassette has been inserted
into intron 1 of the p53 gene. As above the positions of the relevant Bst XI sites,
extent of vector-derived sequences (dotted line) and probe (blue line) are all
indicated. Note, the two diagrams are not at the same scale.
sequence present in targeting vector
ATG site
BstXI (4419)
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Sir XI (1719) \ I I Sir XI (7253)
\ I
Exon 1 SV40 pA
















Photograph of autoradiograph obtained from BstXI digested-genomic DNA
transferred onto a filter and probed with a radiolabeled p53 probe. Lane 1, two
bands are visible, the 4894bp digest product diagnostic of a wild type p53 allele and
the 5699bp digest product diagnostic of a targeted p53 allele. Labe 2, as with lane 1.
Lane 3, only one digest product is visible, the 4894bp digest product which indicates
that both p53 alleles in this clone are wild type. Lane 4, as with lanes 1 and 2.
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alleles were then scored and a targeting frequency of 48% observed (from 31 clones,
15 were scored as being correctly targeted). That is, in 48% of the G418R clones
analysed the linear pIGTV vector had undergone homologous recombination rather
than random insertion into the genome.
4.6.3. Cre-mediated Excisive Recombination
As mentioned in Section 4.5.2, it is desirable to design two Southern blot screening
strategies, one for each end of the targeting vector to confirm that vector-derived
sequences have indeed been inserted into the target locus by homologous
recombination. However, the extreme 5' end of the murine p53 gene is composed of
entirely unknown and unmapped sequence. For that reason it was impossible to
obtain a probe which was external to the 5' of the targeting vector integration site.
Furthermore, repeated attempts to map this region of the gene using internal vector
sequences as Southern probes were unsuccessful (data not shown). Therefore, in an
attempt to further characterise targeted clones identified by the Southern strategy
discussed in Section 4.6.2.1, a recombination state-specific Southern blot strategy
was designed. As shown in Figure 4.14, digestion of the correctly targeted allele
with the restriction enzyme Bst XI yields a 5699bp product. However, if this allele
has undergone Cre-mediated excisive recombination Bst XI digestion is predicted to
yield a 4220bp product. Unfortunately, time constraints prevented the
implementation of this Southern strategy and further characterisation of the clones
identified in Section 4.6.2.1.
4.7. Discussion
This chapter has focussed on the design and implementation of an inducible gene
targeting strategy for the mouse p53 gene. The vast majority of IGT strategies are
designed to permit the conditional inactivation of gene expression (see Figure 4.1).
In an attempt to broaden the applications of Cre/loxP technology it was decided to
develop an IGT strategy for the conditional activation of p53 expression, a floxed
STOP approach. The application of floxed STOP technology to the murine p53 gene
was also biologically relevant. p53 is the most frequently mutated tumour
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Figure 4.14 - Recombination State-Specific Southern Blot Screening Strategy
A) Structure of the targeted locus after the floxed STOP cassette has been inserted
into intron 1 of the p53 gene. The positions of the relevant Est XI sites, extent of
vector-derived sequences (dotted line) and probe (blue line) are all indicated.
Sequence present in targeting vector
ATG site
Bst XI (4419)





















B) Structure of the targeted locus after the floxed STOP cassette has been inserted
into intron 1 of the p53 gene via homologous recombination and then undergone
Cre-mediated excisive recombination. As above the positions of the relevant Est
XI sites, extent ofvector-derived sequences (dotted line) and probe (blue line) are
all indicated. Note, the two diagrams are not on the same scale.














suppressor gene in all human cancers (Hollstein et al, 1994) and a variety of data
indicate its central importance in tumourigenesis (reviewed in section 1.4, Chapter
1). However, relatively little is known about the biological consequences of restoring
p53 function to a previously p53 null cell. For example, whether a tumour that arose
in a p53 null mouse, would continue to survive if wild type levels of p53 expression
were restored. This type of question is directly relevant when considering the
potential of the p53 gene for use in gene therapy protocols and could be addressed
using a floxed STOP-p53 mouse.
Numerous publications have reported the use of floxed STOP cassettes to regulate
exogenous gene expression in vitro (reviewed in Chapter 2). In these examples the
floxed STOP cassette is simply inserted between the promoter and target gene.
However, floxed STOP cassettes can also be used to achieve conditional endogenous
gene expression in vivo. With this aim in mind, there are two alternative floxed
STOP cassette-insertion sites, within an intron directly downstream of the promoter,
or within a more three prime intron (Figure 4.2). Both options are predicted to
abolish target gene expression, although the use of a more three prime insertion site
may result in a truncated protein product being expressed from the target locus.
Because of the pleiotropic nature of p53 function the possible expression of truncated
protein forms was regarded as undesirable. Therefore it was decided to attempt to
introduce the floxed STOP cassette from the pFloxSTOP plasmid into intron 1 of the
p53 gene, directly downstream of the endogenous promoter.
To achieve this, the first requirement was the isolation of a continuous genomic clone
spanning the extreme 5' end of the mouse p53 gene. The failure to obtain such a
clone after the screening of two genomic libraries resulted in the use of a PCR-based
strategy. The successful generation of a PCR-derived 6.3kb genomic clone spanning
the region of interest using an In Vivo Cloning strategy is reported. A potential
drawback that must be considered when using a PCR-based strategy is the risk of
introducing mutations into the amplified products. However, over 95% of the
genomic clone obtained is composed of intronic sequences which contain no known
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regulatory functions (reviewed in Section 1.4.1, Chapter 1). Furthermore, the SR
PCR product, which contains exon 1 and the p53 promoter, was amplified using
High Fidelity™ Taq polymerase (Boehringer Mannheim) which has a three-fold
greater level of fidelity than standard Taq polymerases (Barnes, 1994). However,
DNA sequencing was not undertaken so the possibility of introduced mutations in
any of the three PCR products used cannot be ruled out.
The final step in the construction of an IGT vector was the insertion of the floxed
STOP cassette from the pFloxSTOP vector into the p53 genomic clone to generate
the vector pIGTV. Prior to introduction into ES cells this vector was shown to
undergo efficient Cre-mediated excisive recombination in BNN132 cells.
The linearised pIGTV vector was then electroporated into passage 19 HM-1 ES cells.
The cells were selected with the antibiotic G418 (Southern & Berg, 1982), resistance
to this drug is encoded by the neo component of the Pgeo fusion gene. Importantly,
the Pgeo gene is promoter-less so random integration of the linear pIGTV plasmid
should not permit Pgeo expression. Theoretically, the majority of G418R clones that
survive selection should represent homologous recombination-mediated insertion
events of the pIGTV plasmid. In this situation the Pgeo gene should be integrated
directly downstream of the endogenous p53 promoter and its expression regulated by
this same promoter. Therefore, targeting strategies that use promoter-less selectable
marker genes are predicted to yield high targeting efficiencies, a phenomenon that
has been reported by other authors. For example, the targeted disruption of an
endogenous gene, Hprt, using selection with a promoter-less neo gene has been
demonstrated in ES cells with a targeting frequency of 67% (Doestchman et al,
1988). The use of an enhancerless xanthine guanine phophoribosyltransferase (gpt)
gene resulted in a targeting frequency 44% of the gpt+ cells (Jasin & Berg, 1988) and
the use of a promoter-less Pgeo gene for during the targeted disruption of the Oct-4
locus gave rise to a targeting efficiency of 70-80% (Mountford et al, 1994). The 48%
targeting frequency obtained with the pIGTV vector described in this chapter is
comparable with these reports.
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The work described in this chapter has reported the successful completion of all of
the original aims laid out in Section 4.3. However, the direction of future work is
obvious. First, the completion of the Southern analysis detailed in Figure 4.13 on all
clones identified as being correctly targeted at the 3' end of the allele. Second, the
microinjection of correctly targeted ES cell clones into blastocysts and the breeding
of any subsequent chimaeric offspring to establish a targeted mouse line. Although
time constraints prevented the completion of these steps within the duration of this







This thesis has examined the feasibility of using floxed STOP-based strategies to
achieve conditional gene expression in vitro and in vivo. I have reported the
successful design, construction and testing of a novel floxed STOP cassette. The
ability of the cassette to regulate the expression of two marker genes, the EGFP gene
and the p53 cDNA, has been tested in vitro. This work succeeded in demonstrating a
two-fold upregulation of EGFP transcription and a low level of p53 upregulation
after Cre-mediated excisive recombination of the floxed STOP cassette.
Furthermore, an inducible gene targeting strategy was designed and implemented to
permit the insertion of the floxed STOP cassette into intron 1 of the endogenous
murine p53 gene. Unfortunately, despite the identification of correctly targeted ES
cell clones, time constraints prevented the generation of a targeted mouse line.
Finally, a new histochemical detection protocol was optimised permitting an
examination of SA-Bgal expression in primary MEFs. However, during this work a
number of problems were encountered.
These included, the failure to observe upregulation of EGFP expression at the protein
level after Cre-mediated excisive recombination of the floxed STOP cassette from
the plasmid pFloxEGFP. Four potential explanations were considered in an attempt
to rationalise this observation. First, that the pFloxEGFP transgene had been
inactivated by methylation during the generation of the FE13 cell line. However, this
possibility was eliminated by RT-PCR data that demonstrated that the introduced
EGFP gene was transcriptionally active within FE13 cells. The second explanation
was that a mutation had arisen spontaneously in the EGFP coding sequence during
the construction of the pFloxEGFP vector. This option could not be ruled out. The
third possibility was that AdCre-infection was occurring at such a low efficiency that
the level of EGFP mRNA and therefore protein, were below that detectable using
either UV microscopy or FACS detection systems. This option was ruled out by a
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repeat infection of FE13 ES cells using a new and more accurately titred AdCre stock
that also failed to induce detectable EGFP expression. The fourth and final
possibility was the so-called Reverse loxP Problem, an idea first proposed last year
(Sauer, 1998). This author theorised that the presence two ATG codons in the spacer
region of a loxP site in the reverse orientation could interfere with downstream gene
expression. It should be noted that this idea is purely theoretical and has never been
demonstrated in an experimental system.
In conclusion, the failure to observe EGFP expression in the pFloxEGFP
experimental system may be due to the acquisition of a point mutation within the
EGFP coding sequence or the "Reverse loxP Problem" discussed above. However,
by ensuring that any loxP sites retained after Cre-mediated recombination are in the
forward orientation the potential problem can be avoided altogether. It was for this
reason that the pICDP(for) plasmid discussed in Chapter 3, was rebuilt using the
floxed STOP cassette derived from the pFloxSTOP(for) plasmid.
The second problem encountered with the pFloxEGFP experimental system was
leakiness, i.e., it was possible to detect expression of EGFP mRNA in the absence of
Cre-mediated excisive recombination. Although other authors have theorised that
leakiness from floxed STOP cassettes is due to spontaneous homologous
recombination between loxP sites (Agah et al, 1997; Anton & Graham, 1995), this
phenomenon was not detected with the pFloxEGFP plasmid. The most probable
explanation is that rather than transcription splicing onto the splice acceptor within
the STOP cassette, splicing around occurred, thereby permitting EGFP expression. It
should be noted that both the observation of leaky target gene expression, and the
failure to upregulate target gene expression after floxed STOP cassette excision are
not without precedent in the literature. For example, a recent meeting abstract
produced by the laboratory of Prof. A. Berns detailed numerous problems with a
floxed STOP-LacZ transgenic mouse strain, including failure to upregulate LacZ
gene expression after Cre-mediated excision of the floxed STOP cassette
(Krimpenfort et al, 1998). Furthermore, two independent research groups have
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reported leaky expression from a floxed STOP-luciferase vector (Agah et al, 1997;
Anton & Graham, 1995).
The other challenge encountered during the work discussed in Chapter 2 was the
development of a Cre-delivery strategy. The first approach tested was the transient
transfection of cells with Cre-encoding plasmids. However, variations in transfection
efficiencies and the failure to detect Cre-mediated recombination curtailed this line of
investigation. Nonetheless, as part of this work a novel ES cell differentiation state-
specific enhancer element was characterised (Fiskerstrand et al, 1999). The second
Cre-delivery strategy investigated was the use of replication-defective recombinant
adenoviridae (Anton & Graham, 1995). It was demonstrated that undifferentiated ES
cells are resistant to adenoviral infection, confirming previous reports (Aladjem et al,
1997), although efficient infection of differentiated ES cells was achieved. Having
optimised an adenovirus-infection protocol, the next step was to obtain reproducible
infection efficiencies. Variations in adenoviral infection efficiencies were probably
due to variations in viral titre, a problem that was almost certainly responsible for
some of the observed variations in marker gene expression reported in Chapter 2.
However, the sensitivity of adenoviral stocks to storage conditions is well
documented (for example see, Croyle et al, 1998) and the majority of these problems
were overcome by small alterations to laboratory practice. These included the
aliquoting of viral stocks and increasing the accuracy of titration experiments. These
changes facilitated not only the more successful application of recombinant
adenoviral technology at other points in this thesis, but also by other members of the
laboratory.
As already mentioned the data obtained from the pFloxEGFP plasmid was used to
redesign and rebuild the pICDP(for) plasmid. To avoid the possibility of the Reverse
loxP Problem preventing expression of the p53 cDNA, the plasmid was rebuilt so
that after Cre-mediated excisive recombination the single retained loxP site was in
the forward orientation. The next step was to introduce the pICDP(for) plasmid into
cells. The most significant factor in the selection of the cells to be transfected was
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that they should be p53 null. Therefore, the predicted Cre-mediated upregulation of
p53 expression from the introduced cDNA should be readily detectable by
immunohistochemistry. The chosen cells were primary murine embryonic fibroblasts
(MEFs) that were isolated from embryos which contained a targeted mutation in the
endogenous p53 gene (Purdie et al, 1994).
It was necessary to optimise a protocol for the stable transfection ofMEFs as this had
not previously been reported. Generally, the short lifespan in vitro of wild type
MEFs had precluded prolonged selection experiments. However, the increased
lifespan of p53 null MEFs permitted prolonged selection and the isolation of stable
transformants. Two transfection methods were tested on p53 null MEFs,
electroporation and calcium phosphate precipitation. No clones were obtained after
the electroporation of p53 null MEFs with linearised pICDP(for) plasmid, and
success was only achieved using a modified calcium phosphate transfection protocol
(Chen & Okayama, 1987). The central aim of the work with the pICDP(for) plasmid
was to attempt to develop a new tool for the conditional expression of p53, thereby
facilitating an analysis of p53 function. Therefore by developing and optimising new
MEF transfection methods the long-term aim was to permit the investigation of the
role of p53 in replicative cellular senescence.
However, before this work could begin it was necessary to identify a murine
senescence-specific biomarker. This goal was achieved within the duration of the
project after the development of a histochemical detection system permitting the
visualisation of murine senescence-associated Pgal (SA-Pgal) expression. The
existence of SA-Pgal was first demonstrated in human cells where SA-Pgal positivity
displayed an inverse correlation with DNA synthesis as detected by [3H] thymidine
labelling (Dimri et al, 1995). However, this thesis reports the first description of SA-
Pgal expression in mouse cells and the first analysis of SA-Pgal expression in both
wild type and p53 null MEFs over the duration of a continuous culture experiment.
The only significant difference in the stain solution developed in this thesis and that
developed by Dr. J. Campisi (Dimri et al, 1995) is the magnesium ion concentration,
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the murine SA-Ggal stain reported here contains a 100 times greater concentration of
magnesium. This ion is known to function as an essential cofactor for the G-gal
enzyme and the difference between the two stains may represent an underlying
biochemical difference in the magnesium requirements of the murine and human
forms of G-gal.
Despite the successful isolation of pICDP(for)-transfected MEF cells and the
identification of murine SA-(3gal, further problems were encountered. First, when
pICDP(for)-transfected MEFs were infected with AdCre, or the control DL70 virus, a
recombination state-specific PCR failed to detect the presence of any recombined
plasmid structures. As episomal AdCre molecules were detected in the cells, and the
integrity of the loxP sites within the pICDP(for) plasmid had been confirmed by
DNA sequencing, recombination was almost certainly occurring in these cells.
Two contributory factors may have been responsible for the failure to detect Cre-
mediated excisive recombination. First, small variations in AdCre titre and
subsequent infection efficiencies, therefore, all cells which contained productive
insertion events may not have been infected by AdCre and second, limitations of the
transfection system. That is, the random linearisation events that occur during
calcium phosphate precipitation which render a large proportion of integration events
non-productive. Due to the size and complexity of the pICDP(for) vector, random
linearisation events are predicted to have generated non-productive insertion events
in 76% of clones. However, at the time of this work, no publications had reported
the stable transfection of primary MEFs and the successful transfection reported here
was only accomplished using a modified calcium phosphate transfection protocol and
could not be achieved using an alternative strategy in vitro. As discussed in Chapter
3, an obvious solution to the problem of MEF transfection was the generation of
pICDP(for)-transgenic mice strains. Unfortunately, this was outwith the temporal
and financial constraints of this research project.
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The second problem experienced with the pICDP(for) system was the low level of
p53 upregulation observed after Cre-mediated recombination . Because the
pICDP(for) plasmid was specifically rebuilt to avoid the potential Reverse loxP
Problem, this not a valid explanation for these data. Furthermore, it is improbable
that the p53 cDNA had acquired a mutation during the construction of pICDP(for) as
a low frequency of p53 upregulation was successfully detected by
immunohistochemistry. This observation, and that of the failure to amplify the
recombination-specific PCR product are linked. Although contributing factors such
as the survival of non-transfected MEFs and variations in AdCre titre I believe that
both may best be explained as limitations of the transfection system. That is, only
pICDP(for) plasmids which have undergone productive insertion events give rise to
recombined plasmid structures which both permit the upregulation of p53 expression,
and the amplification of the recombination-specific PCR product. It may be that a
significantly smaller percentage than the predicted 24% of clones, represented
productive insertion events. However, the absence of scientific literature on this
field, and the small amount of experimental material available, which prevented
Southern analysis of transfected MEFs, makes it very difficult to prove this theory.
The final area of research was an examination of the feasibility of using floxed STOP
cassettes to regulate endogenous gene expression in vivo. As part of this work an
inducible gene targeting strategy was applied to the murine p53 gene. A targeting
vector, pIGTV, was constructed to permit the insertion of a floxed STOP cassette
into intron 1 of this gene via homologous recombination in ES cells. The long-term
aim of this work was to use any targeted ES cells for the generation of mice that
carried the floxed STOP cassette within intron 1 of their p53 gene. Such mice could
then be used to investigate the biological consequences of restoring p53 function to a
previously null cell, for example, as part of a study assessing the efficacy of p53-
based gene therapy protocols.
Using a Southern blot-based screening strategy successfully targeted ES cell clones
were identified and a targeting efficiency of 45% was recorded. Unfortunately, the
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injection of targeted ES cells into blastocysts and subsequent generation of chimaeric
progeny were not completed within the time limits of this research project. As germ-
line chimaeras and targeted mice were not obtained an investigation of floxed STOP-
mediated regulation of p53 gene expression in vivo could not be completed.
Only one other paper has reported the use of an analogous system, a flrted STOP
cassette, to regulate gene expression in vivo (Meyers et al, 1998). However, these
authors only detected an approximate 50% reduction in gene expression from the
targeted allele indicating that the flrted STOP cassette was not working at maximal
efficiency. The STOP cassette used by Meyers et al, did not contain a splice acceptor
and this may have been responsible for the significant frequency of splicing around
observed. It would have been interesting to compare this level of leaky expression to
that observed after the insertion of the floxed STOP cassette from the pFloxSTOP
plasmid into intron 1 of the p53 gene.
The work described in this thesis has explored the feasibility of using Cre/loxP-based
technologies to regulate gene expression both in vitro and in vivo. By overcoming
numerous technical problems the limitations of this novel technology have been
explored. Although the basic floxed STOP strategy is theoretically straightforward,
this work has highlighted the potential pitfalls. In conclusion, floxed STOP-based
approaches to achieve conditional gene expression offer an extremely exciting
opportunity. However, this technology is not as straightforward as a cursory glance








6.1. Manipulation of DNA
6.1.1. Transformation of BacteriaWith Plasmid DNA
A 5pl aliquot of Epicurian Coli XL-2 Blue ultracompetent cells (5 x 109 cfu/pg
pUC18 DNA, Stratagene) was removed from storage at -70°C and thawed on ice.
Plasmid DNA was added directly onto the cells and then mixed by pipetting. The
cells and the DNA were incubated on ice for 30 minutes, heat shocked at 42°C for 45
seconds and returned to ice for a further 2 minutes. After which 80pl of Luria Broth
(LB) was added and the tube incubated at 37°C for 1 hour in an orbital incubator at
225rpm. The transformed bacteria were then plated onto LB-agar plates containing
appropriate antibiotics to select for transformants.
Luria Broth: Bactotryptone 10g/l
Yeast Extract 5g/l
NaCl 0.17mM
Made up with ddPLO and autoclaved, supplemented with 1.2% w/v
Bactoagar for plates
1000 X Antibiotic Selection Concentrations:
Ampicillin 50mg/ml in H2O Stored at -20°C
Kanamycin lOmg/ml in H2O Stored at -20°C
Note, when transforming ligation reactions (Section 7.1.7) 15pl aliquots of
ultracompetent cells were used and mixed with no more than 1.5pl of a 20pl ligation
reaction mix.
6.1.2. Calcium Chloride Preparation of Competent BNN 132 Cells
The following protocol using calcium chloride to make competent bacteria is based
on the standard method (see Sambrook et al, 1989). A 5ml starter culture of LB and
50pg/ml of kanamycin was inoculated with a single BNN 132 cell clone and grown
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overnight at 37°C in an orbital incubator at 225rpm. The following day 100|itl of this
culture was added to lOOmls of LB-Kanamycin and grown at 37°C, 225rpm until the
ODgoO was approximately 0.3 units. The culture was then cooled to 4°C before
being split between two 50ml Oakridge tubes and spun down at 4000rpm for 10
minutes. The supernatant was removed and the pellets placed on ice. The bacteria
were kept on ice during resuspension of the pellet in lOmls of ice cold sterile 0.1M
CaCl2- The 0.1M CaCh used was prepared freshly each time from a 1M stock stored
at -20 C. The bacteria were then centrifuged at 2,500xg for 10 minutes, the
supernatant removed and the pellet resuspended in 1ml of CaCl2- At this point the
cells were divided into 200pl aliquots which could be used directly for
transformation. Alternatively aliquots could be stored at 4°C for up to 24 hours but
these cells did not store well at -70°C.
6.1.3. Preparation of Bacterial Glycerol Stocks
A clone picked from a plate of transformed bacteria was used to inoculate 5ml of LB
(supplemented with appropriate antibiotics) and grown at 37°C overnight in an
orbital incubator. Cells were harvested by centrifuging for 3 minutes at 13,000rpm in
a microfuge and the pellet resuspended in 750jli1 of sterile 50% LB: 50% glycerol.
The bacteria were transferred in CryoTube™ vials (Nunc) and stored at -70°C.
6.1.4. Small Scale Preparation of Plasmid DNA
This "miniprep" method is a modification of the procedures described in Sambrook
et al. (Sambrook et al, 1989). A single bacterial clone was picked from an LB-agar
plate using a sterile P200 pipette tip. The clone was then transferred into a Falcon
2059 tube containing 5 ml of LB supplemented with appropriate antibiotics and
incubated in an orbital incubator (225rpm) at 37°C overnight. The following day the
cells were harvested by centrifugation for 2 minutes at 10,000xg in a microfuge.
The supernatant was removed and the pellet resuspended in 200ul of Solution 1.









The lysis reaction was then neutralised with 200ul of Solution 3.
Solution 3: Potassium acetate, pH 4.8 1.32M
A protein precipitate became visible after Solution 3 was added and this was
removed by centrifugation for 3 minutes in a microfuge, the supernatant was then
transferred to a fresh tube. Any proteins remaining in the sample were removed by
the addition of 2 volumes of a 50% phenol: 48% chloroform: 2% isoamyl alcohol
mix. The samples were mixed by inversion and then centrifuged for a further 3
minutes. After centrifugation the sample was present in two phases, the aqueous top
layer was removed and the DNA precipitated by the addition of 2 volumes of ethanol
and 0.1 volumes of 10M Ammonium acetate. During the precipitation the samples
were stored at -70°C for 20-30 minutes and then centrifuged at 10,000g, 4°C for 20
minutes. The pellet was rinsed twice in 100pl of 70% ethanol, air-dried and finally
redissolved in 20ul of TE pH 8.0 (store DNA at -20°C).
TE Buffer: Tris-HCl, pH 8.0 lOmM
6.1.5. Large Scale Preparation of Plasmid DNA
The large-scale isolation of plasmid DNA was carried out using a Plasmid Maxi Kit
(QIAGEN) according to the manufacturers instructions. A flask containing 100ml of
LB, supplemented with the appropriate antibiotics, was inoculated with bacteria
containing the chosen plasmid. Maxipreps can be inoculated using bacteria from
glycerol stocks (Section 6.1.3), miniprep cultures (Section 6.1.4) or with individual
EDTA ImM
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clones from LB-agar plates. The bacteria were then grown for 12- 16 hours in an
orbital incubator. The following morning the cells were harvested by centrifugation
at 2,500xg for 10 minutes at 4°C (Sorvall GSA rotor, Centrikon H-401B). The
cells were resuspended and lysed just as for the miniprep method (Section 7.1.4) and
the protein precipitate was removed by centrifugation at 20,000xg for 30 minutes at
4°C (Sorvall GSA rotor, Centrikon H-401B). The need for an organic extraction
was avoided by adding the supernatant directly onto a QIAGEN-tip that contains a
DNA-binding resin. The QIAGEN-tip column and bound DNA were then washed
twice before the DNA was eluted and precipitated by the addition of 0.7 volumes of
room temperature isopropanol. The sample was then centrifuged immediately at
16,000xg for 30 minutes at 4°C (Sorvall SS-34 rotor, Centrikon H-401B). The
DNA pellet was washed once in 5ml of 70% ethanol, air-dried for 5 minutes and
finally resuspended in 0.5 ml of TE and stored at -20°C.
6.1.6. Restriction Digest Analysis of Plasmid DNA
Depending on the downstream applications planned varying amounts of DNA were
digested. For example less than lpg of DNA would be digested when analysing
miniprep DNA whereas up to 100pg would be used in some applications, such as
electroporation (Section 6.2.6). In all cases a suitable amount of DNA was mixed
with 0.1 volumes of 10X reaction buffer (supplied by the manufacturer) and 0.1
volumes of 10X Bovine serum albumen (10X BSA at lmg/ml). Finally, 0.1 volumes
of restriction endonuclease were added to the reaction mix and any remaining volume
was made up with ddH^O. The digests were then incubated for l-24hrs at the
temperature recommended by the manufacturer (in all cases, New England Biolabs).
To visualise digest patterns samples were run out on agarose gels.
6.1.7. Agarose Gel Electrophoresis of DNA
Agarose gel electrophoresis can be carried out using gels that contain varying
amounts of agarose depending on the size of the DNA molecules to be resolved. All
gels were prepared identically, an appropriate weight of agarose was added to IX
TBE, for example, lg in lOOmls IX TBE to produce a 1% gel. The agarose/lX TBE
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mixture was then heated in a microwave for 2-3 minutes. A small amount of the
fluorescent dye ethidium bromide (lOmg/ml) was added directly to the liquefied gel
mix and the gel then poured into a casting tray.




0.5M EDTA, pH 8.0
(Made up to one litre)
40ml
Samples to be run were mixed with Orange G loading buffer and then loaded directly
into the gel. Molecular weight markers, for example, lkb Ladder (Life
Technologies) were also diluted in identical loading buffer and loaded into the gel.
Electrophoresis was carried out in IX TBE at 50-100V.
6.1.8. Extraction of DNA Fragments From Agarose Gels
The QIAEX II Gel Extraction Kit (QIAGEN) was used for the purification of DNA
fragments from agarose gels. DNA was digested with appropriate restriction
endonucleases, after the digest had gone to completion the sample was run out on an
agarose-TBE gel containing ethidium bromide. The bands were visualised quickly
with UV light (Herolab, gel documentation equipment) and excised form the gel with
a scalpel. The gel slice was then weighed and an appropriate volume of
solubilisation buffer and DNA-binding resin were added to the sample according to
the manufacturers instructions. After solubilisation and adsorption of the DNA to the
resin the sample was centrifuged at 10,000g for 30 sees. The resin pellet was washed
three times and then air-dried for 15 minutes. To elute the DNA, the pellet was
resuspended in 20(0.1 of water and incubated at room temperature for 5 minutes before
centrifuging at 10,000g for 30 sees. The purified DNA was present in the
supernatant. DNA samples extracted from gels in this manner were stored at -20°C.






To ligate an insert into a vector differing ratios of both DNA fragments were mixed
together, see below (Table 6.1). The exact yield of each of these components was
never precisely quantified but for most ligations was between 10-50ng/pl.
Table 6.1. Relative proportions of vector and insert DNA in standard ligation
reactions
Tube Vector DNA/pI Insert DNA/pl Water/pl
IO 0 6 14
V2 2 6 12
V4 4 4 12
V6 6 2 12
VO 6 0 14
The IO tube is included as any colonies that arise from the transformation of this
ligation reaction must represent plasmid backbone contamination of the insert. This
can become a particular problem when large fragments are being inserted into
smaller vectors. The VO tube is included to provide a guide to the level of
background due to vector recircularisation occurring, this can be dramatically
reduced by treating the linear vector DNA with Shrimp Alkaline Phosphatase
(Section 6.1.10). The total volume of all the reaction mixes was 20pl, this was then
added directly into a tube of dehydrated Ready-To-Go™ T4 DNA ligase (Pharmacia
Biotech). The ligation reaction was incubated at room temperature for 5 minutes,
mixed by gentle pipetting and then transferred to a 16°C water bath for 30 minutes.
After this time the ligation is complete, the ligase can be inactivated by heating to
70°C for 10 minutes and the sample used to transform bacteria.
Ready-To-Go T4 DNA ligase:
FPLCpure 6 Weiss units
T4 DNA ligase






(End concentrations when diluted in 20 jliI)
6.1.10. Dephosphorylation of Vectors
The removal of 5' terminal phosphate groups from linearised vector DNA prevents
vector recircularisation in a ligation reaction. This was achieved by incubating the
DNA with 1 unit of Shrimp Alkaline Phosphatase (SAP, United States Biochemical)
for a minimum of 30 minutes at 37°C. The SAP was added directly into the
restriction digest reaction as it is compatible with most enzyme buffers and will be
removed in the subsequent gel purification of the vector DNA. Alternatively, linear
DNA can be SAP treated after gel extraction. In the absence of any restriction
enzyme reaction buffer, such as after the DNA has been extracted from a gel and
resuspended in ddH20, the SAP reaction should carried out in the presence of 0.1
volumes of 10X SAP reaction buffer.
10X SAP Reaction Buffer:
Tris-HCl, pH 8.0 200mM
MgCl2 lOOmM
It is crucial to ensure that all SAP activity is removed before a treated DNA sample is
used in a ligation reaction otherwise other reaction components could also be
dephosphorylated preventing efficient ligation. This was achieved by incubation of
SAP reaction mixtures at 65°C for 10 minutes.
6.1.11. Blunting 3' and 5' Overhangs of Linear DNA
6.1.11.1. Klenow Reaction
The large fragment of DNA polymerase I, Klenow enzyme (United States
Biochemical), retains 5' to 3' polymerase activity but lacks any exonuclease activity.
This polymerase was used to blunt 5' overhangs of DNA generated by restriction
enzyme cleavage when needed. The enzyme (1-5 units, depending on reaction
volume) and 0.1 volumes of 0.5mM dNTP mix can be added directly to a restriction
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digest and incubated at 37°C for 30 minutes. The blunted DNA sample was then run
out on a gel to check no degradation had occurred. If the blunted DNA was to be
used in subsequent ligations the correct size band was excised from the gel, purified
(Section 6.1.8.) and SAP treated if necessary.
6.1.11.2. T4 DNA Polymerase
T4 DNA polymerase catalyses the synthesis of DNA in the 5' to 3' direction so, like
Klenow fragment, can be used to fill in 5' overhangs. However, T4 DNA
polymerase also has a 3' to 5' exonuclease activity that will remove any 3' overhangs
generated by certain restriction enzymes to leave blunt ends. As with Klenow, the
enzyme and other reaction components were added directly to restriction digests after
they had gone to completion. Each reaction contained 3 units of polymerase (New
England Biolabs)/pg of DNA, 0.1 volumes of ImM each NTP mix (Pharmacia
Biotech), 0.1 volumes of 0.5mg/ml BSA and 0.1 volumes of T4 reaction buffer.





(pH 7.9 at 25°C)
The blunting reactions were incubated at 12°C for 20 minutes after which point the
enzyme was heat inactivated at 75°C for 10 minutes.
6.1.12. DNA Sequence Analysis
6.1.12.1. DNA Template Preparation
DNA was sequenced directly supercoiled plasmids (Hattori & Sakaki, 1986). In
order to successfully sequence double stranded template a small excess of template
was needed, 3-5pg of plasmid per primer, which was then denatured in alkali. 5ug of
DNA were diluted to a final volume of 45pl in ddH20 and 5pl of freshly prepared







The DNA was incubated for 5 minutes at room temperature with the Denaturing
Solution after which the reaction was neutralised with 5(il of 2M ammonium acetate
(pH 4.6, filter sterilised). The DNA was then precipitated by the addition of 185pl of
absolute ethanol and storage at -70°C for 30 minutes. The denatured plasmid was
recovered by centrifugation at 10,000g for 20 minutes in a microfuge at 4°C. The
supernatant was discarded and the pellet washed with 200pl of ice cold 70% ethanol.
The DNA was then dried under vacuum and resuspended in 6pl ddPDO. This
denatured template can be stored at -20°C for up to one week or used immediately in
the sequencing reactions described below.
6.1.12.2. Dideoxy Sequencing
Chain-termination sequencing (Sanger et al, 1977) was carried out using the T7
Sequenase® Version 2.0 system (United States Biochemical) according to the
manufacturer's instructions. Briefly, template prepared as described in Section
7.1.12.a was mixed with lpmol of a selected sequencing primer, 2\i\ of 5X
Sequenase Reaction Buffer and the total volume made up to 10|il with dd H2O.
5X Sequenase Reaction Buffer:
Tris-HCl, pH 7.5 200mM
MgCl2 lOOmM
NaCl 250mM
The template and primer mixture was incubated at 65°C for 2 minutes before being
cooled to approximately 37°C over a period of 30 minutes to allow primer annealing.
The tube was then placed on ice prior to the labelling reaction. To each lOpl volume
of template/primer 1 pil of 0.1M DTT, 2|il of labelling mix (diluted 1:5 in ddH20)
and 0.5pl of [a-^S] dATP (10pCi/pl, ICN Biochemicals) was added.
Labelling Mix: dGTP, dCTP, dTTP 7.5|iM each
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To start the labelling reaction 2jli1 (3.25 units) of Sequenase T7 DNA polymerase
(diluted 1:8 in Enzyme Dilution Buffer) was added and the reaction incubated at
room temperature for 5 minutes.
Enzyme Dilution Buffer:




Reactions were then terminated by placing 3.5pl of tempiate/primer mix into each of
four tubes warmed to 37°C, containing one of four (A, C, G or T) termination mixes.
The tubes were then incubated for a further 5 minutes at 37°C and the reaction was
stopped by the addition of 4pl of Stop Solution.






In addition the 'A' mix contains 8pM ddATP, the 'C' mix
8pM ddCTP etc.
Stop Solution: Formamide 95% v/v
EDTA 20mM
Bromophenol Blue 0.5g/l
Xylene Cyanol FF 0.5g/l
The completed sequencing reactions can be stored at -20°C otherwise the samples
were heat denatured at 90°C for 2-3 minutes and immediately run on a 6%
polyacrylamide, 6M urea 0.4mm sequencing gel.
Gel Solution: Urea 250g




The acrylamide/urea gel solution was stored at 4°C in a dark bottle. For each
sequencing gel, 60mls of the above solution was mixed with 60fj.l of TEMED and
60|il of 25% Ammonium persulphate (made fresh for each use) and poured
immediately. The gel was left for one hour at room temperature to polymerise or can
be wrapped up and stored overnight at room temperature. Prior to loading any
samples, the gel was pre-run at 70W for one hour or until the gel reached
approximately 50°C. Electrophoresis was carried out using IX TBE electrophoresis
buffer. After pre-warming the gel, the samples were loaded and electrophoresed at
70W for 1-4 hours. Upon completion of electrophoresis, the gel was fixed by two
washes in 10% methanol, 10% acetic acid and blotted onto Whatman 3MM paper.
The gel was dried under vacuum at 80°C for two hours and exposed to
autoradiography film overnight (Kodak BioMax MR film, Eastman Kodak
Company). The autoradiography film was developed (Amersham Hyperprocessor)
and interpreted the next day.
6.1.13. Southern Blotting
6.1.13.1. Preparation of DNA
10 (ig of genomic DNA was digested with an appropriate restriction enzyme. Once
the digest had gone to completion the sample was run out on a 0.8% agarose gel.
The gel was then prepared for blotting onto nylon membrane. If the fragments of
interest were predicted to be larger than 15kb, transfer of the DNA to the nylon
membrane was improved by partially depurinating the DNA prior to transfer.
Depurination was achieved by soaking the gel for 10 minutes 0.2M HC1. The gel
was then rinsed in deionised water and the DNA was transferred immediately.
6.1.13.2. DNA Transfer
The DNA was transferred from the gel onto a positively charged nylon membrane,
Zeta-Probe® GT, Bio-Rad) according to the manufacturers instructions using 0.4M
Sodium hydroxide as the transfer buffer. After blotting overnight the membrane was




pH to 7.0 with 1M HC1
3M
0.3M
The nylon membrane was then baked at 80°C for 30 minutes and stored between
Whatman 3MM paper at room temperature until needed.
6.1.13.3. Prehybridisation
UltraHYB™ (Ambion) hybridisation buffer was heated to 68°C to ensure complete
solubilisation of all components. 10 mis was then removed and added into a
hybridisation tube containing the baked nylon membrane. The membrane and
UltraHYB™ buffer were then incubated at 42°C for 1 hour in a hybridisation oven
(Hybaid).
6.1.13.4. Generation of Radiolabeled Probes
50ng of appropriate DNA was radiolabeled to a high specific activity with [cc-32P]
dCTP (ICN Biochemicals Inc.) using Prime-It RmT Random Primer Labelling Kit
(Stratagene) according to the manufacturers protocol. Labelled probe was separated
from unincorporated nucleotides using a Sephadex G50 Column (Pharmacia). The
probe was mixed with 20pl of carrier salmon sperm DNA (lOmg/ml) and added to
the top of the column. 400pl of TE was then added and the column eluate collected
in tube 1. A further 400pl of TE was added and the eluate collected in tube 2. Tube
2 should contain the radiolabeled probe. The level of [oc-32P] dCTP incorporation
was assessed by comparing the counts from the column to those from tube 2 and the
probe only used if greater than 50% incorporation was achieved.
6.1.13.5. Hybridisation
After the membrane had been incubated with prehybridisation buffer at 42°C for 1
hour the probe, denatured by boiling for 5 minutes, was added. Hybridisation
proceeded overnight at 42°C and the membrane was washed the following morning.
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Wash 1: 2X SSC, 0.1% SDS
Wash 2: 0.1X SSC, 0.1% SDS
After the final wash the filter(s) were removed from the hybridisation tube, sealed in
a plastic bag and exposed to Hyperfilm™ MP (Amersham) with intensifying screens
at -70°C for 2-5 days. The autoradiography films were then developed (Amersham
Hyperprocessor).
6.1.14. Polymerase Chain Reaction
Unless otherwise stated all PCR reactions were carried out using Taq Polymerase and
accompanying reaction buffer, 1% WI and 50mM Magnesium chloride were supplied
by Life Technologies. Pharmacia Biotech supplied all nucleotides and the
oligonucleotides were synthesised by Cruachem.
6.1.14.1. p53-Based PCR Strategies
6.1.14.1.a. FX PCR
This primer pair and the reaction conditions were designed and optimised by Dr. S.
Lyons (Lyons, 1999).
Table 6.2: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
PIN 1 gAggCACCggTTCAAAgTCTgTAT 64°C 1200
PI gCTCTgTgCTCTTTCCTATCCAg
Reaction conditions: Primers (10pmol/pl) 4pl EACH
50mMMgCl2 1.5(0.1
10X Reaction Buffer 5pl
1% WI detergent 2.5pl
1.25mM dNTP stock mix 2pl
ddH20 26.5pl
2pl of mouse genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase
(Life Technologies) was added to give a total volume of 50pl.
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PCR Thermal Cycler Programme: 94°C, 2 min. Hot start
94°C, 45 sees
64°C, 1 min. Repeated for 10
72°C, 2 min. cycles.
94°C, 45 sees Repeated for 20
64°C, 1 min. cycles with
20sec.
72°C, 2 min, 20secs. increments
added.




This primer pair and the reaction conditions were also designed and optimised by Dr.
S. Lyons (Lyons, 1999).
Table 6.3: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
p3KX TCATCTAgAgCTTACATATgACCCTg 58°C 3200
p3KE gCAgAATTCTCTTgCAATCAgCTAgA
Reaction conditions: Primers (lOpmol/pl) 4pl EACH
50mM MgCl2 1.5pl
10X Reaction Buffer 5pi
1% WI detergent 2.5pi
1.25mM dNTP stock mix 2pl
ddH20 26.5pl
2pl of genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) was added to give a total volume of 50pl.
PCR Thermal Cycler Programme: 94°C, 2 min. Hot start
94°C, 45 sees
58°C, 1 min. Repeated for 10
72°C, 2 min. cycles.
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94°C, 45 sees Repeated for 20
58°C, 1 min. cycles with
20sec.
72°C, 2 min, 20secs. increments
added.




This PCR proved refractory to optimisation using standard Taq polymerase so the
Expand™ High Fidelity blend of Taq and Pwo DNA polymerases (Boehringer
Mannheim) was used instead.
Table 6.4: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
Lizlnl CTgTAgCAgCAggTTATCTTgTg 58°C 2317
Sonl gATggCTATgACTATCTAgCTgg
Reaction Conditions: Primers (lOpmol/pl) 2.5pi EACH
50mM MgCl2 4pl
10X Reaction Buffer 5pi
1.25mM dNTP stock mix 8pl
ddH20 23.5pl
2pl of genomic DNA template and 2.5pl (2.6U) of Expand"^ High Fidelity enzyme
mix (Boehringer Mannheim) was added to give a total volume of 50pl.
PCR Thermal Cycler Programme: 94°C, 1 min.
58°C, 1 min. Repeated for 35
68°C, 2 min. cycles.
68°C, 10 min. One cycle at the
end of the
programme.
6.1.14.1.d. PCR to Genotype the p53 Status of Embryonic Fibroblasts
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The generation of mice with a neo cassette inserted into the p53 genomic sequence
has been described (Clarke et al, 1993). The genotype of progeny was assigned using
PCR designed by Dr J. Armstrong. Three primers were used in this PCR reaction,
the first and second are common to both wild type and targeted alleles, the third is
specific to the targeted allele. In wild type mice a single product of 642 base pairs is
generated, in heterozygotes two products of 642 and 510 base pairs are generated and
finally in homozygous nulls only one band of 510 base pairs is seen.
Table 6.4: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
Exon 6 gTggTggTACCTTATgAgCC 60 642 and 510
Intron 7 CAAAgAgCgTTgggCATgTg
Neo CATCgCCTTCTATCgCCTTC
Reaction Conditions: Primers (lOpmol/pl) 2.5pl EACH
50mM MgCl2 2pl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
DMSO 2.5pl
ddH20 23pi
2pl of genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) were added to give a total volume of 50pl.
PCR Thermal Cycler Programme: 94°C, 2min. Hot start
94°C, 1 min.
62°C, 1 min. Repeated for 30
72°C, 1 min. cycles.
72°C, 10 min. One cycle at the
end of the
programme.
6.1.14.1.e. p53 cDNA PCR
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As with the FX and F3K PCR reactions the primers used here were also designed by
Scott Lyons (Lyons, 1999). However, the original reaction conditions were re-
optimised by myself to increase the efficiency and yield of this PCR.
Table 6.5: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
cDNAIII ATgCTACAgAggAgTCTggA 55 537
Senlll gATCATgAACAgACTgTgAg
Reaction Conditions: Primers (lOpmol/pl) 2.5pl EACH
50mM MgCl2 2pi
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
1% WI detergent 2.5pi
ddH20 23pl
To this end volume of 45.5pl was added 2pl of genomic DNA template and 2.5pl
(1.5U) of Taq DNA polymerase (Life Technologies).
PCR Thermal Cycler Programme: 94°C, lmin. Hot start
94°C, 1 min.
55°C, 1 min. Repeated for 35
72°C, lmin. cycles.




This PCR was designed to look at the recombination status of the pIGTV targeting
vector, and subsequently, the targeted mouse genomic p53 locus. The first primer
anneals within the neo gene of the floxed STOP and the second, downstream primer,
anneals within intron 1. This PCR will generate a 1525bp band only from an
unrecombined locus.
Table 6.6: Primer sequences and annealing temperatures
303




Reaction Conditions: Primers (lOpmol/pl) 2.5pl EACH
50mM MgCl2 2pi
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
1% WI detergent 2.5pi
ddH20 23pi
2pl of genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) were added to give an end volume of 50pl.
PCR Thermal Cycler Programme: 94°C, lmin. Hot start
94°C, 1 min.
58°C, 1 min. Repeated for 35
72°C, lmin, 30secs. cycles.
72°C, 10 min. One cycle at the
end of the
programme.
6.1.14.1.g. Southern Probe PCR
This PCR was designed and optimised by Dr. S. Lyons to generate a small PCR
product that can be used as a Southern blot probe to identify targeted clones that have
integrated the targeting vector, pIGTV, via homologous rather than random
integration mechanisms.
Table 6.7: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs






Reaction Conditions: Primers (lOpmol/pl)
50mM MgCl2
10X Reaction Buffer
1.25mM dNTP stock mix
1% WI detergent
ddH20






2jal of genomic DNA template, 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) and 2jil of heat denatured Pro3B (94°C, lOmin) were added to give an
end volume of 50|ol.
PCR Thermal Cycler Programme: 94°C, 1 min.in. Hot start
94°C, 1 min.
60°C, 45 sees. Repeated for 30
72°C, lmin. cycles.
72°C, 10 min. One cycle at the
end of the
programme.
6.1.14.2. Other PCR Strategies
6.1.14.2.a. neo-EGFP PCR
This PCR reaction was designed as one of a pair to monitor recombination status of
the plasmid pFloxEGFP (see 6.1.14.2.b.). This reaction gives rise to products from
the unrecombined transgene.
Table 6.8: Primer sequences and annealing temperatures







Reaction Conditions: Primers (10pmol/pl) 2.5pl EACH
50mM MgCl2 2jnl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl




2(xl of genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) were added to give an end volume of 50pl.
PCR Thermal Cycler Programme: 94°C, lmin. Hot start
80°C, 1 min.
94°C, 1 min.
55°C, 1 min. Repeated for 40
72°C, lmin. cycles.




This PCR is the second of the pFloxEGFP pair and will only generate a product after
the pFloxEGFP template has undergone Cre-mediated excisive recombination.
Table 6.9: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
CMV ggAgTTCCgCgTTACATA 55°C 1325
EGFP CAgCAggACCATgTgATC
Reaction Conditions: Primers (lOpmol/pl) 2.5pl EACH
50mM MgCl2 lpl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
1 % WI detergent 2.5pl
DMSO 2.5pl
ddH2Q 21.5^.1
2pl of genomic DNA template and 2.5pl (1.5U) of Taq DNA polymerase (Life
Technologies) were added to give an end volume of 50pl.




55°C, 1 min. Repeated for 40
72°C, lmin. cycles.
72°C, 10 min. One cycle at the
end of the
programme.
6.1.14.2.C. Episomal Adenovirus Detection PCR
The PCR primers used here were designed by Dominic Rannie and anneal within the
Cre coding sequence of AdCre (Anton & Graham, 1995). This PCR reaction was
used to demonstrate the successful adenovirus infection of cells as a product will
only be seen if adenoviridae are present as episomes in infected cells.
Table 6.10: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
Cre360FOR AAACgTTgATgCCggTgAACg 55°C 660
Cre3'REV CTAATCgCCATCTTCCTgCAgg
Reaction Conditions: Primers (lOpmol/pl) 2.0pl EACH
50mMMgCl2 1.5pl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pi
1% WI detergent 2.5pi
ddH20 24.5pl
To this end volume of 45.5pl was added 2pl of genomic DNA template and 2.5pl
(1.5U) of Taq DNA polymerase (Life Technologies).
PCR Thermal Cycler Programme: 94°C, lmin. Hot start
94°C, 45 sees.
55°C, 1 min. Repeated for 30
72°C, lmin. cycles.
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6.1.14.3.a. Mouse P-actin RT-PCR
This PCR reaction was designed and optimised to yield a product from the murine P-
actin cDNA generated by reverse transcription (Section 7.5.2).
Table 6.11: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
BA4 CgTAgATgggCACAgTg 55°C 440
BA15 CTCCggCATgTgCAAAg
Reaction Conditions: Primers (lOpmol/pI) 2.5pi EACH
50mM MgCl2 1.5pl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
1% WI detergent 2.5pi
ddH20 23.5pl
To this end volume of 45.5pl was added 2pl of cDNA template and 2.5pl (1.5U) of
Taq DNA polymerase (Life Technologies).
PCR Thermal Cycler Programme: 94°C, lmin. Hot start
94°C, 1 min.
55°C, 1 min. Repeated for 31
72°C, lmin. cycles.





This PCR reaction was designed to allow the detection of EGFP expression at the
mRNA level.
Table 6.12: Primer sequences and annealing temperatures
Primer sequences (written 5' to 3') Annealing Product size/
temperature base pairs
CAP CgTAAACggCCACAAgTT 55°C 660
EGFP CAgCAggACCATgTgATC
Reaction Conditions: Primers (lOpmol/pl) 2.5|il EACH
50mMMgCl2 lpl
10X Reaction Buffer 5pl
1.25mM dNTP stock mix 8pl
1% WI detergent 2.5pl
ddH2Q 24.pl
To this end volume of 45.5pl was added 2pl of cDNA template and 2.5pl (1.5U) of
Taq DNA polymerase (Life Technologies).
PCR Thermal Cycler Programme: 94°C, Imin. Hot start
94°C, 1 min.
55°C, 1 min. Repeated for 30
72°C, lmin. cycles.
72°C, 10 min. One cycle at the
end of the
programme.
6.2. Embryonic Stem Cell Culture
6.2.1. Media Preparation
ES cells were cultured in Glasgow MEM (BHK 21) medium (Life Technologies)
supplemented with the following per 500ml.
Media supplements:
Foetal Calf Serum (Sigma)/Neonatal Calf Serum
(Life Technologies) 5%v/v each
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(3-mercaptoethanol (Sigma) O.lmM
100X MEM Non-essential Amino Acids
(Life Technologies) 5ml
lOOmM Sodium Pyruvate (Life Technologies) 5ml
200mM L-Glutamine (Life Technologies) 5ml
LIF (Leukaemia-inhibiting Lactor) 0.5ml
LIF was prepared by the transfection of Cos-7 cells and subsequent harvesting of the
conditioned medium (Smith et al, 1988).
6.2.2. Culture Conditions
ES cells were routinely cultured by growing in supplemented BHK 21 medium on
tissue culture treated plastic (Falcon, Nunc or Costar) coated with swine skin gelatin
(Sigma). A solution of 1% gelatin was prepared and autoclaved twice. This was
then diluted 1:10 in ddELO and tissue culture plastic was coated by covering the
surface with the 0.1% gelatin solution and leaving the plate or flask at room
temperature for a minimum of 5 minutes. Cultures were kept at a temperature of
37°C, in a humidified atmosphere of 5% CO2, 95% air. Medium was changed as
appropriate, usually every day or every other day, and cells were passaged when 70-
80% confluence was reached.
6.2.3. Passaging ES cells
Fresh medium was used to feed the cells about 2hrs prior to trypsinisation. After this
time the medium was aspirated and the cultures washed twice with an appropriate
volume of sterile phosphate buffered saline (PBS, 1ml for a 25cm2 flask, 3ml for a
50cm2 flask) (Life Technologies).




The PBS was then aspirated off and Trypsin-EDTA (Life Technologies) added to the
cells. To trypsinise a 25cm2 flask of cells 1ml of trypsin was used and the volume
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was increased up to 5mls for a 175cm" flask. The cells and trypsin were then
incubated at 37°C for 1-2 minutes.
IX Trypsin-EDTA: Trypsin 0.5g
EDTA 2.0g
(Made up to 11 with Modified Puck's Saline A)
Cells were disaggregated into a single cell suspension by tapping the side of the flask
and further digestion was prevented by the addition of a minimum of two volumes of
culture medium. The cells were then diluted as appropriate with medium and
transferred into fresh plastic-ware coated with 0.1% gelatin. The ES cells were then
refed after 4hrs to remove any debris from the trypsinisation process.
6.2.4. Freezing ES Cells
Cells were trypsinised as described in Section 6.2.3 but once the trypsin had been
neutralised by the addition of culture medium the cell suspension was transferred into
a sterile universal and centrifuged at 800xg for 3 minutes. The supernatant was
removed by aspiration and the cell pellet resuspended in freezing medium.
Freezing Medium: Supplemented BHK 21 medium 40% v/v
Foetal Calf Serum 50% v/v
Dimethyl Sulfoxide 10% v/v
(Acidified by the addition of a few drops of 1M HC1 and
subsequently filter sterilised.)
The resuspended cells were then aliquoted into CryoTube^^ vials (Nunc) and
cooled at an approximate rate of l°C/minute to -70°C then moved into storage over
liquid nitrogen the next day.
6.2.5. Defrosting ES cells
To bring frozen cells back into culture the CryoTube™ vials (Nunc) were defrosted
as quickly as possible. The cells were the transferred into 5mls of supplemented
BHK 21 medium and centrifuged at 800xg for 3 minutes. The supernatant was
removed by aspiration and the cell pellet resuspended in an appropriate volume of
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fresh culture medium before transferring the cells to fresh plasticware coated with
0.1% gelatin. The ES cells were then refed after 4hrs.
6.2.6. ES Cell Electroporation
g
ES cells were transformed by electroporation using a BioRad Gene Pulser. 10 cells
(approximately 1 confluent 175 cm2 tissue culture flask) were fed with fresh medium
about 4hrs prior to harvesting. After trypsinisation the cell suspension was
centrifuged at 800xg for 3minutes and the cell pellet resuspended in lOmls of
sterile PBS. The exact number of cells was then quantified by counting with a
haemocytometer. The cells were pelleted by centrifugation at 800xg for 3 minutes
and then resuspended in 0.7 mis of PBS before being transferred into an
electroporation cuvette (BioRad, path length 0.4cm). lOpg of linearised DNA
(verified by agarose gel electrophoresis, Section 7.1.7), resuspended in lOOpl of PBS,
was then added. The electric pulse, 3pF, 800V, time constant 0.1 sees, was applied
immediately to minimise DNA degradation. The cells were then removed from the
cuvette and diluted in culture medium before being plated out onto gelatinised
100mm tissue culture dishes (5x 106 cells/lOOmm plate). The following day G418-
sulphate (200pg/ml) selective medium was added and selection maintained for 10
days or until clones were visible to the naked eye.
1000X G418-sulphate: 2mg/ml dissolved in PBS stored at -20°C in
lml aliquots.
6.2.7. Picking and Maintaining Clones
After about 10 days clones which are visible to the naked eye are present on the
culture dishes. The clones were picked using a sterile P200 pipette (Gilson) and filter
tips. To separate the clone into single cells it was added to trypsin pre-aliquoted into
a 96 well plate, mixed vigorously by pipetting and finally transferred into one well of
a 24 well plate containing 1.5mls of medium. Each electroporation resulted in 200-
300 clones picked in this manner. During work to introduce the pFloxEGFP plasmid
into ES cells the clones were grown up and then trypsinised back into the same wells.
A small amount of cells were removed and transferred into a gelatinised 96 well
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plate, after 4 hours these cells were fixed and stained to visualise (3-galactosidase
activity (see Section 6.3.1.1.). However, during targeting experiments described in
Chapter 4 the clones were grown up and duplicated, one sample was frozen down at -
70°C and genomic DNA was extracted from the other.
6.2.8. Extraction of Genomic DNA from ES cells
Prior to genomic DNA extraction cells were rinsed twice with sterile PBS to remove
all traces of culture medium. The cells were then lysed with an appropriate volume
of Lysis Buffer, 3mls for a 25cm2 flask or 500pl / well of a 24 well plate for 3-5hrs at
37°C.




lOOpg of Proteinase K/ml
To precipitate the genomic DNA an equal volume of isopropanol was added and the
samples shaken for 15 minutes on an orbital shaker until a white DNA precipitate
became visible. The precipitate and a small volume of solution were then removed
by pipette and centifuged to pellet out the genomic DNA (10,000xg , 5 minutes).
The pellet was then washed twice in 70% ethanol, air-dried and finally resuspended
inTE.
6.2.9. Karyotyping of ES Cells
A culture of ES cells was seeded into a 25cm2 flask, the aim was to have the cells
growing exponentially and to reach about 50% confluence on the day they were to be
harvested. The cells were then harvested by trypsinisation, centrifuged, 800xg for
3 minutes, and the pellet resuspended in 5mls of hypotonic 0.56% KC1. The cells
were centrifuged once more and the supernatant removed. The pellet was then
resuspended in 5mls of ice cold fix, added dropwise, while vortexing the whole
sample very gently. The fix used consisted of 3:1 methanol to acetic acid made up
fresh each time. The centrifugation and fixing steps were repeated three times and
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after the final fix cells can be stored at 4°C for up to 24 hours. To produce the
metaphase spreads the cells were pelleted by centrifugation and most of the
supernatant was removed leaving only a small volume with which to make a cell
suspension. The cell suspension was then dropped onto microscope slides and left to
dry. The slides were then stained with GIEMSA (Sigma) for 5-10 minutes before
being viewed on the HOME microscope.
6.2.10. Infection of ES and EF Cells with Recombinant Adenovirus
Infection of both ES and embryonic fibroblasts (EF) cells with the adenovirus were
carried out as described below. All adenoviruses were cultured and maintained by
Dominic Rannie. They were supplied as a stock solution of known titre and an
appropriate volume of virus was removed and mixed well with tissue culture
medium. The amount of virus required depended upon the desired multiplicity of
infection (m.o.i) for each experiment. The medium into which the virus was added
contained only 1% serum as this had been shown to facilitate the efficient infection
of cells (D. Rannie, unpublished observations). The volume of adenovirus-
containing medium added to the cells was kept as small as possible, for example, 1ml
for a 25cm2 flask or 200pl for each well of a double chamber slide. Once the
adenovirus had been added to the cells, the cultures were transferred to storage at
37°C, 5% CO2 for one hour. During this incubation the flasks or chamber slides
were rocked gently every 5 minutes. After one hour the adenovirus-containing
medium was aspirated off, the cells were then rinsed in sterile PBS before normal
culture medium was added back. For safety purposes all work involving adenovirus
was carried out in microbiological safety cabinet (Class II), wearing lab coats and
gloves. Any contaminated glass and plastic-ware were immersed in a lOOOppm
Presept solution (Johnson & Johnson) prior to disposal. After use, the safety hood
was UV irradiated overnight.
6.3. Detection of Marker Gene Expression
6.3.1. P-galactosidase Histocheniical Detection
6.3.1.1. Histochemical Detection of Bacterial P-gal (pH7.0)
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This stain was used to detect the expression of the enzyme (3-galactosidase (P-gal)
from the bacterial LacZ gene within mammalian cells. LacZ is a commonly used
marker gene, for example (3-gal is expressed from the LacZ component of Pgeo
fusion gene present within pFloxSTOP. This stain has been optimised to specifically
detect (3-gal activity with a pH optimum of pH7.0, a characteristic unique to the
bacterial enzyme as the endogenous lysozomal (3-gal of mammalian cells has a pH
optimum at pH 4.0 (see next section and Moreau et al, 1989).
Prior to staining ES cells were rinsed in PBS and then fixed for 5 minutes in 0.05%
gluteraldehyde diluted in PBS. This fix was made up fresh each time from a 3%
stock kept at 4°C. After fixing cells were rinsed two more times in PBS, with the
second wash being left on for 10 minutes. An appropriate volume of Stain Solution
was then added, for example 2mls/25cm2 flask, and the cells were left overnight at
37°C in a sealed humid box. After staining was complete the cells were stored at 4°C
under PBS or fix.





6.3.1.2. Histochemical Detection of the Endogenous Mammalian P-gal (pH4.0)
The majority of mammalian cells express a lysozomal P-gal that is optimally active
at pH 4.0 (Moreau et al, 1989). Prior to staining all traces of culture medium were
removed from the cells by two washes with PBS. The cells were then fixed in 3%
formaldehyde (diluted in PBS) for 3 minutes and then washed twice more with PBS.
The cells were incubated overnight at 37°C in the presence of an appropriate volume
of stain solution, for example 2mls/25cm2 flask or 500pl for a chamber slide.
Although positively stained cells become visible after 2-4hrs, the reaction was












Citric acid buffer (see
below)
X-gal





This gives a total volume of lOOmls and after mixing, the stain solution pH should be
adjusted to pH 4.0. The fixation procedure and stain solution are as described by
Dimri et al (Dimri et al, 1995).
6.3.1.3. Histochemical Detection of Mammalian Senescence-associated-(3gal
(pH6.0)
6.3.1.3.a. SA-Pgal in vitro
The identification of a senescence-associated (3-gal (SA-pgal) activity in human cells
was first reported in 1995 (Dimri et al, 1995). The stain used to detect this activity in
human cells was known not to work in mouse cells (J. Campisi, pers. comm) but the
following solution can be used to successfully detect SA (3-gal in mouse EFs. Prior
to staining the cells were washed twice in PBS, fixed for 3 minutes with 3%
formaldehyde and washed two further times. The cells were then incubated
overnight at 37°C in the presence of an appropriate volume of stain solution.




40mM Citric acid/PBS buffer
(see below)
lmg/ml X-gal
Citric acid/PBS buffer: 0.1M Citric acid monohydrate dissolved in PBS rather
than ddH20, pH adjusted to 6.0.
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6.3.1.3.b. SA-|3gal in vivo
Mice were killed and an area of back skin exposed by shaving. A sample was
excised, transferred into a sterile Eppendorf and then snap frozen in liquid nitrogen.
The skin sections were then mounted in OCT (Bayer) and frozen sections cut. The
sections were then transferred onto poly-L-lysine coated microscope slides (Sigma).
Immediately after cutting the frozen sections were fixed in 1% glutaraldehyde for 1
minute at room temperature, rinsed in PBS and then immersed in SA-Pgal stain
solution (as described in Section 6.3.1.3.a) and incubated overnight at 37°C. The
following day the sections were rinsed in PBS, counterstained with eosin and
mounted.
6.3.2. (3-galactosidase Activity Quantification
To quantify the level of soluble P-gal activity within cells the (3-galactosidase
Enzyme Assay System (Promega) was used according to the manufacturers
recommendations. Not all solution compositions were disclosed by the manufacturer
and these are omitted from the subsequent text.
6.3.2.1. Protein Extract Preparation
ES cells were harvested by trypsinisation and the cell pellet was rinsed thoroughly
with PBS. The final PBS wash was removed by pipette and sufficient IX Reporter
Lysis Buffer was added to cover the cells (e.g. 400pl/60mm culture plate or 900p
l/100mm plate). The samples were then incubated at room temperature for 15
minutes to allow complete sample lysis. The cell lysate was then transferred into a
fresh Eppendorf tube. The lysate was vortexed briefly and centrifuged at 10,000 g
for 2 minutes at 4°C to pellet any cell debris. The supernatant was then transferred
into a fresh Eppendorf tube and stored at -20°C for up to 2 months.
6.3.2.2. Protein Concentration Assay
The protein concentrations of cell extracts prepared by the above method were
determined using a Bio-Rad Protein Assay (Bio-Rad). 10-50(xl of the extracts were
diluted in water up to a total volume of 800pl After the addition of 200pl of the 5X
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assay dye reagent, the tubes were vortexed briefly and left for a minimum of 10
minutes to allow the colour change to stabilise. The absorbance of each sample was
then measured at 595nm and compared to a standard curve. Standard curves were set
up for each assay using Bovine Serum Albumin over a concentration range of l-lOpg
of protein.
6.3,2.3. P-gal Enzyme Assay
This assay was carried out in 96 well tissue culture plates that allowed the
simultaneous testing of numerous samples. Between 10 and 50p,l of protein extract
was added to each well, the exact amount depending on the protein concentration of
each sample (as determined in Section 6.3.2.2.). The final volume of each sample
was made up to 50pl with IX Reporter Lysis Buffer. All samples were assayed in
triplicate. 50|fl of 2X Assay Buffer was then added to each well and the samples
incubated at 37°C for up to 2 hours. A standard curve was also set up in duplicate for
each assay with a range of (3-galactosidase activities from 500 milliunits to 0.05
millliunits. A stock of P-gal was supplied with the kit (lu/pl in 50 mM Bicine
Buffer, pH 7.5, with lOOjLtg/ml of BSA). All reactions were stopped by the addition
of 1 50|li1 of 1M Sodium Carbonate. Ideally the absorbance of the samples should be
read at 420nm, however the only available plate reader (Dynatech MR5000) was
unable to read at this wavelength so 405nm was used instead, this is within the range
of suitable wavelengths recommended by Promega. The absorbance data was
analysed using Biolinx v2.0 software and a standard curve was plotted and used to
determine the number of units of (3-galactosidase in each sample. By correlating this
with protein concentration the number of units P-gal/pg of protein was then be
calculated.
6.3.3. EGFPMarker Gene Detection
6.3.3.1. Flow Cytometric Analysis of EGFP Expression in ES Cells
All flow cytometric analysis was carried out using a Coulter EPICS XL-MCL flow
cytometer. The cells were excited at 488nm in an argon laser beam and the
fluorescent forward scatter (FS), side scatter (SS) and fluorescent light emissions
318
recorded. The fluorescent light emissions were collected using an FL4 filter set (660-
700nm). ES cells, which were to be subjected to flow cytometric analysis, were
harvested by trypsinisation and then pelleted by centrifugation at 800xg f°r 3
minutes. The cell pellet was rinsed twice in PBS then diluted in 3-6 mis of PBS.
The cells were not fixed prior to analysis and so were stored on ice and assayed
immediately.
6.4. Embryonic Fibroblast Culture
6.4.1. Isolation Of Primary Embryonic Fibroblasts
Primary fibroblast cultures were derived from 12-14d.p.c. embryos (Todaro & Green,
1963). Pregnant mice were killed and uteri removed and transferred into Petri dishes
containing 5mls of sterile PBS. Individual embryos were dissected out of the uterus
and the placenta and yolk sac removed. The embryo was then decapitated before
being dipped into 70% ethanol and transferred to a sterile universal. The tissue was
homogenised using scissors and incubated at 37°C for twenty minutes after the
addition of 2mls of 2.5% trypsin/PBS (DIFCO). After twenty minutes the
trypsinisation reaction was neutralised with 5mls of EF culture medium and the cell
suspensions were centrifuged for 3 minutes at 800xg .
EF Culture Medium:
Glasgow MEM (BF1K 21) medium
(Life Technologies) 500mls
Foetal Calf Serum (Sigma) and Neonatal
Calf Serum (Life Technologies) 5%v/v each
100X MEM Non-essential Amino Acids
(Life Technologies) 5ml
lOOmM Sodium Pyruvate (Life Technologies) 5ml
200mM L-Glutamine (Life Technologies) 5ml
After centrifugation the supernatant was removed and the cell pellet resuspended in
25mls of culture medium. The cells and medium were transferred into a sterile
75cm2 tissue culture flask and incubated at 37°C, in a humidified atmosphere of 5%
CO2, 95% air. The following day the cell medium was replaced to remove any
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remaining embryo debris. EF cells were treated identically to ES cells (Section 6.2)
for passaging, freeze/thawing and the preparation of genomic DNA.
6.4.2. Calcium Phosphate Transfection of Murine EFs
A modified high efficiency calcium phosphate transfection technique was used to
introduce the pICDP(for) plasmid into primary EFs (Chen & Okayama, 1987). The
EFs were genotyped by PCR immediately after their isolation and only cells that were
identified as p53 null were grown on for transfection. Twenty-four hours prior to
transfection the EFs were harvested by trypsinisation (as described in Section 7.2.3),
counted and 5 x 105 cells were plated out on each lOOmm-culture dish).
The DNA to be introduced was also prepared 24hrs prior to transfection.
Transfections were always done over a range of three DNA concentrations,
lOpg/lOOmm dish, 20pg/100mm dish and 30pg/100mm dish as the optimum DNA
concentration could not be determined. The total amount of DNA needed for each
transfection was calculated and an appropriate volume of plasmid (Section 6.1.5.)
was ethanol precipitated overnight (Section 6.1.4.). The following morning the DNA
was pelleted by microcentrifugation, 10,000g at 4°C for 30 minutes. The pellet was
rinsed with 70% ethanol and then allowed to air dry in sterile conditions. Once the
pellet of DNA had dried it was resuspended in sterile water to give a final
concentration of lpg/pl. The DNA was allowed to resuspend thoroughly prior to use
for transfection.
For each 100mm dish of cells to be transfected an individual mix of DNA/calcium
phosphate was prepared. 10-30pl of the sterile DNA was aliquoted into a sterile
universal and 250pl of 2.5M CaCl2 solution was added. The CaCl2 solution was
prepared in advance, filtered sterilised and stored at -20°C until needed. Lastly,








Adjust to pH 6.95 with conc. HC1, store at -20°C
After the addition of 2XBBS, the DNA/calcium phosphate mix was left at room
temperature for 20 minutes. During this 20-minute incubation the cells to be
transfected were refed with fresh medium (9mls/100mm dish) before the addition of
one individual 500pl DNA/calcium phosphate mix to each dish of cells. The culture
dishes were then transferred into an incubator at 35°C. The cultures were also kept
in low C02, 3%, to allow the calcium phosphate/DNA complex to form slowly
overnight. After overnight exposure to the precipitate the cells were rinsed
thoroughly with PBS then refed with fresh non-selective media. The cells were kept
in non-selective medium and returned to standard culture conditions, 37°C with
5%C02, for the next 48 hours. After 48 hours had elapsed the non-selective medium
was replaced with selective medium containing 2.5p,g/ml of puromycin (Sigma).
Clones became apparent after 15-20 days and at this point the cells were harvested
for further analysis. The concentration of puromycin used to select transfected cells,
2.5p,g/ml, was determined as described in Section 3.5.2.2.
6.4.3. Immunohistochemical Detection of p53 Protein in EFs
The half-life of p53 protein is approximately 15 minutes and it is normally below the
threshold for immunodetection (Kamijo et a\, 1998). However, p53 can be stabilised
in cells by exposing them to a variety of insults, for example UV irradiation. The
half-life of the stabilised protein is then increased to approximately 75 minutes and it
becomes localised in the nucleus (Kamijo et al, 1998). Therefore to facilitate the
detection of p53 expression in transfected primary fibroblasts the cells were exposed
to 10J/m2 of UV irradiation 6 hours prior to fixation (UV Crosslinker, Spectronics
Corporation).
After 6 hours had elapsed the cells, growing on two-well chamber slides (Nunc),
were rinsed with PBS and the slides then immersed in ice-cold 50:50 methanol:
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acetone and kept at -20°C for 5 minutes. After fixation was complete the slides were
air-dried, wrapped in foil and stored at -70°C.
When the slides were removed from storage they were covered with TBS-Tween.
TBS-Tween: Tris-HCl, pH 7.6 0.5M
NaCl 0.15M
Tween 0.1%
The TBS-Tween was poured off and the slides placed in a rack and transferred into
0.5% hydrogen peroxide (diluted in methanol) for 15 minutes with gentle shaking.
The slides were removed from the hydrogen peroxide solution and rinsed twice with
water. After thorough rinsing the slides were removed from the rack, and covered
with TBS-Tween. The TBS-Tween was then poured off and the slides were
incubated in normal swine serum (Sigma) diluted 1:5 with TBS-Tween for 20
minutes at room temperature in a humid chamber. The swine serum was removed
and the primary antibody added to the slides. The p53 primary antibody used was the
rabbit polyclonal CM5 antibody (Novocastra) which was diluted 1:500 with 1:5
swine serum: TBS-Tween solution (300pl/well). The slides were incubated with the
primary antibody in a humid chamber at room temperature for 1 hour. During this
incubation the ABC complex was prepared, this consists of 5mls of ABC buffer
(Tris-HCl, pH7.6) to which 1 drop of streptavidin solution and 1 drop of biotinylated
horse radish peroxidase solution were added (the latter two are kit components of
undisclosed concentration, DAKO).
ABC Buffer: Tris 0.2M
HC1 0.1M
Adjust to pH 7.6
The primary antibody solution was drained off the slides and they were washed three
times at 5 minute intervals in TBS-Tween. After the last wash had been poured off
the secondary antibody was added. The secondary antibody used was a biotinylated
swine anti-rabbit immunoglobulin (DAKO). This antibody was diluted 1:400 with
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1:5 swine serum: TBS-Tween solution and 300jixl was added to each well of the
chamber slide. The samples were incubated for 30 minutes at room temperature with
the secondary antibody. After this incubation had been completed the slides were
washed for three, five minute intervals with TBS-Tween before the ABC complex
made previously was added (300pl/well). The slides were then incubated for a
further 30 minutes at room temperature in a humid chamber. The ABC complex was
the washed off the slides with three, 5 minute washes in TBS-Tween. HRP activity
was visualised with diaminobenzidine (DAB). lOOpl aliquots of DAB (25mg/ml)
were made up and stored at -20°C. One DAB aliquot was defrosted and mixed with
4.9mls of DAB buffer.
DAB Buffer: Tris 0.2M
300pl of the DAB/Buffer mix was added to each well of a chamber slide and the
reaction allowed to proceed for 10 minutes. The transfer of the slides into water
stopped the reaction. The slides were then counterstained with haematoxylin and
mounted.
6.5. Manipulation of RNA
6.5.1. RNA Extraction
RNA was extracted from cells using the High Pure RNA Isolation Kit (Boehringer
Mannheim) according to the manufacturers protocol. Briefly, cells were harvested by
trypsinisation and pelleted by centrifugation at 800xg , 3 minutes. The cell pellet
was then resuspended in 200pl of PBS and lysed by the addition of 400pl of
Lysis/Binding buffer. A High Pure filter tube was then fitted into a collection tube
(both supplied with the kit) and the sample added directly onto the filter. The tubes
were then spun for 15 sees, at 8,000xg and the flow-through discarded. At this
point both the DNA and RNA components of the cell extract are bound to the High
Pure filter. Genomic DNA was then removed by the addition of 90pl of DNase
HC1
Imidazole




incubation buffer and lOpl of DNase I directly onto the filter. Digestion was allowed
to proceed for 15 minutes at room temperature. Further impurities were removed
from the RNA by two subsequent wash steps before elution of the RNA in 50pl of
nuclease free, sterile ddH20. RNA samples extracted by the method were stored at -
70°C. RNA concentrations were determined spectrophotometrically (GeneQuant,
Pharmacia Biotech).
6.5.2. Reverse Transcription
An appropriate amount of RNA, 0.1-lpg was diluted in a total volume of 10pl with
nuclease-free water and lpl of oligo dT primer (500pg/ml, Cruachem) was added.
This procedure was carried out in nuclease-free, sterile 0.5ml Eppendorfs which also
facilitated the use of thermal cycler heating blocks during the protocol.
The sample was heated to 70°C for 10 minutes then transferred onto ice. After 1
minute on ice the sample tube was centrifuged briefly to collect all fluid. To the 1 lpl
sample volume a further 4pl of 5X First Strand Buffer, 2pl of 0.1M Dithiothreitol
and 2pl of dNTP mix (lOmM each) was added.
The samples were then mixed gently and transferred back to the thermal cycler.
After heating the samples to 42°C for 2 minutes, lpl (200 U) of Superscript™ II
RNase H- Reverse Transcriptase (Life Technologies) was added to each tube. The
reaction was then allowed to proceed at 42°C for a further 50 minutes before the
enzyme was heat inactivated by a 15 minute incubation at 70°C. The cDNA
synthesis was then complete and the products can be used as templates of the RT-
PCR reactions described in Section 6.1.14.3.
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INTRODUCTION
The pathogenesis of cancer is a multistep process
haracterized by the accumulation of critical genetic
;sions within the cell. The rate of mutation accumula-
ion is influenced by both external environmental factors
nd the genotype of the cell. To date, many studies have
.escribed a bewildering variety of molecular genetic
bnormalities, the significance of which to pathogenesis
; often obscure. Indeed, it is probable that many of
hese abnormalities are epiphenomenal rather than of
rucial importance.
HISTORICAL BACKGROUND
Epidemiological and genetic studies have led to sub-
tantial advances in our understanding of the pathogen-
sis of cancer. Naturally occurring germline mutations
n humans, manifesting as heritable cancer predisposi-
ion syndromes, provided an insight into the molecular
enetics of tumour suppressor genes. For example, fam-
lial adenomatous polyposis coli (FAP) is transmitted as
n autosomal dominant trait with incomplete pen-
trance.1 FAP patients develop multiple adenomatous
iolyps, especially within the colon and rectum, and
how a high incidence of colorectal adenocarcinoma.
7AP patients also show a predisposition to other neo-
ilasms including osteomas, fibromas, desmoid tumours,
nd hepatoblastomas.2 The tumour suppressor gene
fleeted in FAP3 was localized to human chromosome 5
nd it has since been shown that inactivating mutations
n the adenomatous polyposis coli (APC) gene are
iresent in the majority of cases of colon cancer, both
poradic and familial.
Mutation of the tumour suppressor genes p53 and RB
i responsible for two other cancer predisposition syn-
iromes seen in humans. Germline heterozygosity for a
nutated p53 allele characterizes Li-Fraumeni syn-
irome,4-5 which predisposes to a variety of neoplasms,
if which breast and brain are the most common. Human
etinoblastomas are childhood cancers and can occur
pontaneously or as an autosomal dominant familial
orm. Of people with a mutated RB allele, more than 90
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per cent will develop retinoblastoma and about 15 per
cent will also develop osteosarcoma.6 Somatic mutation
and subsequent loss of RB allele function are also seen
in sporadic lung, breast, prostate, and bladder carci¬
nomas, although no increase in the incidence of these
tumours is observed in the germline heterozygotes.
The study of DNA tumour viruses has facilitated an
understanding of the second class of genes involved in
neoplasia. These oncogenic viruses carry mutated forms
of normal cellular genes which may be truncated or
carry an activating point mutation. The cellular copies
of such genes are referred to as proto-oncogenes and
most are involved with the regulation of growth and
division of the normal cell. Mutations present in viral
oncogenes mimic those arising spontaneously in proto-
oncogenes during malignant progression; both lead
to aberrant activity of these important regulatory
molecules.
Despite the value of these approaches, they are limited
and essentially descriptive. Thus, considerable effort and
resources have been directed towards creating accurate
animal models of this complex disease. Although animal
models may never provide exact representations of a
human disease, they do permit dissection of specific
molecular and biochemical pathways which may be
involved. Furthermore, they allow a variety of genetic
manipulations that would be technically and ethically
impracticable with human tissues.
MOUSE MODELS OF HUMAN NEOPLASIA
Since the production of the first murine models of
human neoplasia, technological advances and refine¬
ment of the concept being examined have led to increas¬
ingly accurate and informative models. Initial work on
chemical carcinogens in rats and mice demonstrated that
exposure results in DNA mutation and then progression
to tumour. This led to the concepts of initiation and
promotion of tumours.
As individual genes important in neoplasia were ident¬
ified, the newer technologies of gene targeting and
transgenic mouse production allowed a more directed
analysis of the molecular function of such gene prod¬
ucts. This increased the complexity of the model of
carcinogenesis from a simple linear progression to a
network of interacting factors. The latest advances with
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e and tissue-specific gene targeting and trans-
ice can only serve to increase the usefulness of
lortant model system.
11 carcinogenesis
irst association between exposure to chemical
^ens and the induction of cancer was made in
. Subsequent work has shown that the same
Is are able to induce tumours in animals. How-
atment of mice with standard carcinogen regime
duce significant variations in tumour incidence,
d age of onset between animals of different
=It is implicit from such heterogeneity that inter-
;xtrapolation is fraught with error. For example,
e treatment of rats initiates a sequence of focal
itive changes in pancreatic acinar cells, the end
"which is the development of carcinomas.7 These
; bear little histological similarity to the majority
in pancreatic carcinomas, which are ductal in
nee, and little genetic similarity; K-ras muta-
'e seen in more than 80 per cent of human
tic carcinomas,8 whereas no K-ras or H-ras
ns can be detected in the azaserine-induced
, 9
umours which arise in humans and animals
to chemical carcinogens are comparable, in that
.h arise due to carcinogen-induced DNA muta-
owever, the precise molecular genetic pathology
uncharacterized and in most cases, similarities
evel are assumed but not proved. It is unjustifi-
accept that because one carcinogen induces
in both mice and humans, such cancers have
ne similar genetic alterations.
germline mutagenesis
inement of the carcinogen-based strategy was
and was first achieved by the use of random
; mutagenesis. Here, carcinogens are exploited to
indom mutations within the germline of mice,
re then mated and the progeny examined for
pic abnormalities. Any progeny displaying a
pe of interest are then further characterized,
ly leading to the identification of the mutant
an approach led to the identification of a mouse
>f the human cancer predisposition syndrome,
'ne of the pedigrees established after random
: point mutagenesis with A-ethyl-nitrosourea
displayed a progressive adult-onset anaemia.10
xamination revealed numerous adenomas within
11 and large intestines of the anaemic mice;
na in situ was seen in some older animals. This
pe was described as multiple intestinal neo-
lence Min mice). Further work revealed that the
use is heterozygous for a nonsense mutation at
50 of the Ape gene, the mouse homologue of
APC,11 the gene affected in FAP. The exact
of adenomas which Min mice develop depends
;netic background of the strain and the effects of
ng loci such as Mom-1.12 Although all cells
within the organism are + / - for Ape, not all intestinal
epithelial cells form adenomas. Thus, heterozygosity at
the Ape locus is necessary but not sufficient for the Min
phenotype. Further genetic events must occur, including
the loss of the remaining wild-type Ape allele, before
adenomas develop and subsequently progress to
carcinoma.
Although at the molecular level, human FAP patients
and the Min mouse have mutations in homologous
genes, the phenotypes are not identical. Firstly, muta¬
tion of the APC gene in humans is predominantly
associated with colorectal neoplasia, whereas Min mice
demonstrate adenomas preferentially in the small intes¬
tine. Secondly, progression to locally invasive carcinoma
occurs in almost 100 per cent of untreated FAP patients,
yet in the mouse progression is relatively rare. This
difference may arise either as a consequence of a higher
adenoma burden in FAP patients, or due to the predi¬
lection for small intestinal involvement in the mouse, or
because of other differences in the genetics of progres¬
sion between mice and humans.
Reverse genetics—transgenic mice
The Min mouse was identified by analysis of pheno¬
type and the genotype responsible was subsequently
identified. Reverse genetics13 refers to the technique of
analysing gene function by modulating or ablating gene
expression either in vivo or in vitro and then studying the
resultant phenotype.
Transgenic mice generated by pronuclear injection—
The first generation of transgenic mice was generated
using simple pronuclear injection of DNA. For example,
in an attempt to model human pancreatic neoplasia,
mice have been produced which are characterized by
pancreatic acinar cell specific expression of an activated
form of a human H-ras transgene.14 While H-ras trans¬
genic mice developed acinar tumours in the fetal
pancreas, no pancreatic tumours of ductal morphology
(the predominant human tumour type associated with
ras mutations) were observed. These experiments
support the conclusion that overexpression of mutant
ras is capable of causing cancer. However, this bears
little resemblance to spontaneously occurring human
pancreatic cancer.
This first generation of transgenic mice is of limited
value and they are not faithful models of human neo¬
plasia. They do have the significant advantages of rela¬
tive simplicity and low cost of production, compared
with the targeted mice discussed later. The major disad¬
vantages are limited control of transgene copy number
and expression and the lack of control of site of integra¬
tion, bringing with it the risk of insertional mutagenesis.
A further limitation is that the transgene must be
dominant to produce an observable phenotype, as new
genetic material can only be added to the existing
genotype.
Transgenic mice generated by gene targeting—The
advent of stem cell technology led to a second genera¬
tion of transgenic mice, circumventing some of the
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above problems. Embryonic stem (ES) cells were first
isolated in the early 1980s15-16 and are pluripotent cell
lines derived from the inner cell mass of mouse blasto¬
cysts. They can be cultured in vitro indefinitely, gen¬
etically manipulated, and then reintroduced into
blastocysts. Once back inside the new blastocyst, they
are able to contribute to all lineages of the resulting
chimaeric embryo, including the germline. Progeny may
constitutively carry any mutations introduced into the
ES cells during culture. These mutations will subse¬
quently be inherited in a stable Mendelian fashion. The
standard approach to gene targeting relies upon the
introduction of exogenous DNA constructs which
replace their endogenous counterparts via homologous
recombination. Alterations such as mutation, interup-
tion, or truncation into the targeted gene are now
commonplace.17
Knockout mice, in which the function of a specific
gene is ablated in all tissues of the mouse, have provided
an ideal framework for the study of the role of tu¬
mour suppressor genes. For example, p53 null mice
were generated independently by four groups.18-20
Homozygous null mice have reduced viability21 and
develop tumours, predominantly thymic T-cell lympho¬
mas, during the first 6 months of life. The tumour
spectrum observed is strain-dependent and mimics
only approximately the tumour spectrum observed in
the human equivalent, Li-Fraumeni syndrome. Both
Li-Fraumeni patients and p53 +/ — mice display a
cancer predisposition that would be predicted due to
their heterozygosity for this important tumour suppres¬
sor gene. Variations within the tumour spectra observed
may represent differences in the molecular control of
oncogenesis in mice and humans, as well as differences in
environment.
Similar techniques were applied to permit analysis of
the retinoblastoma gene product, Rb-1.22-24 These
studies have shown Rb-1 function to be essential for
normal development, as Rb-1 homozygous null embryos
die mid-gestation. Unexpectedly, animals heterozygous
for Rb-1 function failed to develop retinal tumours.
Instead, they have a high incidence of pituitary adeno¬
mas. Thus, Rb-1 deficiency in the mouse does model
malignancy, but with a clearly different tissue specificity
from that seen in humans.
EXISTING MOUSE MODELS—LIMITATIONS
AND LESSONS
While the p53 or Rb-1 knockout mice were of only
limited success in modelling human diseases, they did
provide an unequivocal definition of a tumour suppres¬
sor gene—that loss of function will result in increased
tumour incidence. This important result is taken as the
paradigm for all putative tumour suppressor genes.
The phenotypic differences observed between mice
and humans with analogous genetic mutations, such as
in the retinoblastoma gene, originally called into ques¬
tion the validity of mouse models of human diseases.
However, subsequent work to rationalize and under¬
stand the causes of these differences has led to significant
advances in our understanding of the molecular
nisms of such gene products. Some variations in
type may be due to interspecies differences
function, but others arise as a result of differs
functional redundancy of a specific gene p
Redundancy may vary spatially, for example in ;
specific manner, and temporally, such as in rek
critical windows of gene function during develops
comparison of the Rb-1 mouse and human reti
toma patients illustrates both of these concepts o
dancy. Loss of function of both RB alleles wil
human retina will result in retinoblastoma, in<
that within these cells, RB is non-redundant anc
vating mutations predispose to neoplastic tran
tion. Similarly, within the mouse pituitary, comp
of Rb-1 function results in the development of p
adenomas.22-24 Thus, a major phenotypic v
between mouse and human is explained by tissue
differences in the functional redundancy of the
blastoma gene product. The Rb-1-related gene p
pi07 and pi30 are able to compensate for loss
function in the murine retina. Preliminary da
showing that ablation of these genes in an Rb-
background results in retinoblastoma in the mo
Differences in molecular controls within mo
human cells complete the explanation of the Rb-
phenotype. Rb-1 —/— cells in the murine re
deleted via p53-dependent apoptosis,25 preventi
gression to retinoblastoma; such cells in the
retina are not. If the viral SV40 TAg is expr<
murine retinal cells, thereby inactivating both ]
Rb function, retinoblastoma is the outcome26 an
— / — , Rb +/ — animals retinal dysplasia is coi
observed, but not actual retinoblastoma.27 H
Rb-1 is essential for normal development of the (
indicating that pl07 and pi30 do not display c
functional redundancy.
The constitutive absence of Rb-1 and man
tumour suppressor genes or proto-oncogenes
mouse embryonic development frequently leads 1
of the embryo and is a significant limitation of
strategies to produce targeted mice. In direct coi
the problems of embryonic lethality, complel
tional redundancy can result in knockout mice
any obvious phenotype. For example, with N-ra,<
out mice28 no differences between — / — , +
wild-type animals could be identified, lead
authors to conclude that there is significant redi
within the ras family. Thus, with any gene t
study, it is not always possible to predict the ph
accurately. The information gained, while still
may not be immediately applicable to specific
types in man. In some regards, gene knockoi
more questions than they answer.
INDUCIBLE GENE TARGETING
Potential and benefits
Gene targeting is now an accepted methodc
reverse genetics and the approach has become
routine. While present targeting strategies do p
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/ork within which many questions have been
ed, the problems discussed above will not be
me with the technology as it stands. Inducible
ig strategies now under development will allow
gnificant refinements to be made to the basic
;ch of gene targeting. Conditional knockouts, in
gene function is ablated after embryological
pment in the adult, somatic tissue, should over-
he problem of embryonic lethality in homozygous
ice. Such animals should also better reflect the
of tumorigenesis in humans, since most cancers
t have an inherited germline susceptibility. In
contrast to conditional knockouts, inducible
ng can also be used to restore the function of
vhich were previously inactive, with temporal and
control over this activation, so-called 'knock-on'
These new advances are now past the initial
pment and characterization stages and are being
1 current targeting protocols.
ble promoters
e expression at the level of transcription is gov-
by promoter elements within the DNA sequence,
ety of promoters exist in both prokaryotes and
'otes that can alter levels of transcription in
se to the presence or absence of specific inducers,
i an inducible promoter is positioned upstream of
et gene in place of the normal promoter, then
sion of the target gene can be controlled externally
j inducer. Both eukaryotic and prokaryotic pro-
; have been used in an attempt to provide induc-
xpression of mammalian genes, with varying
s of success. Early attempts with mammalian
1 systems using inducers such as heat shock, heavy
ions, or aromatic hydrocarbons encountered
ms with pleiotropic gene induction, restricted
specificity, toxicity or carcinogenicity of inducing
, and small scale of induction.29 Characterization
re mammalian promoters has led to the discovery
>e more suited to inducible control of gene expres-
;uch as the murine Mx gene promoter which is
d in response to interferon or virus exposure.30
inherent complexity of mammalian transcrip-
regulation means that these endogenous systems
t ideal for induction of one specific experimental
To avoid these problems altogether, transcription
ds from bacteria were adapted for use in mamma-
ells. Much recent effort has concentrated on
■ichia coli tetracycline responsive promoters,31 33
considerable success. For any of the inducible
iters which have been developed to make a signifi-
ontribution to the modelling of human neoplasia,
,t be demonstrated that they allow tight control
ene expression and that they are able to regulate
xpression of genes important in neoplasia,
ycline-inducible luciferase expression has since
lemonstrated in transgenic mice and expression of
larker gene was shown to be highly inducible,
ible, and without any tetracycline side-effects.34 As
o in vivo work with tetracycline-regulated onco-
or tumour suppressor genes has been published,
but in vitro studies have demonstrated that the expres¬
sion of such genes can be controlled in this way. For
example, a tetracycline-inducible p53 was used in the
human Saos-2 osteosarcoma cell line35 and in p53 null
glioblastoma cells, to investigate the role of p53 in
the angiogenic process.36 More recently, tetracycline-
inducible expression of p21WAFI and WT1 was achieved
in human tumour cell lines.37-38 Thus, the tetracycline
system has satisfied both of the original requirements
and it seems reasonable to conclude that it will make a
significant contribution to murine models of human
neoplasia.
Site-specific recombinases
All inducible promoter-based strategies rely on the
removal of endogenous control sequences and their
replacement with inducible promoters via gene target¬
ing. Although the presence of the inducible promoter
allows control of gene expression, there are problems
associated with the loss of the normal promoter. The
targeted gene is no longer responsive to normal cell
signals which would induce expression, and the levels of
expression seen after addition of the inducer may not be
an accurate representation of the standard physiological
levels nor the time course of induction. Site-specific
recombinase-based strategies circumvent this problem
by manipulating sequences out with the promoter or
coding regions of a gene to allow inducible control of
gene expression.
Site-specific recombinases, such as Cre or FFP, bind
specific recognition sequences within the DNA (called
loxP and FRT sites, respectively). When these recogni¬
tion sites are directly repeated within a gene sequence,
the intervening DNA is spliced out by recombinase,
leaving one recognition site retained. Inversely repeated
sites do not lead to the excision of the intervening DNA,
but instead to the inversion of the flanked sequence.39 It
is the ability of the recombinase enzymes to catalyse
excessive recombination which is being manipulated to
achieve inducible gene targeting. Thus, recombinase-
based strategies are being developed which allow either
the inducible activation or inactivation of a target gene,
depending on the site-specific deletion introduced via
excessive recombination. Furthermore, by combining
this approach with inducible expression systems and by
driving Cre from a tissue-specific promoter, this genetic
manipulation can be finely controlled both temporally
and spatially.
Conditional inactivation of gene function can be
achieved by inserting loxP sites around coding regions of
the target gene. In the presence of active recombinase,
the intervening DNA will be excised and gene function
abolished. Alternatively, if a 'stop' codon surrounded by
loxP recognition sites is inserted upstream of a coding
region, transcription will be abolished. Activation of Cre
will remove this impediment and thus allow activation of
gene expression, a potential model for germline gene
therapy. Preliminary studies have highlighted the poten¬
tial of inducible targeting strategies based on conditional
inactivation.40
Embryos which are homozygous null for DNApol/i,
an enzyme thought to be part of mammalian DNA
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repair machinery, are non-viable41 but an inducible
targeting strategy allowed inactivation of the DNApol/i
gene only in tissues of the adult mouse.40 LoxP sites
were introduced into the DNApol/? gene which did not
affect gene expression in the absence of Cre. Induction
of Cre expression in the adult mice caused excision of
the LoxP flanked DNA, creating a conditional knock¬
out. Control of gene inactivation was achieved as Cre
recombinase expression was under the control of the
Mx;7-inducible promoter. Interestingly, differences in the
efficiency of DNApol/f inactivation were seen between
tissues, with up to 100 per cent efficiency in the liver and
spleen but only 20 per cent or below in the tail and brain.
Inducible control of gene expression is not the only
way in which the Cre/lox system could further attempt
to model human neoplasia. It may also provide an
in vivo approach for chromosome manipulation both in
cells and in the whole mouse. The introduction of loxP
sites into non-homologous chromosomes via targeting,
followed by Cre expression, can lead to chromosome
translocation which mimic those seen in a variety of
disease processes. For example, the chromosome trans¬
location t(6;9) seen in a subtype of human acute myeloid
leukaemia was created artificially in murine ES cells.42
THE FUTURE OF INDUCIBLE, TISSUE-SPECIFIC
GENE TARGETING
In the long term, inducible and tissue-specific control
of gene expression will undoubtedly make an important
contribution to the modelling of all human genetic
diseases, particularly cancer. The ability to inactivate
gene function within specific tissues of adult mice should
provide an excellent model of the somatic mutational
events characteristic of human neoplasia. The engi¬
neered mice may provide not only models of disease, but
also models for possible gene therapy. Most human
cancers have mutations in more than one oncogene or
tumour suppressor gene, so there are many candidate
genes which could be used in gene therapy for cancer.
p53 is an obvious candidate and mice with inducible
expression of this gene should provide information
about the usefulness of a p53-based gene therapy
protocol.
It is clear that the development of these technologies
for precise identification of critical steps in cancer pro¬
gression requires careful interpretation. For example,
many tissue-specific promoters operate only in differ¬
entiated cells. Thus, one possible problem in future
tumorigenesis studies is that the critical stem cell com¬
partment is not targeted. Such questions remain to be
answered and emphasize the importance of a histo-
pathological and molecular genetic partnership as we
seek to unravel the pathogenesis of cancer and design
new strategies for treatment.
ACKNOWLEDGEMENTS
EAL is supported by a studentship awarded by the
Pathological Society of Great Britain and Ireland. ARC
is a Royal Society University Research Fellow
authors are supported by CRC, MRC, and AICI
REFERENCES
1. Foulkes WD. A tale of four syndromes: familial adenomatous p
Gardner syndrome, attenuated APC and Turcot syndrome. Q J A
88: 853-863.
2. Li FP, Thurber WA, Seddon J, Holmes GE. Hepatoblastoma in
with polyposis coli. J Am Med Assoc 1987; 257: 2475-2477.
3. Bodmer WF, Bailey CJ, Bodmer J, et al. Localisation of the
familial adenomatous polyposis on chromosome 5. Nature H
614-616.
4. Malkin D, Li FP, Strong LC, et al. Germ line mutations in a
syndrome of breast cancer, sarcomas and other neoplasms. Sciei
250: 1233-1238.
5. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-li
mission of a mutated p53 gene in a cancer-prone family with Li—I
syndrome. Nature 1990; 348: 747-749.
6. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad
1993; 90: 10914-10921.
7. Longnecker DS. The azerserine-induced model of pancreatic carcii
in rats. In: Scarpelli DG, Reddy JK, Longnecker DS, eds. Expi
Pancreatic Carcinogenesis. Boca Raton, FL: CRC Press, 1987; 11
8. Shibata D, Capella G, Perucho M. Mutational activation of the c
human pancreatic carcinoma. Ballieres Clin Gastroenterol 1990; 4:
9. Schaefffer BK, Zurlo J, Longnecker DS. Activtion of c-K-ra
detectable in adenomas or adenocarcinomas arising in the art panci
Carcinogen 1990; 3: 165-170.
10. Moser AR, Pitot HC, Dove WF. A dominant mutation that predi
multiple instestinal neoplasia in the mouse. Science 1990; 247: 322
11. Su L-K, Kinzler KW, Vogelstein B, et al. Multiple intestinal i
caused by a mutation in the murine homologue of the APC gene
1992; 256: 668-670.
12. Dietrich WF, Lander ES, Smith JS, et al. Genetic identification ol
a major modifier locus affecting Min-induced intestinal neoplas
mouse. Cell 1993; 75: 631-639.
13. Berg P. Co-chairman's remarks: reverse genetics: directed modifii
DNA for functional analysis. Gene 1993; 135: 261-264.
14. Quaife CJ, Pinkert CA, Ornitz DM, Palmiter RD, Brinster RL. P
neoplasia induced by ras expression in acinar cells of transgenic n
1987; 48: 1023-1034.
15. Evans MJ, Kaufman MH. Establishment in culture of pluripotent c
mouse embryos. Nature 1981; 292: 154-156.
16. Martin G. Isolation of a pluripotent cell line from early mouse
cultured in medium conditioned by teratocarcinoma stem cells. /




18. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Brt
Donehower LA. Spontaneous and carcinogen-ionduced tumourig
p53 deficient mice. Nature Genet 1993; 5: 225-229.
19. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spect
ploidy in mice with a large deletion in the p53 gene. Oncogene
603-609.
20. Jacks T, Remington L, Williams BO, et al. Tumour spectrum analy:
mutant mice. Curr Biol 1994; 4: 1-7.
21. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High fi
developmental abnormalities in p53-deficient mice. Curr Biol
931-936.
22. Clarke AR, Maandag ER, van Roon M, et al. Requirement for a fi
Rb-1 gene in murine development. Nature 1992; 359: 328-330.
23. Lee EY-HP, Chang C-Y, Hu N, et al. Mice deficient for RB are n
and show defects in neurogenesis and haematopoiesis. Nature \i
849-851.
24. Jacks T, Fazeli A, Schimdt E, Bronson R, Goodel M, Weinberg R
of an RB mutation in the mouse. Nature 1992; 359: 295-300.
25. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-d<
apoptosis produced by Rb-deficiency in the developing mouse lens
1994; 371: 72-74.
26. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in tr
mice. Nature 1990; 343: 665-669.
27. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT,
Cooperative tumourigenic effects of germline mutations in Rb i
Nature Genet 1994; 7: 480-484.
28. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murii
gene is not essential for growth and development. Proc Natl Acad
1995;92:1709-1713.
29. Yarranton GT. Inducible vectors for expression in mammalian ce
Opin Biotechno! 1992; 3: 506-511.
30. Hug H, Costas M, Staeheli P, Aebi M, Weissman C. Organisatio
murine Mx gene and characterisation of its interferon- and virus-i
promoter. Mol Cell Biol 1988; 8: 3065-3079.
ANIMAL MODELS AND THE MOLECULAR PATHOLOGY OF CANCER 135
n M, Bonin AL, Bujard H. Control of gene activity in higher
/otic cells by prokaryotic regulatory elements. Trends Biochem Sci
18: 471-475.
n M, Bujard H. Tight control of gene expression in mammalian cells
racycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89:
5551.
n M, Freundlieb S, Bender G, Muller G, Hillen W. Bujard H.
:riptional activation in mammalian cells. Science 1995; 268: 1766—
ett P, Difilippantonio M, Hellman N, Schatz DG. A modified
/cline-regulated system provides autoregulatory, inducible gene
sion in cultured cells and transgenic mice. Proc Natl Acad Sci USA
93: 6522-6526.
tinder L, Talbott R, Seeiziger BR, Kley N. Gene regulation by
rature sensitive p53 mutants: identification of p53 response genes.
Vatl Acad Sci USA 1994; 91: 10640-10644.
4eir EG, Polverini PJ, Chazin VR, Su Huang H-J, de Tribolet N,
ee WK. Release of an inhibitor of angiogenesis upon induction of
wild type p53 expression in glioblastoma cells. Nature Genet 1994; 8:
171-176.
37. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by
p21WAFI. Cancer Res 1995; 55; 4536-4539.
38. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of
epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14:
4662-4675.
39. Baringa M. Knockout mice: round two. Science 1994; 265: 26-28.
40. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in
mice. Science 1995; 269: 1427-1429.
41. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a
DNA polymerase /? gene segment in T cells using cell type specific gene
targeting. Science 1994; 265: 103-106.
42. van Deursen J, Fornerod M, van Rees B, Grosveld G. Cre-mediated
site-specific translocation between nonhomologous mouse chromosomes.
Proc Natl Acad Sci USA 1995; 92: 7376-7380.
An intronic domain within the rat Preprotachykinin-A gene
containing a CCCT repetitive motif acts as an enhancer in
differentiating embryonic stem cells
C.E Fiskerstrand, E. Lovejoy1, L. Gerrard and J.P. Quinn*
Department of Veterinary Pathology, Summerhall and Department of Pathology, Teviot
Building1, University of Edinburgh EH9 1QH
Corresponding Author
Telephone 0131 650 7925
fax 0131 650 6511
email i.guinn@ed.ac.uk
Keywords: PPT, substance P, gene expression, transcription, ES cells, enhancer, intron,
nociception.
2
Previous attempts by several groups to clone fragments containing intron 2 of the rat
preprotachykinin-A gene have generated deletions of various sizes. We have
determined that these deletions occur within a specific region of the intron spanning a
CCCT tandem repeat domain. We show that this intronic domain is able to support
reporter gene expression in mouse embryonic stem (ES) cells that have been induced to
differentiate but not in undifferentiated ES cells. No significant expression was observed
in the HeLa clonal cell line. This demonstrates that this intron 2 domain is a highly
restrictive enhancer and may be associated with differentiation.
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The rat preprotachykinin-A gene (rPPT) encodes the neuropeptides substance
P, neurokinin A, neuropeptide K and neuropeptide y, which are derived by alternative
splicing of primary RNA transcripts and post translational processing of the peptide
precursors [6]. There is a plethora of in vivo observations on the expression of the
preprotachykinin-A gene or modulation of tachykinin peptide content in a variety of
physiological and pathological conditions [1, 4, 5, 19]. A molecular model for
transcription of this gene will allow us to generate hypotheses concerning the
mechanisms that result in these observations. The expression of PPT in vivo is
restricted to specific tissues and under stimulus inducible regulation. Analysis of rPPT
transcriptional control has focused on a proximal promoter region spanning -3500 to
+500 relative to the transcriptional start [3, 8, 9, 12-16]. This region, or fragments
derived from it, have been demonstrated to restrict promoter activity in reporter gene
constructs to neurons rather than non neuronal cells in primary cultures of DRG or cell
lines [8, 10, 16]. This restricted tissue specific expression is regulated by the
combinatorial action of multiple positive and negative c/s-acting regulatory domains.
However this region of the promoter does not support any expression in a transgenic
model of gene expression [10, 16].
Historically the region spanning -3500 to +500 was used because of the ease of
manipulating various subfragments spanning the major transcriptional start site
contained within a lambda clone. The initial region we cloned and analysed was a 5 Kb
BamH1 fragment that extended the sequence at least 1 kb 3' of +500 [15]. However this
fragment was unstable when cloned in high copy number plasmids. Further analysis
demonstrated that deletions were occurring in the region 3' of +500 (J. Quinn, personal
observations). The original DNA sequence of the lambda clone identified was also
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incomplete over this region [2], Published DNA sequence was available to +871
followed by CCTCCCTCCCT then a gap of of 0.58kb and resumed with CCCT
suggesting that the gap may consist entirely of CCCT repeated units. As the 'continued'
sequence began CCCT the assumption was that the entire 0.58kb might consist of
CCCT repeated units. Although eukaryotic sequences that are difficult to clone in
bacteria often contain endonuclease recognition sites, they can also contain structures
that might have secondary structures such as palindromes and origins [17], We
therefore set out to clone, sequence and determine the function if any of this region.
The cloning of the region in intron 2 normally deleted in previous experiments
was obtained by PCR of a 5.5Kb Bam HI restriction fragment spanning intron 2 using
primers derived from the original sequence of Carter and Krause, 1990. These primers
use the original numbering of Carter and Krause and are: the sense primer, termed
holel 5'TGTCCTGGGTTCAGTGTCT, 5' spanning bases +822 to 840, and the antisense
primer, termed hole2, 5'GGCGATTCTCTGAAGAAGATGCTCAAAGGG spanning bases
+1707to +1688 which is within exon 3. The PCR fragment generated was termed the
HOLE. An equivalent PCR product was obtained from rat tail genomic DNA as
template. This PCR product was cloned into PCR2.1 (InVitrogen) and sequenced. A
~920bp PCR product was obtained which consisted of 128 bases of CCCT repeats plus
511 bases of new sequence flanking the CCCT in addition to the known sequence, Fig.
1. An internal antisense primer, hole3, 5'TGCAACTCACTAAGATCCAG was derived
from this new flanking sequence adjacent to the CCCT region. When used with hole
primer 1 to obtain a PCR fragment containing the CCCT region with minimal flanking
bases, the CCCT region was again deleted upon cloning. This highlights the instability
5
of the region. Intermediate sized clones using restriction fragments of the 'Hole' PCR2.1
clone have also proved to be unstable.
To test the ability of the HOLE region to act as a transcriptional enhancer we
made reporter gene constructs in which luciferase expression is directed by this
fragment. Reporter gene constructs used for transfection analyses consisted of the
pGL3 promoter vector (pGL3p, Promega) with the HOLE sequence subcloned into the
BamHI site. A chloramphenicol acetyl transferase (CAT) construct under the control of
the RSV promoter was used to control for transfection efficiencies. There are no good
cell line models for PPT gene expression or cells that support reporter gene expression
directed by PPT promoter fragments. However PPT expression has been demonstrated
in sub-populations of ES cells which are differentiated to a neuronal phenotype. We
therefore used ES cells for testing reporter gene expression of our HOLE construct.
HeLa were used as non-neuronal cell line.
ES cells, HM-1, were cultured as per Magin et al [7] in the presence of LIF
(leukaemia inhibitory factor). Cells at 70-80% confluence in 24 well plates were used for
transfections. 45min prior to transfection, cells were transferred to serum-free medium.
Lipofectin (Life Technologies) was used as the transfection agent, following the
manufacturer's directions. DNA and lipofectin were incubated separately in serum-free
medium + or - LIF as required, for 45min then the two solutions combined for a further
45min. 250pl of the mix was added to each well and 3 separate wells transfected for
each sample. Each transfection contained 1ug specific PPT intron plasmid construct plus
366ng RSV-CAT. Post transfection, cells were transferred to specific medium + / - LIF
and + / - retinoic acid (RA). All trans retinoic acid, when required, was dissolved in
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ethanol and used immediately. After a further 64h incubation cells were washed twice
with PBS, 250ul Promega lysis buffer was added. After 15-30min at room temperature
lysates were harvested, vortexed and microfuged for 15sec. Supernatants were stored at
-70°C. HeLa cells were grown in Dulbecco's modified Eagle's media (DMEM)
supplemented with 10% heat inactivated calf serum. HeLa cells were transfected by
electroporation in 4mm cuvettes using the EquiBio Easyject at 250V and 1500uF
(optimal settings). 20pg specific PPT intron 2 construct plus 2pg RSV-CAT was
transfected per 5x106 HeLa cells in 800pl medium + 0.5% serum. The cells were
immediately resuspended in fresh medium in 6 well plates and incubated for 48h at 37°C
then treated in the same way as the ES cells. For each sample, 20pl was assayed for
luciferase activity using the Promega system and the Life Sciences Labsystems
Luminoskan RT and 200pl was assayed for CAT activity using the Promega CAT ELISA
system. Luciferase results were normalised to CAT values to control for transfection
efficiency.
ES cells are pluripotent cells derived from the inner cell mass of blastocysts. The
culturing of ES cells in the presence of LIF allows them to be maintained in an
undifferentiated state for many passages in culture [18]. When such undifferentiated
cells were transfected with the PPT-luciferase construct reporter gene expression over
that of the vector alone was not increased. Reporter gene expression in general was
higher when cells were transfected in the presence of LIF Fig2a. However, withdrawal of
LIF permitted the PPT intronic domain to act as a strong enhancer of reporter gene
expression, with a 150-fold increase in activity observed, Fig. 2a and b. There was no
further enhancement with RA. Withdrawal of LIF is sufficient to induce the differentiation
of ES cells into endoderm-like cells. Although differentiation of ES cells into
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morphologically distinguishable cell populations normally occurs over a period of days,
changes at the molecular level can be seen as early as 36hrs after LIF withdrawal or 12
hours after the addition of RA [11],
In conclusion, the withdrawal of LIF for 64 hours is insufficient to induce gross
morphological changes in ES cell appearance. However, it is sufficient to induce
molecular alterations within these cells that permit the enhancer activity of the novel PPT
intronic domain. This domain contains a tandem CCCT repeat motif of 148bp that was
previously uncharacterised within the rPPT promoter as this region is unstable when
cloned into high copy number plasmids in bacteria. It will be of interest to determine
precisely the enhancer domain within intron 2 and test it both individually and within the
context of transgenic models of PPT gene expression that we are developing.
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Figure 1 PCR of rPPT Intron 2 'HOLE'
a) A ~900bp HOLE PCR product was obtained from both genomic DNA (lane 2)
and a 5.5Kb BamHI restriction fragment derived from the >14Kb genomic A11.1
clone of Carter and Krause, 1990 (lane 3). PCR primers holel, hole2 and hole3
were used at an annealing temperature of 55°C. b) Sequence of the HOLE PCR
product showing the position of the CCCT repeat. PCR primers are underlined and
previously unpublished sequence is shown in bold characters. The start and end of
the sequence correspond to positions +822 and +1707 of Carter and Krause
respectively.
bp
21226 5146 3530 2027 1904 1709 1375
947 831 564
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Figure 2 Enhancer Activity of rPPT Intron 2 CCCT Element in ES Cells
a) Luciferase expression from cells transfected with either the pGL3p vector or
CCCT-pGL3p construct. Luciferase units are normalised using RSVCAT
expression in each sample to correct for transfection effiiciencies. Results are
shown for roughly equivalent numbers of cells in HeLa and ES + and - LIF with no
added retinoic acid, b) The enhancer activity of the rPPT Intron 2 CCCT element is
shown as the increase in luciferase units over the basal activity of the expression
vector. Results are corrected for transfection efficiencies. Data is shown as + and -
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